chr	pos	ref	alt	aaref	aaalt	rs_dbSNP151	hg19_chr	hg19_pos	hg18_chr	hg18_pos	aapos	genename	Ensembl_geneid	Ensembl_transcriptid	Uniprot_acc	Uniprot_entry	HGVSc_ANNOVAR	HGVSp_ANNOVAR	HGVSc_snpEff	HGVSp_snpEff	HGVSc_VEP	HGVSp_VEP	APPRIS	GENCODE_basic	TSL	VEP_canonical	cds_strand	refcodon	codonpos	codon_degeneracy	Ancestral_allele	AltaiNeandertal	Denisova	VindijiaNeandertal	SIFT_score	SIFT_converted_rankscore	SIFT_pred	SIFT4G_score	SIFT4G_converted_rankscore	SIFT4G_pred	Polyphen2_HDIV_score	Polyphen2_HDIV_rankscore	Polyphen2_HDIV_pred	Polyphen2_HVAR_score	Polyphen2_HVAR_rankscore	Polyphen2_HVAR_pred	LRT_score	LRT_converted_rankscore	LRT_pred	LRT_Omega	MutationTaster_score	MutationTaster_converted_rankscore	MutationTaster_pred	MutationTaster_model	MutationTaster_AAE	MutationAssessor_score	MutationAssessor_rankscore	MutationAssessor_pred	FATHMM_score	FATHMM_converted_rankscore	FATHMM_pred	PROVEAN_score	PROVEAN_converted_rankscore	PROVEAN_pred	VEST4_score	VEST4_rankscore	MetaSVM_score	MetaSVM_rankscore	MetaSVM_pred	MetaLR_score	MetaLR_rankscore	MetaLR_pred	Reliability_index	M_CAP_score	M_CAP_rankscore	M_CAP_pred	REVEL_score	REVEL_rankscore	MutPred_score	MutPred_rankscore	MutPred_protID	MutPred_AAchange	MutPred_Top5features	MVP_score	MVP_rankscore	MPC_score	MPC_rankscore	PrimateAI_score	PrimateAI_rankscore	PrimateAI_pred	DEOGEN2_score	DEOGEN2_rankscore	DEOGEN2_pred	BayesDel_addAF_score	BayesDel_addAF_rankscore	BayesDel_addAF_pred	BayesDel_noAF_score	BayesDel_noAF_rankscore	BayesDel_noAF_pred	ClinPred_score	ClinPred_rankscore	ClinPred_pred	LIST_S2_score	LIST_S2_rankscore	LIST_S2_pred	Aloft_Fraction_transcripts_affected	Aloft_prob_Tolerant	Aloft_prob_Recessive	Aloft_prob_Dominant	Aloft_pred	Aloft_Confidence	CADD_raw	CADD_raw_rankscore	CADD_phred	CADD_raw_hg19	CADD_raw_rankscore_hg19	CADD_phred_hg19	DANN_score	DANN_rankscore	fathmm_MKL_coding_score	fathmm_MKL_coding_rankscore	fathmm_MKL_coding_pred	fathmm_MKL_coding_group	fathmm_XF_coding_score	fathmm_XF_coding_rankscore	fathmm_XF_coding_pred	Eigen_raw_coding	Eigen_raw_coding_rankscore	Eigen_pred_coding	Eigen_PC_raw_coding	Eigen_PC_raw_coding_rankscore	Eigen_PC_phred_coding	GenoCanyon_score	GenoCanyon_rankscore	Integrated_fitCons_score	Integrated_fitCons_rankscore	Integrated_confidence_value	GM12878_fitCons_score	GM12878_fitCons_rankscore	GM12878_confidence_value	H1_hESC_fitCons_score	H1_hESC_fitCons_rankscore	H1_hESC_confidence_value	HUVEC_fitCons_score	HUVEC_fitCons_rankscore	HUVEC_confidence_value	LINSIGHT	LINSIGHT_rankscore	GERP_NR	GERP_RS	GERP_RS_rankscore	phyloP100way_vertebrate	phyloP100way_vertebrate_rankscore	phyloP30way_mammalian	phyloP30way_mammalian_rankscore	phyloP17way_primate	phyloP17way_primate_rankscore	phastCons100way_vertebrate	phastCons100way_vertebrate_rankscore	phastCons30way_mammalian	phastCons30way_mammalian_rankscore	phastCons17way_primate	phastCons17way_primate_rankscore	SiPhy_29way_pi	SiPhy_29way_logOdds	SiPhy_29way_logOdds_rankscore	bStatistic	bStatistic_converted_rankscore	c1000Gp3_AC	c1000Gp3_AF	c1000Gp3_AFR_AC	c1000Gp3_AFR_AF	c1000Gp3_EUR_AC	c1000Gp3_EUR_AF	c1000Gp3_AMR_AC	c1000Gp3_AMR_AF	c1000Gp3_EAS_AC	c1000Gp3_EAS_AF	c1000Gp3_SAS_AC	c1000Gp3_SAS_AF	TWINSUK_AC	TWINSUK_AF	ALSPAC_AC	ALSPAC_AF	UK10K_AC	UK10K_AF	ESP6500_AA_AC	ESP6500_AA_AF	ESP6500_EA_AC	ESP6500_EA_AF	ExAC_AC	ExAC_AF	ExAC_Adj_AC	ExAC_Adj_AF	ExAC_AFR_AC	ExAC_AFR_AF	ExAC_AMR_AC	ExAC_AMR_AF	ExAC_EAS_AC	ExAC_EAS_AF	ExAC_FIN_AC	ExAC_FIN_AF	ExAC_NFE_AC	ExAC_NFE_AF	ExAC_SAS_AC	ExAC_SAS_AF	ExAC_nonTCGA_AC	ExAC_nonTCGA_AF	ExAC_nonTCGA_Adj_AC	ExAC_nonTCGA_Adj_AF	ExAC_nonTCGA_AFR_AC	ExAC_nonTCGA_AFR_AF	ExAC_nonTCGA_AMR_AC	ExAC_nonTCGA_AMR_AF	ExAC_nonTCGA_EAS_AC	ExAC_nonTCGA_EAS_AF	ExAC_nonTCGA_FIN_AC	ExAC_nonTCGA_FIN_AF	ExAC_nonTCGA_NFE_AC	ExAC_nonTCGA_NFE_AF	ExAC_nonTCGA_SAS_AC	ExAC_nonTCGA_SAS_AF	ExAC_nonpsych_AC	ExAC_nonpsych_AF	ExAC_nonpsych_Adj_AC	ExAC_nonpsych_Adj_AF	ExAC_nonpsych_AFR_AC	ExAC_nonpsych_AFR_AF	ExAC_nonpsych_AMR_AC	ExAC_nonpsych_AMR_AF	ExAC_nonpsych_EAS_AC	ExAC_nonpsych_EAS_AF	ExAC_nonpsych_FIN_AC	ExAC_nonpsych_FIN_AF	ExAC_nonpsych_NFE_AC	ExAC_nonpsych_NFE_AF	ExAC_nonpsych_SAS_AC	ExAC_nonpsych_SAS_AF	gnomAD_exomes_flag	gnomAD_exomes_AC	gnomAD_exomes_AN	gnomAD_exomes_AF	gnomAD_exomes_nhomalt	gnomAD_exomes_AFR_AC	gnomAD_exomes_AFR_AN	gnomAD_exomes_AFR_AF	gnomAD_exomes_AFR_nhomalt	gnomAD_exomes_AMR_AC	gnomAD_exomes_AMR_AN	gnomAD_exomes_AMR_AF	gnomAD_exomes_AMR_nhomalt	gnomAD_exomes_ASJ_AC	gnomAD_exomes_ASJ_AN	gnomAD_exomes_ASJ_AF	gnomAD_exomes_ASJ_nhomalt	gnomAD_exomes_EAS_AC	gnomAD_exomes_EAS_AN	gnomAD_exomes_EAS_AF	gnomAD_exomes_EAS_nhomalt	gnomAD_exomes_FIN_AC	gnomAD_exomes_FIN_AN	gnomAD_exomes_FIN_AF	gnomAD_exomes_FIN_nhomalt	gnomAD_exomes_NFE_AC	gnomAD_exomes_NFE_AN	gnomAD_exomes_NFE_AF	gnomAD_exomes_NFE_nhomalt	gnomAD_exomes_SAS_AC	gnomAD_exomes_SAS_AN	gnomAD_exomes_SAS_AF	gnomAD_exomes_SAS_nhomalt	gnomAD_exomes_POPMAX_AC	gnomAD_exomes_POPMAX_AN	gnomAD_exomes_POPMAX_AF	gnomAD_exomes_POPMAX_nhomalt	gnomAD_exomes_controls_AC	gnomAD_exomes_controls_AN	gnomAD_exomes_controls_AF	gnomAD_exomes_controls_nhomalt	gnomAD_exomes_controls_AFR_AC	gnomAD_exomes_controls_AFR_AN	gnomAD_exomes_controls_AFR_AF	gnomAD_exomes_controls_AFR_nhomalt	gnomAD_exomes_controls_AMR_AC	gnomAD_exomes_controls_AMR_AN	gnomAD_exomes_controls_AMR_AF	gnomAD_exomes_controls_AMR_nhomalt	gnomAD_exomes_controls_ASJ_AC	gnomAD_exomes_controls_ASJ_AN	gnomAD_exomes_controls_ASJ_AF	gnomAD_exomes_controls_ASJ_nhomalt	gnomAD_exomes_controls_EAS_AC	gnomAD_exomes_controls_EAS_AN	gnomAD_exomes_controls_EAS_AF	gnomAD_exomes_controls_EAS_nhomalt	gnomAD_exomes_controls_FIN_AC	gnomAD_exomes_controls_FIN_AN	gnomAD_exomes_controls_FIN_AF	gnomAD_exomes_controls_FIN_nhomalt	gnomAD_exomes_controls_NFE_AC	gnomAD_exomes_controls_NFE_AN	gnomAD_exomes_controls_NFE_AF	gnomAD_exomes_controls_NFE_nhomalt	gnomAD_exomes_controls_SAS_AC	gnomAD_exomes_controls_SAS_AN	gnomAD_exomes_controls_SAS_AF	gnomAD_exomes_controls_SAS_nhomalt	gnomAD_exomes_controls_POPMAX_AC	gnomAD_exomes_controls_POPMAX_AN	gnomAD_exomes_controls_POPMAX_AF	gnomAD_exomes_controls_POPMAX_nhomalt	gnomAD_genomes_flag	gnomAD_genomes_AC	gnomAD_genomes_AN	gnomAD_genomes_AF	gnomAD_genomes_nhomalt	gnomAD_genomes_AFR_AC	gnomAD_genomes_AFR_AN	gnomAD_genomes_AFR_AF	gnomAD_genomes_AFR_nhomalt	gnomAD_genomes_AMR_AC	gnomAD_genomes_AMR_AN	gnomAD_genomes_AMR_AF	gnomAD_genomes_AMR_nhomalt	gnomAD_genomes_ASJ_AC	gnomAD_genomes_ASJ_AN	gnomAD_genomes_ASJ_AF	gnomAD_genomes_ASJ_nhomalt	gnomAD_genomes_EAS_AC	gnomAD_genomes_EAS_AN	gnomAD_genomes_EAS_AF	gnomAD_genomes_EAS_nhomalt	gnomAD_genomes_FIN_AC	gnomAD_genomes_FIN_AN	gnomAD_genomes_FIN_AF	gnomAD_genomes_FIN_nhomalt	gnomAD_genomes_NFE_AC	gnomAD_genomes_NFE_AN	gnomAD_genomes_NFE_AF	gnomAD_genomes_NFE_nhomalt	gnomAD_genomes_POPMAX_AC	gnomAD_genomes_POPMAX_AN	gnomAD_genomes_POPMAX_AF	gnomAD_genomes_POPMAX_nhomalt	clinvar_id	clinvar_clnsig	clinvar_trait	clinvar_review	clinvar_hgvs	clinvar_var_source	clinvar_MedGen_id	clinvar_OMIM_id	clinvar_Orphanet_id	Interpro_domain	GTEx_V8_gene	GTEx_V8_tissue	Geuvadis_eQTL_target_gene
1	9972126	A	G	N	S	rs748902766	1	10032184	1	9954771	18	NMNAT1	ENSG00000173614	ENST00000377205	ENSP00000366410	NMNA1_HUMAN	c.53A>G	p.N18S	c.53A>G	p.Asn18Ser	c.53A>G	p.Asn18Ser	principal1	Y	1	YES	+	AAT	2	0	A	./.	./.	./.	0.181	0.26629	T	0.265	0.34359	T	1.0	0.90584	D	0.997	0.86255	D	0.005222	0.32979	N	0.329333	0.999998;0.999998	0.58761	D;D	simple_aae;simple_aae	N18S;N18S	1.85	0.49092	L	-4.26	0.97078	D	-4.49	0.78553	D	0.961	0.97095	0.9374	0.96209	D	0.9180	0.97284	D	10	0.585484	0.96300	D	0.928	0.98294	0.8	0.91943	Q9HAN9	N18S	Gain of sheet (P = 0.1208); Gain of catalytic residue at N18 (P = 0.1736); Loss of helix (P = 0.3949); Loss of stability (P = 0.4009); Gain of phosphorylation at T21 (P = 0.405)	0.994030760964	0.99396	0.284013172596	0.30833	0.676469683647	0.63763	T	0.662236	0.89878	D	0.118711	0.66242	D	0.0295984	0.72253	D	0.905950725078583	0.55983	D	NULL	0.93846	.	.	.	.	.	.	.	3.188741	0.56330	23.8	2.840055	0.51168	23.2	0.99821658874215435	0.90414	0.98786	0.86836	D	AEFDBI	0.855270	0.77237	D	0.595664088784045	0.72903	5.879593	0.556801905973401	0.71870	5.721466	0.99926775035103	0.38940	0.706298	0.61202	0	0.709663	0.81188	0	0.709663	0.75317	0	0.714379	0.83352	0	NULL	NULL	4.09	4.09	0.47038	8.795000	0.91499	0.314000	0.27911	-0.106000	0.15538	1.000000	0.71638	0.996000	0.59523	0.979000	0.57723	1.0:0.0:0.0:0.0	13.5614	0.61253	764	0.49969	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	1	2.594706798131811E-4	1	1.322401481089659E-4	NULL	NULL	NULL	NULL	1	8.236e-06	1	8.239e-06	0	0	0	0	0	0	0	0	1	1.499e-05	0	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	1.102e-05	1	1.102e-05	0	0	0	0	0	0	0	0	1	2.375e-05	0	0	segdup	4	251146	1.592699e-05	0	0	16254	0	0	0	34592	0	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	3	113430	2.644803e-05	0	1	30616	3.266266e-05	0	1	30616	3.266266e-05	0	3	109408	2.742030e-05	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	2	42768	4.676394e-05	0	1	15690	6.373486e-05	0	1	15690	6.373486e-05	0	.	2	143194	1.396707e-05	0	1	42022	2.379706e-05	0	0	13608	0	0	0	3324	0	0	0	3134	0	0	0	10462	0	0	1	64548	1.549235e-05	0	1	64548	1.549235e-05	0	190977	Pathogenic/Likely_pathogenic	Retinal_dystrophy|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.9972126A>G	.	C0854723|CN517202	.	ORPHA71862	Cytidyltransferase-like domain	.	. 	.
1	9972126	A	G	N	S	rs748902766	1	10032184	1	9954771	18	NMNAT1	ENSG00000173614	ENST00000403197	ENSP00000385131	B1AN62_HUMAN	c.53A>G	p.N18S	c.53A>G	p.Asn18Ser	c.53A>G	p.Asn18Ser	.	Y	2	.	+	AAT	2	0	A	./.	./.	./.	0.131	0.26629	T	0.133	0.34359	T	NULL	0.90584	.	NULL	0.86255	.	0.005222	0.32979	N	0.329333	0.999998;0.999998	0.58761	D;D	simple_aae;simple_aae	N18S;N18S	NULL	0.49092	.	-4.26	0.97078	D	-4.55	0.78553	D	0.937	0.97095	0.9374	0.96209	D	0.9180	0.97284	D	10	0.585484	0.96300	D	0.928	0.98294	0.8	0.91943	Q9HAN9	N18S	Gain of sheet (P = 0.1208); Gain of catalytic residue at N18 (P = 0.1736); Loss of helix (P = 0.3949); Loss of stability (P = 0.4009); Gain of phosphorylation at T21 (P = 0.405)	0.994030760964	0.99396	NULL	0.30833	0.676469683647	0.63763	T	0.660167	0.89878	D	0.118711	0.66242	D	0.0295984	0.72253	D	0.905950725078583	0.55983	D	0.981802	0.93846	D	.	.	.	.	.	.	3.188741	0.56330	23.8	2.840055	0.51168	23.2	0.99821658874215435	0.90414	0.98786	0.86836	D	AEFDBI	0.855270	0.77237	D	0.595664088784045	0.72903	5.879593	0.556801905973401	0.71870	5.721466	0.99926775035103	0.38940	0.706298	0.61202	0	0.709663	0.81188	0	0.709663	0.75317	0	0.714379	0.83352	0	NULL	NULL	4.09	4.09	0.47038	8.795000	0.91499	0.314000	0.27911	-0.106000	0.15538	1.000000	0.71638	0.996000	0.59523	0.979000	0.57723	1.0:0.0:0.0:0.0	13.5614	0.61253	764	0.49969	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	1	2.594706798131811E-4	1	1.322401481089659E-4	NULL	NULL	NULL	NULL	1	8.236e-06	1	8.239e-06	0	0	0	0	0	0	0	0	1	1.499e-05	0	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	1.102e-05	1	1.102e-05	0	0	0	0	0	0	0	0	1	2.375e-05	0	0	segdup	4	251146	1.592699e-05	0	0	16254	0	0	0	34592	0	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	3	113430	2.644803e-05	0	1	30616	3.266266e-05	0	1	30616	3.266266e-05	0	3	109408	2.742030e-05	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	2	42768	4.676394e-05	0	1	15690	6.373486e-05	0	1	15690	6.373486e-05	0	.	2	143194	1.396707e-05	0	1	42022	2.379706e-05	0	0	13608	0	0	0	3324	0	0	0	3134	0	0	0	10462	0	0	1	64548	1.549235e-05	0	1	64548	1.549235e-05	0	190977	Pathogenic/Likely_pathogenic	Retinal_dystrophy|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.9972126A>G	.	C0854723|CN517202	.	ORPHA71862	Cytidyltransferase-like domain	.	. 	.
1	10303606	G	T	M	I	rs41274458	1	10363664	1	10286251	807	KIF1B	ENSG00000054523	ENST00000377083	ENSP00000366287	KIF1B_HUMAN	c.2421G>T	p.M807I	c.2421G>T	p.Met807Ile	c.2421G>T	p.Met807Ile	.	Y	1	.	+	ATG	3	0	G	T/T	T/T	T/T	0.484	0.08140	T	0.557	0.09205	T	0.0	0.02946	B	0.001	0.04355	B	NULL	NULL	.	NULL	1;1;1;0.998315;0.998315	0.81001	D;D;D;N;N	without_aae;without_aae;without_aae;simple_aae;simple_aae	.;.;.;M807I;M807I	NULL	NULL	.	-0.62	0.71895	T	-0.29	0.11728	N	0.08	0.05929	-0.9097	0.46891	T	0.1001	0.37213	T	8	NULL	NULL	.	0.109	0.31302	.	NULL	.	.	.	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	.	-0.54531	0.00311	T	-0.535805	0.18712	T	0.0123466003209037	0.00201	T	0.676832	0.28555	T	.	.	.	.	.	.	1.965935	0.29931	19.00	1.250357	0.20238	14.93	0.6082950596041844	0.06558	0.92753	0.56461	D	AEFBI	0.254323	0.37366	N	-0.123365316042506	0.36375	2.101837	0.0112743739789945	0.40237	2.398175	0.999884034633309	0.44867	0.706548	0.73137	0	0.546412	0.12157	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.58	5.58	0.84361	2.475000	0.44821	1.172000	0.72986	0.669000	0.69127	1.000000	0.71638	0.882000	0.36666	0.265000	0.23644	0.0:0.0:0.8526:0.1474	14.4174	0.66732	236	0.90801	33	0.006589456869009584	0	0.0	23	0.02286282306163022	7	0.010086455331412104	0	0.0	3	0.003067484662576687	101	0.027238403451995685	104	0.026984950700570835	205	0.027109230362338005	22	0.004993191103041307	221	0.02569767441860465	2155	1.775e-02	2154	1.783e-02	43	4.176e-03	89	7.706e-03	1	1.161e-04	260	3.932e-02	1701	2.565e-02	40	2.425e-03	1813	1.707e-02	1813	1.711e-02	37	4.110e-03	87	7.768e-03	1	1.274e-04	260	3.932e-02	1373	2.533e-02	40	2.441e-03	1328	1.463e-02	1327	1.472e-02	43	4.184e-03	89	7.714e-03	1	1.788e-04	145	3.814e-02	994	2.382e-02	40	2.427e-03	.	4605	250618	1.837458e-02	78	65	16222	4.006904e-03	0	336	34564	9.721097e-03	2	68	10030	6.779661e-03	0	1	18374	5.442473e-05	0	922	21646	4.259447e-02	26	2997	113054	2.650946e-02	42	87	30608	2.842394e-03	4	2997	113054	2.650946e-02	42	2084	109374	1.905389e-02	40	30	7156	4.192286e-03	0	181	17104	1.058232e-02	0	15	2320	6.465517e-03	0	1	9036	1.106684e-04	0	626	13394	4.673735e-02	20	1142	42768	2.670221e-02	18	47	15682	2.997067e-03	2	1142	42768	2.670221e-02	18	.	2752	143272	1.920822e-02	38	205	42046	4.875612e-03	0	197	13652	1.443012e-02	0	32	3322	9.632751e-03	0	0	3134	0	0	475	10448	4.546325e-02	10	1795	64572	2.779843e-02	27	2	3046	6.565988e-04	0	218862	Benign	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10303606G>T	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:570113	CN169374	.	.	.	NMNAT1|KIF1B|KIF1B|KIF1B|KIF1B|KIF1B|KIF1B|UBE4B|CENPS|KIF1B|KIF1B|CENPS|KIF1B|CENPS|KIF1B|RBP7	Adipose_Subcutaneous|Adipose_Subcutaneous|Adipose_Visceral_Omentum|Adrenal_Gland|Artery_Tibial|Breast_Mammary_Tissue|Cells_Cultured_fibroblasts|Esophagus_Mucosa|Esophagus_Mucosa|Nerve_Tibial|Skin_Not_Sun_Exposed_Suprapubic|Skin_Not_Sun_Exposed_Suprapubic|Skin_Sun_Exposed_Lower_leg|Skin_Sun_Exposed_Lower_leg|Thyroid|Whole_Blood 	.
1	10303606	G	T	M	I	rs41274458	1	10363664	1	10286251	807	KIF1B	ENSG00000054523	ENST00000377093	ENSP00000366297	KIF1B_HUMAN	c.2421G>T	p.M807I	c.2421G>T	p.Met807Ile	c.2421G>T	p.Met807Ile	.	Y	1	.	+	ATG	3	0	G	T/T	T/T	T/T	0.484	0.08140	T	0.557	0.09205	T	0.0	0.02946	B	0.001	0.04355	B	NULL	NULL	.	NULL	1;1;1;0.998315;0.998315	0.81001	D;D;D;N;N	without_aae;without_aae;without_aae;simple_aae;simple_aae	.;.;.;M807I;M807I	NULL	NULL	.	-0.62	0.71895	T	-0.29	0.11728	N	0.083	0.05929	-0.9097	0.46891	T	0.1001	0.37213	T	8	NULL	NULL	.	0.109	0.31302	.	NULL	.	.	.	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	.	-0.54531	0.00311	T	-0.535805	0.18712	T	0.0123466003209037	0.00201	T	NULL	0.28555	.	.	.	.	.	.	.	1.965935	0.29931	19.00	1.250357	0.20238	14.93	0.6082950596041844	0.06558	0.92753	0.56461	D	AEFBI	0.254323	0.37366	N	-0.123365316042506	0.36375	2.101837	0.0112743739789945	0.40237	2.398175	0.999884034633309	0.44867	0.706548	0.73137	0	0.546412	0.12157	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.58	5.58	0.84361	2.475000	0.44821	1.172000	0.72986	0.669000	0.69127	1.000000	0.71638	0.882000	0.36666	0.265000	0.23644	0.0:0.0:0.8526:0.1474	14.4174	0.66732	236	0.90801	33	0.006589456869009584	0	0.0	23	0.02286282306163022	7	0.010086455331412104	0	0.0	3	0.003067484662576687	101	0.027238403451995685	104	0.026984950700570835	205	0.027109230362338005	22	0.004993191103041307	221	0.02569767441860465	2155	1.775e-02	2154	1.783e-02	43	4.176e-03	89	7.706e-03	1	1.161e-04	260	3.932e-02	1701	2.565e-02	40	2.425e-03	1813	1.707e-02	1813	1.711e-02	37	4.110e-03	87	7.768e-03	1	1.274e-04	260	3.932e-02	1373	2.533e-02	40	2.441e-03	1328	1.463e-02	1327	1.472e-02	43	4.184e-03	89	7.714e-03	1	1.788e-04	145	3.814e-02	994	2.382e-02	40	2.427e-03	.	4605	250618	1.837458e-02	78	65	16222	4.006904e-03	0	336	34564	9.721097e-03	2	68	10030	6.779661e-03	0	1	18374	5.442473e-05	0	922	21646	4.259447e-02	26	2997	113054	2.650946e-02	42	87	30608	2.842394e-03	4	2997	113054	2.650946e-02	42	2084	109374	1.905389e-02	40	30	7156	4.192286e-03	0	181	17104	1.058232e-02	0	15	2320	6.465517e-03	0	1	9036	1.106684e-04	0	626	13394	4.673735e-02	20	1142	42768	2.670221e-02	18	47	15682	2.997067e-03	2	1142	42768	2.670221e-02	18	.	2752	143272	1.920822e-02	38	205	42046	4.875612e-03	0	197	13652	1.443012e-02	0	32	3322	9.632751e-03	0	0	3134	0	0	475	10448	4.546325e-02	10	1795	64572	2.779843e-02	27	2	3046	6.565988e-04	0	218862	Benign	not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10303606G>T	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:570113	CN169374	.	.	.	NMNAT1|KIF1B|KIF1B|KIF1B|KIF1B|KIF1B|KIF1B|UBE4B|CENPS|KIF1B|KIF1B|CENPS|KIF1B|CENPS|KIF1B|RBP7	Adipose_Subcutaneous|Adipose_Subcutaneous|Adipose_Visceral_Omentum|Adrenal_Gland|Artery_Tibial|Breast_Mammary_Tissue|Cells_Cultured_fibroblasts|Esophagus_Mucosa|Esophagus_Mucosa|Nerve_Tibial|Skin_Not_Sun_Exposed_Suprapubic|Skin_Not_Sun_Exposed_Suprapubic|Skin_Sun_Exposed_Lower_leg|Skin_Sun_Exposed_Lower_leg|Thyroid|Whole_Blood 	.
1	10321744	T	C	W	R	rs551543997	1	10381802	1	10304389	703	KIF1B	ENSG00000054523	ENST00000263934	ENSP00000263934	KIF1B_HUMAN	c.2107T>C	p.W703R	c.2107T>C	p.Trp703Arg	c.2107T>C	p.Trp703Arg	.	Y	1	YES	+	TGG	1	0	T	T/T	T/T	T/T	0.008	0.58626	D	0.376	0.16182	T	0.994	0.66517	D	0.991	0.79672	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	W703R;W749R;W749R	NULL	0.63160	.	-0.93	0.75215	T	-10.01	0.99038	D	0.836	0.89912	-0.2610	0.76060	T	0.4806	0.80144	T	10	NULL	NULL	.	0.692	0.88963	0.428	0.47501	O60333	W749R	Gain of disorder (P = 0.0151); Gain of solvent accessibility (P = 0.0273); Gain of methylation at K753 (P = 0.0451); Loss of catalytic residue at W749 (P = 0.0487); Gain of relative solvent accessibility (P = 0.0507)	0.652031612068	0.64913	1.68067603589	0.89969	0.924147903919	0.98622	D	NULL	0.95011	.	-0.0227224	0.48466	T	0.21217	0.83777	D	0.113643345620668	0.13797	T	0.940673	0.78488	D	.	.	.	.	.	.	4.223632	0.86187	28.9	4.063933	0.84478	28.3	0.98869539206305013	0.47615	0.98768	0.86602	D	AEFBI	0.847288	0.76414	D	0.547404780244847	0.69925	5.426705	0.573787006493	0.73068	5.910141	0.999999797024527	0.74766	0.732398	0.92422	0	0.633656	0.55848	0	0.743671	0.96076	0	0.635551	0.53088	0	NULL	NULL	5.32	5.32	0.75377	7.664000	0.82811	1.138000	0.64695	0.663000	0.56723	1.000000	0.71638	0.993000	0.55118	0.988000	0.63387	0.0:0.0:0.0:1.0	15.5925	0.76288	230	0.91032	27	0.005391373801916933	0	0.0	0	0.0	0	0.0	0	0.0	27	0.027607361963190184	1	2.6968716289104636E-4	1	2.594706798131811E-4	2	2.644802962179318E-4	NULL	NULL	NULL	NULL	399	3.286e-03	399	3.287e-03	1	9.626e-05	4	3.457e-04	2	2.313e-04	0	0	6	8.991e-05	386	2.338e-02	392	3.691e-03	392	3.692e-03	1	1.105e-04	4	3.568e-04	1	1.272e-04	0	0	4	7.361e-05	382	2.328e-02	398	4.386e-03	398	4.387e-03	1	9.643e-05	4	3.460e-04	2	3.551e-04	0	0	5	1.187e-04	386	2.339e-02	.	720	251420	2.863734e-03	11	0	16256	0	0	0	34588	0	0	0	10076	0	0	3	18388	1.631499e-04	0	0	21648	0	0	12	113712	1.055298e-04	0	696	30616	2.273321e-02	11	696	30616	2.273321e-02	11	339	109404	3.098607e-03	4	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9042	0	0	0	13394	0	0	2	42768	4.676394e-05	0	335	15690	2.135118e-02	4	335	15690	2.135118e-02	4	.	61	143334	4.255794e-04	0	3	42058	7.133007e-05	0	0	13666	0	0	0	3322	0	0	0	3134	0	0	0	10480	0	0	2	64574	3.097222e-05	0	55	3046	1.805647e-02	0	240956	Benign	Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10321744T>C	Illumina_Clinical_Services_Laboratory,Illumina:878892	C2749484|C0270914	256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10321744	T	C	W	R	rs551543997	1	10381802	1	10304389	723	KIF1B	ENSG00000054523	ENST00000622724	ENSP00000480063	A0A087WWA3_HUMAN	c.2167T>C	p.W723R	c.2167T>C	p.Trp723Arg	c.2167T>C	p.Trp723Arg	.	Y	1	.	+	TGG	1	0	T	T/T	T/T	T/T	NULL	0.58626	.	0.386	0.16182	T	NULL	0.66517	.	NULL	0.79672	.	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	W703R;W749R;W749R	NULL	0.63160	.	NULL	0.75215	.	NULL	0.99038	.	0.899	0.89912	-0.2610	0.76060	T	0.4806	0.80144	T	10	NULL	NULL	.	0.692	0.88963	0.428	0.47501	O60333	W749R	Gain of disorder (P = 0.0151); Gain of solvent accessibility (P = 0.0273); Gain of methylation at K753 (P = 0.0451); Loss of catalytic residue at W749 (P = 0.0487); Gain of relative solvent accessibility (P = 0.0507)	0.652031612068	0.64913	NULL	0.89969	0.924147903919	0.98622	D	NULL	0.95011	.	-0.0227224	0.48466	T	0.21217	0.83777	D	0.113643345620668	0.13797	T	0.942906	0.78488	D	.	.	.	.	.	.	4.223632	0.86187	28.9	4.063933	0.84478	28.3	0.98869539206305013	0.47615	0.98768	0.86602	D	AEFBI	0.847288	0.76414	D	0.547404780244847	0.69925	5.426705	0.573787006493	0.73068	5.910141	0.999999797024527	0.74766	0.732398	0.92422	0	0.633656	0.55848	0	0.743671	0.96076	0	0.635551	0.53088	0	NULL	NULL	5.32	5.32	0.75377	7.664000	0.82811	1.138000	0.64695	0.663000	0.56723	1.000000	0.71638	0.993000	0.55118	0.988000	0.63387	0.0:0.0:0.0:1.0	15.5925	0.76288	230	0.91032	27	0.005391373801916933	0	0.0	0	0.0	0	0.0	0	0.0	27	0.027607361963190184	1	2.6968716289104636E-4	1	2.594706798131811E-4	2	2.644802962179318E-4	NULL	NULL	NULL	NULL	399	3.286e-03	399	3.287e-03	1	9.626e-05	4	3.457e-04	2	2.313e-04	0	0	6	8.991e-05	386	2.338e-02	392	3.691e-03	392	3.692e-03	1	1.105e-04	4	3.568e-04	1	1.272e-04	0	0	4	7.361e-05	382	2.328e-02	398	4.386e-03	398	4.387e-03	1	9.643e-05	4	3.460e-04	2	3.551e-04	0	0	5	1.187e-04	386	2.339e-02	.	720	251420	2.863734e-03	11	0	16256	0	0	0	34588	0	0	0	10076	0	0	3	18388	1.631499e-04	0	0	21648	0	0	12	113712	1.055298e-04	0	696	30616	2.273321e-02	11	696	30616	2.273321e-02	11	339	109404	3.098607e-03	4	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9042	0	0	0	13394	0	0	2	42768	4.676394e-05	0	335	15690	2.135118e-02	4	335	15690	2.135118e-02	4	.	61	143334	4.255794e-04	0	3	42058	7.133007e-05	0	0	13666	0	0	0	3322	0	0	0	3134	0	0	0	10480	0	0	2	64574	3.097222e-05	0	55	3046	1.805647e-02	0	240956	Benign	Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10321744T>C	Illumina_Clinical_Services_Laboratory,Illumina:878892	C2749484|C0270914	256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10321744	T	C	W	R	rs551543997	1	10381802	1	10304389	735	KIF1B	ENSG00000054523	ENST00000620295	ENSP00000478500	Q4R9M9_HUMAN	c.2203T>C	p.W735R	c.2203T>C	p.Trp735Arg	c.2203T>C	p.Trp735Arg	.	Y	1	.	+	TGG	1	0	T	T/T	T/T	T/T	NULL	0.58626	.	0.386	0.16182	T	0.968	0.66517	D	0.706	0.79672	P	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	W703R;W749R;W749R	NULL	0.63160	.	NULL	0.75215	.	NULL	0.99038	.	0.885	0.89912	-0.2610	0.76060	T	0.4806	0.80144	T	10	NULL	NULL	.	0.692	0.88963	0.428	0.47501	O60333	W749R	Gain of disorder (P = 0.0151); Gain of solvent accessibility (P = 0.0273); Gain of methylation at K753 (P = 0.0451); Loss of catalytic residue at W749 (P = 0.0487); Gain of relative solvent accessibility (P = 0.0507)	0.652031612068	0.64913	NULL	0.89969	0.924147903919	0.98622	D	NULL	0.95011	.	-0.0227224	0.48466	T	0.21217	0.83777	D	0.113643345620668	0.13797	T	0.942906	0.78488	D	.	.	.	.	.	.	4.223632	0.86187	28.9	4.063933	0.84478	28.3	0.98869539206305013	0.47615	0.98768	0.86602	D	AEFBI	0.847288	0.76414	D	0.547404780244847	0.69925	5.426705	0.573787006493	0.73068	5.910141	0.999999797024527	0.74766	0.732398	0.92422	0	0.633656	0.55848	0	0.743671	0.96076	0	0.635551	0.53088	0	NULL	NULL	5.32	5.32	0.75377	7.664000	0.82811	1.138000	0.64695	0.663000	0.56723	1.000000	0.71638	0.993000	0.55118	0.988000	0.63387	0.0:0.0:0.0:1.0	15.5925	0.76288	230	0.91032	27	0.005391373801916933	0	0.0	0	0.0	0	0.0	0	0.0	27	0.027607361963190184	1	2.6968716289104636E-4	1	2.594706798131811E-4	2	2.644802962179318E-4	NULL	NULL	NULL	NULL	399	3.286e-03	399	3.287e-03	1	9.626e-05	4	3.457e-04	2	2.313e-04	0	0	6	8.991e-05	386	2.338e-02	392	3.691e-03	392	3.692e-03	1	1.105e-04	4	3.568e-04	1	1.272e-04	0	0	4	7.361e-05	382	2.328e-02	398	4.386e-03	398	4.387e-03	1	9.643e-05	4	3.460e-04	2	3.551e-04	0	0	5	1.187e-04	386	2.339e-02	.	720	251420	2.863734e-03	11	0	16256	0	0	0	34588	0	0	0	10076	0	0	3	18388	1.631499e-04	0	0	21648	0	0	12	113712	1.055298e-04	0	696	30616	2.273321e-02	11	696	30616	2.273321e-02	11	339	109404	3.098607e-03	4	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9042	0	0	0	13394	0	0	2	42768	4.676394e-05	0	335	15690	2.135118e-02	4	335	15690	2.135118e-02	4	.	61	143334	4.255794e-04	0	3	42058	7.133007e-05	0	0	13666	0	0	0	3322	0	0	0	3134	0	0	0	10480	0	0	2	64574	3.097222e-05	0	55	3046	1.805647e-02	0	240956	Benign	Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10321744T>C	Illumina_Clinical_Services_Laboratory,Illumina:878892	C2749484|C0270914	256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10321744	T	C	W	R	rs551543997	1	10381802	1	10304389	749	KIF1B	ENSG00000054523	ENST00000377081	ENSP00000366284	KIF1B_HUMAN	c.2245T>C	p.W749R	c.2245T>C	p.Trp749Arg	c.2245T>C	p.Trp749Arg	.	Y	1	.	+	TGG	1	0	T	T/T	T/T	T/T	0.077	0.58626	T	0.385	0.16182	T	NULL	0.66517	.	NULL	0.79672	.	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	W703R;W749R;W749R	2.235	0.63160	M	-0.93	0.75215	T	-10.46	0.99038	D	0.851	0.89912	-0.2610	0.76060	T	0.4806	0.80144	T	10	NULL	NULL	.	0.692	0.88963	0.428	0.47501	O60333	W749R	Gain of disorder (P = 0.0151); Gain of solvent accessibility (P = 0.0273); Gain of methylation at K753 (P = 0.0451); Loss of catalytic residue at W749 (P = 0.0487); Gain of relative solvent accessibility (P = 0.0507)	0.652031612068	0.64913	NULL	0.89969	0.924147903919	0.98622	D	NULL	0.95011	.	-0.0227224	0.48466	T	0.21217	0.83777	D	0.113643345620668	0.13797	T	0.942906	0.78488	D	.	.	.	.	.	.	4.223632	0.86187	28.9	4.063933	0.84478	28.3	0.98869539206305013	0.47615	0.98768	0.86602	D	AEFBI	0.847288	0.76414	D	0.547404780244847	0.69925	5.426705	0.573787006493	0.73068	5.910141	0.999999797024527	0.74766	0.732398	0.92422	0	0.633656	0.55848	0	0.743671	0.96076	0	0.635551	0.53088	0	NULL	NULL	5.32	5.32	0.75377	7.664000	0.82811	1.138000	0.64695	0.663000	0.56723	1.000000	0.71638	0.993000	0.55118	0.988000	0.63387	0.0:0.0:0.0:1.0	15.5925	0.76288	230	0.91032	27	0.005391373801916933	0	0.0	0	0.0	0	0.0	0	0.0	27	0.027607361963190184	1	2.6968716289104636E-4	1	2.594706798131811E-4	2	2.644802962179318E-4	NULL	NULL	NULL	NULL	399	3.286e-03	399	3.287e-03	1	9.626e-05	4	3.457e-04	2	2.313e-04	0	0	6	8.991e-05	386	2.338e-02	392	3.691e-03	392	3.692e-03	1	1.105e-04	4	3.568e-04	1	1.272e-04	0	0	4	7.361e-05	382	2.328e-02	398	4.386e-03	398	4.387e-03	1	9.643e-05	4	3.460e-04	2	3.551e-04	0	0	5	1.187e-04	386	2.339e-02	.	720	251420	2.863734e-03	11	0	16256	0	0	0	34588	0	0	0	10076	0	0	3	18388	1.631499e-04	0	0	21648	0	0	12	113712	1.055298e-04	0	696	30616	2.273321e-02	11	696	30616	2.273321e-02	11	339	109404	3.098607e-03	4	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9042	0	0	0	13394	0	0	2	42768	4.676394e-05	0	335	15690	2.135118e-02	4	335	15690	2.135118e-02	4	.	61	143334	4.255794e-04	0	3	42058	7.133007e-05	0	0	13666	0	0	0	3322	0	0	0	3134	0	0	0	10480	0	0	2	64574	3.097222e-05	0	55	3046	1.805647e-02	0	240956	Benign	Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10321744T>C	Illumina_Clinical_Services_Laboratory,Illumina:878892	C2749484|C0270914	256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10321744	T	C	W	R	rs551543997	1	10381802	1	10304389	749	KIF1B	ENSG00000054523	ENST00000377086	ENSP00000366290	KIF1B_HUMAN	c.2245T>C	p.W749R	c.2245T>C	p.Trp749Arg	c.2245T>C	p.Trp749Arg	principal1	Y	1	.	+	TGG	1	0	T	T/T	T/T	T/T	0.008	0.58626	D	0.383	0.16182	T	0.964	0.66517	D	0.614	0.79672	P	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	W703R;W749R;W749R	2.235	0.63160	M	-0.93	0.75215	T	-10.46	0.99038	D	0.856	0.89912	-0.2610	0.76060	T	0.4806	0.80144	T	10	NULL	NULL	.	0.692	0.88963	0.428	0.47501	O60333	W749R	Gain of disorder (P = 0.0151); Gain of solvent accessibility (P = 0.0273); Gain of methylation at K753 (P = 0.0451); Loss of catalytic residue at W749 (P = 0.0487); Gain of relative solvent accessibility (P = 0.0507)	0.652031612068	0.64913	NULL	0.89969	0.924147903919	0.98622	D	0.803401	0.95011	D	-0.0227224	0.48466	T	0.21217	0.83777	D	0.113643345620668	0.13797	T	0.942906	0.78488	D	.	.	.	.	.	.	4.223632	0.86187	28.9	4.063933	0.84478	28.3	0.98869539206305013	0.47615	0.98768	0.86602	D	AEFBI	0.847288	0.76414	D	0.547404780244847	0.69925	5.426705	0.573787006493	0.73068	5.910141	0.999999797024527	0.74766	0.732398	0.92422	0	0.633656	0.55848	0	0.743671	0.96076	0	0.635551	0.53088	0	NULL	NULL	5.32	5.32	0.75377	7.664000	0.82811	1.138000	0.64695	0.663000	0.56723	1.000000	0.71638	0.993000	0.55118	0.988000	0.63387	0.0:0.0:0.0:1.0	15.5925	0.76288	230	0.91032	27	0.005391373801916933	0	0.0	0	0.0	0	0.0	0	0.0	27	0.027607361963190184	1	2.6968716289104636E-4	1	2.594706798131811E-4	2	2.644802962179318E-4	NULL	NULL	NULL	NULL	399	3.286e-03	399	3.287e-03	1	9.626e-05	4	3.457e-04	2	2.313e-04	0	0	6	8.991e-05	386	2.338e-02	392	3.691e-03	392	3.692e-03	1	1.105e-04	4	3.568e-04	1	1.272e-04	0	0	4	7.361e-05	382	2.328e-02	398	4.386e-03	398	4.387e-03	1	9.643e-05	4	3.460e-04	2	3.551e-04	0	0	5	1.187e-04	386	2.339e-02	.	720	251420	2.863734e-03	11	0	16256	0	0	0	34588	0	0	0	10076	0	0	3	18388	1.631499e-04	0	0	21648	0	0	12	113712	1.055298e-04	0	696	30616	2.273321e-02	11	696	30616	2.273321e-02	11	339	109404	3.098607e-03	4	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9042	0	0	0	13394	0	0	2	42768	4.676394e-05	0	335	15690	2.135118e-02	4	335	15690	2.135118e-02	4	.	61	143334	4.255794e-04	0	3	42058	7.133007e-05	0	0	13666	0	0	0	3322	0	0	0	3134	0	0	0	10480	0	0	2	64574	3.097222e-05	0	55	3046	1.805647e-02	0	240956	Benign	Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10321744T>C	Illumina_Clinical_Services_Laboratory,Illumina:878892	C2749484|C0270914	256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10321829	A	G	N	S	rs117525287	1	10381887	1	10304474	731	KIF1B	ENSG00000054523	ENST00000263934	ENSP00000263934	KIF1B_HUMAN	c.2192A>G	p.N731S	c.2192A>G	p.Asn731Ser	c.2192A>G	p.Asn731Ser	.	Y	1	YES	+	AAT	2	0	A	A/A	A/A	A/A	0.01	0.59928	D	0.008	0.69154	D	0.974	0.70673	D	0.969	0.72001	D	0.000007	0.62929	N	0.142496	0.999848;0.99995;0.99995	0.52396	D;D;D	simple_aae;simple_aae;simple_aae	N731S;N777S;N777S	NULL	0.81625	.	-1.25	0.79072	T	-4.12	0.75854	D	0.377	0.41853	-0.4905	0.68991	T	0.2037	0.56128	T	10	NULL	NULL	.	0.373	0.69509	.	NULL	.	.	.	0.85986107607	0.85850	1.09154679072	0.77449	0.731094121933	0.71666	T	NULL	0.95594	.	-0.451757	0.01103	T	-0.388113	0.34772	T	0.0493439212441444	0.05384	T	0.887111	0.61653	D	.	.	.	.	.	.	2.966708	0.51309	23.3	2.236375	0.37933	21.7	0.99455562274353237	0.65530	0.94524	0.61445	D	AEFBI	0.304397	0.41211	N	0.0547612606146839	0.44363	2.711658	-0.068092361401802	0.36717	2.140418	0.00249266329175324	0.09478	0.732398	0.92422	0	0.633656	0.55848	0	0.743671	0.96076	0	0.714379	0.83352	0	NULL	NULL	5.47	-1.04	0.09555	5.040000	0.63987	0.325000	0.29070	-0.042000	0.17409	1.000000	0.71638	0.995000	0.57719	0.985000	0.61073	0.6303:0.0:0.2568:0.1128	5.5904	0.16579	230	0.91032	39	0.007787539936102236	0	0.0	1	9.940357852882703E-4	0	0.0	38	0.037698412698412696	0	0.0	0	0.0	1	2.594706798131811E-4	1	1.322401481089659E-4	1	2.2696323195642307E-4	1	1.1627906976744187E-4	567	4.670e-03	567	4.679e-03	2	1.942e-04	2	1.730e-04	391	4.524e-02	72	1.089e-02	89	1.335e-03	4	2.423e-04	513	4.830e-03	513	4.839e-03	1	1.116e-04	2	1.786e-04	354	4.506e-02	72	1.089e-02	76	1.400e-03	4	2.439e-04	338	3.724e-03	338	3.732e-03	2	1.945e-04	2	1.732e-04	256	4.549e-02	38	9.995e-03	29	6.889e-04	4	2.425e-04	.	1214	251392	4.829112e-03	14	4	16256	2.460630e-04	0	4	34584	1.156604e-04	0	0	10074	0	0	800	18386	4.351137e-02	13	287	21648	1.325758e-02	1	79	113690	6.948720e-04	0	7	30616	2.286386e-04	0	800	18386	4.351137e-02	13	627	109400	5.731261e-03	7	1	7164	1.395868e-04	0	2	17110	1.168907e-04	0	0	2320	0	0	386	9040	4.269912e-02	6	179	13394	1.336419e-02	1	42	42768	9.820426e-04	0	6	15690	3.824092e-04	0	386	9040	4.269912e-02	6	.	324	143320	2.260675e-03	7	12	42054	2.853474e-04	0	2	13658	1.464343e-04	0	0	3320	0	0	135	3134	4.307594e-02	5	132	10480	1.259542e-02	2	31	64574	4.800694e-04	0	4	3046	1.313198e-03	0	240957	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10321829A>G	Illumina_Clinical_Services_Laboratory,Illumina:269987	C0031511|C2749484|C0270914	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10321829	A	G	N	S	rs117525287	1	10381887	1	10304474	751	KIF1B	ENSG00000054523	ENST00000622724	ENSP00000480063	A0A087WWA3_HUMAN	c.2252A>G	p.N751S	c.2252A>G	p.Asn751Ser	c.2252A>G	p.Asn751Ser	.	Y	1	.	+	AAT	2	0	A	A/A	A/A	A/A	NULL	0.59928	.	0.008	0.69154	D	NULL	0.70673	.	NULL	0.72001	.	0.000007	0.62929	N	0.142496	0.999848;0.99995;0.99995	0.52396	D;D;D	simple_aae;simple_aae;simple_aae	N731S;N777S;N777S	NULL	0.81625	.	NULL	0.79072	.	NULL	0.75854	.	0.303	0.41853	-0.4905	0.68991	T	0.2037	0.56128	T	10	NULL	NULL	.	0.373	0.69509	.	NULL	.	.	.	0.85986107607	0.85850	NULL	0.77449	0.731094121933	0.71666	T	NULL	0.95594	.	-0.451757	0.01103	T	-0.388113	0.34772	T	0.0493439212441444	0.05384	T	0.887111	0.61653	D	.	.	.	.	.	.	2.966708	0.51309	23.3	2.236375	0.37933	21.7	0.99455562274353237	0.65530	0.94524	0.61445	D	AEFBI	0.304397	0.41211	N	0.0547612606146839	0.44363	2.711658	-0.068092361401802	0.36717	2.140418	0.00249266329175324	0.09478	0.732398	0.92422	0	0.633656	0.55848	0	0.743671	0.96076	0	0.714379	0.83352	0	NULL	NULL	5.47	-1.04	0.09555	5.040000	0.63987	0.325000	0.29070	-0.042000	0.17409	1.000000	0.71638	0.995000	0.57719	0.985000	0.61073	0.6303:0.0:0.2568:0.1128	5.5904	0.16579	230	0.91032	39	0.007787539936102236	0	0.0	1	9.940357852882703E-4	0	0.0	38	0.037698412698412696	0	0.0	0	0.0	1	2.594706798131811E-4	1	1.322401481089659E-4	1	2.2696323195642307E-4	1	1.1627906976744187E-4	567	4.670e-03	567	4.679e-03	2	1.942e-04	2	1.730e-04	391	4.524e-02	72	1.089e-02	89	1.335e-03	4	2.423e-04	513	4.830e-03	513	4.839e-03	1	1.116e-04	2	1.786e-04	354	4.506e-02	72	1.089e-02	76	1.400e-03	4	2.439e-04	338	3.724e-03	338	3.732e-03	2	1.945e-04	2	1.732e-04	256	4.549e-02	38	9.995e-03	29	6.889e-04	4	2.425e-04	.	1214	251392	4.829112e-03	14	4	16256	2.460630e-04	0	4	34584	1.156604e-04	0	0	10074	0	0	800	18386	4.351137e-02	13	287	21648	1.325758e-02	1	79	113690	6.948720e-04	0	7	30616	2.286386e-04	0	800	18386	4.351137e-02	13	627	109400	5.731261e-03	7	1	7164	1.395868e-04	0	2	17110	1.168907e-04	0	0	2320	0	0	386	9040	4.269912e-02	6	179	13394	1.336419e-02	1	42	42768	9.820426e-04	0	6	15690	3.824092e-04	0	386	9040	4.269912e-02	6	.	324	143320	2.260675e-03	7	12	42054	2.853474e-04	0	2	13658	1.464343e-04	0	0	3320	0	0	135	3134	4.307594e-02	5	132	10480	1.259542e-02	2	31	64574	4.800694e-04	0	4	3046	1.313198e-03	0	240957	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10321829A>G	Illumina_Clinical_Services_Laboratory,Illumina:269987	C0031511|C2749484|C0270914	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10321829	A	G	N	S	rs117525287	1	10381887	1	10304474	763	KIF1B	ENSG00000054523	ENST00000620295	ENSP00000478500	Q4R9M9_HUMAN	c.2288A>G	p.N763S	c.2288A>G	p.Asn763Ser	c.2288A>G	p.Asn763Ser	.	Y	1	.	+	AAT	2	0	A	A/A	A/A	A/A	NULL	0.59928	.	0.007	0.69154	D	0.989	0.70673	D	0.887	0.72001	P	0.000007	0.62929	N	0.142496	0.999848;0.99995;0.99995	0.52396	D;D;D	simple_aae;simple_aae;simple_aae	N731S;N777S;N777S	NULL	0.81625	.	NULL	0.79072	.	NULL	0.75854	.	0.243	0.41853	-0.4905	0.68991	T	0.2037	0.56128	T	10	NULL	NULL	.	0.373	0.69509	.	NULL	.	.	.	0.85986107607	0.85850	NULL	0.77449	0.731094121933	0.71666	T	NULL	0.95594	.	-0.451757	0.01103	T	-0.388113	0.34772	T	0.0493439212441444	0.05384	T	0.887811	0.61653	D	.	.	.	.	.	.	2.966708	0.51309	23.3	2.236375	0.37933	21.7	0.99455562274353237	0.65530	0.94524	0.61445	D	AEFBI	0.304397	0.41211	N	0.0547612606146839	0.44363	2.711658	-0.068092361401802	0.36717	2.140418	0.00249266329175324	0.09478	0.732398	0.92422	0	0.633656	0.55848	0	0.743671	0.96076	0	0.714379	0.83352	0	NULL	NULL	5.47	-1.04	0.09555	5.040000	0.63987	0.325000	0.29070	-0.042000	0.17409	1.000000	0.71638	0.995000	0.57719	0.985000	0.61073	0.6303:0.0:0.2568:0.1128	5.5904	0.16579	230	0.91032	39	0.007787539936102236	0	0.0	1	9.940357852882703E-4	0	0.0	38	0.037698412698412696	0	0.0	0	0.0	1	2.594706798131811E-4	1	1.322401481089659E-4	1	2.2696323195642307E-4	1	1.1627906976744187E-4	567	4.670e-03	567	4.679e-03	2	1.942e-04	2	1.730e-04	391	4.524e-02	72	1.089e-02	89	1.335e-03	4	2.423e-04	513	4.830e-03	513	4.839e-03	1	1.116e-04	2	1.786e-04	354	4.506e-02	72	1.089e-02	76	1.400e-03	4	2.439e-04	338	3.724e-03	338	3.732e-03	2	1.945e-04	2	1.732e-04	256	4.549e-02	38	9.995e-03	29	6.889e-04	4	2.425e-04	.	1214	251392	4.829112e-03	14	4	16256	2.460630e-04	0	4	34584	1.156604e-04	0	0	10074	0	0	800	18386	4.351137e-02	13	287	21648	1.325758e-02	1	79	113690	6.948720e-04	0	7	30616	2.286386e-04	0	800	18386	4.351137e-02	13	627	109400	5.731261e-03	7	1	7164	1.395868e-04	0	2	17110	1.168907e-04	0	0	2320	0	0	386	9040	4.269912e-02	6	179	13394	1.336419e-02	1	42	42768	9.820426e-04	0	6	15690	3.824092e-04	0	386	9040	4.269912e-02	6	.	324	143320	2.260675e-03	7	12	42054	2.853474e-04	0	2	13658	1.464343e-04	0	0	3320	0	0	135	3134	4.307594e-02	5	132	10480	1.259542e-02	2	31	64574	4.800694e-04	0	4	3046	1.313198e-03	0	240957	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10321829A>G	Illumina_Clinical_Services_Laboratory,Illumina:269987	C0031511|C2749484|C0270914	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10321829	A	G	N	S	rs117525287	1	10381887	1	10304474	777	KIF1B	ENSG00000054523	ENST00000377081	ENSP00000366284	KIF1B_HUMAN	c.2330A>G	p.N777S	c.2330A>G	p.Asn777Ser	c.2330A>G	p.Asn777Ser	.	Y	1	.	+	AAT	2	0	A	A/A	A/A	A/A	0.007	0.59928	D	0.007	0.69154	D	NULL	0.70673	.	NULL	0.72001	.	0.000007	0.62929	N	0.142496	0.999848;0.99995;0.99995	0.52396	D;D;D	simple_aae;simple_aae;simple_aae	N731S;N777S;N777S	2.8	0.81625	M	-1.25	0.79072	T	-4.22	0.75854	D	0.269	0.41853	-0.4905	0.68991	T	0.2037	0.56128	T	10	NULL	NULL	.	0.373	0.69509	.	NULL	.	.	.	0.85986107607	0.85850	NULL	0.77449	0.731094121933	0.71666	T	NULL	0.95594	.	-0.451757	0.01103	T	-0.388113	0.34772	T	0.0493439212441444	0.05384	T	0.887811	0.61653	D	.	.	.	.	.	.	2.966708	0.51309	23.3	2.236375	0.37933	21.7	0.99455562274353237	0.65530	0.94524	0.61445	D	AEFBI	0.304397	0.41211	N	0.0547612606146839	0.44363	2.711658	-0.068092361401802	0.36717	2.140418	0.00249266329175324	0.09478	0.732398	0.92422	0	0.633656	0.55848	0	0.743671	0.96076	0	0.714379	0.83352	0	NULL	NULL	5.47	-1.04	0.09555	5.040000	0.63987	0.325000	0.29070	-0.042000	0.17409	1.000000	0.71638	0.995000	0.57719	0.985000	0.61073	0.6303:0.0:0.2568:0.1128	5.5904	0.16579	230	0.91032	39	0.007787539936102236	0	0.0	1	9.940357852882703E-4	0	0.0	38	0.037698412698412696	0	0.0	0	0.0	1	2.594706798131811E-4	1	1.322401481089659E-4	1	2.2696323195642307E-4	1	1.1627906976744187E-4	567	4.670e-03	567	4.679e-03	2	1.942e-04	2	1.730e-04	391	4.524e-02	72	1.089e-02	89	1.335e-03	4	2.423e-04	513	4.830e-03	513	4.839e-03	1	1.116e-04	2	1.786e-04	354	4.506e-02	72	1.089e-02	76	1.400e-03	4	2.439e-04	338	3.724e-03	338	3.732e-03	2	1.945e-04	2	1.732e-04	256	4.549e-02	38	9.995e-03	29	6.889e-04	4	2.425e-04	.	1214	251392	4.829112e-03	14	4	16256	2.460630e-04	0	4	34584	1.156604e-04	0	0	10074	0	0	800	18386	4.351137e-02	13	287	21648	1.325758e-02	1	79	113690	6.948720e-04	0	7	30616	2.286386e-04	0	800	18386	4.351137e-02	13	627	109400	5.731261e-03	7	1	7164	1.395868e-04	0	2	17110	1.168907e-04	0	0	2320	0	0	386	9040	4.269912e-02	6	179	13394	1.336419e-02	1	42	42768	9.820426e-04	0	6	15690	3.824092e-04	0	386	9040	4.269912e-02	6	.	324	143320	2.260675e-03	7	12	42054	2.853474e-04	0	2	13658	1.464343e-04	0	0	3320	0	0	135	3134	4.307594e-02	5	132	10480	1.259542e-02	2	31	64574	4.800694e-04	0	4	3046	1.313198e-03	0	240957	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10321829A>G	Illumina_Clinical_Services_Laboratory,Illumina:269987	C0031511|C2749484|C0270914	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10321829	A	G	N	S	rs117525287	1	10381887	1	10304474	777	KIF1B	ENSG00000054523	ENST00000377086	ENSP00000366290	KIF1B_HUMAN	c.2330A>G	p.N777S	c.2330A>G	p.Asn777Ser	c.2330A>G	p.Asn777Ser	principal1	Y	1	.	+	AAT	2	0	A	A/A	A/A	A/A	0.007	0.59928	D	0.007	0.69154	D	0.997	0.70673	D	0.937	0.72001	D	0.000007	0.62929	N	0.142496	0.999848;0.99995;0.99995	0.52396	D;D;D	simple_aae;simple_aae;simple_aae	N731S;N777S;N777S	2.8	0.81625	M	-1.25	0.79072	T	-4.22	0.75854	D	0.276	0.41853	-0.4905	0.68991	T	0.2037	0.56128	T	10	NULL	NULL	.	0.373	0.69509	.	NULL	.	.	.	0.85986107607	0.85850	NULL	0.77449	0.731094121933	0.71666	T	0.82017	0.95594	D	-0.451757	0.01103	T	-0.388113	0.34772	T	0.0493439212441444	0.05384	T	0.887811	0.61653	D	.	.	.	.	.	.	2.966708	0.51309	23.3	2.236375	0.37933	21.7	0.99455562274353237	0.65530	0.94524	0.61445	D	AEFBI	0.304397	0.41211	N	0.0547612606146839	0.44363	2.711658	-0.068092361401802	0.36717	2.140418	0.00249266329175324	0.09478	0.732398	0.92422	0	0.633656	0.55848	0	0.743671	0.96076	0	0.714379	0.83352	0	NULL	NULL	5.47	-1.04	0.09555	5.040000	0.63987	0.325000	0.29070	-0.042000	0.17409	1.000000	0.71638	0.995000	0.57719	0.985000	0.61073	0.6303:0.0:0.2568:0.1128	5.5904	0.16579	230	0.91032	39	0.007787539936102236	0	0.0	1	9.940357852882703E-4	0	0.0	38	0.037698412698412696	0	0.0	0	0.0	1	2.594706798131811E-4	1	1.322401481089659E-4	1	2.2696323195642307E-4	1	1.1627906976744187E-4	567	4.670e-03	567	4.679e-03	2	1.942e-04	2	1.730e-04	391	4.524e-02	72	1.089e-02	89	1.335e-03	4	2.423e-04	513	4.830e-03	513	4.839e-03	1	1.116e-04	2	1.786e-04	354	4.506e-02	72	1.089e-02	76	1.400e-03	4	2.439e-04	338	3.724e-03	338	3.732e-03	2	1.945e-04	2	1.732e-04	256	4.549e-02	38	9.995e-03	29	6.889e-04	4	2.425e-04	.	1214	251392	4.829112e-03	14	4	16256	2.460630e-04	0	4	34584	1.156604e-04	0	0	10074	0	0	800	18386	4.351137e-02	13	287	21648	1.325758e-02	1	79	113690	6.948720e-04	0	7	30616	2.286386e-04	0	800	18386	4.351137e-02	13	627	109400	5.731261e-03	7	1	7164	1.395868e-04	0	2	17110	1.168907e-04	0	0	2320	0	0	386	9040	4.269912e-02	6	179	13394	1.336419e-02	1	42	42768	9.820426e-04	0	6	15690	3.824092e-04	0	386	9040	4.269912e-02	6	.	324	143320	2.260675e-03	7	12	42054	2.853474e-04	0	2	13658	1.464343e-04	0	0	3320	0	0	135	3134	4.307594e-02	5	132	10480	1.259542e-02	2	31	64574	4.800694e-04	0	4	3046	1.313198e-03	0	240957	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10321829A>G	Illumina_Clinical_Services_Laboratory,Illumina:269987	C0031511|C2749484|C0270914	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10324813	A	C	S	R	rs140015591	1	10384871	1	10307458	819	KIF1B	ENSG00000054523	ENST00000263934	ENSP00000263934	KIF1B_HUMAN	c.2455A>C	p.S819R	c.2455A>C	p.Ser819Arg	c.2455A>C	p.Ser819Arg	.	Y	1	YES	+	AGT	1	0	A	A/A	A/A	A/A	0.07	0.36113	T	0.231	0.26066	T	0.018	0.39346	B	0.005	0.33763	B	0.113296	0.19321	N	0.594135	1;1;1	0.08975	N;N;N	simple_aae;simple_aae;simple_aae	S819R;S865R;S865R	NULL	0.30952	.	-1.04	0.76561	T	-2.19	0.52451	N	0.388	0.42931	-0.5797	0.65629	T	0.3472	0.71186	T	10	0.055254	0.66166	D	0.203	0.49351	.	NULL	.	.	.	0.358461578395	0.35455	0.480496331412	0.47068	0.340876281261	0.16569	T	NULL	0.57142	.	-0.433936	0.01404	T	-0.41511	0.31636	T	0.0315681055838614	0.02238	T	0.937606	0.76517	D	.	.	.	.	.	.	0.627177	0.10566	7.774	0.411931	0.09728	8.526	0.97799280949174983	0.36052	0.14046	0.18193	N	AEFDBI	0.126548	0.24354	N	-1.11769318026756	0.06328	0.291007	-1.19571223126447	0.05981	0.2865523	0.00432771497233626	0.10502	0.732398	0.92422	0	0.601575	0.49859	0	0.743671	0.96076	0	0.683762	0.67416	0	NULL	NULL	5.69	-2.96	0.05212	0.211000	0.17268	-0.891000	0.02836	-0.566000	0.04804	0.000000	0.06391	0.598000	0.28902	0.475000	0.28453	0.3743:0.1118:0.5139:0.0	10.3929	0.43367	230	0.91032	1	1.9968051118210862E-4	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0010224948875255625	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	3	3.488372093023256E-4	56	4.612e-04	56	4.613e-04	0	0	1	8.637e-05	0	0	0	0	22	3.296e-04	33	1.999e-03	51	4.802e-04	51	4.802e-04	0	0	1	8.916e-05	0	0	0	0	17	3.128e-04	33	2.011e-03	54	5.950e-04	54	5.951e-04	0	0	1	8.646e-05	0	0	0	0	20	4.746e-04	33	2.000e-03	.	92	251470	3.658488e-04	2	0	16256	0	0	0	34592	0	0	1	10080	9.920635e-05	0	0	18384	0	0	0	21648	0	0	37	113754	3.252633e-04	0	51	30616	1.665796e-03	2	51	30616	1.665796e-03	2	46	109402	4.204676e-04	1	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9040	0	0	0	13394	0	0	15	42768	3.507295e-04	0	29	15690	1.848311e-03	1	29	15690	1.848311e-03	1	.	18	143310	1.256018e-04	0	0	42056	0	0	1	13656	7.322789e-05	0	0	3322	0	0	0	3128	0	0	0	10474	0	0	14	64578	2.167921e-04	0	3	3044	9.855453e-04	0	215880	Conflicting_interpretations_of_pathogenicity	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_conflicting_interpretations	NC_000001.11:g.10324813A>C	Illumina_Clinical_Services_Laboratory,Illumina:800131	C0031511|C2749484|C0270914	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10324813	A	C	S	R	rs140015591	1	10384871	1	10307458	839	KIF1B	ENSG00000054523	ENST00000622724	ENSP00000480063	A0A087WWA3_HUMAN	c.2515A>C	p.S839R	c.2515A>C	p.Ser839Arg	c.2515A>C	p.Ser839Arg	.	Y	1	.	+	AGT	1	0	A	A/A	A/A	A/A	NULL	0.36113	.	0.221	0.26066	T	NULL	0.39346	.	NULL	0.33763	.	0.113296	0.19321	N	0.594135	1;1;1	0.08975	N;N;N	simple_aae;simple_aae;simple_aae	S819R;S865R;S865R	NULL	0.30952	.	NULL	0.76561	.	NULL	0.52451	.	0.338	0.42931	-0.5797	0.65629	T	0.3472	0.71186	T	10	0.055254	0.66166	D	0.203	0.49351	.	NULL	.	.	.	0.358461578395	0.35455	NULL	0.47068	0.340876281261	0.16569	T	NULL	0.57142	.	-0.433936	0.01404	T	-0.41511	0.31636	T	0.0315681055838614	0.02238	T	0.937606	0.76517	D	.	.	.	.	.	.	0.627177	0.10566	7.774	0.411931	0.09728	8.526	0.97799280949174983	0.36052	0.14046	0.18193	N	AEFDBI	0.126548	0.24354	N	-1.11769318026756	0.06328	0.291007	-1.19571223126447	0.05981	0.2865523	0.00432771497233626	0.10502	0.732398	0.92422	0	0.601575	0.49859	0	0.743671	0.96076	0	0.683762	0.67416	0	NULL	NULL	5.69	-2.96	0.05212	0.211000	0.17268	-0.891000	0.02836	-0.566000	0.04804	0.000000	0.06391	0.598000	0.28902	0.475000	0.28453	0.3743:0.1118:0.5139:0.0	10.3929	0.43367	230	0.91032	1	1.9968051118210862E-4	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0010224948875255625	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	3	3.488372093023256E-4	56	4.612e-04	56	4.613e-04	0	0	1	8.637e-05	0	0	0	0	22	3.296e-04	33	1.999e-03	51	4.802e-04	51	4.802e-04	0	0	1	8.916e-05	0	0	0	0	17	3.128e-04	33	2.011e-03	54	5.950e-04	54	5.951e-04	0	0	1	8.646e-05	0	0	0	0	20	4.746e-04	33	2.000e-03	.	92	251470	3.658488e-04	2	0	16256	0	0	0	34592	0	0	1	10080	9.920635e-05	0	0	18384	0	0	0	21648	0	0	37	113754	3.252633e-04	0	51	30616	1.665796e-03	2	51	30616	1.665796e-03	2	46	109402	4.204676e-04	1	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9040	0	0	0	13394	0	0	15	42768	3.507295e-04	0	29	15690	1.848311e-03	1	29	15690	1.848311e-03	1	.	18	143310	1.256018e-04	0	0	42056	0	0	1	13656	7.322789e-05	0	0	3322	0	0	0	3128	0	0	0	10474	0	0	14	64578	2.167921e-04	0	3	3044	9.855453e-04	0	215880	Conflicting_interpretations_of_pathogenicity	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_conflicting_interpretations	NC_000001.11:g.10324813A>C	Illumina_Clinical_Services_Laboratory,Illumina:800131	C0031511|C2749484|C0270914	171300|256700	ORPHA635|ORPHA64746	Kinesin-like KIF1-type	.	. 	.
1	10324813	A	C	S	R	rs140015591	1	10384871	1	10307458	851	KIF1B	ENSG00000054523	ENST00000620295	ENSP00000478500	Q4R9M9_HUMAN	c.2551A>C	p.S851R	c.2551A>C	p.Ser851Arg	c.2551A>C	p.Ser851Arg	.	Y	1	.	+	AGT	1	0	A	A/A	A/A	A/A	NULL	0.36113	.	0.218	0.26066	T	0.254	0.39346	B	0.143	0.33763	B	0.113296	0.19321	N	0.594135	1;1;1	0.08975	N;N;N	simple_aae;simple_aae;simple_aae	S819R;S865R;S865R	NULL	0.30952	.	NULL	0.76561	.	NULL	0.52451	.	0.323	0.42931	-0.5797	0.65629	T	0.3472	0.71186	T	10	0.055254	0.66166	D	0.203	0.49351	.	NULL	.	.	.	0.358461578395	0.35455	NULL	0.47068	0.340876281261	0.16569	T	NULL	0.57142	.	-0.433936	0.01404	T	-0.41511	0.31636	T	0.0315681055838614	0.02238	T	0.937106	0.76517	D	.	.	.	.	.	.	0.627177	0.10566	7.774	0.411931	0.09728	8.526	0.97799280949174983	0.36052	0.14046	0.18193	N	AEFDBI	0.126548	0.24354	N	-1.11769318026756	0.06328	0.291007	-1.19571223126447	0.05981	0.2865523	0.00432771497233626	0.10502	0.732398	0.92422	0	0.601575	0.49859	0	0.743671	0.96076	0	0.683762	0.67416	0	NULL	NULL	5.69	-2.96	0.05212	0.211000	0.17268	-0.891000	0.02836	-0.566000	0.04804	0.000000	0.06391	0.598000	0.28902	0.475000	0.28453	0.3743:0.1118:0.5139:0.0	10.3929	0.43367	230	0.91032	1	1.9968051118210862E-4	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0010224948875255625	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	3	3.488372093023256E-4	56	4.612e-04	56	4.613e-04	0	0	1	8.637e-05	0	0	0	0	22	3.296e-04	33	1.999e-03	51	4.802e-04	51	4.802e-04	0	0	1	8.916e-05	0	0	0	0	17	3.128e-04	33	2.011e-03	54	5.950e-04	54	5.951e-04	0	0	1	8.646e-05	0	0	0	0	20	4.746e-04	33	2.000e-03	.	92	251470	3.658488e-04	2	0	16256	0	0	0	34592	0	0	1	10080	9.920635e-05	0	0	18384	0	0	0	21648	0	0	37	113754	3.252633e-04	0	51	30616	1.665796e-03	2	51	30616	1.665796e-03	2	46	109402	4.204676e-04	1	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9040	0	0	0	13394	0	0	15	42768	3.507295e-04	0	29	15690	1.848311e-03	1	29	15690	1.848311e-03	1	.	18	143310	1.256018e-04	0	0	42056	0	0	1	13656	7.322789e-05	0	0	3322	0	0	0	3128	0	0	0	10474	0	0	14	64578	2.167921e-04	0	3	3044	9.855453e-04	0	215880	Conflicting_interpretations_of_pathogenicity	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_conflicting_interpretations	NC_000001.11:g.10324813A>C	Illumina_Clinical_Services_Laboratory,Illumina:800131	C0031511|C2749484|C0270914	171300|256700	ORPHA635|ORPHA64746	Kinesin-like KIF1-type	.	. 	.
1	10324813	A	C	S	R	rs140015591	1	10384871	1	10307458	865	KIF1B	ENSG00000054523	ENST00000377081	ENSP00000366284	KIF1B_HUMAN	c.2593A>C	p.S865R	c.2593A>C	p.Ser865Arg	c.2593A>C	p.Ser865Arg	.	Y	1	.	+	AGT	1	0	A	A/A	A/A	A/A	0.097	0.36113	T	0.225	0.26066	T	NULL	0.39346	.	NULL	0.33763	.	0.113296	0.19321	N	0.594135	1;1;1	0.08975	N;N;N	simple_aae;simple_aae;simple_aae	S819R;S865R;S865R	1.24	0.30952	L	-1.04	0.76561	T	-2.38	0.52451	N	0.357	0.42931	-0.5797	0.65629	T	0.3472	0.71186	T	10	0.055254	0.66166	D	0.203	0.49351	.	NULL	.	.	.	0.358461578395	0.35455	NULL	0.47068	0.340876281261	0.16569	T	NULL	0.57142	.	-0.433936	0.01404	T	-0.41511	0.31636	T	0.0315681055838614	0.02238	T	0.937106	0.76517	D	.	.	.	.	.	.	0.627177	0.10566	7.774	0.411931	0.09728	8.526	0.97799280949174983	0.36052	0.14046	0.18193	N	AEFDBI	0.126548	0.24354	N	-1.11769318026756	0.06328	0.291007	-1.19571223126447	0.05981	0.2865523	0.00432771497233626	0.10502	0.732398	0.92422	0	0.601575	0.49859	0	0.743671	0.96076	0	0.683762	0.67416	0	NULL	NULL	5.69	-2.96	0.05212	0.211000	0.17268	-0.891000	0.02836	-0.566000	0.04804	0.000000	0.06391	0.598000	0.28902	0.475000	0.28453	0.3743:0.1118:0.5139:0.0	10.3929	0.43367	230	0.91032	1	1.9968051118210862E-4	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0010224948875255625	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	3	3.488372093023256E-4	56	4.612e-04	56	4.613e-04	0	0	1	8.637e-05	0	0	0	0	22	3.296e-04	33	1.999e-03	51	4.802e-04	51	4.802e-04	0	0	1	8.916e-05	0	0	0	0	17	3.128e-04	33	2.011e-03	54	5.950e-04	54	5.951e-04	0	0	1	8.646e-05	0	0	0	0	20	4.746e-04	33	2.000e-03	.	92	251470	3.658488e-04	2	0	16256	0	0	0	34592	0	0	1	10080	9.920635e-05	0	0	18384	0	0	0	21648	0	0	37	113754	3.252633e-04	0	51	30616	1.665796e-03	2	51	30616	1.665796e-03	2	46	109402	4.204676e-04	1	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9040	0	0	0	13394	0	0	15	42768	3.507295e-04	0	29	15690	1.848311e-03	1	29	15690	1.848311e-03	1	.	18	143310	1.256018e-04	0	0	42056	0	0	1	13656	7.322789e-05	0	0	3322	0	0	0	3128	0	0	0	10474	0	0	14	64578	2.167921e-04	0	3	3044	9.855453e-04	0	215880	Conflicting_interpretations_of_pathogenicity	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_conflicting_interpretations	NC_000001.11:g.10324813A>C	Illumina_Clinical_Services_Laboratory,Illumina:800131	C0031511|C2749484|C0270914	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10324813	A	C	S	R	rs140015591	1	10384871	1	10307458	865	KIF1B	ENSG00000054523	ENST00000377086	ENSP00000366290	KIF1B_HUMAN	c.2593A>C	p.S865R	c.2593A>C	p.Ser865Arg	c.2593A>C	p.Ser865Arg	principal1	Y	1	.	+	AGT	1	0	A	A/A	A/A	A/A	0.066	0.36113	T	0.23	0.26066	T	0.601	0.39346	P	0.116	0.33763	B	0.113296	0.19321	N	0.594135	1;1;1	0.08975	N;N;N	simple_aae;simple_aae;simple_aae	S819R;S865R;S865R	1.24	0.30952	L	-1.04	0.76561	T	-2.38	0.52451	N	0.321	0.42931	-0.5797	0.65629	T	0.3472	0.71186	T	10	0.055254	0.66166	D	0.203	0.49351	.	NULL	.	.	.	0.358461578395	0.35455	NULL	0.47068	0.340876281261	0.16569	T	0.21082	0.57142	T	-0.433936	0.01404	T	-0.41511	0.31636	T	0.0315681055838614	0.02238	T	0.937106	0.76517	D	.	.	.	.	.	.	0.627177	0.10566	7.774	0.411931	0.09728	8.526	0.97799280949174983	0.36052	0.14046	0.18193	N	AEFDBI	0.126548	0.24354	N	-1.11769318026756	0.06328	0.291007	-1.19571223126447	0.05981	0.2865523	0.00432771497233626	0.10502	0.732398	0.92422	0	0.601575	0.49859	0	0.743671	0.96076	0	0.683762	0.67416	0	NULL	NULL	5.69	-2.96	0.05212	0.211000	0.17268	-0.891000	0.02836	-0.566000	0.04804	0.000000	0.06391	0.598000	0.28902	0.475000	0.28453	0.3743:0.1118:0.5139:0.0	10.3929	0.43367	230	0.91032	1	1.9968051118210862E-4	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0010224948875255625	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	3	3.488372093023256E-4	56	4.612e-04	56	4.613e-04	0	0	1	8.637e-05	0	0	0	0	22	3.296e-04	33	1.999e-03	51	4.802e-04	51	4.802e-04	0	0	1	8.916e-05	0	0	0	0	17	3.128e-04	33	2.011e-03	54	5.950e-04	54	5.951e-04	0	0	1	8.646e-05	0	0	0	0	20	4.746e-04	33	2.000e-03	.	92	251470	3.658488e-04	2	0	16256	0	0	0	34592	0	0	1	10080	9.920635e-05	0	0	18384	0	0	0	21648	0	0	37	113754	3.252633e-04	0	51	30616	1.665796e-03	2	51	30616	1.665796e-03	2	46	109402	4.204676e-04	1	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9040	0	0	0	13394	0	0	15	42768	3.507295e-04	0	29	15690	1.848311e-03	1	29	15690	1.848311e-03	1	.	18	143310	1.256018e-04	0	0	42056	0	0	1	13656	7.322789e-05	0	0	3322	0	0	0	3128	0	0	0	10474	0	0	14	64578	2.167921e-04	0	3	3044	9.855453e-04	0	215880	Conflicting_interpretations_of_pathogenicity	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_conflicting_interpretations	NC_000001.11:g.10324813A>C	Illumina_Clinical_Services_Laboratory,Illumina:800131	C0031511|C2749484|C0270914	171300|256700	ORPHA635|ORPHA64746	Kinesin-like KIF1-type	.	. 	.
1	10343234	C	T	P	L	rs141224290	1	10403292	1	10325879	1166	KIF1B	ENSG00000054523	ENST00000263934	ENSP00000263934	KIF1B_HUMAN	c.3497C>T	p.P1166L	c.3497C>T	p.Pro1166Leu	c.3497C>T	p.Pro1166Leu	.	Y	1	YES	+	CCG	2	0	C	C/C	C/C	C/C	0.069	0.35918	T	0.269	0.22426	T	1.0	0.90584	D	0.995	0.83170	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	P1166L;P1212L;P1212L	NULL	0.43825	.	-1.3	0.79571	T	-4.98	0.87760	D	0.426	0.50778	-0.1404	0.79155	T	0.4841	0.80321	T	10	0.09098	0.75620	D	0.536	0.80772	.	NULL	.	.	.	0.620872450057	0.61779	1.26958207487	0.82244	0.649640023708	0.59934	T	NULL	0.90003	.	-0.136421	0.30462	T	0.037662	0.72775	D	0.0365719992597702	0.03081	T	0.954405	0.82627	D	.	.	.	.	.	.	2.888664	0.49630	23.2	3.377437	0.63973	24.6	0.99655850051133754	0.77631	0.98610	0.84669	D	AEFBI	0.653570	0.62655	D	0.175251581388208	0.50013	3.195526	0.237418716985339	0.51937	3.372081	0.999999998696797	0.74766	0.706548	0.73137	0	0.601575	0.49859	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	4.78	4.78	0.60666	5.710000	0.68045	1.026000	0.45946	0.597000	0.34315	1.000000	0.71638	0.967000	0.44423	0.180000	0.21296	0.0:1.0:0.0:0.0	18.214	0.89815	226	0.91233	6	0.0011980830670926517	6	0.0045385779122541605	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	21	0.004766227871084884	0	0.0	96	7.907e-04	96	7.945e-04	84	8.118e-03	0	0	0	0	0	0	11	1.654e-04	1	6.101e-05	83	7.815e-04	83	7.852e-04	72	7.980e-03	0	0	0	0	0	0	10	1.847e-04	1	6.139e-05	95	1.047e-03	95	1.053e-03	84	8.132e-03	0	0	0	0	0	0	10	2.383e-04	1	6.104e-05	.	163	251332	6.485446e-04	0	135	16252	8.306670e-03	0	8	34584	2.313208e-04	0	0	10078	0	0	0	18380	0	0	0	21636	0	0	12	113658	1.055799e-04	0	2	30612	6.533386e-05	0	135	16252	8.306670e-03	0	63	109382	5.759631e-04	0	55	7162	7.679419e-03	0	5	17108	2.922609e-04	0	0	2320	0	0	0	9038	0	0	0	13392	0	0	1	42760	2.338634e-05	0	1	15688	6.374299e-05	0	55	7162	7.679419e-03	0	.	439	143204	3.065557e-03	4	399	41992	9.501810e-03	4	25	13640	1.832845e-03	0	1	3320	3.012048e-04	0	0	3130	0	0	0	10464	0	0	5	64564	7.744254e-05	0	5	64564	7.744254e-05	0	215882	Benign	Hereditary_cancer-predisposing_syndrome|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10343234C>T	.	C0027672|C0270914	.	ORPHA140162|ORPHA64746	.	.	. 	.
1	10343234	C	T	P	L	rs141224290	1	10403292	1	10325879	1186	KIF1B	ENSG00000054523	ENST00000622724	ENSP00000480063	A0A087WWA3_HUMAN	c.3557C>T	p.P1186L	c.3557C>T	p.Pro1186Leu	c.3557C>T	p.Pro1186Leu	.	Y	1	.	+	CCG	2	0	C	C/C	C/C	C/C	NULL	0.35918	.	0.285	0.22426	T	NULL	0.90584	.	NULL	0.83170	.	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	P1166L;P1212L;P1212L	NULL	0.43825	.	NULL	0.79571	.	NULL	0.87760	.	0.325	0.50778	-0.1404	0.79155	T	0.4841	0.80321	T	10	0.09098	0.75620	D	0.536	0.80772	.	NULL	.	.	.	0.620872450057	0.61779	NULL	0.82244	0.649640023708	0.59934	T	NULL	0.90003	.	-0.136421	0.30462	T	0.037662	0.72775	D	0.0365719992597702	0.03081	T	0.954405	0.82627	D	.	.	.	.	.	.	2.888664	0.49630	23.2	3.377437	0.63973	24.6	0.99655850051133754	0.77631	0.98610	0.84669	D	AEFBI	0.653570	0.62655	D	0.175251581388208	0.50013	3.195526	0.237418716985339	0.51937	3.372081	0.999999998696797	0.74766	0.706548	0.73137	0	0.601575	0.49859	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	4.78	4.78	0.60666	5.710000	0.68045	1.026000	0.45946	0.597000	0.34315	1.000000	0.71638	0.967000	0.44423	0.180000	0.21296	0.0:1.0:0.0:0.0	18.214	0.89815	226	0.91233	6	0.0011980830670926517	6	0.0045385779122541605	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	21	0.004766227871084884	0	0.0	96	7.907e-04	96	7.945e-04	84	8.118e-03	0	0	0	0	0	0	11	1.654e-04	1	6.101e-05	83	7.815e-04	83	7.852e-04	72	7.980e-03	0	0	0	0	0	0	10	1.847e-04	1	6.139e-05	95	1.047e-03	95	1.053e-03	84	8.132e-03	0	0	0	0	0	0	10	2.383e-04	1	6.104e-05	.	163	251332	6.485446e-04	0	135	16252	8.306670e-03	0	8	34584	2.313208e-04	0	0	10078	0	0	0	18380	0	0	0	21636	0	0	12	113658	1.055799e-04	0	2	30612	6.533386e-05	0	135	16252	8.306670e-03	0	63	109382	5.759631e-04	0	55	7162	7.679419e-03	0	5	17108	2.922609e-04	0	0	2320	0	0	0	9038	0	0	0	13392	0	0	1	42760	2.338634e-05	0	1	15688	6.374299e-05	0	55	7162	7.679419e-03	0	.	439	143204	3.065557e-03	4	399	41992	9.501810e-03	4	25	13640	1.832845e-03	0	1	3320	3.012048e-04	0	0	3130	0	0	0	10464	0	0	5	64564	7.744254e-05	0	5	64564	7.744254e-05	0	215882	Benign	Hereditary_cancer-predisposing_syndrome|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10343234C>T	.	C0027672|C0270914	.	ORPHA140162|ORPHA64746	.	.	. 	.
1	10343234	C	T	P	L	rs141224290	1	10403292	1	10325879	1198	KIF1B	ENSG00000054523	ENST00000620295	ENSP00000478500	Q4R9M9_HUMAN	c.3593C>T	p.P1198L	c.3593C>T	p.Pro1198Leu	c.3593C>T	p.Pro1198Leu	.	Y	1	.	+	CCG	2	0	C	C/C	C/C	C/C	NULL	0.35918	.	0.29	0.22426	T	0.107	0.90584	B	0.021	0.83170	B	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	P1166L;P1212L;P1212L	NULL	0.43825	.	NULL	0.79571	.	NULL	0.87760	.	0.453	0.50778	-0.1404	0.79155	T	0.4841	0.80321	T	10	0.09098	0.75620	D	0.536	0.80772	.	NULL	.	.	.	0.620872450057	0.61779	NULL	0.82244	0.649640023708	0.59934	T	NULL	0.90003	.	-0.136421	0.30462	T	0.037662	0.72775	D	0.0365719992597702	0.03081	T	0.954405	0.82627	D	.	.	.	.	.	.	2.888664	0.49630	23.2	3.377437	0.63973	24.6	0.99655850051133754	0.77631	0.98610	0.84669	D	AEFBI	0.653570	0.62655	D	0.175251581388208	0.50013	3.195526	0.237418716985339	0.51937	3.372081	0.999999998696797	0.74766	0.706548	0.73137	0	0.601575	0.49859	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	4.78	4.78	0.60666	5.710000	0.68045	1.026000	0.45946	0.597000	0.34315	1.000000	0.71638	0.967000	0.44423	0.180000	0.21296	0.0:1.0:0.0:0.0	18.214	0.89815	226	0.91233	6	0.0011980830670926517	6	0.0045385779122541605	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	21	0.004766227871084884	0	0.0	96	7.907e-04	96	7.945e-04	84	8.118e-03	0	0	0	0	0	0	11	1.654e-04	1	6.101e-05	83	7.815e-04	83	7.852e-04	72	7.980e-03	0	0	0	0	0	0	10	1.847e-04	1	6.139e-05	95	1.047e-03	95	1.053e-03	84	8.132e-03	0	0	0	0	0	0	10	2.383e-04	1	6.104e-05	.	163	251332	6.485446e-04	0	135	16252	8.306670e-03	0	8	34584	2.313208e-04	0	0	10078	0	0	0	18380	0	0	0	21636	0	0	12	113658	1.055799e-04	0	2	30612	6.533386e-05	0	135	16252	8.306670e-03	0	63	109382	5.759631e-04	0	55	7162	7.679419e-03	0	5	17108	2.922609e-04	0	0	2320	0	0	0	9038	0	0	0	13392	0	0	1	42760	2.338634e-05	0	1	15688	6.374299e-05	0	55	7162	7.679419e-03	0	.	439	143204	3.065557e-03	4	399	41992	9.501810e-03	4	25	13640	1.832845e-03	0	1	3320	3.012048e-04	0	0	3130	0	0	0	10464	0	0	5	64564	7.744254e-05	0	5	64564	7.744254e-05	0	215882	Benign	Hereditary_cancer-predisposing_syndrome|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10343234C>T	.	C0027672|C0270914	.	ORPHA140162|ORPHA64746	.	.	. 	.
1	10343234	C	T	P	L	rs141224290	1	10403292	1	10325879	1212	KIF1B	ENSG00000054523	ENST00000377081	ENSP00000366284	KIF1B_HUMAN	c.3635C>T	p.P1212L	c.3635C>T	p.Pro1212Leu	c.3635C>T	p.Pro1212Leu	.	Y	1	.	+	CCG	2	0	C	C/C	C/C	C/C	0.069	0.35918	T	0.297	0.22426	T	NULL	0.90584	.	NULL	0.83170	.	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	P1166L;P1212L;P1212L	1.7	0.43825	L	-1.3	0.79571	T	-5.75	0.87760	D	0.469	0.50778	-0.1404	0.79155	T	0.4841	0.80321	T	10	0.09098	0.75620	D	0.536	0.80772	.	NULL	.	.	.	0.620872450057	0.61779	NULL	0.82244	0.649640023708	0.59934	T	NULL	0.90003	.	-0.136421	0.30462	T	0.037662	0.72775	D	0.0365719992597702	0.03081	T	0.954405	0.82627	D	.	.	.	.	.	.	2.888664	0.49630	23.2	3.377437	0.63973	24.6	0.99655850051133754	0.77631	0.98610	0.84669	D	AEFBI	0.653570	0.62655	D	0.175251581388208	0.50013	3.195526	0.237418716985339	0.51937	3.372081	0.999999998696797	0.74766	0.706548	0.73137	0	0.601575	0.49859	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	4.78	4.78	0.60666	5.710000	0.68045	1.026000	0.45946	0.597000	0.34315	1.000000	0.71638	0.967000	0.44423	0.180000	0.21296	0.0:1.0:0.0:0.0	18.214	0.89815	226	0.91233	6	0.0011980830670926517	6	0.0045385779122541605	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	21	0.004766227871084884	0	0.0	96	7.907e-04	96	7.945e-04	84	8.118e-03	0	0	0	0	0	0	11	1.654e-04	1	6.101e-05	83	7.815e-04	83	7.852e-04	72	7.980e-03	0	0	0	0	0	0	10	1.847e-04	1	6.139e-05	95	1.047e-03	95	1.053e-03	84	8.132e-03	0	0	0	0	0	0	10	2.383e-04	1	6.104e-05	.	163	251332	6.485446e-04	0	135	16252	8.306670e-03	0	8	34584	2.313208e-04	0	0	10078	0	0	0	18380	0	0	0	21636	0	0	12	113658	1.055799e-04	0	2	30612	6.533386e-05	0	135	16252	8.306670e-03	0	63	109382	5.759631e-04	0	55	7162	7.679419e-03	0	5	17108	2.922609e-04	0	0	2320	0	0	0	9038	0	0	0	13392	0	0	1	42760	2.338634e-05	0	1	15688	6.374299e-05	0	55	7162	7.679419e-03	0	.	439	143204	3.065557e-03	4	399	41992	9.501810e-03	4	25	13640	1.832845e-03	0	1	3320	3.012048e-04	0	0	3130	0	0	0	10464	0	0	5	64564	7.744254e-05	0	5	64564	7.744254e-05	0	215882	Benign	Hereditary_cancer-predisposing_syndrome|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10343234C>T	.	C0027672|C0270914	.	ORPHA140162|ORPHA64746	.	.	. 	.
1	10343234	C	T	P	L	rs141224290	1	10403292	1	10325879	1212	KIF1B	ENSG00000054523	ENST00000377086	ENSP00000366290	KIF1B_HUMAN	c.3635C>T	p.P1212L	c.3635C>T	p.Pro1212Leu	c.3635C>T	p.Pro1212Leu	principal1	Y	1	.	+	CCG	2	0	C	C/C	C/C	C/C	0.067	0.35918	T	0.299	0.22426	T	0.206	0.90584	B	0.009	0.83170	B	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	P1166L;P1212L;P1212L	1.7	0.43825	L	-1.3	0.79571	T	-5.75	0.87760	D	0.472	0.50778	-0.1404	0.79155	T	0.4841	0.80321	T	10	0.09098	0.75620	D	0.536	0.80772	.	NULL	.	.	.	0.620872450057	0.61779	NULL	0.82244	0.649640023708	0.59934	T	0.665276	0.90003	D	-0.136421	0.30462	T	0.037662	0.72775	D	0.0365719992597702	0.03081	T	0.954405	0.82627	D	.	.	.	.	.	.	2.888664	0.49630	23.2	3.377437	0.63973	24.6	0.99655850051133754	0.77631	0.98610	0.84669	D	AEFBI	0.653570	0.62655	D	0.175251581388208	0.50013	3.195526	0.237418716985339	0.51937	3.372081	0.999999998696797	0.74766	0.706548	0.73137	0	0.601575	0.49859	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	4.78	4.78	0.60666	5.710000	0.68045	1.026000	0.45946	0.597000	0.34315	1.000000	0.71638	0.967000	0.44423	0.180000	0.21296	0.0:1.0:0.0:0.0	18.214	0.89815	226	0.91233	6	0.0011980830670926517	6	0.0045385779122541605	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	21	0.004766227871084884	0	0.0	96	7.907e-04	96	7.945e-04	84	8.118e-03	0	0	0	0	0	0	11	1.654e-04	1	6.101e-05	83	7.815e-04	83	7.852e-04	72	7.980e-03	0	0	0	0	0	0	10	1.847e-04	1	6.139e-05	95	1.047e-03	95	1.053e-03	84	8.132e-03	0	0	0	0	0	0	10	2.383e-04	1	6.104e-05	.	163	251332	6.485446e-04	0	135	16252	8.306670e-03	0	8	34584	2.313208e-04	0	0	10078	0	0	0	18380	0	0	0	21636	0	0	12	113658	1.055799e-04	0	2	30612	6.533386e-05	0	135	16252	8.306670e-03	0	63	109382	5.759631e-04	0	55	7162	7.679419e-03	0	5	17108	2.922609e-04	0	0	2320	0	0	0	9038	0	0	0	13392	0	0	1	42760	2.338634e-05	0	1	15688	6.374299e-05	0	55	7162	7.679419e-03	0	.	439	143204	3.065557e-03	4	399	41992	9.501810e-03	4	25	13640	1.832845e-03	0	1	3320	3.012048e-04	0	0	3130	0	0	0	10464	0	0	5	64564	7.744254e-05	0	5	64564	7.744254e-05	0	215882	Benign	Hereditary_cancer-predisposing_syndrome|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10343234C>T	.	C0027672|C0270914	.	ORPHA140162|ORPHA64746	.	.	. 	.
1	10368512	G	A	V	M	rs77172218	1	10428570	1	10351157	1554	KIF1B	ENSG00000054523	ENST00000263934	ENSP00000263934	KIF1B_HUMAN	c.4660G>A	p.V1554M	c.4660G>A	p.Val1554Met	c.4660G>A	p.Val1554Met	.	Y	1	YES	+	GTG	1	0	G	G/G	G/G	G/G	0.076	0.34269	T	0.138	0.34359	T	0.005	0.12996	B	0.009	0.14300	B	0.000117	0.50451	D	0.137650	0.999435;0.999435;0.999435	0.47043	D;D;D	simple_aae;simple_aae;simple_aae	V1554M;V1600M;V1600M	NULL	0.55033	.	-0.6	0.72568	T	-0.59	0.19085	N	0.278	0.31478	-0.8270	0.53493	T	0.1474	0.47273	T	10	NULL	NULL	.	0.061	0.18007	.	NULL	.	.	.	NULL	NULL	0.426311001703	0.43007	0.593209862709	0.51947	T	NULL	0.70075	.	-0.440613	0.01283	T	-0.390091	0.34542	T	0.00535055751996542	0.00058	T	0.912409	0.69206	D	.	.	.	.	.	.	2.195298	0.34609	20.8	2.349485	0.40403	22.2	0.97560388223654537	0.34620	0.95503	0.64980	D	AEFDBI	0.472857	0.51779	N	-0.15844287863367	0.34877	1.996334	0.00546473550712644	0.39967	2.377935	0.999999164709875	0.74766	0.706548	0.73137	0	0.653731	0.59785	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.31	4.39	0.52211	3.399000	0.52333	1.176000	0.78918	0.674000	0.70861	1.000000	0.71638	0.989000	0.51752	0.858000	0.40661	0.0:0.1321:0.8679:0.0	16.3589	0.83079	226	0.91233	22	0.00439297124600639	0	0.0	16	0.015904572564612324	2	0.002881844380403458	0	0.0	4	0.00408997955010225	66	0.01779935275080906	58	0.015049299429164505	124	0.01639777836551177	8	0.0018157058556513845	145	0.01686046511627907	1231	1.014e-02	1231	1.014e-02	16	1.538e-03	24	2.073e-03	0	0	77	1.164e-02	1067	1.599e-02	39	2.362e-03	1008	9.491e-03	1008	9.491e-03	13	1.434e-03	24	2.140e-03	0	0	77	1.164e-02	849	1.562e-02	39	2.377e-03	765	8.430e-03	765	8.430e-03	16	1.540e-03	24	2.075e-03	0	0	47	1.236e-02	635	1.507e-02	39	2.363e-03	.	2500	251470	9.941544e-03	26	26	16256	1.599409e-03	0	104	34584	3.007171e-03	0	50	10080	4.960317e-03	0	0	18394	0	0	281	21636	1.298761e-02	3	1928	113766	1.694707e-02	22	59	30616	1.927097e-03	1	1928	113766	1.694707e-02	22	1017	109392	9.296841e-03	14	11	7164	1.535455e-03	0	51	17110	2.980713e-03	0	14	2320	6.034483e-03	0	0	9046	0	0	158	13382	1.180690e-02	3	732	42766	1.711640e-02	11	32	15690	2.039516e-03	0	732	42766	1.711640e-02	11	.	1546	143274	1.079051e-02	11	125	42014	2.975199e-03	0	95	13652	6.958687e-03	1	10	3320	3.012048e-03	0	0	3134	0	0	124	10474	1.183884e-02	0	1142	64580	1.768349e-02	10	9	3046	2.954695e-03	0	240959	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10368512G>A	Illumina_Clinical_Services_Laboratory,Illumina:79024	C0031511|C2749484|C0270914|CN169374	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10368512	G	A	V	M	rs77172218	1	10428570	1	10351157	1574	KIF1B	ENSG00000054523	ENST00000622724	ENSP00000480063	A0A087WWA3_HUMAN	c.4720G>A	p.V1574M	c.4720G>A	p.Val1574Met	c.4720G>A	p.Val1574Met	.	Y	1	.	+	GTG	1	0	G	G/G	G/G	G/G	NULL	0.34269	.	0.14	0.34359	T	NULL	0.12996	.	NULL	0.14300	.	0.000117	0.50451	D	0.137650	0.999435;0.999435;0.999435	0.47043	D;D;D	simple_aae;simple_aae;simple_aae	V1554M;V1600M;V1600M	NULL	0.55033	.	NULL	0.72568	.	NULL	0.19085	.	0.259	0.31478	-0.8270	0.53493	T	0.1474	0.47273	T	10	NULL	NULL	.	0.061	0.18007	.	NULL	.	.	.	NULL	NULL	NULL	0.43007	0.593209862709	0.51947	T	NULL	0.70075	.	-0.440613	0.01283	T	-0.390091	0.34542	T	0.00535055751996542	0.00058	T	0.913509	0.69206	D	.	.	.	.	.	.	2.195298	0.34609	20.8	2.349485	0.40403	22.2	0.97560388223654537	0.34620	0.95503	0.64980	D	AEFDBI	0.472857	0.51779	N	-0.15844287863367	0.34877	1.996334	0.00546473550712644	0.39967	2.377935	0.999999164709875	0.74766	0.706548	0.73137	0	0.653731	0.59785	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.31	4.39	0.52211	3.399000	0.52333	1.176000	0.78918	0.674000	0.70861	1.000000	0.71638	0.989000	0.51752	0.858000	0.40661	0.0:0.1321:0.8679:0.0	16.3589	0.83079	226	0.91233	22	0.00439297124600639	0	0.0	16	0.015904572564612324	2	0.002881844380403458	0	0.0	4	0.00408997955010225	66	0.01779935275080906	58	0.015049299429164505	124	0.01639777836551177	8	0.0018157058556513845	145	0.01686046511627907	1231	1.014e-02	1231	1.014e-02	16	1.538e-03	24	2.073e-03	0	0	77	1.164e-02	1067	1.599e-02	39	2.362e-03	1008	9.491e-03	1008	9.491e-03	13	1.434e-03	24	2.140e-03	0	0	77	1.164e-02	849	1.562e-02	39	2.377e-03	765	8.430e-03	765	8.430e-03	16	1.540e-03	24	2.075e-03	0	0	47	1.236e-02	635	1.507e-02	39	2.363e-03	.	2500	251470	9.941544e-03	26	26	16256	1.599409e-03	0	104	34584	3.007171e-03	0	50	10080	4.960317e-03	0	0	18394	0	0	281	21636	1.298761e-02	3	1928	113766	1.694707e-02	22	59	30616	1.927097e-03	1	1928	113766	1.694707e-02	22	1017	109392	9.296841e-03	14	11	7164	1.535455e-03	0	51	17110	2.980713e-03	0	14	2320	6.034483e-03	0	0	9046	0	0	158	13382	1.180690e-02	3	732	42766	1.711640e-02	11	32	15690	2.039516e-03	0	732	42766	1.711640e-02	11	.	1546	143274	1.079051e-02	11	125	42014	2.975199e-03	0	95	13652	6.958687e-03	1	10	3320	3.012048e-03	0	0	3134	0	0	124	10474	1.183884e-02	0	1142	64580	1.768349e-02	10	9	3046	2.954695e-03	0	240959	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10368512G>A	Illumina_Clinical_Services_Laboratory,Illumina:79024	C0031511|C2749484|C0270914|CN169374	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10368512	G	A	V	M	rs77172218	1	10428570	1	10351157	1586	KIF1B	ENSG00000054523	ENST00000620295	ENSP00000478500	Q4R9M9_HUMAN	c.4756G>A	p.V1586M	c.4756G>A	p.Val1586Met	c.4756G>A	p.Val1586Met	.	Y	1	.	+	GTG	1	0	G	G/G	G/G	G/G	NULL	0.34269	.	0.137	0.34359	T	0.005	0.12996	B	0.009	0.14300	B	0.000117	0.50451	D	0.137650	0.999435;0.999435;0.999435	0.47043	D;D;D	simple_aae;simple_aae;simple_aae	V1554M;V1600M;V1600M	NULL	0.55033	.	NULL	0.72568	.	NULL	0.19085	.	0.262	0.31478	-0.8270	0.53493	T	0.1474	0.47273	T	10	NULL	NULL	.	0.061	0.18007	.	NULL	.	.	.	NULL	NULL	NULL	0.43007	0.593209862709	0.51947	T	NULL	0.70075	.	-0.440613	0.01283	T	-0.390091	0.34542	T	0.00535055751996542	0.00058	T	0.912409	0.69206	D	.	.	.	.	.	.	2.195298	0.34609	20.8	2.349485	0.40403	22.2	0.97560388223654537	0.34620	0.95503	0.64980	D	AEFDBI	0.472857	0.51779	N	-0.15844287863367	0.34877	1.996334	0.00546473550712644	0.39967	2.377935	0.999999164709875	0.74766	0.706548	0.73137	0	0.653731	0.59785	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.31	4.39	0.52211	3.399000	0.52333	1.176000	0.78918	0.674000	0.70861	1.000000	0.71638	0.989000	0.51752	0.858000	0.40661	0.0:0.1321:0.8679:0.0	16.3589	0.83079	226	0.91233	22	0.00439297124600639	0	0.0	16	0.015904572564612324	2	0.002881844380403458	0	0.0	4	0.00408997955010225	66	0.01779935275080906	58	0.015049299429164505	124	0.01639777836551177	8	0.0018157058556513845	145	0.01686046511627907	1231	1.014e-02	1231	1.014e-02	16	1.538e-03	24	2.073e-03	0	0	77	1.164e-02	1067	1.599e-02	39	2.362e-03	1008	9.491e-03	1008	9.491e-03	13	1.434e-03	24	2.140e-03	0	0	77	1.164e-02	849	1.562e-02	39	2.377e-03	765	8.430e-03	765	8.430e-03	16	1.540e-03	24	2.075e-03	0	0	47	1.236e-02	635	1.507e-02	39	2.363e-03	.	2500	251470	9.941544e-03	26	26	16256	1.599409e-03	0	104	34584	3.007171e-03	0	50	10080	4.960317e-03	0	0	18394	0	0	281	21636	1.298761e-02	3	1928	113766	1.694707e-02	22	59	30616	1.927097e-03	1	1928	113766	1.694707e-02	22	1017	109392	9.296841e-03	14	11	7164	1.535455e-03	0	51	17110	2.980713e-03	0	14	2320	6.034483e-03	0	0	9046	0	0	158	13382	1.180690e-02	3	732	42766	1.711640e-02	11	32	15690	2.039516e-03	0	732	42766	1.711640e-02	11	.	1546	143274	1.079051e-02	11	125	42014	2.975199e-03	0	95	13652	6.958687e-03	1	10	3320	3.012048e-03	0	0	3134	0	0	124	10474	1.183884e-02	0	1142	64580	1.768349e-02	10	9	3046	2.954695e-03	0	240959	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10368512G>A	Illumina_Clinical_Services_Laboratory,Illumina:79024	C0031511|C2749484|C0270914|CN169374	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10368512	G	A	V	M	rs77172218	1	10428570	1	10351157	1600	KIF1B	ENSG00000054523	ENST00000377081	ENSP00000366284	KIF1B_HUMAN	c.4798G>A	p.V1600M	c.4798G>A	p.Val1600Met	c.4798G>A	p.Val1600Met	.	Y	1	.	+	GTG	1	0	G	G/G	G/G	G/G	0.076	0.34269	T	0.136	0.34359	T	NULL	0.12996	.	NULL	0.14300	.	0.000117	0.50451	D	0.137650	0.999435;0.999435;0.999435	0.47043	D;D;D	simple_aae;simple_aae;simple_aae	V1554M;V1600M;V1600M	2.015	0.55033	M	-0.68	0.72568	T	-0.66	0.19085	N	0.277	0.31478	-0.8270	0.53493	T	0.1474	0.47273	T	10	NULL	NULL	.	0.061	0.18007	.	NULL	.	.	.	NULL	NULL	NULL	0.43007	0.593209862709	0.51947	T	NULL	0.70075	.	-0.440613	0.01283	T	-0.390091	0.34542	T	0.00535055751996542	0.00058	T	0.911209	0.69206	D	.	.	.	.	.	.	2.195298	0.34609	20.8	2.349485	0.40403	22.2	0.97560388223654537	0.34620	0.95503	0.64980	D	AEFDBI	0.472857	0.51779	N	-0.15844287863367	0.34877	1.996334	0.00546473550712644	0.39967	2.377935	0.999999164709875	0.74766	0.706548	0.73137	0	0.653731	0.59785	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.31	4.39	0.52211	3.399000	0.52333	1.176000	0.78918	0.674000	0.70861	1.000000	0.71638	0.989000	0.51752	0.858000	0.40661	0.0:0.1321:0.8679:0.0	16.3589	0.83079	226	0.91233	22	0.00439297124600639	0	0.0	16	0.015904572564612324	2	0.002881844380403458	0	0.0	4	0.00408997955010225	66	0.01779935275080906	58	0.015049299429164505	124	0.01639777836551177	8	0.0018157058556513845	145	0.01686046511627907	1231	1.014e-02	1231	1.014e-02	16	1.538e-03	24	2.073e-03	0	0	77	1.164e-02	1067	1.599e-02	39	2.362e-03	1008	9.491e-03	1008	9.491e-03	13	1.434e-03	24	2.140e-03	0	0	77	1.164e-02	849	1.562e-02	39	2.377e-03	765	8.430e-03	765	8.430e-03	16	1.540e-03	24	2.075e-03	0	0	47	1.236e-02	635	1.507e-02	39	2.363e-03	.	2500	251470	9.941544e-03	26	26	16256	1.599409e-03	0	104	34584	3.007171e-03	0	50	10080	4.960317e-03	0	0	18394	0	0	281	21636	1.298761e-02	3	1928	113766	1.694707e-02	22	59	30616	1.927097e-03	1	1928	113766	1.694707e-02	22	1017	109392	9.296841e-03	14	11	7164	1.535455e-03	0	51	17110	2.980713e-03	0	14	2320	6.034483e-03	0	0	9046	0	0	158	13382	1.180690e-02	3	732	42766	1.711640e-02	11	32	15690	2.039516e-03	0	732	42766	1.711640e-02	11	.	1546	143274	1.079051e-02	11	125	42014	2.975199e-03	0	95	13652	6.958687e-03	1	10	3320	3.012048e-03	0	0	3134	0	0	124	10474	1.183884e-02	0	1142	64580	1.768349e-02	10	9	3046	2.954695e-03	0	240959	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10368512G>A	Illumina_Clinical_Services_Laboratory,Illumina:79024	C0031511|C2749484|C0270914|CN169374	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10368512	G	A	V	M	rs77172218	1	10428570	1	10351157	1600	KIF1B	ENSG00000054523	ENST00000377086	ENSP00000366290	KIF1B_HUMAN	c.4798G>A	p.V1600M	c.4798G>A	p.Val1600Met	c.4798G>A	p.Val1600Met	principal1	Y	1	.	+	GTG	1	0	G	G/G	G/G	G/G	0.093	0.34269	T	0.133	0.34359	T	0.003	0.12996	B	0.004	0.14300	B	0.000117	0.50451	D	0.137650	0.999435;0.999435;0.999435	0.47043	D;D;D	simple_aae;simple_aae;simple_aae	V1554M;V1600M;V1600M	2.015	0.55033	M	-0.67	0.72568	T	-0.66	0.19085	N	0.266	0.31478	-0.8270	0.53493	T	0.1474	0.47273	T	10	NULL	NULL	.	0.061	0.18007	.	NULL	.	.	.	NULL	NULL	NULL	0.43007	0.593209862709	0.51947	T	0.330582	0.70075	T	-0.440613	0.01283	T	-0.390091	0.34542	T	0.00535055751996542	0.00058	T	0.911209	0.69206	D	.	.	.	.	.	.	2.195298	0.34609	20.8	2.349485	0.40403	22.2	0.97560388223654537	0.34620	0.95503	0.64980	D	AEFDBI	0.472857	0.51779	N	-0.15844287863367	0.34877	1.996334	0.00546473550712644	0.39967	2.377935	0.999999164709875	0.74766	0.706548	0.73137	0	0.653731	0.59785	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.31	4.39	0.52211	3.399000	0.52333	1.176000	0.78918	0.674000	0.70861	1.000000	0.71638	0.989000	0.51752	0.858000	0.40661	0.0:0.1321:0.8679:0.0	16.3589	0.83079	226	0.91233	22	0.00439297124600639	0	0.0	16	0.015904572564612324	2	0.002881844380403458	0	0.0	4	0.00408997955010225	66	0.01779935275080906	58	0.015049299429164505	124	0.01639777836551177	8	0.0018157058556513845	145	0.01686046511627907	1231	1.014e-02	1231	1.014e-02	16	1.538e-03	24	2.073e-03	0	0	77	1.164e-02	1067	1.599e-02	39	2.362e-03	1008	9.491e-03	1008	9.491e-03	13	1.434e-03	24	2.140e-03	0	0	77	1.164e-02	849	1.562e-02	39	2.377e-03	765	8.430e-03	765	8.430e-03	16	1.540e-03	24	2.075e-03	0	0	47	1.236e-02	635	1.507e-02	39	2.363e-03	.	2500	251470	9.941544e-03	26	26	16256	1.599409e-03	0	104	34584	3.007171e-03	0	50	10080	4.960317e-03	0	0	18394	0	0	281	21636	1.298761e-02	3	1928	113766	1.694707e-02	22	59	30616	1.927097e-03	1	1928	113766	1.694707e-02	22	1017	109392	9.296841e-03	14	11	7164	1.535455e-03	0	51	17110	2.980713e-03	0	14	2320	6.034483e-03	0	0	9046	0	0	158	13382	1.180690e-02	3	732	42766	1.711640e-02	11	32	15690	2.039516e-03	0	732	42766	1.711640e-02	11	.	1546	143274	1.079051e-02	11	125	42014	2.975199e-03	0	95	13652	6.958687e-03	1	10	3320	3.012048e-03	0	0	3134	0	0	124	10474	1.183884e-02	0	1142	64580	1.768349e-02	10	9	3046	2.954695e-03	0	240959	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10368512G>A	Illumina_Clinical_Services_Laboratory,Illumina:79024	C0031511|C2749484|C0270914|CN169374	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10374389	G	A	E	K	rs143669846	1	10434447	1	10357034	1628	KIF1B	ENSG00000054523	ENST00000263934	ENSP00000263934	KIF1B_HUMAN	c.4882G>A	p.E1628K	c.4882G>A	p.Glu1628Lys	c.4882G>A	p.Glu1628Lys	.	Y	1	YES	+	GAA	1	0	G	./.	./.	./.	0.205	0.20002	T	0.334	0.18340	T	0.718	0.42284	P	0.201	0.36881	B	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	E1628K;E1674K;E1674K	NULL	0.36909	.	-0.49	0.71307	T	-1.09	0.28290	N	0.747	0.87917	-0.8261	0.53550	T	0.1182	0.41516	T	10	NULL	NULL	.	0.216	0.51387	.	NULL	.	.	.	0.580066648918	0.57677	0.740666527485	0.63242	0.673709094524	0.63366	T	NULL	0.57665	.	-0.298142	0.08835	T	-0.191642	0.55436	T	0.0368646402071213	0.03132	T	0.940406	0.77539	D	.	.	.	.	.	.	2.792126	0.47570	23.0	2.885603	0.52160	23.3	0.9949963808706298	0.67973	0.97399	0.74502	D	AEFDBCI	0.877737	0.80257	D	0.138718458396147	0.48278	3.042131	0.324171748953513	0.56962	3.860678	0.999999999999999	0.74766	0.706548	0.73137	0	0.546412	0.12157	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	5.46	5.46	0.80021	9.351000	0.96472	1.176000	0.78918	0.669000	0.69127	1.000000	0.71638	0.993000	0.55118	0.968000	0.53726	0.0:0.0:1.0:0.0	19.3245	0.94243	233	0.90919	10	0.001996805111821086	9	0.00680786686838124	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	51	0.011575124829777576	1	1.1627906976744187E-4	113	9.307e-04	113	9.341e-04	104	1.025e-02	7	6.048e-04	1	1.157e-04	0	0	1	1.502e-05	0	0	96	9.039e-04	96	9.075e-04	87	9.873e-03	7	6.242e-04	1	1.273e-04	0	0	1	1.845e-05	0	0	112	1.234e-03	112	1.240e-03	104	1.026e-02	7	6.054e-04	0	0	0	0	1	2.382e-05	0	0	.	185	251408	7.358557e-04	2	169	16216	1.042181e-02	2	12	34590	3.469211e-04	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	3	113730	2.637826e-05	0	1	30614	3.266479e-05	0	169	16216	1.042181e-02	2	81	109404	7.403751e-04	0	72	7164	1.005025e-02	0	7	17110	4.091175e-04	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	1	42768	2.338197e-05	0	1	15688	6.374299e-05	0	72	7164	1.005025e-02	0	.	444	143272	3.099001e-03	2	429	42036	1.020554e-02	2	6	13656	4.393673e-04	0	0	3320	0	0	0	3132	0	0	0	10458	0	0	2	64576	3.097126e-05	0	2	64576	3.097126e-05	0	219797	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10374389G>A	Illumina_Clinical_Services_Laboratory,Illumina:752286	C0031511|C2749484|C0270914	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10374389	G	A	E	K	rs143669846	1	10434447	1	10357034	1648	KIF1B	ENSG00000054523	ENST00000622724	ENSP00000480063	A0A087WWA3_HUMAN	c.4942G>A	p.E1648K	c.4942G>A	p.Glu1648Lys	c.4942G>A	p.Glu1648Lys	.	Y	1	.	+	GAA	1	0	G	./.	./.	./.	NULL	0.20002	.	0.377	0.18340	T	NULL	0.42284	.	NULL	0.36881	.	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	E1628K;E1674K;E1674K	NULL	0.36909	.	NULL	0.71307	.	NULL	0.28290	.	0.872	0.87917	-0.8261	0.53550	T	0.1182	0.41516	T	10	NULL	NULL	.	0.216	0.51387	.	NULL	.	.	.	0.580066648918	0.57677	NULL	0.63242	0.673709094524	0.63366	T	NULL	0.57665	.	-0.298142	0.08835	T	-0.191642	0.55436	T	0.0368646402071213	0.03132	T	0.940406	0.77539	D	.	.	.	.	.	.	2.792126	0.47570	23.0	2.885603	0.52160	23.3	0.9949963808706298	0.67973	0.97399	0.74502	D	AEFDBCI	0.877737	0.80257	D	0.138718458396147	0.48278	3.042131	0.324171748953513	0.56962	3.860678	0.999999999999999	0.74766	0.706548	0.73137	0	0.546412	0.12157	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	5.46	5.46	0.80021	9.351000	0.96472	1.176000	0.78918	0.669000	0.69127	1.000000	0.71638	0.993000	0.55118	0.968000	0.53726	0.0:0.0:1.0:0.0	19.3245	0.94243	233	0.90919	10	0.001996805111821086	9	0.00680786686838124	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	51	0.011575124829777576	1	1.1627906976744187E-4	113	9.307e-04	113	9.341e-04	104	1.025e-02	7	6.048e-04	1	1.157e-04	0	0	1	1.502e-05	0	0	96	9.039e-04	96	9.075e-04	87	9.873e-03	7	6.242e-04	1	1.273e-04	0	0	1	1.845e-05	0	0	112	1.234e-03	112	1.240e-03	104	1.026e-02	7	6.054e-04	0	0	0	0	1	2.382e-05	0	0	.	185	251408	7.358557e-04	2	169	16216	1.042181e-02	2	12	34590	3.469211e-04	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	3	113730	2.637826e-05	0	1	30614	3.266479e-05	0	169	16216	1.042181e-02	2	81	109404	7.403751e-04	0	72	7164	1.005025e-02	0	7	17110	4.091175e-04	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	1	42768	2.338197e-05	0	1	15688	6.374299e-05	0	72	7164	1.005025e-02	0	.	444	143272	3.099001e-03	2	429	42036	1.020554e-02	2	6	13656	4.393673e-04	0	0	3320	0	0	0	3132	0	0	0	10458	0	0	2	64576	3.097126e-05	0	2	64576	3.097126e-05	0	219797	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10374389G>A	Illumina_Clinical_Services_Laboratory,Illumina:752286	C0031511|C2749484|C0270914	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10374389	G	A	E	K	rs143669846	1	10434447	1	10357034	1660	KIF1B	ENSG00000054523	ENST00000620295	ENSP00000478500	Q4R9M9_HUMAN	c.4978G>A	p.E1660K	c.4978G>A	p.Glu1660Lys	c.4978G>A	p.Glu1660Lys	.	Y	1	.	+	GAA	1	0	G	./.	./.	./.	NULL	0.20002	.	0.363	0.18340	T	0.349	0.42284	B	0.108	0.36881	B	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	E1628K;E1674K;E1674K	NULL	0.36909	.	NULL	0.71307	.	NULL	0.28290	.	0.881	0.87917	-0.8261	0.53550	T	0.1182	0.41516	T	10	NULL	NULL	.	0.216	0.51387	.	NULL	.	.	.	0.580066648918	0.57677	NULL	0.63242	0.673709094524	0.63366	T	NULL	0.57665	.	-0.298142	0.08835	T	-0.191642	0.55436	T	0.0368646402071213	0.03132	T	0.940406	0.77539	D	.	.	.	.	.	.	2.792126	0.47570	23.0	2.885603	0.52160	23.3	0.9949963808706298	0.67973	0.97399	0.74502	D	AEFDBCI	0.877737	0.80257	D	0.138718458396147	0.48278	3.042131	0.324171748953513	0.56962	3.860678	0.999999999999999	0.74766	0.706548	0.73137	0	0.546412	0.12157	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	5.46	5.46	0.80021	9.351000	0.96472	1.176000	0.78918	0.669000	0.69127	1.000000	0.71638	0.993000	0.55118	0.968000	0.53726	0.0:0.0:1.0:0.0	19.3245	0.94243	233	0.90919	10	0.001996805111821086	9	0.00680786686838124	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	51	0.011575124829777576	1	1.1627906976744187E-4	113	9.307e-04	113	9.341e-04	104	1.025e-02	7	6.048e-04	1	1.157e-04	0	0	1	1.502e-05	0	0	96	9.039e-04	96	9.075e-04	87	9.873e-03	7	6.242e-04	1	1.273e-04	0	0	1	1.845e-05	0	0	112	1.234e-03	112	1.240e-03	104	1.026e-02	7	6.054e-04	0	0	0	0	1	2.382e-05	0	0	.	185	251408	7.358557e-04	2	169	16216	1.042181e-02	2	12	34590	3.469211e-04	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	3	113730	2.637826e-05	0	1	30614	3.266479e-05	0	169	16216	1.042181e-02	2	81	109404	7.403751e-04	0	72	7164	1.005025e-02	0	7	17110	4.091175e-04	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	1	42768	2.338197e-05	0	1	15688	6.374299e-05	0	72	7164	1.005025e-02	0	.	444	143272	3.099001e-03	2	429	42036	1.020554e-02	2	6	13656	4.393673e-04	0	0	3320	0	0	0	3132	0	0	0	10458	0	0	2	64576	3.097126e-05	0	2	64576	3.097126e-05	0	219797	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10374389G>A	Illumina_Clinical_Services_Laboratory,Illumina:752286	C0031511|C2749484|C0270914	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10374389	G	A	E	K	rs143669846	1	10434447	1	10357034	1674	KIF1B	ENSG00000054523	ENST00000377081	ENSP00000366284	KIF1B_HUMAN	c.5020G>A	p.E1674K	c.5020G>A	p.Glu1674Lys	c.5020G>A	p.Glu1674Lys	.	Y	1	.	+	GAA	1	0	G	./.	./.	./.	0.268	0.20002	T	0.374	0.18340	T	NULL	0.42284	.	NULL	0.36881	.	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	E1628K;E1674K;E1674K	1.465	0.36909	L	-0.57	0.71307	T	-0.9	0.28290	N	0.732	0.87917	-0.8261	0.53550	T	0.1182	0.41516	T	10	NULL	NULL	.	0.216	0.51387	.	NULL	.	.	.	0.580066648918	0.57677	NULL	0.63242	0.673709094524	0.63366	T	NULL	0.57665	.	-0.298142	0.08835	T	-0.191642	0.55436	T	0.0368646402071213	0.03132	T	0.940406	0.77539	D	.	.	.	.	.	.	2.792126	0.47570	23.0	2.885603	0.52160	23.3	0.9949963808706298	0.67973	0.97399	0.74502	D	AEFDBCI	0.877737	0.80257	D	0.138718458396147	0.48278	3.042131	0.324171748953513	0.56962	3.860678	0.999999999999999	0.74766	0.706548	0.73137	0	0.546412	0.12157	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	5.46	5.46	0.80021	9.351000	0.96472	1.176000	0.78918	0.669000	0.69127	1.000000	0.71638	0.993000	0.55118	0.968000	0.53726	0.0:0.0:1.0:0.0	19.3245	0.94243	233	0.90919	10	0.001996805111821086	9	0.00680786686838124	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	51	0.011575124829777576	1	1.1627906976744187E-4	113	9.307e-04	113	9.341e-04	104	1.025e-02	7	6.048e-04	1	1.157e-04	0	0	1	1.502e-05	0	0	96	9.039e-04	96	9.075e-04	87	9.873e-03	7	6.242e-04	1	1.273e-04	0	0	1	1.845e-05	0	0	112	1.234e-03	112	1.240e-03	104	1.026e-02	7	6.054e-04	0	0	0	0	1	2.382e-05	0	0	.	185	251408	7.358557e-04	2	169	16216	1.042181e-02	2	12	34590	3.469211e-04	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	3	113730	2.637826e-05	0	1	30614	3.266479e-05	0	169	16216	1.042181e-02	2	81	109404	7.403751e-04	0	72	7164	1.005025e-02	0	7	17110	4.091175e-04	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	1	42768	2.338197e-05	0	1	15688	6.374299e-05	0	72	7164	1.005025e-02	0	.	444	143272	3.099001e-03	2	429	42036	1.020554e-02	2	6	13656	4.393673e-04	0	0	3320	0	0	0	3132	0	0	0	10458	0	0	2	64576	3.097126e-05	0	2	64576	3.097126e-05	0	219797	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10374389G>A	Illumina_Clinical_Services_Laboratory,Illumina:752286	C0031511|C2749484|C0270914	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10374389	G	A	E	K	rs143669846	1	10434447	1	10357034	1674	KIF1B	ENSG00000054523	ENST00000377086	ENSP00000366290	KIF1B_HUMAN	c.5020G>A	p.E1674K	c.5020G>A	p.Glu1674Lys	c.5020G>A	p.Glu1674Lys	principal1	Y	1	.	+	GAA	1	0	G	./.	./.	./.	0.22	0.20002	T	0.378	0.18340	T	0.364	0.42284	B	0.057	0.36881	B	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	E1628K;E1674K;E1674K	1.465	0.36909	L	-0.57	0.71307	T	-0.9	0.28290	N	0.774	0.87917	-0.8261	0.53550	T	0.1182	0.41516	T	10	NULL	NULL	.	0.216	0.51387	.	NULL	.	.	.	0.580066648918	0.57677	NULL	0.63242	0.673709094524	0.63366	T	0.214923	0.57665	T	-0.298142	0.08835	T	-0.191642	0.55436	T	0.0368646402071213	0.03132	T	0.940406	0.77539	D	.	.	.	.	.	.	2.792126	0.47570	23.0	2.885603	0.52160	23.3	0.9949963808706298	0.67973	0.97399	0.74502	D	AEFDBCI	0.877737	0.80257	D	0.138718458396147	0.48278	3.042131	0.324171748953513	0.56962	3.860678	0.999999999999999	0.74766	0.706548	0.73137	0	0.546412	0.12157	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	5.46	5.46	0.80021	9.351000	0.96472	1.176000	0.78918	0.669000	0.69127	1.000000	0.71638	0.993000	0.55118	0.968000	0.53726	0.0:0.0:1.0:0.0	19.3245	0.94243	233	0.90919	10	0.001996805111821086	9	0.00680786686838124	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	51	0.011575124829777576	1	1.1627906976744187E-4	113	9.307e-04	113	9.341e-04	104	1.025e-02	7	6.048e-04	1	1.157e-04	0	0	1	1.502e-05	0	0	96	9.039e-04	96	9.075e-04	87	9.873e-03	7	6.242e-04	1	1.273e-04	0	0	1	1.845e-05	0	0	112	1.234e-03	112	1.240e-03	104	1.026e-02	7	6.054e-04	0	0	0	0	1	2.382e-05	0	0	.	185	251408	7.358557e-04	2	169	16216	1.042181e-02	2	12	34590	3.469211e-04	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	3	113730	2.637826e-05	0	1	30614	3.266479e-05	0	169	16216	1.042181e-02	2	81	109404	7.403751e-04	0	72	7164	1.005025e-02	0	7	17110	4.091175e-04	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	1	42768	2.338197e-05	0	1	15688	6.374299e-05	0	72	7164	1.005025e-02	0	.	444	143272	3.099001e-03	2	429	42036	1.020554e-02	2	6	13656	4.393673e-04	0	0	3320	0	0	0	3132	0	0	0	10458	0	0	2	64576	3.097126e-05	0	2	64576	3.097126e-05	0	219797	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10374389G>A	Illumina_Clinical_Services_Laboratory,Illumina:752286	C0031511|C2749484|C0270914	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10376568	C	T	P	L	rs61999305	1	10436626	1	10359213	1765	KIF1B	ENSG00000054523	ENST00000263934	ENSP00000263934	KIF1B_HUMAN	c.5294C>T	p.P1765L	c.5294C>T	p.Pro1765Leu	c.5294C>T	p.Pro1765Leu	.	Y	1	YES	+	CCG	2	0	C	C/C	C/C	C/C	0.005	0.63226	D	0.063	0.45110	T	0.021	0.18474	B	0.011	0.15521	B	NULL	NULL	.	NULL	0.919365;0.87287;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	P1765L;P1811L;.	NULL	0.08828	.	-0.56	0.72125	T	-1.12	0.29525	N	0.101	0.08366	-0.9550	0.40096	T	0.0474	0.20275	T	9	NULL	NULL	.	0.132	0.36411	.	NULL	.	.	.	0.215239754934	0.21150	0.425933821982	0.42983	0.312648177147	0.12307	T	NULL	0.68981	.	-0.50531	0.00534	T	-0.467919	0.25742	T	0.0172139164584985	0.00464	T	0.844715	0.52235	T	.	.	.	.	.	.	2.368782	0.38358	21.9	3.036492	0.55554	23.6	0.99745104147279062	0.83778	0.97530	0.75350	D	AEFDBI	0.335144	0.43368	N	-0.0900648389812193	0.37826	2.206443	0.114886476306494	0.45310	2.796373	0.999999978088269	0.74766	0.719381	0.83141	0	0.601575	0.49859	0	0.724815	0.87919	0	0.733575	0.97253	0	NULL	NULL	5.57	5.57	0.84021	3.741000	0.54810	1.026000	0.45946	0.593000	0.32247	0.984000	0.35821	0.838000	0.34779	0.627000	0.32078	0.0:1.0:0.0:0.0	19.5547	0.95331	235	0.90838	61	0.012180511182108627	61	0.046142208774583963	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	187	0.04244212437585111	0	0.0	452	3.723e-03	452	3.772e-03	427	4.229e-02	13	1.126e-03	0	0	0	0	8	1.215e-04	2	1.212e-04	382	3.597e-03	382	3.640e-03	364	4.147e-02	11	9.832e-04	0	0	0	0	5	9.311e-05	2	1.219e-04	451	4.970e-03	451	5.054e-03	427	4.237e-02	13	1.127e-03	0	0	0	0	7	1.698e-04	2	1.212e-04	.	757	250502	3.021932e-03	10	681	16022	4.250406e-02	9	54	34566	1.562229e-03	0	0	10066	0	0	0	18344	0	0	0	21558	0	0	11	113206	9.716799e-05	1	2	30616	6.532532e-05	0	681	16022	4.250406e-02	9	343	109098	3.143962e-03	6	309	7094	4.355794e-02	6	28	17086	1.638769e-03	0	0	2314	0	0	0	9000	0	0	0	13362	0	0	3	42644	7.034987e-05	0	1	15690	6.373486e-05	0	309	7094	4.355794e-02	6	.	1813	143242	1.265690e-02	34	1695	42032	4.032642e-02	33	102	13642	7.476910e-03	1	0	3322	0	0	0	3132	0	0	0	10470	0	0	4	64554	6.196363e-05	0	4	64554	6.196363e-05	0	240960	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10376568C>T	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:163151|Illumina_Clinical_Services_Laboratory,Illumina:582683	C0031511|C2749484|C0270914|CN169374|CN517202	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10376568	C	T	P	L	rs61999305	1	10436626	1	10359213	1811	KIF1B	ENSG00000054523	ENST00000377086	ENSP00000366290	KIF1B_HUMAN	c.5432C>T	p.P1811L	c.5432C>T	p.Pro1811Leu	c.5432C>T	p.Pro1811Leu	principal1	Y	1	.	+	CCG	2	0	C	C/C	C/C	C/C	0.005	0.63226	D	0.064	0.45110	T	0.012	0.18474	B	0.005	0.15521	B	NULL	NULL	.	NULL	0.919365;0.87287;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	P1765L;P1811L;.	0.145	0.08828	N	-0.64	0.72125	T	-1.15	0.29525	N	0.057	0.08366	-0.9550	0.40096	T	0.0474	0.20275	T	9	NULL	NULL	.	0.132	0.36411	.	NULL	.	.	.	0.215239754934	0.21150	NULL	0.42983	0.312648177147	0.12307	T	0.318437	0.68981	T	-0.50531	0.00534	T	-0.467919	0.25742	T	0.0172139164584985	0.00464	T	0.844715	0.52235	T	.	.	.	.	.	.	2.368782	0.38358	21.9	3.036492	0.55554	23.6	0.99745104147279062	0.83778	0.97530	0.75350	D	AEFDBI	0.335144	0.43368	N	-0.0900648389812193	0.37826	2.206443	0.114886476306494	0.45310	2.796373	0.999999978088269	0.74766	0.719381	0.83141	0	0.601575	0.49859	0	0.724815	0.87919	0	0.733575	0.97253	0	NULL	NULL	5.57	5.57	0.84021	3.741000	0.54810	1.026000	0.45946	0.593000	0.32247	0.984000	0.35821	0.838000	0.34779	0.627000	0.32078	0.0:1.0:0.0:0.0	19.5547	0.95331	235	0.90838	61	0.012180511182108627	61	0.046142208774583963	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	187	0.04244212437585111	0	0.0	452	3.723e-03	452	3.772e-03	427	4.229e-02	13	1.126e-03	0	0	0	0	8	1.215e-04	2	1.212e-04	382	3.597e-03	382	3.640e-03	364	4.147e-02	11	9.832e-04	0	0	0	0	5	9.311e-05	2	1.219e-04	451	4.970e-03	451	5.054e-03	427	4.237e-02	13	1.127e-03	0	0	0	0	7	1.698e-04	2	1.212e-04	.	757	250502	3.021932e-03	10	681	16022	4.250406e-02	9	54	34566	1.562229e-03	0	0	10066	0	0	0	18344	0	0	0	21558	0	0	11	113206	9.716799e-05	1	2	30616	6.532532e-05	0	681	16022	4.250406e-02	9	343	109098	3.143962e-03	6	309	7094	4.355794e-02	6	28	17086	1.638769e-03	0	0	2314	0	0	0	9000	0	0	0	13362	0	0	3	42644	7.034987e-05	0	1	15690	6.373486e-05	0	309	7094	4.355794e-02	6	.	1813	143242	1.265690e-02	34	1695	42032	4.032642e-02	33	102	13642	7.476910e-03	1	0	3322	0	0	0	3132	0	0	0	10470	0	0	4	64554	6.196363e-05	0	4	64554	6.196363e-05	0	240960	Benign/Likely_benign	Pheochromocytoma|Neuroblastoma|Charcot-Marie-Tooth_disease,_type_2|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10376568C>T	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:163151|Illumina_Clinical_Services_Laboratory,Illumina:582683	C0031511|C2749484|C0270914|CN169374|CN517202	171300|256700	ORPHA635|ORPHA64746	.	.	. 	.
1	10618382	G	T	A	S	rs12061667	1	10678439	1	10601026	112	PEX14	ENSG00000142655	ENST00000491661	ENSP00000465473	K7EK59_HUMAN	.	.	c.334G>T	p.Ala112Ser	c.334G>T	p.Ala112Ser	.	.	2	.	+	GCA	1	0	G	G/G	G/G	G/G	NULL	0.09572	.	0.052	0.47828	T	NULL	0.24799	.	NULL	0.31615	.	0.000010	0.62929	D	0.110354	0.999967;0.999995	0.58761	D;D	simple_aae;simple_aae	A117S;A53S	NULL	0.25427	.	1.52	0.30669	T	NULL	0.21215	.	NULL	0.58713	-1.1077	0.03274	T	0.0466	0.19958	T	10	0.010917	0.28000	T	0.083	0.24629	.	NULL	.	.	.	0.367638622828	0.36380	NULL	0.70963	0.516353726387	0.41114	T	0.252023	0.65859	T	-0.433741	0.01408	T	-0.38642	0.34972	T	0.039060174646475	0.03521	T	0.928207	0.73493	D	.	.	.	.	.	.	2.490720	0.41038	22.4	2.391196	0.41304	22.3	0.98975947035092371	0.49640	0.98406	0.82449	D	AEFDBI	0.775116	0.70863	D	0.0084865192258464	0.42241	2.541396	0.134860887086199	0.46345	2.881976	0.999997423744	0.74766	0.706298	0.61202	0	0.724815	0.89359	0	0.709663	0.75317	0	0.714379	0.83352	0	NULL	NULL	4.94	4.03	0.46115	6.562000	0.73855	0.222000	0.24560	0.676000	0.76740	1.000000	0.71638	0.978000	0.47047	0.993000	0.69303	0.0773:0.0:0.9227:0.0	13.1662	0.58994	709	0.56835	13	0.002595846645367412	13	0.009833585476550681	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	38	0.008624602814344077	0	0.0	108	8.895e-04	108	8.924e-04	100	9.679e-03	5	4.325e-04	0	0	0	0	1	1.504e-05	1	6.059e-05	94	8.850e-04	94	8.856e-04	88	9.719e-03	4	3.569e-04	0	0	0	0	1	1.841e-05	1	6.098e-05	108	1.190e-03	108	1.195e-03	100	9.696e-03	5	4.330e-04	0	0	0	0	1	2.386e-05	1	6.063e-05	.	179	250938	7.133236e-04	0	155	16242	9.543160e-03	0	20	34586	5.782687e-04	0	0	10076	0	0	0	18390	0	0	0	21314	0	0	2	113582	1.760842e-05	0	1	30616	3.266266e-05	0	155	16242	9.543160e-03	0	88	109066	8.068509e-04	0	72	7164	1.005025e-02	0	15	17112	8.765778e-04	0	0	2320	0	0	0	9046	0	0	0	13062	0	0	1	42764	2.338415e-05	0	0	15690	0	0	72	7164	1.005025e-02	0	.	454	143350	3.167074e-03	1	415	42060	9.866857e-03	0	31	13662	2.269067e-03	1	0	3324	0	0	0	3132	0	0	0	10488	0	0	0	64580	0	0	31	13662	2.269067e-03	1	197764	Benign/Likely_benign	Peroxisome_biogenesis_disorder_13A|Peroxisome_biogenesis_disorder,_complementation_group_K|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10618382G>T	Illumina_Clinical_Services_Laboratory,Illumina:745005|UniProtKB_(protein):O75381#VAR_051269	C3554004|C1866257|CN169374	614887	.	Peroxisome membrane anchor protein Pex14p, N-terminal	.	. 	.
1	10618382	G	T	A	S	rs12061667	1	10678439	1	10601026	117	PEX14	ENSG00000142655	ENST00000356607	ENSP00000349016	PEX14_HUMAN	c.349G>T	p.A117S	c.349G>T	p.Ala117Ser	c.349G>T	p.Ala117Ser	principal1	Y	1	YES	+	GCA	1	0	G	G/G	G/G	G/G	0.429	0.09572	T	0.051	0.47828	T	0.084	0.24799	B	0.112	0.31615	B	0.000010	0.62929	D	0.110354	0.999967;0.999995	0.58761	D;D	simple_aae;simple_aae	A117S;A53S	1.015	0.25427	L	1.52	0.30669	T	-0.76	0.21215	N	0.563	0.58713	-1.1077	0.03274	T	0.0466	0.19958	T	10	0.010917	0.28000	T	0.083	0.24629	.	NULL	.	.	.	0.367638622828	0.36380	0.908931419662	0.70963	0.516353726387	0.41114	T	0.285806	0.65859	T	-0.433741	0.01408	T	-0.38642	0.34972	T	0.039060174646475	0.03521	T	0.928207	0.73493	D	.	.	.	.	.	.	2.490720	0.41038	22.4	2.391196	0.41304	22.3	0.98975947035092371	0.49640	0.98406	0.82449	D	AEFDBI	0.775116	0.70863	D	0.0084865192258464	0.42241	2.541396	0.134860887086199	0.46345	2.881976	0.999997423744	0.74766	0.706298	0.61202	0	0.724815	0.89359	0	0.709663	0.75317	0	0.714379	0.83352	0	NULL	NULL	4.94	4.03	0.46115	6.562000	0.73855	0.222000	0.24560	0.676000	0.76740	1.000000	0.71638	0.978000	0.47047	0.993000	0.69303	0.0773:0.0:0.9227:0.0	13.1662	0.58994	709	0.56835	13	0.002595846645367412	13	0.009833585476550681	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	38	0.008624602814344077	0	0.0	108	8.895e-04	108	8.924e-04	100	9.679e-03	5	4.325e-04	0	0	0	0	1	1.504e-05	1	6.059e-05	94	8.850e-04	94	8.856e-04	88	9.719e-03	4	3.569e-04	0	0	0	0	1	1.841e-05	1	6.098e-05	108	1.190e-03	108	1.195e-03	100	9.696e-03	5	4.330e-04	0	0	0	0	1	2.386e-05	1	6.063e-05	.	179	250938	7.133236e-04	0	155	16242	9.543160e-03	0	20	34586	5.782687e-04	0	0	10076	0	0	0	18390	0	0	0	21314	0	0	2	113582	1.760842e-05	0	1	30616	3.266266e-05	0	155	16242	9.543160e-03	0	88	109066	8.068509e-04	0	72	7164	1.005025e-02	0	15	17112	8.765778e-04	0	0	2320	0	0	0	9046	0	0	0	13062	0	0	1	42764	2.338415e-05	0	0	15690	0	0	72	7164	1.005025e-02	0	.	454	143350	3.167074e-03	1	415	42060	9.866857e-03	0	31	13662	2.269067e-03	1	0	3324	0	0	0	3132	0	0	0	10488	0	0	0	64580	0	0	31	13662	2.269067e-03	1	197764	Benign/Likely_benign	Peroxisome_biogenesis_disorder_13A|Peroxisome_biogenesis_disorder,_complementation_group_K|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.10618382G>T	Illumina_Clinical_Services_Laboratory,Illumina:745005|UniProtKB_(protein):O75381#VAR_051269	C3554004|C1866257|CN169374	614887	.	Peroxisome membrane anchor protein Pex14p, N-terminal	.	. 	.
1	11117039	C	T	M	I	rs878855328	1	11177096	1	11099683	2327	MTOR	ENSG00000198793	ENST00000361445	ENSP00000354558	MTOR_HUMAN	c.6981G>A	p.M2327I	c.6981G>A	p.Met2327Ile	c.6981G>A	p.Met2327Ile	principal1	Y	1	YES	-	ATG	3	0	C	C/C	C/C	C/C	0.001	0.91255	D	0.003	0.79402	D	0.999	0.77913	D	0.998	0.88582	D	0.000000	0.84330	D	0.000000	1;1	0.81001	D;D	simple_aae;simple_aae	M2327I;M532I	2.9	0.83903	M	-0.94	0.75325	T	-3.56	0.74051	D	0.902	0.94550	0.4744	0.90183	D	0.6665	0.88429	D	10	0.303596	0.90962	D	0.838	0.94986	0.767	0.89447	P42345	M2327I	Loss of phosphorylation at Y2332 (P = 0.1632); Loss of MoRF binding (P = 0.2189); Loss of sheet (P = 0.3635); Loss of helix (P = 0.3949); Gain of catalytic residue at R2322 (P = 0.4047)	0.955350077477	0.95488	2.59650284428	0.98161	0.915879964828	0.97994	D	0.778443	0.94129	D	0.397176	0.89750	D	0.33274	0.89621	D	0.993636694687476	0.84513	D	0.987701	0.95793	D	.	.	.	.	.	.	3.968782	0.77544	26.8	4.148968	0.87014	29.0	0.99777814520563435	0.86519	0.98679	0.85488	D	AEFDBI	0.861080	0.77907	D	0.92407513605851	0.92887	11.69006	0.877187839828783	0.94501	12.80957	0.999999989880169	0.74766	0.706298	0.61202	0	0.724815	0.89359	0	0.709663	0.75317	0	0.714379	0.83352	0	NULL	NULL	5.69	5.69	0.88346	7.349000	0.78620	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	1.000000	0.97212	0.0:1.0:0.0:0.0	18.7966	0.91963	400	0.82730	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	242349	Pathogenic	Smith-Kingsmore_syndrome	criteria_provided,_single_submitter	NC_000001.11:g.11117039C>T	OMIM_Allelic_Variant:601231.0010	C4225259	616638	ORPHA457485	Phosphatidylinositol 3-/4-kinase, catalytic domain|Phosphatidylinositol 3/4-kinase, conserved site|Phosphatidylinositol 3-/4-kinase, catalytic domain|Phosphatidylinositol 3-/4-kinase, catalytic domain	.	. 	.
1	11117039	C	T	M	I	rs878855328	1	11177096	1	11099683	532	MTOR	ENSG00000198793	ENST00000376838	ENSP00000366034	B1AKP8_HUMAN	c.1596G>A	p.M532I	c.1596G>A	p.Met532Ile	c.1596G>A	p.Met532Ile	.	Y	2	.	-	ATG	3	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.002	0.79402	D	NULL	0.77913	.	NULL	0.88582	.	0.000000	0.84330	D	0.000000	1;1	0.81001	D;D	simple_aae;simple_aae	M2327I;M532I	NULL	0.83903	.	-0.94	0.75325	T	-4.0	0.74051	D	0.939	0.94550	0.4744	0.90183	D	0.6665	0.88429	D	10	0.303596	0.90962	D	0.838	0.94986	0.767	0.89447	P42345	M2327I	Loss of phosphorylation at Y2332 (P = 0.1632); Loss of MoRF binding (P = 0.2189); Loss of sheet (P = 0.3635); Loss of helix (P = 0.3949); Gain of catalytic residue at R2322 (P = 0.4047)	0.955350077477	0.95488	NULL	0.98161	0.915879964828	0.97994	D	0.4652	0.94129	T	0.397176	0.89750	D	0.33274	0.89621	D	0.993636694687476	0.84513	D	0.987701	0.95793	D	.	.	.	.	.	.	3.968782	0.77544	26.8	4.148968	0.87014	29.0	0.99777814520563435	0.86519	0.98679	0.85488	D	AEFDBI	0.861080	0.77907	D	0.92407513605851	0.92887	11.69006	0.877187839828783	0.94501	12.80957	0.999999989880169	0.74766	0.706298	0.61202	0	0.724815	0.89359	0	0.709663	0.75317	0	0.714379	0.83352	0	NULL	NULL	5.69	5.69	0.88346	7.349000	0.78620	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	1.000000	0.97212	0.0:1.0:0.0:0.0	18.7966	0.91963	400	0.82730	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	242349	Pathogenic	Smith-Kingsmore_syndrome	criteria_provided,_single_submitter	NC_000001.11:g.11117039C>T	OMIM_Allelic_Variant:601231.0010	C4225259	616638	ORPHA457485	Phosphatidylinositol 3-/4-kinase, catalytic domain|Phosphatidylinositol 3/4-kinase, conserved site|Phosphatidylinositol 3-/4-kinase, catalytic domain|Phosphatidylinositol 3-/4-kinase, catalytic domain	.	. 	.
1	11129789	A	C	F	C	rs869312666	1	11189846	1	11112433	1888	MTOR	ENSG00000198793	ENST00000361445	ENSP00000354558	MTOR_HUMAN	c.5663T>G	p.F1888C	c.5663T>G	p.Phe1888Cys	c.5663T>G	p.Phe1888Cys	principal1	Y	1	YES	-	TTC	2	0	A	A/A	A/A	A/A	0.001	0.91255	D	0.0	0.92824	D	1.0	0.90584	D	1.0	0.97372	D	0.000000	0.84330	D	0.000000	1;1	0.81001	D;D	simple_aae;simple_aae	F1888C;F93C	3.375	0.91388	M	-1.07	0.76948	T	-7.11	0.95015	D	0.967	0.97750	0.7299	0.93546	D	0.7374	0.91026	D	10	0.829262	0.98676	D	0.951	0.99105	0.846	0.94965	P42345	F1888C	Gain of catalytic residue at F1888 (P = 0.0829); Loss of stability (P = 0.1259); Loss of phosphorylation at S1893 (P = 0.2597); Loss of MoRF binding (P = 0.2713); Loss of disorder (P = 0.3417)	0.972034797702	0.97173	2.25880593895	0.96158	0.862345337868	0.91457	D	0.762888	0.93591	D	0.427041	0.91382	D	0.375639	0.91275	D	0.996696472167969	0.89883	D	0.9966	0.98779	D	.	.	.	.	.	.	4.440024	0.90628	31	4.390584	0.91040	32	0.99428591797327392	0.64130	0.99554	0.97383	D	AEFDBI	0.902432	0.85032	D	1.01411977015788	0.96163	14.37159	0.944055637308976	0.97222	15.77695	0.999999844580454	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.79	5.79	0.91751	8.908000	0.92231	1.312000	0.94714	0.756000	0.94297	1.000000	0.71638	1.000000	0.86279	0.994000	0.71098	1.0:0.0:0.0:0.0	16.1354	0.81292	369	0.84396	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	224083	Pathogenic/Likely_pathogenic	Smith-Kingsmore_syndrome|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11129789A>C	OMIM_Allelic_Variant:601231.0009	C4225259|CN517202	616638	ORPHA457485	PIK-related kinase, FAT|PIK-related kinase	.	. 	.
1	11129789	A	C	F	C	rs869312666	1	11189846	1	11112433	93	MTOR	ENSG00000198793	ENST00000376838	ENSP00000366034	B1AKP8_HUMAN	c.278T>G	p.F93C	c.278T>G	p.Phe93Cys	c.278T>G	p.Phe93Cys	.	Y	2	.	-	TTC	2	0	A	A/A	A/A	A/A	0.0	0.91255	D	0.0	0.92824	D	NULL	0.90584	.	NULL	0.97372	.	0.000000	0.84330	D	0.000000	1;1	0.81001	D;D	simple_aae;simple_aae	F1888C;F93C	NULL	0.91388	.	-1.07	0.76948	T	-7.49	0.95015	D	0.962	0.97750	0.7299	0.93546	D	0.7374	0.91026	D	10	0.829262	0.98676	D	0.951	0.99105	0.846	0.94965	P42345	F1888C	Gain of catalytic residue at F1888 (P = 0.0829); Loss of stability (P = 0.1259); Loss of phosphorylation at S1893 (P = 0.2597); Loss of MoRF binding (P = 0.2713); Loss of disorder (P = 0.3417)	0.972034797702	0.97173	NULL	0.96158	0.862345337868	0.91457	D	0.503023	0.93591	D	0.427041	0.91382	D	0.375639	0.91275	D	0.996696472167969	0.89883	D	0.9966	0.98779	D	.	.	.	.	.	.	4.440024	0.90628	31	4.390584	0.91040	32	0.99428591797327392	0.64130	0.99554	0.97383	D	AEFDBI	0.902432	0.85032	D	1.01411977015788	0.96163	14.37159	0.944055637308976	0.97222	15.77695	0.999999844580454	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.79	5.79	0.91751	8.908000	0.92231	1.312000	0.94714	0.756000	0.94297	1.000000	0.71638	1.000000	0.86279	0.994000	0.71098	1.0:0.0:0.0:0.0	16.1354	0.81292	369	0.84396	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	224083	Pathogenic/Likely_pathogenic	Smith-Kingsmore_syndrome|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11129789A>C	OMIM_Allelic_Variant:601231.0009	C4225259|CN517202	616638	ORPHA457485	PIK-related kinase, FAT|PIK-related kinase	.	. 	.
1	11144735	C	T	M	I	rs869312671	1	11204792	1	11127379	1595	MTOR	ENSG00000198793	ENST00000361445	ENSP00000354558	MTOR_HUMAN	c.4785G>A	p.M1595I	c.4785G>A	p.Met1595Ile	c.4785G>A	p.Met1595Ile	principal1	Y	1	YES	-	ATG	3	0	C	C/C	C/C	C/C	0.005	0.63226	D	0.01	0.65728	D	0.705	0.41986	P	0.708	0.54437	P	0.000000	0.84330	D	0.000000	1	0.81001	D	simple_aae	M1595I	1.84	0.48285	L	-0.48	0.70249	T	-2.99	0.62151	D	0.941	0.94786	0.0316	0.82882	D	0.5287	0.82487	D	10	0.380238	0.92954	D	0.869	0.96117	0.749	0.87983	P42345	M1595I	Loss of catalytic residue at M1595 (P = 0.0233); Loss of phosphorylation at S1592 (P = 0.3323); Loss of disorder (P = 0.3747); Loss of MoRF binding (P = 0.593); Loss of helix (P = 0.6835)	0.955601620499	0.95512	1.96641412935	0.93527	0.867446482182	0.92202	D	0.535763	0.84015	D	0.324855	0.84814	D	0.228855	0.84615	D	0.955372980501727	0.64492	D	0.877812	0.59215	D	.	.	.	.	.	.	3.842657	0.73480	26.0	4.139578	0.86754	28.9	0.99656639802318792	0.77631	0.98634	0.84950	D	ALL	0.870665	0.79171	D	0.724451974140102	0.81237	7.474916	0.742925847948718	0.85629	8.637558	1.0	0.98316	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.6	5.6	0.84997	7.539000	0.80984	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	0.999000	0.91618	0.0:1.0:0.0:0.0	19.6251	0.95668	336	0.86165	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	224088	Pathogenic	Smith-Kingsmore_syndrome	criteria_provided,_single_submitter	NC_000001.11:g.11144735C>T	.	C4225259	616638	ORPHA457485	PIK-related kinase, FAT|PIK-related kinase	.	. 	.
1	11157173	C	A	C	F	rs786205165	1	11217230	1	11139817	1483	MTOR	ENSG00000198793	ENST00000361445	ENSP00000354558	MTOR_HUMAN	c.4448G>T	p.C1483F	c.4448G>T	p.Cys1483Phe	c.4448G>T	p.Cys1483Phe	principal1	Y	1	YES	-	TGC	2	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.001	0.83351	D	0.985	0.61118	D	0.704	0.54300	P	0.000000	0.84330	D	0.000000	1	0.81001	D	simple_aae	C1483F	3.425	0.91960	M	-0.43	0.69657	T	-9.57	0.98503	D	0.933	0.93841	0.2022	0.85945	D	0.4952	0.80869	T	10	0.789992	0.98351	D	0.947	0.98972	0.649	0.78639	P42345	C1483F	Loss of catalytic residue at L1484 (P = 0.0231); Loss of helix (P = 0.079); Gain of methylation at R1480 (P = 0.1111); Loss of loop (P = 0.2237); Loss of disorder (P = 0.26)	0.947854268699	0.94731	2.31019610544	0.96564	0.852634191513	0.90011	D	0.922815	0.98631	D	0.396633	0.89721	D	0.331959	0.89592	D	0.999757587909698	0.98831	D	0.933407	0.75038	D	.	.	.	.	.	.	3.884610	0.74783	26.3	4.084691	0.85134	28.4	0.99260897906456091	0.57222	0.98766	0.86576	D	AEFBI	0.915751	0.88096	D	0.852096215805684	0.89227	9.885945	0.811058815372225	0.90552	10.45933	0.999999999999704	0.74766	0.722319	0.85440	0	0.724815	0.89359	0	0.644132	0.48003	0	0.735409	0.98432	0	NULL	NULL	5.32	5.32	0.75377	7.536000	0.80930	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	0.999000	0.70432	0.978000	0.57271	0.0:1.0:0.0:0.0	19.0009	0.92812	332	0.86382	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	190121	Pathogenic	Renal_cell_carcinoma,_papillary,_1|Neoplasm_of_the_breast|Smith-Kingsmore_syndrome|Glioblastoma|not_provided	criteria_provided,_single_submitter	NC_000001.11:g.11157173C>A	OMIM_Allelic_Variant:601231.0001	C0007134|C1458155|C4225259|C0017636|CN517202	605074|616638	ORPHA217071|ORPHA180250|ORPHA457485|ORPHA360	PIK-related kinase	.	. 	.
1	11253848	C	A	M	I	rs752049917	1	11313905	1	11236492	277	MTOR	ENSG00000198793	ENST00000361445	ENSP00000354558	MTOR_HUMAN	c.831G>T	p.M277I	c.831G>T	p.Met277Ile	c.831G>T	p.Met277Ile	principal1	Y	1	YES	-	ATG	3	0	-	C/C	C/C	C/C	0.129	0.26852	T	0.379	0.16037	T	0.003	0.11197	B	0.007	0.12992	B	0.000000	0.84330	D	0.000000	0.999982	0.54805	D	simple_aae	M277I	2.015	0.55033	M	-0.08	0.63911	T	-0.93	0.24898	N	0.54	0.56748	-0.8234	0.53720	T	0.2091	0.56866	T	10	0.033301	0.54882	D	0.133	0.36620	0.321	0.30053	P42345	M277I	Gain of catalytic residue at L282 (P = 0.0447); Loss of disorder (P = 0.0718); Loss of MoRF binding (P = 0.2354); Loss of helix (P = 0.3949); Loss of stability (P = 0.4783)	0.699443158265	0.69684	0.888851575013	0.70127	0.739541292191	0.72905	T	0.400523	0.75807	T	-0.323526	0.06614	T	-0.235165	0.51269	T	0.154603164828954	0.17464	T	0.953205	0.82144	D	.	.	.	.	.	.	2.514088	0.41551	22.5	2.314750	0.39624	22.1	0.98277954223959185	0.39823	0.98726	0.86069	D	AEFDBI	0.824395	0.74430	D	0.013529985387572	0.42470	2.559511	0.154653878209169	0.47391	2.969867	0.999992293032025	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.11	4.2	0.48814	7.533000	0.80893	1.026000	0.45946	0.593000	0.32247	1.000000	0.71638	1.000000	0.86279	0.995000	0.73285	0.0:0.9243:0.0:0.0757	13.5452	0.61160	277	0.89083	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	29	2.389e-04	29	2.389e-04	0	0	29	2.505e-03	0	0	0	0	0	0	0	0	29	2.730e-04	29	2.731e-04	0	0	29	2.586e-03	0	0	0	0	0	0	0	0	29	3.196e-04	29	3.196e-04	0	0	29	2.507e-03	0	0	0	0	0	0	0	0	.	71	251464	2.823466e-04	0	0	16256	0	0	71	34592	2.052498e-03	0	0	10080	0	0	0	18394	0	0	0	21642	0	0	0	113746	0	0	0	30616	0	0	71	34592	2.052498e-03	0	31	109402	2.833586e-04	0	0	7164	0	0	31	17112	1.811594e-03	0	0	2320	0	0	0	9046	0	0	0	13390	0	0	0	42766	0	0	0	15690	0	0	31	17112	1.811594e-03	0	.	5	143310	3.488940e-05	0	0	42052	0	0	5	13656	3.661394e-04	0	0	3324	0	0	0	3132	0	0	0	10474	0	0	0	64572	0	0	5	13656	3.661394e-04	0	240082	Likely_benign	not_provided	criteria_provided,_single_submitter	NC_000001.11:g.11253848C>A	.	CN517202	.	.	.	.	. 	.
1	11949899	G	A	A	T	rs7551175	1	12009956	1	11932543	146	PLOD1	ENSG00000083444	ENST00000449038	ENSP00000414443	Q5JXB8_HUMAN	.	.	c.436G>A	p.Ala146Thr	c.436G>A	p.Ala146Thr	.	.	5	.	+	GCA	1	0	A	G/G	A/A	G/G	1.0	0.00964	T	0.651	0.06713	T	NULL	0.02946	.	NULL	0.01387	.	0.144421	0.18179	N	0.556046	1;1;1	0.08975	P;P;P	simple_aae;simple_aae;simple_aae	A146T;A99T;A99T	NULL	0.00067	.	1.99	0.21666	T	1.36	0.00878	N	NULL	0.06990	-0.9196	0.45608	T	0.0000	0.00011	T	9	NULL	NULL	.	0.150	0.40031	.	NULL	.	.	.	NULL	NULL	NULL	0.22245	0.416005015373	0.27286	T	NULL	0.28748	.	-0.597	0.00152	T	-0.486505	0.23758	T	0.00179262724432209	0.00018	T	0.640736	0.25328	T	.	.	.	.	.	.	1.467364	0.21395	15.53	1.210568	0.19694	14.71	0.71769974327546604	0.09742	0.03132	0.08084	N	AEFBI	0.116811	0.22910	N	-1.20284821396254	0.04958	0.2249324	-0.924560781725627	0.11515	0.5871014	0.822970201208674	0.24557	0.732398	0.92422	0	0.743671	0.97443	0	0.709663	0.75317	0	0.714379	0.83352	0	NULL	NULL	4.02	2.9	0.32809	1.264000	0.32618	-0.036000	0.13547	-0.044000	0.17373	0.368000	0.25908	0.912000	0.38435	0.985000	0.61073	0.7311:0.0:0.2689:0.0	7.7151	0.27866	792	0.45996	1500	0.2995207667731629	760	0.5748865355521936	147	0.14612326043737575	89	0.1282420749279539	272	0.2698412698412698	232	0.23721881390593047	579	0.15614886731391586	628	0.16294758692267775	1207	0.15961385876752182	2356	0.5347253744893328	1293	0.15034883720930234	23472	1.933e-01	23452	1.934e-01	5664	5.457e-01	983	8.501e-02	2108	2.441e-01	753	1.138e-01	10262	1.540e-01	3540	2.145e-01	20625	1.942e-01	20621	1.942e-01	4961	5.475e-01	934	8.332e-02	1907	2.427e-01	753	1.138e-01	8456	1.556e-01	3513	2.142e-01	18234	2.009e-01	18214	2.011e-01	5656	5.458e-01	979	8.475e-02	1366	2.426e-01	433	1.139e-01	6124	1.457e-01	3539	2.146e-01	.	45490	251356	1.809784e-01	5642	8936	16238	5.503141e-01	2459	3090	34580	8.935801e-02	145	1457	10080	1.445437e-01	122	4647	18392	2.526642e-01	612	2560	21648	1.182557e-01	159	17343	113670	1.525732e-01	1366	6508	30612	2.125964e-01	704	8936	16238	5.503141e-01	2459	20094	109400	1.836746e-01	2496	3946	7164	5.508096e-01	1077	1505	17108	8.797054e-02	67	327	2320	1.409483e-01	29	2321	9046	2.565775e-01	299	1581	13394	1.180379e-01	96	6657	42768	1.556538e-01	518	3439	15686	2.192401e-01	378	3946	7164	5.508096e-01	1077	.	37799	143038	2.642584e-01	7301	22556	41906	5.382523e-01	6079	1901	13628	1.394922e-01	152	434	3324	1.305656e-01	35	782	3120	2.506410e-01	113	1187	10450	1.135885e-01	68	9657	64524	1.496652e-01	705	637	3042	2.094017e-01	71	196247	Benign	Ehlers-Danlos_syndrome,_hydroxylysine-deficient|not_specified|Cardiovascular_phenotype	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11949899G>A	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:1969|Illumina_Clinical_Services_Laboratory,Illumina:419|UniProtKB_(protein):Q02809#VAR_014220	C0268342|CN169374|CN230736	225400	ORPHA1900	.	PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|MFN2|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|MIIP	Adipose_Subcutaneous|Adipose_Visceral_Omentum|Artery_Aorta|Artery_Tibial|Brain_Caudate_basal_ganglia|Brain_Cerebellum|Brain_Cortex|Brain_Hypothalamus|Brain_Nucleus_accumbens_basal_ganglia|Brain_Spinal_cord_cervical_c-1|Breast_Mammary_Tissue|Colon_Sigmoid|Colon_Transverse|Esophagus_Mucosa|Esophagus_Muscularis|Lung|Muscle_Skeletal|Nerve_Tibial|Pancreas|Spleen|Thyroid 	ENSG00000083444
1	11949899	G	A	A	T	rs7551175	1	12009956	1	11932543	99	PLOD1	ENSG00000083444	ENST00000196061	ENSP00000196061	PLOD1_HUMAN	c.295G>A	p.A99T	c.295G>A	p.Ala99Thr	c.295G>A	p.Ala99Thr	principal1	Y	1	YES	+	GCA	1	0	A	G/G	A/A	G/G	1.0	0.00964	T	1.0	0.06713	T	0.0	0.02946	B	0.0	0.01387	B	0.144421	0.18179	N	0.556046	1;1;1	0.08975	P;P;P	simple_aae;simple_aae;simple_aae	A146T;A99T;A99T	-2.44	0.00067	N	1.99	0.21666	T	2.58	0.00878	N	0.091	0.06990	-0.9196	0.45608	T	0.0000	0.00011	T	9	NULL	NULL	.	0.150	0.40031	.	NULL	.	.	.	NULL	NULL	0.198662114267	0.22245	0.416005015373	0.27286	T	0.050979	0.28748	T	-0.597	0.00152	T	-0.486505	0.23758	T	0.00179262724432209	0.00018	T	0.59724	0.25328	T	.	.	.	.	.	.	1.467364	0.21395	15.53	1.210568	0.19694	14.71	0.71769974327546604	0.09742	0.03132	0.08084	N	AEFBI	0.116811	0.22910	N	-1.20284821396254	0.04958	0.2249324	-0.924560781725627	0.11515	0.5871014	0.822970201208674	0.24557	0.732398	0.92422	0	0.743671	0.97443	0	0.709663	0.75317	0	0.714379	0.83352	0	NULL	NULL	4.02	2.9	0.32809	1.264000	0.32618	-0.036000	0.13547	-0.044000	0.17373	0.368000	0.25908	0.912000	0.38435	0.985000	0.61073	0.7311:0.0:0.2689:0.0	7.7151	0.27866	792	0.45996	1500	0.2995207667731629	760	0.5748865355521936	147	0.14612326043737575	89	0.1282420749279539	272	0.2698412698412698	232	0.23721881390593047	579	0.15614886731391586	628	0.16294758692267775	1207	0.15961385876752182	2356	0.5347253744893328	1293	0.15034883720930234	23472	1.933e-01	23452	1.934e-01	5664	5.457e-01	983	8.501e-02	2108	2.441e-01	753	1.138e-01	10262	1.540e-01	3540	2.145e-01	20625	1.942e-01	20621	1.942e-01	4961	5.475e-01	934	8.332e-02	1907	2.427e-01	753	1.138e-01	8456	1.556e-01	3513	2.142e-01	18234	2.009e-01	18214	2.011e-01	5656	5.458e-01	979	8.475e-02	1366	2.426e-01	433	1.139e-01	6124	1.457e-01	3539	2.146e-01	.	45490	251356	1.809784e-01	5642	8936	16238	5.503141e-01	2459	3090	34580	8.935801e-02	145	1457	10080	1.445437e-01	122	4647	18392	2.526642e-01	612	2560	21648	1.182557e-01	159	17343	113670	1.525732e-01	1366	6508	30612	2.125964e-01	704	8936	16238	5.503141e-01	2459	20094	109400	1.836746e-01	2496	3946	7164	5.508096e-01	1077	1505	17108	8.797054e-02	67	327	2320	1.409483e-01	29	2321	9046	2.565775e-01	299	1581	13394	1.180379e-01	96	6657	42768	1.556538e-01	518	3439	15686	2.192401e-01	378	3946	7164	5.508096e-01	1077	.	37799	143038	2.642584e-01	7301	22556	41906	5.382523e-01	6079	1901	13628	1.394922e-01	152	434	3324	1.305656e-01	35	782	3120	2.506410e-01	113	1187	10450	1.135885e-01	68	9657	64524	1.496652e-01	705	637	3042	2.094017e-01	71	196247	Benign	Ehlers-Danlos_syndrome,_hydroxylysine-deficient|not_specified|Cardiovascular_phenotype	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11949899G>A	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:1969|Illumina_Clinical_Services_Laboratory,Illumina:419|UniProtKB_(protein):Q02809#VAR_014220	C0268342|CN169374|CN230736	225400	ORPHA1900	.	PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|MFN2|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|MIIP	Adipose_Subcutaneous|Adipose_Visceral_Omentum|Artery_Aorta|Artery_Tibial|Brain_Caudate_basal_ganglia|Brain_Cerebellum|Brain_Cortex|Brain_Hypothalamus|Brain_Nucleus_accumbens_basal_ganglia|Brain_Spinal_cord_cervical_c-1|Breast_Mammary_Tissue|Colon_Sigmoid|Colon_Transverse|Esophagus_Mucosa|Esophagus_Muscularis|Lung|Muscle_Skeletal|Nerve_Tibial|Pancreas|Spleen|Thyroid 	ENSG00000083444
1	11949899	G	A	A	T	rs7551175	1	12009956	1	11932543	99	PLOD1	ENSG00000083444	ENST00000429000	ENSP00000405372	Q5JXB7_HUMAN	.	.	c.295G>A	p.Ala99Thr	c.295G>A	p.Ala99Thr	.	.	5	.	+	GCA	1	0	A	G/G	A/A	G/G	1.0	0.00964	T	0.659	0.06713	T	NULL	0.02946	.	NULL	0.01387	.	0.144421	0.18179	N	0.556046	1;1;1	0.08975	P;P;P	simple_aae;simple_aae;simple_aae	A146T;A99T;A99T	NULL	0.00067	.	1.99	0.21666	T	1.5	0.00878	N	NULL	0.06990	-0.9196	0.45608	T	0.0000	0.00011	T	9	NULL	NULL	.	0.150	0.40031	.	NULL	.	.	.	NULL	NULL	NULL	0.22245	0.416005015373	0.27286	T	0.009487	0.28748	T	-0.597	0.00152	T	-0.486505	0.23758	T	0.00179262724432209	0.00018	T	0.592841	0.25328	T	.	.	.	.	.	.	1.467364	0.21395	15.53	1.210568	0.19694	14.71	0.71769974327546604	0.09742	0.03132	0.08084	N	AEFBI	0.116811	0.22910	N	-1.20284821396254	0.04958	0.2249324	-0.924560781725627	0.11515	0.5871014	0.822970201208674	0.24557	0.732398	0.92422	0	0.743671	0.97443	0	0.709663	0.75317	0	0.714379	0.83352	0	NULL	NULL	4.02	2.9	0.32809	1.264000	0.32618	-0.036000	0.13547	-0.044000	0.17373	0.368000	0.25908	0.912000	0.38435	0.985000	0.61073	0.7311:0.0:0.2689:0.0	7.7151	0.27866	792	0.45996	1500	0.2995207667731629	760	0.5748865355521936	147	0.14612326043737575	89	0.1282420749279539	272	0.2698412698412698	232	0.23721881390593047	579	0.15614886731391586	628	0.16294758692267775	1207	0.15961385876752182	2356	0.5347253744893328	1293	0.15034883720930234	23472	1.933e-01	23452	1.934e-01	5664	5.457e-01	983	8.501e-02	2108	2.441e-01	753	1.138e-01	10262	1.540e-01	3540	2.145e-01	20625	1.942e-01	20621	1.942e-01	4961	5.475e-01	934	8.332e-02	1907	2.427e-01	753	1.138e-01	8456	1.556e-01	3513	2.142e-01	18234	2.009e-01	18214	2.011e-01	5656	5.458e-01	979	8.475e-02	1366	2.426e-01	433	1.139e-01	6124	1.457e-01	3539	2.146e-01	.	45490	251356	1.809784e-01	5642	8936	16238	5.503141e-01	2459	3090	34580	8.935801e-02	145	1457	10080	1.445437e-01	122	4647	18392	2.526642e-01	612	2560	21648	1.182557e-01	159	17343	113670	1.525732e-01	1366	6508	30612	2.125964e-01	704	8936	16238	5.503141e-01	2459	20094	109400	1.836746e-01	2496	3946	7164	5.508096e-01	1077	1505	17108	8.797054e-02	67	327	2320	1.409483e-01	29	2321	9046	2.565775e-01	299	1581	13394	1.180379e-01	96	6657	42768	1.556538e-01	518	3439	15686	2.192401e-01	378	3946	7164	5.508096e-01	1077	.	37799	143038	2.642584e-01	7301	22556	41906	5.382523e-01	6079	1901	13628	1.394922e-01	152	434	3324	1.305656e-01	35	782	3120	2.506410e-01	113	1187	10450	1.135885e-01	68	9657	64524	1.496652e-01	705	637	3042	2.094017e-01	71	196247	Benign	Ehlers-Danlos_syndrome,_hydroxylysine-deficient|not_specified|Cardiovascular_phenotype	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11949899G>A	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:1969|Illumina_Clinical_Services_Laboratory,Illumina:419|UniProtKB_(protein):Q02809#VAR_014220	C0268342|CN169374|CN230736	225400	ORPHA1900	.	PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|MFN2|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|PLOD1|MIIP	Adipose_Subcutaneous|Adipose_Visceral_Omentum|Artery_Aorta|Artery_Tibial|Brain_Caudate_basal_ganglia|Brain_Cerebellum|Brain_Cortex|Brain_Hypothalamus|Brain_Nucleus_accumbens_basal_ganglia|Brain_Spinal_cord_cervical_c-1|Breast_Mammary_Tissue|Colon_Sigmoid|Colon_Transverse|Esophagus_Mucosa|Esophagus_Muscularis|Lung|Muscle_Skeletal|Nerve_Tibial|Pancreas|Spleen|Thyroid 	ENSG00000083444
1	11989226	C	T	H	Y	rs201715603	1	12049283	1	11971870	20	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.58C>T	p.H20Y	c.58C>T	p.His20Tyr	c.58C>T	p.His20Tyr	principal1	Y	1	YES	+	CAC	1	0	C	C/C	C/C	C/C	0.438	0.09319	T	1.0	0.02365	T	0.014	0.16867	B	0.016	0.17743	B	0.000024	0.55875	D	0.120307	0.990071;0.990071;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	H20Y;H20Y;.	0.895	0.22405	L	-5.69	0.99278	D	-0.98	0.29114	N	0.844	0.83987	0.6493	0.92533	D	0.8818	0.96075	D	10	0.390537	0.93178	D	0.751	0.91569	.	NULL	.	.	.	0.692574078516	0.68992	0.857835516012	0.68829	0.770535469055	0.77505	T	0.229557	0.59540	T	-0.00151599	0.51446	T	-0.0142523	0.69406	D	0.0322916130481146	0.02354	T	NULL	0.76632	.	.	.	.	.	.	.	1.771637	0.26315	17.53	2.098258	0.34975	20.6	0.82351554174675745	0.14147	0.95126	0.63533	D	AEFBCI	0.733844	0.68015	D	-0.180576906782614	0.33945	1.931644	0.0695772429355043	0.43029	2.613139	0.999999999776807	0.74766	0.722319	0.85440	0	0.698795	0.70079	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.88	5.88	0.94564	3.783000	0.55114	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	0.997000	0.79791	0.0:0.9247:0.0:0.0753	12.5265	0.55435	787	0.46738	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	1	1.1627906976744187E-4	14	1.153e-04	14	1.153e-04	0	0	1	8.637e-05	0	0	0	0	10	1.498e-04	2	1.211e-04	12	1.130e-04	12	1.130e-04	0	0	1	8.916e-05	0	0	0	0	10	1.840e-04	1	6.095e-05	9	9.917e-05	9	9.918e-05	0	0	1	8.646e-05	0	0	0	0	5	1.187e-04	2	1.212e-04	.	19	251490	7.554972e-05	0	0	16256	0	0	3	34592	8.672525e-05	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	12	113764	1.054815e-04	0	2	30616	6.532532e-05	0	12	113764	1.054815e-04	0	8	109408	7.312080e-05	0	0	7164	0	0	2	17112	1.168770e-04	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	5	42768	1.169098e-04	0	0	15690	0	0	5	42768	1.169098e-04	0	.	7	143220	4.887586e-05	0	0	42022	0	0	2	13622	1.468213e-04	0	0	3324	0	0	0	3130	0	0	0	10460	0	0	4	64572	6.194635e-05	0	1	3042	3.287311e-04	0	214656	Conflicting_interpretations_of_pathogenicity	Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2|Hereditary_motor_and_sensory_neuropathy_with_optic_atrophy|not_specified	criteria_provided,_conflicting_interpretations	NC_000001.11:g.11989226C>T	Illumina_Clinical_Services_Laboratory,Illumina:545564	C0007959|C0270914|C0393807|CN169374	601152	ORPHA166|ORPHA64746|ORPHA90120	.	.	. 	.
1	11989226	C	T	H	Y	rs201715603	1	12049283	1	11971870	20	MFN2	ENSG00000116688	ENST00000412236	ENSP00000412023	Q5JXC5_HUMAN	.	.	c.58C>T	p.His20Tyr	c.58C>T	p.His20Tyr	.	.	3	.	+	CAC	1	0	C	C/C	C/C	C/C	0.909	0.09319	T	0.99	0.02365	T	NULL	0.16867	.	NULL	0.17743	.	0.000024	0.55875	D	0.120307	0.990071;0.990071;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	H20Y;H20Y;.	NULL	0.22405	.	-3.51	0.99278	D	-1.13	0.29114	N	NULL	0.83987	0.6493	0.92533	D	0.8818	0.96075	D	10	0.390537	0.93178	D	0.751	0.91569	.	NULL	.	.	.	0.692574078516	0.68992	NULL	0.68829	0.770535469055	0.77505	T	NULL	0.59540	.	-0.00151599	0.51446	T	-0.0142523	0.69406	D	0.0322916130481146	0.02354	T	0.937806	0.76632	D	.	.	.	.	.	.	1.771637	0.26315	17.53	2.098258	0.34975	20.6	0.82351554174675745	0.14147	0.95126	0.63533	D	AEFBCI	0.733844	0.68015	D	-0.180576906782614	0.33945	1.931644	0.0695772429355043	0.43029	2.613139	0.999999999776807	0.74766	0.722319	0.85440	0	0.698795	0.70079	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.88	5.88	0.94564	3.783000	0.55114	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	0.997000	0.79791	0.0:0.9247:0.0:0.0753	12.5265	0.55435	787	0.46738	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	1	1.1627906976744187E-4	14	1.153e-04	14	1.153e-04	0	0	1	8.637e-05	0	0	0	0	10	1.498e-04	2	1.211e-04	12	1.130e-04	12	1.130e-04	0	0	1	8.916e-05	0	0	0	0	10	1.840e-04	1	6.095e-05	9	9.917e-05	9	9.918e-05	0	0	1	8.646e-05	0	0	0	0	5	1.187e-04	2	1.212e-04	.	19	251490	7.554972e-05	0	0	16256	0	0	3	34592	8.672525e-05	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	12	113764	1.054815e-04	0	2	30616	6.532532e-05	0	12	113764	1.054815e-04	0	8	109408	7.312080e-05	0	0	7164	0	0	2	17112	1.168770e-04	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	5	42768	1.169098e-04	0	0	15690	0	0	5	42768	1.169098e-04	0	.	7	143220	4.887586e-05	0	0	42022	0	0	2	13622	1.468213e-04	0	0	3324	0	0	0	3130	0	0	0	10460	0	0	4	64572	6.194635e-05	0	1	3042	3.287311e-04	0	214656	Conflicting_interpretations_of_pathogenicity	Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2|Hereditary_motor_and_sensory_neuropathy_with_optic_atrophy|not_specified	criteria_provided,_conflicting_interpretations	NC_000001.11:g.11989226C>T	Illumina_Clinical_Services_Laboratory,Illumina:545564	C0007959|C0270914|C0393807|CN169374	601152	ORPHA166|ORPHA64746|ORPHA90120	.	.	. 	.
1	11989226	C	T	H	Y	rs201715603	1	12049283	1	11971870	20	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.58C>T	p.H20Y	c.58C>T	p.His20Tyr	c.58C>T	p.His20Tyr	principal1	Y	2	.	+	CAC	1	0	C	C/C	C/C	C/C	0.438	0.09319	T	1.0	0.02365	T	0.014	0.16867	B	0.016	0.17743	B	0.000024	0.55875	D	0.120307	0.990071;0.990071;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	H20Y;H20Y;.	0.895	0.22405	L	-5.69	0.99278	D	-0.98	0.29114	N	0.614	0.83987	0.6493	0.92533	D	0.8818	0.96075	D	10	0.390537	0.93178	D	0.751	0.91569	.	NULL	.	.	.	0.692574078516	0.68992	NULL	0.68829	0.770535469055	0.77505	T	0.229557	0.59540	T	-0.00151599	0.51446	T	-0.0142523	0.69406	D	0.0322916130481146	0.02354	T	0.935406	0.76632	D	.	.	.	.	.	.	1.771637	0.26315	17.53	2.098258	0.34975	20.6	0.82351554174675745	0.14147	0.95126	0.63533	D	AEFBCI	0.733844	0.68015	D	-0.180576906782614	0.33945	1.931644	0.0695772429355043	0.43029	2.613139	0.999999999776807	0.74766	0.722319	0.85440	0	0.698795	0.70079	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.88	5.88	0.94564	3.783000	0.55114	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	0.997000	0.79791	0.0:0.9247:0.0:0.0753	12.5265	0.55435	787	0.46738	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	1	1.1627906976744187E-4	14	1.153e-04	14	1.153e-04	0	0	1	8.637e-05	0	0	0	0	10	1.498e-04	2	1.211e-04	12	1.130e-04	12	1.130e-04	0	0	1	8.916e-05	0	0	0	0	10	1.840e-04	1	6.095e-05	9	9.917e-05	9	9.918e-05	0	0	1	8.646e-05	0	0	0	0	5	1.187e-04	2	1.212e-04	.	19	251490	7.554972e-05	0	0	16256	0	0	3	34592	8.672525e-05	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	12	113764	1.054815e-04	0	2	30616	6.532532e-05	0	12	113764	1.054815e-04	0	8	109408	7.312080e-05	0	0	7164	0	0	2	17112	1.168770e-04	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	5	42768	1.169098e-04	0	0	15690	0	0	5	42768	1.169098e-04	0	.	7	143220	4.887586e-05	0	0	42022	0	0	2	13622	1.468213e-04	0	0	3324	0	0	0	3130	0	0	0	10460	0	0	4	64572	6.194635e-05	0	1	3042	3.287311e-04	0	214656	Conflicting_interpretations_of_pathogenicity	Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2|Hereditary_motor_and_sensory_neuropathy_with_optic_atrophy|not_specified	criteria_provided,_conflicting_interpretations	NC_000001.11:g.11989226C>T	Illumina_Clinical_Services_Laboratory,Illumina:545564	C0007959|C0270914|C0393807|CN169374	601152	ORPHA166|ORPHA64746|ORPHA90120	.	.	. 	.
1	11992606	T	C	L	P	rs28940293	1	12052663	1	11975250	76	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.227T>C	p.L76P	c.227T>C	p.Leu76Pro	c.227T>C	p.Leu76Pro	principal1	Y	1	YES	+	CTG	2	0	T	T/T	T/T	T/T	0.257	0.25457	T	0.28	0.24767	T	0.74	0.42962	P	0.243	0.38752	B	0.009231	0.30456	N	0.315251	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	L76P;L76P;.	1.895	0.50365	L	-5.81	0.99381	D	-1.66	0.54382	N	0.909	0.91047	1.0405	0.97921	D	0.9249	0.97517	D	10	0.422151	0.93815	D	0.721	0.90274	0.727	0.86105	O95140	L76P	Gain of disorder (P = 0.0109); Loss of stability (P = 0.0328); Gain of ubiquitination at K79 (P = 0.0571); Gain of glycosylation at T71 (P = 0.0774); Gain of phosphorylation at T71 (P = 0.1091)	0.98363308971	0.98345	1.2428521837	0.81604	0.592939972878	0.51909	T	0.522062	0.83304	D	0.419362	0.90987	D	0.364608	0.90874	D	0.656943261623383	0.38762	D	NULL	0.53011	.	.	.	.	.	.	.	2.661472	0.44769	22.8	2.384476	0.41162	22.3	0.99251273124123018	0.56891	0.88626	0.48642	D	AEFDBI	0.333646	0.43267	N	0.183437067158245	0.50403	3.230708	0.267377501239808	0.53645	3.532357	0.999767772100805	0.42728	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.39	5.39	0.77615	1.888000	0.39342	1.138000	0.64695	0.665000	0.62972	0.972000	0.34453	0.997000	0.62031	0.978000	0.57271	0.0:0.0:0.0:1.0	14.5862	0.67920	793	0.45818	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	143304	6.978172e-06	0	0	42044	0	0	0	13656	0	0	0	3324	0	0	0	3134	0	0	0	10476	0	0	1	64570	1.548707e-05	0	1	64570	1.548707e-05	0	2270	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11992606T>C	OMIM_Allelic_Variant:608507.0003|UniProtKB_(protein):O95140#VAR_018608	C4721887|C0270914|CN517202	609260	ORPHA99947|ORPHA64746	.	.	. 	.
1	11992606	T	C	L	P	rs28940293	1	12052663	1	11975250	76	MFN2	ENSG00000116688	ENST00000412236	ENSP00000412023	Q5JXC5_HUMAN	.	.	c.227T>C	p.Leu76Pro	c.227T>C	p.Leu76Pro	.	.	3	.	+	CTG	2	0	T	T/T	T/T	T/T	0.142	0.25457	T	0.235	0.24767	T	NULL	0.42962	.	NULL	0.38752	.	0.009231	0.30456	N	0.315251	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	L76P;L76P;.	NULL	0.50365	.	-3.61	0.99381	D	-2.5	0.54382	D	NULL	0.91047	1.0405	0.97921	D	0.9249	0.97517	D	10	0.422151	0.93815	D	0.721	0.90274	0.727	0.86105	O95140	L76P	Gain of disorder (P = 0.0109); Loss of stability (P = 0.0328); Gain of ubiquitination at K79 (P = 0.0571); Gain of glycosylation at T71 (P = 0.0774); Gain of phosphorylation at T71 (P = 0.1091)	0.98363308971	0.98345	NULL	0.81604	0.592939972878	0.51909	T	NULL	0.83304	.	0.419362	0.90987	D	0.364608	0.90874	D	0.656943261623383	0.38762	D	0.848615	0.53011	T	.	.	.	.	.	.	2.661472	0.44769	22.8	2.384476	0.41162	22.3	0.99251273124123018	0.56891	0.88626	0.48642	D	AEFDBI	0.333646	0.43267	N	0.183437067158245	0.50403	3.230708	0.267377501239808	0.53645	3.532357	0.999767772100805	0.42728	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.39	5.39	0.77615	1.888000	0.39342	1.138000	0.64695	0.665000	0.62972	0.972000	0.34453	0.997000	0.62031	0.978000	0.57271	0.0:0.0:0.0:1.0	14.5862	0.67920	793	0.45818	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	143304	6.978172e-06	0	0	42044	0	0	0	13656	0	0	0	3324	0	0	0	3134	0	0	0	10476	0	0	1	64570	1.548707e-05	0	1	64570	1.548707e-05	0	2270	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11992606T>C	OMIM_Allelic_Variant:608507.0003|UniProtKB_(protein):O95140#VAR_018608	C4721887|C0270914|CN517202	609260	ORPHA99947|ORPHA64746	.	.	. 	.
1	11992606	T	C	L	P	rs28940293	1	12052663	1	11975250	76	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.227T>C	p.L76P	c.227T>C	p.Leu76Pro	c.227T>C	p.Leu76Pro	principal1	Y	2	.	+	CTG	2	0	T	T/T	T/T	T/T	0.257	0.25457	T	0.28	0.24767	T	0.74	0.42962	P	0.243	0.38752	B	0.009231	0.30456	N	0.315251	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	L76P;L76P;.	1.895	0.50365	L	-5.81	0.99381	D	-1.66	0.54382	N	0.753	0.91047	1.0405	0.97921	D	0.9249	0.97517	D	10	0.422151	0.93815	D	0.721	0.90274	0.727	0.86105	O95140	L76P	Gain of disorder (P = 0.0109); Loss of stability (P = 0.0328); Gain of ubiquitination at K79 (P = 0.0571); Gain of glycosylation at T71 (P = 0.0774); Gain of phosphorylation at T71 (P = 0.1091)	0.98363308971	0.98345	NULL	0.81604	0.592939972878	0.51909	T	0.522062	0.83304	D	0.419362	0.90987	D	0.364608	0.90874	D	0.656943261623383	0.38762	D	0.844815	0.53011	T	.	.	.	.	.	.	2.661472	0.44769	22.8	2.384476	0.41162	22.3	0.99251273124123018	0.56891	0.88626	0.48642	D	AEFDBI	0.333646	0.43267	N	0.183437067158245	0.50403	3.230708	0.267377501239808	0.53645	3.532357	0.999767772100805	0.42728	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.39	5.39	0.77615	1.888000	0.39342	1.138000	0.64695	0.665000	0.62972	0.972000	0.34453	0.997000	0.62031	0.978000	0.57271	0.0:0.0:0.0:1.0	14.5862	0.67920	793	0.45818	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	143304	6.978172e-06	0	0	42044	0	0	0	13656	0	0	0	3324	0	0	0	3134	0	0	0	10476	0	0	1	64570	1.548707e-05	0	1	64570	1.548707e-05	0	2270	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11992606T>C	OMIM_Allelic_Variant:608507.0003|UniProtKB_(protein):O95140#VAR_018608	C4721887|C0270914|CN517202	609260	ORPHA99947|ORPHA64746	.	.	. 	.
1	11992659	C	T	R	W	rs119103263	1	12052716	1	11975303	94	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.280C>T	p.R94W	c.280C>T	p.Arg94Trp	c.280C>T	p.Arg94Trp	principal1	Y	1	YES	+	CGG	1	2	C	./.	./.	./.	0.0	0.91255	D	0.0	0.92824	D	1.0	0.90584	D	0.999	0.92359	D	0.000003	0.62929	D	0.061301	1;1;1	0.81001	A;A;A	simple_aae;simple_aae;without_aae	R94W;R94W;.	3.31	0.90591	M	-3.78	0.98468	D	-7.15	0.96426	D	0.87	0.86725	1.1274	0.99920	D	0.9579	0.98639	D	9	0.495876	0.95074	D	0.926	0.98220	0.847	0.95024	O95140	R94W	Gain of catalytic residue at M97 (P = 0.0043); Loss of helix (P = 0.079); Loss of phosphorylation at S89 (P = 0.0829); Gain of ubiquitination at K98 (P = 0.0918); Loss of disorder (P = 0.135)	0.983147521638	0.98296	1.81973249962	0.91917	0.866561889648	0.92072	D	0.809748	0.95233	D	0.52775	0.95077	D	0.5203	0.95003	D	0.994825899600983	0.86360	D	NULL	0.96720	.	.	.	.	.	.	.	3.995548	0.78459	26.9	3.933172	0.79943	27.1	0.99892903702494884	0.96666	0.96764	0.70813	D	AEFDBI	0.757278	0.69628	D	0.544588954840303	0.69751	5.40195	0.470371984488615	0.66036	4.89999	0.999699646834589	0.41870	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.5	3.57	0.40014	3.140000	0.50281	-0.352000	0.06810	0.599000	0.40250	0.997000	0.40164	0.992000	0.54103	0.990000	0.65344	0.4445:0.5555:0.0:0.0	13.3207	0.59868	793	0.45818	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	2276	Pathogenic	Abnormality_of_the_dentition|Microcephaly|Abnormality_of_dental_enamel|Hyperpigmentation_of_the_skin|Failure_to_thrive|Alopecia_of_scalp|Distal_muscle_weakness|EMG_abnormality|Short_stature|Decreased_body_weight|Scarring_alopecia_of_scalp|Abnormal_blistering_of_the_skin|Nail_dystrophy|Scarring|Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease,_type_2|Hereditary_motor_and_sensory_neuropathy_with_optic_atrophy|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11992659C>T	Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana:CMGVARID00460|OMIM_Allelic_Variant:608507.0009|UniProtKB_(protein):O95140#VAR_029876	C0262444|C4551563|C4021800|C0162834|C2315100|C1860137|C0427065|C0476403|C0349588|C1844806|C3806301|C2132198|C0221260|C0008767|C4721887|C0270914|C0393807|CN517202	609260|601152	ORPHA79375|ORPHA99947|ORPHA64746|ORPHA90120	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11992659	C	T	R	W	rs119103263	1	12052716	1	11975303	94	MFN2	ENSG00000116688	ENST00000412236	ENSP00000412023	Q5JXC5_HUMAN	.	.	c.280C>T	p.Arg94Trp	c.280C>T	p.Arg94Trp	.	.	3	.	+	CGG	1	2	C	./.	./.	./.	0.0	0.91255	D	0.0	0.92824	D	NULL	0.90584	.	NULL	0.92359	.	0.000003	0.62929	D	0.061301	1;1;1	0.81001	A;A;A	simple_aae;simple_aae;without_aae	R94W;R94W;.	NULL	0.90591	.	-4.97	0.98468	D	-7.99	0.96426	D	NULL	0.86725	1.1274	0.99920	D	0.9579	0.98639	D	9	0.495876	0.95074	D	0.926	0.98220	0.847	0.95024	O95140	R94W	Gain of catalytic residue at M97 (P = 0.0043); Loss of helix (P = 0.079); Loss of phosphorylation at S89 (P = 0.0829); Gain of ubiquitination at K98 (P = 0.0918); Loss of disorder (P = 0.135)	0.983147521638	0.98296	NULL	0.91917	0.866561889648	0.92072	D	NULL	0.95233	.	0.52775	0.95077	D	0.5203	0.95003	D	0.994825899600983	0.86360	D	0.965303	0.96720	D	.	.	.	.	.	.	3.995548	0.78459	26.9	3.933172	0.79943	27.1	0.99892903702494884	0.96666	0.96764	0.70813	D	AEFDBI	0.757278	0.69628	D	0.544588954840303	0.69751	5.40195	0.470371984488615	0.66036	4.89999	0.999699646834589	0.41870	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.5	3.57	0.40014	3.140000	0.50281	-0.352000	0.06810	0.599000	0.40250	0.997000	0.40164	0.992000	0.54103	0.990000	0.65344	0.4445:0.5555:0.0:0.0	13.3207	0.59868	793	0.45818	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	2276	Pathogenic	Abnormality_of_the_dentition|Microcephaly|Abnormality_of_dental_enamel|Hyperpigmentation_of_the_skin|Failure_to_thrive|Alopecia_of_scalp|Distal_muscle_weakness|EMG_abnormality|Short_stature|Decreased_body_weight|Scarring_alopecia_of_scalp|Abnormal_blistering_of_the_skin|Nail_dystrophy|Scarring|Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease,_type_2|Hereditary_motor_and_sensory_neuropathy_with_optic_atrophy|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11992659C>T	Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana:CMGVARID00460|OMIM_Allelic_Variant:608507.0009|UniProtKB_(protein):O95140#VAR_029876	C0262444|C4551563|C4021800|C0162834|C2315100|C1860137|C0427065|C0476403|C0349588|C1844806|C3806301|C2132198|C0221260|C0008767|C4721887|C0270914|C0393807|CN517202	609260|601152	ORPHA79375|ORPHA99947|ORPHA64746|ORPHA90120	.	.	. 	.
1	11992659	C	T	R	W	rs119103263	1	12052716	1	11975303	94	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.280C>T	p.R94W	c.280C>T	p.Arg94Trp	c.280C>T	p.Arg94Trp	principal1	Y	2	.	+	CGG	1	2	C	./.	./.	./.	0.0	0.91255	D	0.0	0.92824	D	1.0	0.90584	D	0.999	0.92359	D	0.000003	0.62929	D	0.061301	1;1;1	0.81001	A;A;A	simple_aae;simple_aae;without_aae	R94W;R94W;.	3.31	0.90591	M	-3.78	0.98468	D	-7.15	0.96426	D	0.841	0.86725	1.1274	0.99920	D	0.9579	0.98639	D	9	0.495876	0.95074	D	0.926	0.98220	0.847	0.95024	O95140	R94W	Gain of catalytic residue at M97 (P = 0.0043); Loss of helix (P = 0.079); Loss of phosphorylation at S89 (P = 0.0829); Gain of ubiquitination at K98 (P = 0.0918); Loss of disorder (P = 0.135)	0.983147521638	0.98296	NULL	0.91917	0.866561889648	0.92072	D	0.809748	0.95233	D	0.52775	0.95077	D	0.5203	0.95003	D	0.994825899600983	0.86360	D	0.989801	0.96720	D	.	.	.	.	.	.	3.995548	0.78459	26.9	3.933172	0.79943	27.1	0.99892903702494884	0.96666	0.96764	0.70813	D	AEFDBI	0.757278	0.69628	D	0.544588954840303	0.69751	5.40195	0.470371984488615	0.66036	4.89999	0.999699646834589	0.41870	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.5	3.57	0.40014	3.140000	0.50281	-0.352000	0.06810	0.599000	0.40250	0.997000	0.40164	0.992000	0.54103	0.990000	0.65344	0.4445:0.5555:0.0:0.0	13.3207	0.59868	793	0.45818	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	2276	Pathogenic	Abnormality_of_the_dentition|Microcephaly|Abnormality_of_dental_enamel|Hyperpigmentation_of_the_skin|Failure_to_thrive|Alopecia_of_scalp|Distal_muscle_weakness|EMG_abnormality|Short_stature|Decreased_body_weight|Scarring_alopecia_of_scalp|Abnormal_blistering_of_the_skin|Nail_dystrophy|Scarring|Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease,_type_2|Hereditary_motor_and_sensory_neuropathy_with_optic_atrophy|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11992659C>T	Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana:CMGVARID00460|OMIM_Allelic_Variant:608507.0009|UniProtKB_(protein):O95140#VAR_029876	C0262444|C4551563|C4021800|C0162834|C2315100|C1860137|C0427065|C0476403|C0349588|C1844806|C3806301|C2132198|C0221260|C0008767|C4721887|C0270914|C0393807|CN517202	609260|601152	ORPHA79375|ORPHA99947|ORPHA64746|ORPHA90120	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11992660	G	A	R	Q	rs28940291	1	12052717	1	11975304	94	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.281G>A	p.R94Q	c.281G>A	p.Arg94Gln	c.281G>A	p.Arg94Gln	principal1	Y	1	YES	+	CGG	2	0	G	./.	./.	./.	0.0	0.91255	D	0.004	0.92824	D	1.0	0.90584	D	0.99	0.78936	D	0.000003	0.62929	D	0.061301	1;1;1	0.81001	A;A;A	simple_aae;simple_aae;without_aae	R94Q;R94Q;.	3.31	0.90591	M	-3.75	0.98390	D	-3.39	0.73893	D	0.923	0.92667	1.0957	0.99477	D	0.9624	0.98793	D	9	0.34369	0.92083	D	0.929	0.98330	0.755	0.88480	O95140	R94Q	Loss of MoRF binding (P = 0.0474); Loss of helix (P = 0.079); Loss of phosphorylation at S89 (P = 0.1003); Loss of catalytic residue at R94 (P = 0.1019); Gain of ubiquitination at K98 (P = 0.1497)	0.969007089203	0.96867	1.90927124322	0.92899	0.781873226166	0.79210	T	0.691988	0.91053	D	0.538192	0.95363	D	0.535299	0.95294	D	0.990925669670105	0.81164	D	NULL	0.95230	.	.	.	.	.	.	.	4.496815	0.91215	32	4.293969	0.89947	31	0.999562910397362	0.99975	0.99632	0.98173	D	AEFDBI	0.923043	0.89892	D	0.890312950561235	0.91277	10.80278	0.85981019542601	0.93576	12.13508	0.999999999998828	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.4	5.4	0.77957	9.602000	0.97623	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.996000	0.59523	0.989000	0.64315	0.0:0.0:1.0:0.0	18.1538	0.89617	793	0.45818	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251490	3.976301e-06	0	0	16256	0	0	0	34592	0	0	0	10080	0	0	0	18394	0	0	0	21644	0	0	1	113768	8.789818e-06	0	0	30616	0	0	1	113768	8.789818e-06	0	0	109408	0	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	0	0	0	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	2268	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11992660G>A	OMIM_Allelic_Variant:608507.0001|UniProtKB_(protein):O95140#VAR_018609	C4721887|C0007959|C0270914|CN517202	609260	ORPHA99947|ORPHA166|ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11992660	G	A	R	Q	rs28940291	1	12052717	1	11975304	94	MFN2	ENSG00000116688	ENST00000412236	ENSP00000412023	Q5JXC5_HUMAN	.	.	c.281G>A	p.Arg94Gln	c.281G>A	p.Arg94Gln	.	.	3	.	+	CGG	2	0	G	./.	./.	./.	0.0	0.91255	D	0.0	0.92824	D	NULL	0.90584	.	NULL	0.78936	.	0.000003	0.62929	D	0.061301	1;1;1	0.81001	A;A;A	simple_aae;simple_aae;without_aae	R94Q;R94Q;.	NULL	0.90591	.	-4.93	0.98390	D	-3.99	0.73893	D	NULL	0.92667	1.0957	0.99477	D	0.9624	0.98793	D	9	0.34369	0.92083	D	0.929	0.98330	0.755	0.88480	O95140	R94Q	Loss of MoRF binding (P = 0.0474); Loss of helix (P = 0.079); Loss of phosphorylation at S89 (P = 0.1003); Loss of catalytic residue at R94 (P = 0.1019); Gain of ubiquitination at K98 (P = 0.1497)	0.969007089203	0.96867	NULL	0.92899	0.781873226166	0.79210	T	NULL	0.91053	.	0.538192	0.95363	D	0.535299	0.95294	D	0.990925669670105	0.81164	D	0.954105	0.95230	D	.	.	.	.	.	.	4.496815	0.91215	32	4.293969	0.89947	31	0.999562910397362	0.99975	0.99632	0.98173	D	AEFDBI	0.923043	0.89892	D	0.890312950561235	0.91277	10.80278	0.85981019542601	0.93576	12.13508	0.999999999998828	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.4	5.4	0.77957	9.602000	0.97623	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.996000	0.59523	0.989000	0.64315	0.0:0.0:1.0:0.0	18.1538	0.89617	793	0.45818	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251490	3.976301e-06	0	0	16256	0	0	0	34592	0	0	0	10080	0	0	0	18394	0	0	0	21644	0	0	1	113768	8.789818e-06	0	0	30616	0	0	1	113768	8.789818e-06	0	0	109408	0	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	0	0	0	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	2268	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11992660G>A	OMIM_Allelic_Variant:608507.0001|UniProtKB_(protein):O95140#VAR_018609	C4721887|C0007959|C0270914|CN517202	609260	ORPHA99947|ORPHA166|ORPHA64746	.	.	. 	.
1	11992660	G	A	R	Q	rs28940291	1	12052717	1	11975304	94	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.281G>A	p.R94Q	c.281G>A	p.Arg94Gln	c.281G>A	p.Arg94Gln	principal1	Y	2	.	+	CGG	2	0	G	./.	./.	./.	0.0	0.91255	D	0.004	0.92824	D	1.0	0.90584	D	0.99	0.78936	D	0.000003	0.62929	D	0.061301	1;1;1	0.81001	A;A;A	simple_aae;simple_aae;without_aae	R94Q;R94Q;.	3.31	0.90591	M	-3.75	0.98390	D	-3.39	0.73893	D	0.846	0.92667	1.0957	0.99477	D	0.9624	0.98793	D	9	0.34369	0.92083	D	0.929	0.98330	0.755	0.88480	O95140	R94Q	Loss of MoRF binding (P = 0.0474); Loss of helix (P = 0.079); Loss of phosphorylation at S89 (P = 0.1003); Loss of catalytic residue at R94 (P = 0.1019); Gain of ubiquitination at K98 (P = 0.1497)	0.969007089203	0.96867	NULL	0.92899	0.781873226166	0.79210	T	0.691988	0.91053	D	0.538192	0.95363	D	0.535299	0.95294	D	0.990925669670105	0.81164	D	0.985868	0.95230	D	.	.	.	.	.	.	4.496815	0.91215	32	4.293969	0.89947	31	0.999562910397362	0.99975	0.99632	0.98173	D	AEFDBI	0.923043	0.89892	D	0.890312950561235	0.91277	10.80278	0.85981019542601	0.93576	12.13508	0.999999999998828	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.4	5.4	0.77957	9.602000	0.97623	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.996000	0.59523	0.989000	0.64315	0.0:0.0:1.0:0.0	18.1538	0.89617	793	0.45818	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251490	3.976301e-06	0	0	16256	0	0	0	34592	0	0	0	10080	0	0	0	18394	0	0	0	21644	0	0	1	113768	8.789818e-06	0	0	30616	0	0	1	113768	8.789818e-06	0	0	109408	0	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	0	0	0	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	2268	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11992660G>A	OMIM_Allelic_Variant:608507.0001|UniProtKB_(protein):O95140#VAR_018609	C4721887|C0007959|C0270914|CN517202	609260	ORPHA99947|ORPHA166|ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11992689	C	T	R	W	rs119103268	1	12052746	1	11975333	104	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.310C>T	p.R104W	c.310C>T	p.Arg104Trp	c.310C>T	p.Arg104Trp	principal1	Y	1	YES	+	CGG	1	2	C	C/C	C/C	C/C	0.0	0.91255	D	0.001	0.83351	D	1.0	0.90584	D	1.0	0.97372	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	A;A;A	simple_aae;simple_aae;without_aae	R104W;R104W;.	3.515	0.92918	H	-4.18	0.96882	D	-7.36	0.94647	D	0.961	0.97095	1.1108	0.99870	D	0.9297	0.97679	D	9	0.515612	0.95368	D	0.933	0.98477	0.849	0.95142	O95140	R104W	Loss of disorder (P = 0.0255); Loss of methylation at R104 (P = 0.0596); Loss of MoRF binding (P = 0.0789); Loss of phosphorylation at T105 (P = 0.1106); Loss of sheet (P = 0.1158)	0.984275377713	0.98410	1.82215970064	0.91975	0.891783475876	0.95480	D	0.963939	0.99555	D	0.541944	0.95494	D	0.540689	0.95427	D	0.996000051498413	0.88484	D	NULL	0.89491	.	.	.	.	.	.	.	4.107923	0.82358	27.8	4.002579	0.82396	27.7	0.99879631995631368	0.95572	0.94877	0.62640	D	AEFDBI	0.792697	0.72092	D	0.516356366743475	0.68057	5.165037	0.412244621590025	0.62325	4.446253	0.998246555574262	0.36633	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.5	2.2	0.26966	3.545000	0.53401	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	0.994000	0.56301	0.842000	0.39752	0.6865:0.3135:0.0:0.0	12.6347	0.56037	793	0.45818	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	2281	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease,_axonal,_autosomal_recessive,_type_2A2B|Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2|Hereditary_motor_and_sensory_neuropathy_with_optic_atrophy|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11992689C>T	OMIM_Allelic_Variant:608507.0014	C4721887|C4310725|C0007959|C0270914|C0393807|CN517202	609260|617087|601152	ORPHA99947|ORPHA166|ORPHA64746|ORPHA90120	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11992689	C	T	R	W	rs119103268	1	12052746	1	11975333	104	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.310C>T	p.R104W	c.310C>T	p.Arg104Trp	c.310C>T	p.Arg104Trp	principal1	Y	2	.	+	CGG	1	2	C	C/C	C/C	C/C	0.0	0.91255	D	0.001	0.83351	D	1.0	0.90584	D	1.0	0.97372	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	A;A;A	simple_aae;simple_aae;without_aae	R104W;R104W;.	3.515	0.92918	H	-4.18	0.96882	D	-7.36	0.94647	D	0.948	0.97095	1.1108	0.99870	D	0.9297	0.97679	D	9	0.515612	0.95368	D	0.933	0.98477	0.849	0.95142	O95140	R104W	Loss of disorder (P = 0.0255); Loss of methylation at R104 (P = 0.0596); Loss of MoRF binding (P = 0.0789); Loss of phosphorylation at T105 (P = 0.1106); Loss of sheet (P = 0.1158)	0.984275377713	0.98410	NULL	0.91975	0.891783475876	0.95480	D	0.963939	0.99555	D	0.541944	0.95494	D	0.540689	0.95427	D	0.996000051498413	0.88484	D	0.970703	0.89491	D	.	.	.	.	.	.	4.107923	0.82358	27.8	4.002579	0.82396	27.7	0.99879631995631368	0.95572	0.94877	0.62640	D	AEFDBI	0.792697	0.72092	D	0.516356366743475	0.68057	5.165037	0.412244621590025	0.62325	4.446253	0.998246555574262	0.36633	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.5	2.2	0.26966	3.545000	0.53401	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	0.994000	0.56301	0.842000	0.39752	0.6865:0.3135:0.0:0.0	12.6347	0.56037	793	0.45818	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	2281	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease,_axonal,_autosomal_recessive,_type_2A2B|Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2|Hereditary_motor_and_sensory_neuropathy_with_optic_atrophy|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11992689C>T	OMIM_Allelic_Variant:608507.0014	C4721887|C4310725|C0007959|C0270914|C0393807|CN517202	609260|617087|601152	ORPHA99947|ORPHA166|ORPHA64746|ORPHA90120	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11992690	G	T	R	L	rs863224068	1	12052747	1	11975334	104	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.311G>T	p.R104L	c.311G>T	p.Arg104Leu	c.311G>T	p.Arg104Leu	principal1	Y	1	YES	+	CGG	2	0	G	G/G	G/G	G/G	0.0	0.91255	D	0.004	0.74150	D	1.0	0.90584	D	0.994	0.82059	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	R104L;R104L;.	2.415	0.69758	M	-4.15	0.96798	D	-6.44	0.91353	D	0.948	0.95608	1.0311	0.97738	D	0.9111	0.97053	D	10	0.341071	0.92016	D	0.945	0.98904	0.69	0.82741	O95140	R104L	Loss of MoRF binding (P = 0.0192); Loss of disorder (P = 0.0525); Loss of methylation at R104 (P = 0.0596); Gain of ubiquitination at K109 (P = 0.1062); Loss of sheet (P = 0.1158)	0.993529388208	0.99345	2.00226819047	0.93838	0.865937113762	0.91982	D	0.88779	0.97696	D	0.545015	0.95624	D	0.5451	0.95559	D	0.989687025547028	0.79907	D	NULL	0.80130	.	.	.	.	.	.	.	5.579648	0.94785	34	5.434423	0.94244	33	0.99831557609853938	0.91284	0.99693	0.98721	D	AEFDBI	0.925339	0.90473	D	0.762758748056215	0.83733	8.095391	0.759022670195828	0.86831	9.016637	0.999999999999311	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.5	5.5	0.81386	9.602000	0.97623	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.985000	0.49585	0.775000	0.36711	0.0:0.0:1.0:0.0	18.3893	0.90421	793	0.45818	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	214651	Conflicting_interpretations_of_pathogenicity	Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.11992690G>T	.	C0007959|C0270914|CN517202	.	ORPHA166|ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11992690	G	T	R	L	rs863224068	1	12052747	1	11975334	104	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.311G>T	p.R104L	c.311G>T	p.Arg104Leu	c.311G>T	p.Arg104Leu	principal1	Y	2	.	+	CGG	2	0	G	G/G	G/G	G/G	0.0	0.91255	D	0.004	0.74150	D	1.0	0.90584	D	0.994	0.82059	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	R104L;R104L;.	2.415	0.69758	M	-4.15	0.96798	D	-6.44	0.91353	D	0.913	0.95608	1.0311	0.97738	D	0.9111	0.97053	D	10	0.341071	0.92016	D	0.945	0.98904	0.69	0.82741	O95140	R104L	Loss of MoRF binding (P = 0.0192); Loss of disorder (P = 0.0525); Loss of methylation at R104 (P = 0.0596); Gain of ubiquitination at K109 (P = 0.1062); Loss of sheet (P = 0.1158)	0.993529388208	0.99345	NULL	0.93838	0.865937113762	0.91982	D	0.88779	0.97696	D	0.545015	0.95624	D	0.5451	0.95559	D	0.989687025547028	0.79907	D	0.948405	0.80130	D	.	.	.	.	.	.	5.579648	0.94785	34	5.434423	0.94244	33	0.99831557609853938	0.91284	0.99693	0.98721	D	AEFDBI	0.925339	0.90473	D	0.762758748056215	0.83733	8.095391	0.759022670195828	0.86831	9.016637	0.999999999999311	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.5	5.5	0.81386	9.602000	0.97623	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.985000	0.49585	0.775000	0.36711	0.0:0.0:1.0:0.0	18.3893	0.90421	793	0.45818	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	214651	Conflicting_interpretations_of_pathogenicity	Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.11992690G>T	.	C0007959|C0270914|CN517202	.	ORPHA166|ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11996158	C	T	T	M	rs863224069	1	12056215	1	11978802	105	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.314C>T	p.T105M	c.314C>T	p.Thr105Met	c.314C>T	p.Thr105Met	principal1	Y	1	YES	+	ACG	2	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.0	0.92824	D	1.0	0.90584	D	1.0	0.97372	D	0.000001	0.62929	D	0.096949	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	T105M;T105M;.	3.53	0.93071	H	-4.13	0.96745	D	-5.53	0.86073	D	0.84	0.84713	1.0293	0.97704	D	0.9341	0.97829	D	10	0.516886	0.95387	D	0.939	0.98693	0.814	0.92923	O95140	T105M	Gain of MoRF binding (P = 0.0657); Loss of phosphorylation at T105 (P = 0.0691); Loss of disorder (P = 0.1017); Loss of sheet (P = 0.1158); Loss of ubiquitination at K109 (P = 0.1231)	0.99005442514	0.98994	1.82215970064	0.91975	0.786411046982	0.79897	T	0.87541	0.97344	D	0.565087	0.96337	D	0.573932	0.96277	D	0.996368408203125	0.89195	D	NULL	0.97830	.	.	.	.	.	.	.	4.038762	0.79945	27.3	3.897120	0.78710	26.9	0.99919452328340108	0.98654	0.94769	0.62266	D	AEFGBCI	0.885297	0.81571	D	0.743889590055459	0.82504	7.779521	0.696125724841268	0.82082	7.680341	0.999999972900581	0.74766	0.706548	0.73137	0	0.702456	0.74545	0	0.702456	0.68683	0	0.714379	0.83352	0	NULL	NULL	5.63	4.7	0.58776	7.568000	0.81546	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	0.996000	0.59523	0.989000	0.64315	0.1426:0.8574:0.0:0.0	15.1139	0.72058	794	0.45591	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	214652	Pathogenic/Likely_pathogenic	Cerebellar_ataxia|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11996158C>T	.	C0007758|C0270914|CN517202	.	ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11996158	C	T	T	M	rs863224069	1	12056215	1	11978802	105	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.314C>T	p.T105M	c.314C>T	p.Thr105Met	c.314C>T	p.Thr105Met	principal1	Y	2	.	+	ACG	2	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.0	0.92824	D	1.0	0.90584	D	1.0	0.97372	D	0.000001	0.62929	D	0.096949	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	T105M;T105M;.	3.53	0.93071	H	-4.13	0.96745	D	-5.53	0.86073	D	0.851	0.84713	1.0293	0.97704	D	0.9341	0.97829	D	10	0.516886	0.95387	D	0.939	0.98693	0.814	0.92923	O95140	T105M	Gain of MoRF binding (P = 0.0657); Loss of phosphorylation at T105 (P = 0.0691); Loss of disorder (P = 0.1017); Loss of sheet (P = 0.1158); Loss of ubiquitination at K109 (P = 0.1231)	0.99005442514	0.98994	NULL	0.91975	0.786411046982	0.79897	T	0.87541	0.97344	D	0.565087	0.96337	D	0.573932	0.96277	D	0.996368408203125	0.89195	D	0.993376	0.97830	D	.	.	.	.	.	.	4.038762	0.79945	27.3	3.897120	0.78710	26.9	0.99919452328340108	0.98654	0.94769	0.62266	D	AEFGBCI	0.885297	0.81571	D	0.743889590055459	0.82504	7.779521	0.696125724841268	0.82082	7.680341	0.999999972900581	0.74766	0.706548	0.73137	0	0.702456	0.74545	0	0.702456	0.68683	0	0.714379	0.83352	0	NULL	NULL	5.63	4.7	0.58776	7.568000	0.81546	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	0.996000	0.59523	0.989000	0.64315	0.1426:0.8574:0.0:0.0	15.1139	0.72058	794	0.45591	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	214652	Pathogenic/Likely_pathogenic	Cerebellar_ataxia|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11996158C>T	.	C0007758|C0270914|CN517202	.	ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11996280	C	T	L	F	rs863224969	1	12056337	1	11978924	146	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.436C>T	p.L146F	c.436C>T	p.Leu146Phe	c.436C>T	p.Leu146Phe	principal1	Y	1	YES	+	CTC	1	0	C	C/C	C/C	C/C	0.002	0.72154	D	0.008	0.67890	D	0.986	0.61523	D	0.956	0.69739	D	0.000015	0.62929	D	0.069388	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	L146F;L146F;.	2.655	0.77738	M	-3.77	0.95595	D	-3.35	0.66436	D	0.795	0.79118	1.0339	0.97791	D	0.9302	0.97696	D	10	0.232288	0.88314	D	0.850	0.95426	0.499	0.58978	O95140	L146F	Loss of stability (P = 0.0717); Loss of disorder (P = 0.1784); Loss of glycosylation at T148 (P = 0.226); Loss of phosphorylation at S151 (P = 0.2551); Gain of catalytic residue at L146 (P = 0.2711)	0.947914922325	0.94737	1.72783042209	0.90689	0.777217447758	0.78508	T	0.869494	0.97169	D	0.444288	0.92224	D	0.400413	0.92128	D	0.965108750791859	0.67164	D	NULL	0.83260	.	.	.	.	.	.	.	3.682891	0.68894	25.3	3.896975	0.78672	26.9	0.99906976004524439	0.97726	0.90122	0.51054	D	AEFDGBHCI	0.615356	0.60233	D	0.763939045497572	0.83811	8.115847	0.717268608916253	0.83690	8.088413	0.999999953233758	0.74766	0.706548	0.73137	0	0.702456	0.74545	0	0.702456	0.68683	0	0.714379	0.83352	0	NULL	NULL	5.34	5.34	0.75982	3.460000	0.52793	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	0.999000	0.70432	0.977000	0.56843	0.0:1.0:0.0:0.0	18.3811	0.90395	794	0.45591	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	217163	Likely_pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11996280C>T	.	C4721887|CN517202	609260	ORPHA99947	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11996280	C	T	L	F	rs863224969	1	12056337	1	11978924	146	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.436C>T	p.L146F	c.436C>T	p.Leu146Phe	c.436C>T	p.Leu146Phe	principal1	Y	2	.	+	CTC	1	0	C	C/C	C/C	C/C	0.002	0.72154	D	0.008	0.67890	D	0.986	0.61523	D	0.956	0.69739	D	0.000015	0.62929	D	0.069388	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	L146F;L146F;.	2.655	0.77738	M	-3.77	0.95595	D	-3.35	0.66436	D	0.735	0.79118	1.0339	0.97791	D	0.9302	0.97696	D	10	0.232288	0.88314	D	0.850	0.95426	0.499	0.58978	O95140	L146F	Loss of stability (P = 0.0717); Loss of disorder (P = 0.1784); Loss of glycosylation at T148 (P = 0.226); Loss of phosphorylation at S151 (P = 0.2551); Gain of catalytic residue at L146 (P = 0.2711)	0.947914922325	0.94737	NULL	0.90689	0.777217447758	0.78508	T	0.869494	0.97169	D	0.444288	0.92224	D	0.400413	0.92128	D	0.965108750791859	0.67164	D	0.956004	0.83260	D	.	.	.	.	.	.	3.682891	0.68894	25.3	3.896975	0.78672	26.9	0.99906976004524439	0.97726	0.90122	0.51054	D	AEFDGBHCI	0.615356	0.60233	D	0.763939045497572	0.83811	8.115847	0.717268608916253	0.83690	8.088413	0.999999953233758	0.74766	0.706548	0.73137	0	0.702456	0.74545	0	0.702456	0.68683	0	0.714379	0.83352	0	NULL	NULL	5.34	5.34	0.75982	3.460000	0.52793	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	0.999000	0.70432	0.977000	0.56843	0.0:1.0:0.0:0.0	18.3811	0.90395	794	0.45591	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	217163	Likely_pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11996280C>T	.	C4721887|CN517202	609260	ORPHA99947	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11997301	T	G	V	G	rs879253861	1	12057358	1	11979945	160	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.479T>G	p.V160G	c.479T>G	p.Val160Gly	c.479T>G	p.Val160Gly	principal1	Y	1	YES	+	GTG	2	0	T	T/T	T/T	T/T	0.0	0.91255	D	0.001	0.83351	D	1.0	0.90584	D	0.991	0.79672	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	V160G;V160G;.	3.165	0.88605	M	-4.23	0.97006	D	-6.26	0.90608	D	0.892	0.89131	1.0917	0.99307	D	0.9427	0.98122	D	10	0.648603	0.97021	D	0.980	0.99860	0.634	0.77022	O95140	V160G	Gain of sheet (P = 4e-04); Loss of stability (P = 0.0038); Loss of loop (P = 0.0145); Gain of disorder (P = 0.0175); Loss of helix (P = 0.0196)	0.983655166124	0.98347	2.03905293338	0.94204	0.741235136986	0.73155	T	0.878358	0.97430	D	0.570204	0.96612	D	0.581282	0.96556	D	0.998434245586395	0.94140	D	NULL	0.56549	.	.	.	.	.	.	.	4.122162	0.82857	27.9	3.876522	0.77973	26.7	0.99701575102773232	0.80660	0.96124	0.67642	D	AEFDBCIJ	0.947365	0.95783	D	0.796934572860399	0.85914	8.720662	0.75563867251142	0.86576	8.934266	0.999999995879604	0.74766	0.719381	0.83141	0	0.724815	0.89359	0	0.724815	0.87919	0	0.733575	0.97253	0	NULL	NULL	5.3	5.3	0.74745	7.667000	0.82852	1.138000	0.64695	0.654000	0.53741	1.000000	0.71638	1.000000	0.86279	0.975000	0.56047	0.0:0.0:0.0:1.0	14.4621	0.67034	789	0.46346	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	243073	Likely_pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A	criteria_provided,_single_submitter	NC_000001.11:g.11997301T>G	.	C4721887	609260	ORPHA99947	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11997301	T	G	V	G	rs879253861	1	12057358	1	11979945	160	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.479T>G	p.V160G	c.479T>G	p.Val160Gly	c.479T>G	p.Val160Gly	principal1	Y	2	.	+	GTG	2	0	T	T/T	T/T	T/T	0.0	0.91255	D	0.001	0.83351	D	1.0	0.90584	D	0.991	0.79672	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	V160G;V160G;.	3.165	0.88605	M	-4.23	0.97006	D	-6.26	0.90608	D	0.852	0.89131	1.0917	0.99307	D	0.9427	0.98122	D	10	0.648603	0.97021	D	0.980	0.99860	0.634	0.77022	O95140	V160G	Gain of sheet (P = 4e-04); Loss of stability (P = 0.0038); Loss of loop (P = 0.0145); Gain of disorder (P = 0.0175); Loss of helix (P = 0.0196)	0.983655166124	0.98347	NULL	0.94204	0.741235136986	0.73155	T	0.878358	0.97430	D	0.570204	0.96612	D	0.581282	0.96556	D	0.998434245586395	0.94140	D	0.865813	0.56549	D	.	.	.	.	.	.	4.122162	0.82857	27.9	3.876522	0.77973	26.7	0.99701575102773232	0.80660	0.96124	0.67642	D	AEFDBCIJ	0.947365	0.95783	D	0.796934572860399	0.85914	8.720662	0.75563867251142	0.86576	8.934266	0.999999995879604	0.74766	0.719381	0.83141	0	0.724815	0.89359	0	0.724815	0.87919	0	0.733575	0.97253	0	NULL	NULL	5.3	5.3	0.74745	7.667000	0.82852	1.138000	0.64695	0.654000	0.53741	1.000000	0.71638	1.000000	0.86279	0.975000	0.56047	0.0:0.0:0.0:1.0	14.4621	0.67034	789	0.46346	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	243073	Likely_pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A	criteria_provided,_single_submitter	NC_000001.11:g.11997301T>G	.	C4721887	609260	ORPHA99947	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11997316	A	G	H	R	rs863224970	1	12057373	1	11979960	165	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.494A>G	p.H165R	c.494A>G	p.His165Arg	c.494A>G	p.His165Arg	principal1	Y	1	YES	+	CAT	2	0	A	A/A	A/A	A/A	0.001	0.78490	D	0.005	0.72224	D	1.0	0.90584	D	0.991	0.79672	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	H165R;H165R;.	2.09	0.57893	M	-4.07	0.96562	D	-5.63	0.86836	D	0.913	0.91505	0.9501	0.96396	D	0.9060	0.96882	D	10	0.547564	0.95815	D	0.901	0.97290	0.848	0.95084	O95140	H165R	Gain of MoRF binding (P = 0.0054); Loss of catalytic residue at L167 (P = 0.0917); Gain of relative solvent accessibility (P = 0.1259); Gain of solvent accessibility (P = 0.1319); Loss of helix (P = 0.1706)	0.991623395076	0.99153	1.94421044628	0.93273	0.85531437397	0.90415	D	0.865987	0.97065	D	0.529573	0.95161	D	0.522919	0.95089	D	0.994332623676035	0.85562	D	NULL	0.99707	.	.	.	.	.	.	.	3.828631	0.73058	26.0	3.607123	0.69897	25.4	0.99600849519179502	0.74219	0.96845	0.71251	D	AEFDBCIJ	0.942785	0.94780	D	0.655284285948297	0.76713	6.537244	0.63094919403135	0.77197	6.633543	0.999999995879604	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.3	5.3	0.74745	8.938000	0.92462	1.312000	0.94714	0.743000	0.86499	1.000000	0.71638	0.977000	0.46756	0.612000	0.31691	1.0:0.0:0.0:0.0	14.4621	0.67034	789	0.46346	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	217164	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11997316A>G	.	C4721887|C0270914|CN517202	609260	ORPHA99947|ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11997316	A	G	H	R	rs863224970	1	12057373	1	11979960	165	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.494A>G	p.H165R	c.494A>G	p.His165Arg	c.494A>G	p.His165Arg	principal1	Y	2	.	+	CAT	2	0	A	A/A	A/A	A/A	0.001	0.78490	D	0.005	0.72224	D	1.0	0.90584	D	0.991	0.79672	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	H165R;H165R;.	2.09	0.57893	M	-4.07	0.96562	D	-5.63	0.86836	D	0.853	0.91505	0.9501	0.96396	D	0.9060	0.96882	D	10	0.547564	0.95815	D	0.901	0.97290	0.848	0.95084	O95140	H165R	Gain of MoRF binding (P = 0.0054); Loss of catalytic residue at L167 (P = 0.0917); Gain of relative solvent accessibility (P = 0.1259); Gain of solvent accessibility (P = 0.1319); Loss of helix (P = 0.1706)	0.991623395076	0.99153	NULL	0.93273	0.85531437397	0.90415	D	0.865987	0.97065	D	0.529573	0.95161	D	0.522919	0.95089	D	0.994332623676035	0.85562	D	0.999243	0.99707	D	.	.	.	.	.	.	3.828631	0.73058	26.0	3.607123	0.69897	25.4	0.99600849519179502	0.74219	0.96845	0.71251	D	AEFDBCIJ	0.942785	0.94780	D	0.655284285948297	0.76713	6.537244	0.63094919403135	0.77197	6.633543	0.999999995879604	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.3	5.3	0.74745	8.938000	0.92462	1.312000	0.94714	0.743000	0.86499	1.000000	0.71638	0.977000	0.46756	0.612000	0.31691	1.0:0.0:0.0:0.0	14.4621	0.67034	789	0.46346	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	217164	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11997316A>G	.	C4721887|C0270914|CN517202	609260	ORPHA99947|ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11997348	G	A	G	S	rs879253862	1	12057405	1	11979992	176	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.526G>A	p.G176S	c.526G>A	p.Gly176Ser	c.526G>A	p.Gly176Ser	principal1	Y	1	YES	+	GGC	1	0	G	G/G	G/G	G/G	0.712	0.04020	T	0.747	0.04860	T	0.629	0.40170	P	0.277	0.40197	B	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	G176S;G176S;.	-0.2	0.04182	N	-4.22	0.96982	D	0.01	0.06868	N	0.769	0.78546	0.5393	0.91090	D	0.7585	0.91774	D	10	0.142157	0.82455	D	0.621	0.85482	0.659	0.79680	O95140	G176S	Gain of disorder (P = 0.0407); Gain of sheet (P = 0.1451); Loss of catalytic residue at A175 (P = 0.1561); Gain of loop (P = 0.2045); Gain of helix (P = 0.2059)	0.946511638508	0.94594	1.68067603589	0.89969	0.823376119137	0.85546	D	0.546504	0.84567	D	0.337435	0.85664	D	0.246925	0.85476	D	0.952769219875336	0.63868	D	NULL	0.85970	.	.	.	.	.	.	.	2.665065	0.44846	22.8	2.545960	0.44725	22.6	0.99429962410704609	0.64227	0.97288	0.73812	D	AEFDBCIJ	0.946614	0.95626	D	0.229729598980057	0.52643	3.437323	0.394185476212533	0.61204	4.317465	0.999999999992233	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.3	5.3	0.74745	9.593000	0.97414	1.176000	0.78918	0.665000	0.62972	1.000000	0.71638	0.987000	0.50568	0.990000	0.65344	0.0:0.0:1.0:0.0	17.9795	0.89058	789	0.46346	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	243074	Likely_pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease,_axonal,_autosomal_recessive,_type_2A2B	criteria_provided,_single_submitter	NC_000001.11:g.11997348G>A	.	C4721887|C4310725	609260|617087	ORPHA99947	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11997348	G	A	G	S	rs879253862	1	12057405	1	11979992	176	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.526G>A	p.G176S	c.526G>A	p.Gly176Ser	c.526G>A	p.Gly176Ser	principal1	Y	2	.	+	GGC	1	0	G	G/G	G/G	G/G	0.712	0.04020	T	0.747	0.04860	T	0.629	0.40170	P	0.277	0.40197	B	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	G176S;G176S;.	-0.2	0.04182	N	-4.22	0.96982	D	0.01	0.06868	N	0.789	0.78546	0.5393	0.91090	D	0.7585	0.91774	D	10	0.142157	0.82455	D	0.621	0.85482	0.659	0.79680	O95140	G176S	Gain of disorder (P = 0.0407); Gain of sheet (P = 0.1451); Loss of catalytic residue at A175 (P = 0.1561); Gain of loop (P = 0.2045); Gain of helix (P = 0.2059)	0.946511638508	0.94594	NULL	0.89969	0.823376119137	0.85546	D	0.546504	0.84567	D	0.337435	0.85664	D	0.246925	0.85476	D	0.952769219875336	0.63868	D	0.962504	0.85970	D	.	.	.	.	.	.	2.665065	0.44846	22.8	2.545960	0.44725	22.6	0.99429962410704609	0.64227	0.97288	0.73812	D	AEFDBCIJ	0.946614	0.95626	D	0.229729598980057	0.52643	3.437323	0.394185476212533	0.61204	4.317465	0.999999999992233	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.3	5.3	0.74745	9.593000	0.97414	1.176000	0.78918	0.665000	0.62972	1.000000	0.71638	0.987000	0.50568	0.990000	0.65344	0.0:0.0:1.0:0.0	17.9795	0.89058	789	0.46346	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	243074	Likely_pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease,_axonal,_autosomal_recessive,_type_2A2B	criteria_provided,_single_submitter	NC_000001.11:g.11997348G>A	.	C4721887|C4310725	609260|617087	ORPHA99947	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11997363	G	A	V	M	rs863224064	1	12057420	1	11980007	181	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.541G>A	p.V181M	c.541G>A	p.Val181Met	c.541G>A	p.Val181Met	principal1	Y	1	YES	+	GTG	1	0	G	G/G	G/G	G/G	0.001	0.78490	D	0.002	0.79402	D	1.0	0.90584	D	0.997	0.86255	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	V181M;V181M;.	3.095	0.87515	M	-3.86	0.95891	D	-2.42	0.53096	N	0.686	0.71055	1.0714	0.98628	D	0.9360	0.97893	D	10	0.229128	0.88170	D	0.862	0.95863	0.656	0.79370	O95140	V181M	Gain of disorder (P = 0.0871); Gain of glycosylation at P184 (P = 0.1231); Loss of loop (P = 0.1242); Gain of sheet (P = 0.1451); Loss of catalytic residue at V181 (P = 0.1943)	0.922326513392	0.92154	1.68699775569	0.90071	0.890999317169	0.95384	D	0.872939	0.97271	D	0.391498	0.89417	D	0.324583	0.89284	D	0.964948299889758	0.67114	D	NULL	0.94055	.	.	.	.	.	.	.	4.435165	0.90568	31	4.409804	0.91206	32	0.99877947146852497	0.95491	0.96410	0.69001	D	AEFDBCI	0.938922	0.93882	D	0.913202289753707	0.92391	11.39647	0.856605675510414	0.93395	12.01505	0.999999999992233	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.3	5.3	0.74745	7.739000	0.83905	1.176000	0.78918	0.665000	0.62972	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	0.0:0.0:1.0:0.0	17.9795	0.89058	789	0.46346	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251480	3.976459e-06	0	0	16256	0	0	0	34590	0	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	1	113756	8.790745e-06	0	0	30616	0	0	1	113756	8.790745e-06	0	0	109408	0	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	0	0	0	0	.	1	143310	6.977880e-06	0	0	42042	0	0	0	13654	0	0	0	3322	0	0	0	3134	0	0	0	10474	0	0	1	64582	1.548419e-05	0	1	64582	1.548419e-05	0	214640	Likely_pathogenic	not_provided	criteria_provided,_single_submitter	NC_000001.11:g.11997363G>A	.	CN517202	.	.	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11997363	G	A	V	M	rs863224064	1	12057420	1	11980007	181	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.541G>A	p.V181M	c.541G>A	p.Val181Met	c.541G>A	p.Val181Met	principal1	Y	2	.	+	GTG	1	0	G	G/G	G/G	G/G	0.001	0.78490	D	0.002	0.79402	D	1.0	0.90584	D	0.997	0.86255	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	V181M;V181M;.	3.095	0.87515	M	-3.86	0.95891	D	-2.42	0.53096	N	0.707	0.71055	1.0714	0.98628	D	0.9360	0.97893	D	10	0.229128	0.88170	D	0.862	0.95863	0.656	0.79370	O95140	V181M	Gain of disorder (P = 0.0871); Gain of glycosylation at P184 (P = 0.1231); Loss of loop (P = 0.1242); Gain of sheet (P = 0.1451); Loss of catalytic residue at V181 (P = 0.1943)	0.922326513392	0.92154	NULL	0.90071	0.890999317169	0.95384	D	0.872939	0.97271	D	0.391498	0.89417	D	0.324583	0.89284	D	0.964948299889758	0.67114	D	0.982402	0.94055	D	.	.	.	.	.	.	4.435165	0.90568	31	4.409804	0.91206	32	0.99877947146852497	0.95491	0.96410	0.69001	D	AEFDBCI	0.938922	0.93882	D	0.913202289753707	0.92391	11.39647	0.856605675510414	0.93395	12.01505	0.999999999992233	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.3	5.3	0.74745	7.739000	0.83905	1.176000	0.78918	0.665000	0.62972	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	0.0:0.0:1.0:0.0	17.9795	0.89058	789	0.46346	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251480	3.976459e-06	0	0	16256	0	0	0	34590	0	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	1	113756	8.790745e-06	0	0	30616	0	0	1	113756	8.790745e-06	0	0	109408	0	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	0	0	0	0	.	1	143310	6.977880e-06	0	0	42042	0	0	0	13654	0	0	0	3322	0	0	0	3134	0	0	0	10474	0	0	1	64582	1.548419e-05	0	1	64582	1.548419e-05	0	214640	Likely_pathogenic	not_provided	criteria_provided,_single_submitter	NC_000001.11:g.11997363G>A	.	CN517202	.	.	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11998817	T	C	F	S	rs387906990	1	12058874	1	11981461	216	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.647T>C	p.F216S	c.647T>C	p.Phe216Ser	c.647T>C	p.Phe216Ser	principal1	Y	1	YES	+	TTT	2	0	T	T/T	T/T	T/T	0.125	0.27310	T	0.059	0.45961	T	0.045	0.21781	B	0.261	0.39516	B	0.000055	0.53742	D	0.162441	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	F216S;F216S;.	0.935	0.23595	L	-4.19	0.96908	D	-3.16	0.64246	D	0.908	0.91505	0.4890	0.90393	D	0.7989	0.93191	D	10	0.324004	0.91558	D	0.794	0.93319	0.89	0.97320	O95140	F216S	Loss of stability (P = 0.0098); Loss of methylation at K215 (P = 0.035); Loss of helix (P = 0.0558); Gain of loop (P = 0.069); Loss of ubiquitination at K215 (P = 0.0818)	0.991314513656	0.99122	1.33609069953	0.83747	0.903146743774	0.96781	D	0.816524	0.95468	D	0.483721	0.93825	D	0.457055	0.93747	D	0.884348511695862	0.53458	D	NULL	0.94289	.	.	.	.	.	.	.	3.713763	0.69730	25.5	3.376974	0.63973	24.6	0.99705508686827959	0.80936	0.99074	0.90844	D	AEFBCI	0.935196	0.92970	D	0.0322367827641978	0.43327	2.627719	0.192105055512562	0.49413	3.144832	0.999999759102906	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	4.6	4.6	0.56512	7.576000	0.81770	1.134000	0.58424	0.661000	0.55757	1.000000	0.71638	1.000000	0.86279	0.993000	0.69303	0.0:0.0:0.0:1.0	13.4914	0.60852	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	1	2.594706798131811E-4	1	1.322401481089659E-4	NULL	NULL	NULL	NULL	1	8.236e-06	1	8.236e-06	0	0	0	0	0	0	0	0	1	1.498e-05	0	0	1	9.415e-06	1	9.415e-06	0	0	0	0	0	0	0	0	1	1.840e-05	0	0	1	1.102e-05	1	1.102e-05	0	0	0	0	0	0	0	0	1	2.373e-05	0	0	.	1	251496	3.976206e-06	0	0	16256	0	0	0	34592	0	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	1	113770	8.789663e-06	0	0	30616	0	0	1	113770	8.789663e-06	0	0	109408	0	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	0	0	0	0	.	6	143236	4.188891e-05	0	2	42012	4.760545e-05	0	0	13642	0	0	0	3320	0	0	0	3128	0	0	0	10476	0	0	4	64560	6.195787e-05	0	4	64560	6.195787e-05	0	30736	Pathogenic/Likely_pathogenic	Charcot-Marie-Tooth_disease,_axonal,_autosomal_recessive,_type_2A2B|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11998817T>C	OMIM_Allelic_Variant:608507.0017|UniProtKB_(protein):O95140#VAR_076896	C4310725|C0270914|CN517202	617087	ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11998817	T	C	F	S	rs387906990	1	12058874	1	11981461	216	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.647T>C	p.F216S	c.647T>C	p.Phe216Ser	c.647T>C	p.Phe216Ser	principal1	Y	2	.	+	TTT	2	0	T	T/T	T/T	T/T	0.125	0.27310	T	0.059	0.45961	T	0.045	0.21781	B	0.261	0.39516	B	0.000055	0.53742	D	0.162441	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	F216S;F216S;.	0.935	0.23595	L	-4.19	0.96908	D	-3.16	0.64246	D	0.913	0.91505	0.4890	0.90393	D	0.7989	0.93191	D	10	0.324004	0.91558	D	0.794	0.93319	0.89	0.97320	O95140	F216S	Loss of stability (P = 0.0098); Loss of methylation at K215 (P = 0.035); Loss of helix (P = 0.0558); Gain of loop (P = 0.069); Loss of ubiquitination at K215 (P = 0.0818)	0.991314513656	0.99122	NULL	0.83747	0.903146743774	0.96781	D	0.816524	0.95468	D	0.483721	0.93825	D	0.457055	0.93747	D	0.884348511695862	0.53458	D	0.983202	0.94289	D	.	.	.	.	.	.	3.713763	0.69730	25.5	3.376974	0.63973	24.6	0.99705508686827959	0.80936	0.99074	0.90844	D	AEFBCI	0.935196	0.92970	D	0.0322367827641978	0.43327	2.627719	0.192105055512562	0.49413	3.144832	0.999999759102906	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	4.6	4.6	0.56512	7.576000	0.81770	1.134000	0.58424	0.661000	0.55757	1.000000	0.71638	1.000000	0.86279	0.993000	0.69303	0.0:0.0:0.0:1.0	13.4914	0.60852	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	1	2.594706798131811E-4	1	1.322401481089659E-4	NULL	NULL	NULL	NULL	1	8.236e-06	1	8.236e-06	0	0	0	0	0	0	0	0	1	1.498e-05	0	0	1	9.415e-06	1	9.415e-06	0	0	0	0	0	0	0	0	1	1.840e-05	0	0	1	1.102e-05	1	1.102e-05	0	0	0	0	0	0	0	0	1	2.373e-05	0	0	.	1	251496	3.976206e-06	0	0	16256	0	0	0	34592	0	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	1	113770	8.789663e-06	0	0	30616	0	0	1	113770	8.789663e-06	0	0	109408	0	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	0	0	0	0	.	6	143236	4.188891e-05	0	2	42012	4.760545e-05	0	0	13642	0	0	0	3320	0	0	0	3128	0	0	0	10476	0	0	4	64560	6.195787e-05	0	4	64560	6.195787e-05	0	30736	Pathogenic/Likely_pathogenic	Charcot-Marie-Tooth_disease,_axonal,_autosomal_recessive,_type_2A2B|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11998817T>C	OMIM_Allelic_Variant:608507.0017|UniProtKB_(protein):O95140#VAR_076896	C4310725|C0270914|CN517202	617087	ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11998829	C	T	A	V	rs879254010	1	12058886	1	11981473	220	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.659C>T	p.A220V	c.659C>T	p.Ala220Val	c.659C>T	p.Ala220Val	principal1	Y	1	YES	+	GCT	2	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.0	0.92824	D	0.987	0.61912	D	0.988	0.77976	D	0.000002	0.62929	D	0.057644	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	A220V;A220V;.	2.8	0.81625	M	-3.99	0.96308	D	-3.35	0.66436	D	0.941	0.94786	1.0479	0.98073	D	0.9370	0.97927	D	10	0.364814	0.92601	D	0.877	0.96407	0.602	0.73336	O95140	A220V	Loss of catalytic residue at A220 (P = 0.044); Gain of ubiquitination at K215 (P = 0.0828); Gain of methylation at K215 (P = 0.1346); Loss of loop (P = 0.2237); Gain of helix (P = 0.2684)	0.987515976674	0.98738	1.39367733198	0.85049	0.894833922386	0.95847	D	0.867815	0.97119	D	0.537935	0.95359	D	0.53493	0.95290	D	0.992385803187789	0.82850	D	NULL	0.98297	.	.	.	.	.	.	.	4.055084	0.80524	27.4	4.098003	0.85535	28.6	0.99910956515543647	0.98022	0.99057	0.90596	D	AEFBCI	0.922027	0.89640	D	0.798328196362659	0.86000	8.747613	0.735317458857802	0.85057	8.468255	0.99999999915839	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	4.6	4.6	0.56512	7.471000	0.79986	1.022000	0.39869	0.596000	0.33519	1.000000	0.71638	1.000000	0.86279	1.000000	0.97212	0.0:1.0:0.0:0.0	16.798	0.85469	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	245943	Likely_pathogenic	not_provided	criteria_provided,_single_submitter	NC_000001.11:g.11998829C>T	.	CN517202	.	.	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11998829	C	T	A	V	rs879254010	1	12058886	1	11981473	220	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.659C>T	p.A220V	c.659C>T	p.Ala220Val	c.659C>T	p.Ala220Val	principal1	Y	2	.	+	GCT	2	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.0	0.92824	D	0.987	0.61912	D	0.988	0.77976	D	0.000002	0.62929	D	0.057644	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	A220V;A220V;.	2.8	0.81625	M	-3.99	0.96308	D	-3.35	0.66436	D	0.931	0.94786	1.0479	0.98073	D	0.9370	0.97927	D	10	0.364814	0.92601	D	0.877	0.96407	0.602	0.73336	O95140	A220V	Loss of catalytic residue at A220 (P = 0.044); Gain of ubiquitination at K215 (P = 0.0828); Gain of methylation at K215 (P = 0.1346); Loss of loop (P = 0.2237); Gain of helix (P = 0.2684)	0.987515976674	0.98738	NULL	0.85049	0.894833922386	0.95847	D	0.867815	0.97119	D	0.537935	0.95359	D	0.53493	0.95290	D	0.992385803187789	0.82850	D	0.994967	0.98297	D	.	.	.	.	.	.	4.055084	0.80524	27.4	4.098003	0.85535	28.6	0.99910956515543647	0.98022	0.99057	0.90596	D	AEFBCI	0.922027	0.89640	D	0.798328196362659	0.86000	8.747613	0.735317458857802	0.85057	8.468255	0.99999999915839	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	4.6	4.6	0.56512	7.471000	0.79986	1.022000	0.39869	0.596000	0.33519	1.000000	0.71638	1.000000	0.86279	1.000000	0.97212	0.0:1.0:0.0:0.0	16.798	0.85469	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	245943	Likely_pathogenic	not_provided	criteria_provided,_single_submitter	NC_000001.11:g.11998829C>T	.	CN517202	.	.	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11998877	C	T	T	M	rs773159585	1	12058934	1	11981521	236	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.707C>T	p.T236M	c.707C>T	p.Thr236Met	c.707C>T	p.Thr236Met	principal1	Y	1	YES	+	ACG	2	0	C	C/C	C/C	C/C	0.001	0.78490	D	0.005	0.72224	D	0.821	0.45737	P	0.296	0.40883	B	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	T236M;T236M;.	2.255	0.64187	M	-4.21	0.96957	D	-4.97	0.82063	D	0.912	0.91391	0.8818	0.95428	D	0.8397	0.94642	D	10	0.436393	0.94080	D	0.899	0.97215	0.86	0.95773	O95140	T236M	Loss of disorder (P = 0.1205); Gain of helix (P = 0.132); Loss of ubiquitination at K238 (P = 0.1435); Gain of MoRF binding (P = 0.2743); Loss of loop (P = 0.3664)	0.991528006888	0.99143	1.5806642636	0.88385	0.793151974678	0.80922	T	0.897306	0.97959	D	0.525359	0.95038	D	0.516866	0.94964	D	0.984637677669525	0.75878	D	NULL	0.82069	.	.	.	.	.	.	.	4.028869	0.79601	27.2	4.004505	0.82434	27.7	0.99738288944312725	0.83264	0.97993	0.78710	D	AEFBCI	0.932198	0.92218	D	0.477358871526967	0.65770	4.864486	0.510391323692697	0.68686	5.2547	0.999999999620705	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	4.9	4.9	0.63643	7.537000	0.80946	1.022000	0.39869	0.596000	0.33519	1.000000	0.71638	1.000000	0.86279	0.989000	0.64315	0.0:1.0:0.0:0.0	17.0951	0.86509	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	8.236e-06	1	8.236e-06	0	0	0	0	0	0	0	0	1	1.498e-05	0	0	1	9.415e-06	1	9.415e-06	0	0	0	0	0	0	0	0	1	1.840e-05	0	0	1	1.102e-05	1	1.102e-05	0	0	0	0	0	0	0	0	1	2.373e-05	0	0	.	2	251478	7.952982e-06	0	0	16254	0	0	0	34592	0	0	1	10080	9.920635e-05	0	0	18394	0	0	0	21646	0	0	1	113762	8.790281e-06	0	0	30616	0	0	1	113762	8.790281e-06	0	0	109406	0	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42766	0	0	0	15690	0	0	0	0	0	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	217165	Pathogenic/Likely_pathogenic	Distal_muscle_weakness|Peripheral_axonal_neuropathy|Distal_lower_limb_amyotrophy|Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11998877C>T	Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana:CMGVARID00618	C0427065|C1263857|C1836451|C4721887|C0007959|C0270914	609260	ORPHA99947|ORPHA166|ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11998877	C	T	T	M	rs773159585	1	12058934	1	11981521	236	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.707C>T	p.T236M	c.707C>T	p.Thr236Met	c.707C>T	p.Thr236Met	principal1	Y	2	.	+	ACG	2	0	C	C/C	C/C	C/C	0.001	0.78490	D	0.005	0.72224	D	0.821	0.45737	P	0.296	0.40883	B	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	T236M;T236M;.	2.255	0.64187	M	-4.21	0.96957	D	-4.97	0.82063	D	0.883	0.91391	0.8818	0.95428	D	0.8397	0.94642	D	10	0.436393	0.94080	D	0.899	0.97215	0.86	0.95773	O95140	T236M	Loss of disorder (P = 0.1205); Gain of helix (P = 0.132); Loss of ubiquitination at K238 (P = 0.1435); Gain of MoRF binding (P = 0.2743); Loss of loop (P = 0.3664)	0.991528006888	0.99143	NULL	0.88385	0.793151974678	0.80922	T	0.897306	0.97959	D	0.525359	0.95038	D	0.516866	0.94964	D	0.984637677669525	0.75878	D	0.953005	0.82069	D	.	.	.	.	.	.	4.028869	0.79601	27.2	4.004505	0.82434	27.7	0.99738288944312725	0.83264	0.97993	0.78710	D	AEFBCI	0.932198	0.92218	D	0.477358871526967	0.65770	4.864486	0.510391323692697	0.68686	5.2547	0.999999999620705	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	4.9	4.9	0.63643	7.537000	0.80946	1.022000	0.39869	0.596000	0.33519	1.000000	0.71638	1.000000	0.86279	0.989000	0.64315	0.0:1.0:0.0:0.0	17.0951	0.86509	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	8.236e-06	1	8.236e-06	0	0	0	0	0	0	0	0	1	1.498e-05	0	0	1	9.415e-06	1	9.415e-06	0	0	0	0	0	0	0	0	1	1.840e-05	0	0	1	1.102e-05	1	1.102e-05	0	0	0	0	0	0	0	0	1	2.373e-05	0	0	.	2	251478	7.952982e-06	0	0	16254	0	0	0	34592	0	0	1	10080	9.920635e-05	0	0	18394	0	0	0	21646	0	0	1	113762	8.790281e-06	0	0	30616	0	0	1	113762	8.790281e-06	0	0	109406	0	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42766	0	0	0	15690	0	0	0	0	0	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	217165	Pathogenic/Likely_pathogenic	Distal_muscle_weakness|Peripheral_axonal_neuropathy|Distal_lower_limb_amyotrophy|Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11998877C>T	Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana:CMGVARID00618	C0427065|C1263857|C1836451|C4721887|C0007959|C0270914	609260	ORPHA99947|ORPHA166|ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11998999	C	A	F	L	rs864622480	1	12059056	1	11981643	240	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.720C>A	p.F240L	c.720C>A	p.Phe240Leu	c.720C>A	p.Phe240Leu	principal1	Y	1	YES	+	TTC	3	2	C	C/C	C/C	C/C	0.0	0.91255	D	0.0	0.92824	D	0.941	0.52883	P	0.766	0.56676	P	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	F240L;F240L;.	2.185	0.61350	M	-3.47	0.94546	D	-5.63	0.86836	D	0.911	0.95139	0.5454	0.91173	D	0.7922	0.92956	D	10	0.276939	0.90090	D	0.801	0.93593	0.826	0.93720	O95140	F240L	Gain of ubiquitination at K238 (P = 0.1062); Gain of loop (P = 0.1069); Loss of helix (P = 0.1299); Gain of disorder (P = 0.1536); Gain of MoRF binding (P = 0.1639)	0.982355181837	0.98216	1.93016318214	0.93125	0.763370394707	0.76432	T	0.870345	0.97194	D	0.454969	0.92703	D	0.415755	0.92613	D	0.986976683139801	0.77566	D	NULL	0.97691	.	.	.	.	.	.	.	3.890621	0.74982	26.3	3.697325	0.72385	25.8	0.99810480415888736	0.89442	0.91314	0.53284	D	AEFBCI	0.535138	0.55389	D	0.277247690735312	0.54996	3.664184	0.2690751527618	0.53743	3.541709	0.848888463891532	0.25006	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.64	2.75	0.31439	1.217000	0.32059	-0.242000	0.08444	0.596000	0.33519	1.000000	0.71638	0.993000	0.55118	0.996000	0.76049	0.0:0.7102:0.0:0.2898	8.9087	0.34698	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	220333	Likely_pathogenic	Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_single_submitter	NC_000001.11:g.11998999C>A	.	C0270914	.	ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11998999	C	A	F	L	rs864622480	1	12059056	1	11981643	240	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.720C>A	p.F240L	c.720C>A	p.Phe240Leu	c.720C>A	p.Phe240Leu	principal1	Y	2	.	+	TTC	3	2	C	C/C	C/C	C/C	0.0	0.91255	D	0.0	0.92824	D	0.941	0.52883	P	0.766	0.56676	P	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	F240L;F240L;.	2.185	0.61350	M	-3.47	0.94546	D	-5.63	0.86836	D	0.944	0.95139	0.5454	0.91173	D	0.7922	0.92956	D	10	0.276939	0.90090	D	0.801	0.93593	0.826	0.93720	O95140	F240L	Gain of ubiquitination at K238 (P = 0.1062); Gain of loop (P = 0.1069); Loss of helix (P = 0.1299); Gain of disorder (P = 0.1536); Gain of MoRF binding (P = 0.1639)	0.982355181837	0.98216	NULL	0.93125	0.763370394707	0.76432	T	0.870345	0.97194	D	0.454969	0.92703	D	0.415755	0.92613	D	0.986976683139801	0.77566	D	0.992884	0.97691	D	.	.	.	.	.	.	3.890621	0.74982	26.3	3.697325	0.72385	25.8	0.99810480415888736	0.89442	0.91314	0.53284	D	AEFBCI	0.535138	0.55389	D	0.277247690735312	0.54996	3.664184	0.2690751527618	0.53743	3.541709	0.848888463891532	0.25006	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.64	2.75	0.31439	1.217000	0.32059	-0.242000	0.08444	0.596000	0.33519	1.000000	0.71638	0.993000	0.55118	0.996000	0.76049	0.0:0.7102:0.0:0.2898	8.9087	0.34698	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	220333	Likely_pathogenic	Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_single_submitter	NC_000001.11:g.11998999C>A	.	C0270914	.	ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11999004	A	G	H	R	rs863224065	1	12059061	1	11981648	242	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.725A>G	p.H242R	c.725A>G	p.His242Arg	c.725A>G	p.His242Arg	principal1	Y	1	YES	+	CAC	2	0	A	A/A	A/A	A/A	0.001	0.78490	D	0.018	0.59732	D	0.999	0.77913	D	0.983	0.75793	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	H242R;H242R;.	2.125	0.59049	M	-3.54	0.94799	D	-7.18	0.94171	D	0.891	0.89020	0.8375	0.94874	D	0.8698	0.95671	D	10	0.242523	0.88764	D	0.871	0.96189	0.393	0.41757	O95140	H242R	Gain of MoRF binding (P = 0.0083); Gain of phosphorylation at S245 (P = 0.062); Loss of ubiquitination at K238 (P = 0.064); Gain of methylation at K243 (P = 0.0669); Loss of disorder (P = 0.1161)	0.980265532537	0.98004	1.97820565408	0.93628	0.818157017231	0.84746	D	0.842178	0.96329	D	0.493449	0.94095	D	0.471029	0.94017	D	0.995197270673811	0.86995	D	NULL	0.94867	.	.	.	.	.	.	.	3.975406	0.77772	26.8	3.748078	0.73866	26.0	0.99728929108750086	0.82619	0.98149	0.80022	D	AEFBCI	0.935538	0.93054	D	0.742588832862478	0.82422	7.758413	0.75141047369294	0.86263	8.833358	0.999999991782255	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.64	5.64	0.86480	8.947000	0.92735	1.307000	0.88494	0.751000	0.87719	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	1.0:0.0:0.0:0.0	15.0525	0.71551	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	143254	6.980608e-06	0	0	42028	0	0	0	13646	0	0	0	3320	0	0	0	3134	0	0	0	10474	0	0	1	64564	1.548851e-05	0	1	64564	1.548851e-05	0	214641	Conflicting_interpretations_of_pathogenicity	Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.11999004A>G	.	C0007959|C0270914|CN517202	.	ORPHA166|ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11999004	A	G	H	R	rs863224065	1	12059061	1	11981648	242	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.725A>G	p.H242R	c.725A>G	p.His242Arg	c.725A>G	p.His242Arg	principal1	Y	2	.	+	CAC	2	0	A	A/A	A/A	A/A	0.001	0.78490	D	0.018	0.59732	D	0.999	0.77913	D	0.983	0.75793	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	H242R;H242R;.	2.125	0.59049	M	-3.54	0.94799	D	-7.18	0.94171	D	0.89	0.89020	0.8375	0.94874	D	0.8698	0.95671	D	10	0.242523	0.88764	D	0.871	0.96189	0.393	0.41757	O95140	H242R	Gain of MoRF binding (P = 0.0083); Gain of phosphorylation at S245 (P = 0.062); Loss of ubiquitination at K238 (P = 0.064); Gain of methylation at K243 (P = 0.0669); Loss of disorder (P = 0.1161)	0.980265532537	0.98004	NULL	0.93628	0.818157017231	0.84746	D	0.842178	0.96329	D	0.493449	0.94095	D	0.471029	0.94017	D	0.995197270673811	0.86995	D	0.985101	0.94867	D	.	.	.	.	.	.	3.975406	0.77772	26.8	3.748078	0.73866	26.0	0.99728929108750086	0.82619	0.98149	0.80022	D	AEFBCI	0.935538	0.93054	D	0.742588832862478	0.82422	7.758413	0.75141047369294	0.86263	8.833358	0.999999991782255	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.64	5.64	0.86480	8.947000	0.92735	1.307000	0.88494	0.751000	0.87719	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	1.0:0.0:0.0:0.0	15.0525	0.71551	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	143254	6.980608e-06	0	0	42028	0	0	0	13646	0	0	0	3320	0	0	0	3134	0	0	0	10474	0	0	1	64564	1.548851e-05	0	1	64564	1.548851e-05	0	214641	Conflicting_interpretations_of_pathogenicity	Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.11999004A>G	.	C0007959|C0270914|CN517202	.	ORPHA166|ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11999009	G	A	V	M	rs879253777	1	12059066	1	11981653	244	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.730G>A	p.V244M	c.730G>A	p.Val244Met	c.730G>A	p.Val244Met	principal1	Y	1	YES	+	GTG	1	0	G	G/G	G/G	G/G	0.0	0.91255	D	0.0	0.92824	D	1.0	0.90584	D	0.998	0.88582	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	V244M;V244M;.	3.365	0.91266	M	-3.88	0.95953	D	-2.65	0.56787	D	0.85	0.85979	1.0189	0.97514	D	0.9118	0.97076	D	10	0.332774	0.91798	D	0.911	0.97661	0.798	0.91799	O95140	V244M	Gain of catalytic residue at V244 (P = 0.051); Loss of methylation at K243 (P = 0.0517); Gain of disorder (P = 0.0599); Gain of MoRF binding (P = 0.1037); Gain of phosphorylation at S245 (P = 0.1773)	0.970305830279	0.96998	1.79716229483	0.91593	0.787971735001	0.80134	T	0.862642	0.96965	D	0.558557	0.96068	D	0.564552	0.96005	D	0.987706411477598	0.78149	D	NULL	0.99827	.	.	.	.	.	.	.	4.162799	0.84247	28.3	4.023906	0.83142	27.9	0.99914600760549732	0.98309	0.97617	0.75933	D	AEFBCI	0.933589	0.92571	D	0.889768846607124	0.91249	10.78911	0.886298559870611	0.94947	13.17784	0.999999999989603	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.64	5.64	0.86480	9.602000	0.97623	1.172000	0.72986	0.672000	0.70159	1.000000	0.71638	0.998000	0.65909	0.995000	0.73285	0.0:0.0:1.0:0.0	18.7056	0.91599	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	243066	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11999009G>A	.	C4721887|C0270914	609260	ORPHA99947|ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11999009	G	A	V	M	rs879253777	1	12059066	1	11981653	244	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.730G>A	p.V244M	c.730G>A	p.Val244Met	c.730G>A	p.Val244Met	principal1	Y	2	.	+	GTG	1	0	G	G/G	G/G	G/G	0.0	0.91255	D	0.0	0.92824	D	1.0	0.90584	D	0.998	0.88582	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	V244M;V244M;.	3.365	0.91266	M	-3.88	0.95953	D	-2.65	0.56787	D	0.863	0.85979	1.0189	0.97514	D	0.9118	0.97076	D	10	0.332774	0.91798	D	0.911	0.97661	0.798	0.91799	O95140	V244M	Gain of catalytic residue at V244 (P = 0.051); Loss of methylation at K243 (P = 0.0517); Gain of disorder (P = 0.0599); Gain of MoRF binding (P = 0.1037); Gain of phosphorylation at S245 (P = 0.1773)	0.970305830279	0.96998	NULL	0.91593	0.787971735001	0.80134	T	0.862642	0.96965	D	0.558557	0.96068	D	0.564552	0.96005	D	0.987706411477598	0.78149	D	0.9996	0.99827	D	.	.	.	.	.	.	4.162799	0.84247	28.3	4.023906	0.83142	27.9	0.99914600760549732	0.98309	0.97617	0.75933	D	AEFBCI	0.933589	0.92571	D	0.889768846607124	0.91249	10.78911	0.886298559870611	0.94947	13.17784	0.999999999989603	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.64	5.64	0.86480	9.602000	0.97623	1.172000	0.72986	0.672000	0.70159	1.000000	0.71638	0.998000	0.65909	0.995000	0.73285	0.0:0.0:1.0:0.0	18.7056	0.91599	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	243066	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease,_type_2	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11999009G>A	.	C4721887|C0270914	609260	ORPHA99947|ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11999009	G	T	V	L	rs879253777	1	12059066	1	11981653	244	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.730G>T	p.V244L	c.730G>T	p.Val244Leu	c.730G>T	p.Val244Leu	principal1	Y	1	YES	+	GTG	1	0	G	G/G	G/G	G/G	0.0	0.91255	D	0.0	0.92824	D	0.941	0.52883	P	0.887	0.62952	P	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	V244L;V244L;.	1.575	0.39704	L	-3.5	0.94658	D	-2.65	0.56787	D	0.97	0.98065	0.8116	0.94554	D	0.8572	0.95244	D	10	0.204432	0.86930	D	0.830	0.94691	0.649	0.78639	O95140	V244L	Loss of methylation at K243 (P = 0.0807); Gain of helix (P = 0.0854); Loss of MoRF binding (P = 0.0954); Loss of loop (P = 0.1242); Gain of disorder (P = 0.1593)	0.960646269291	0.96023	1.77135503122	0.91287	0.766544938087	0.76906	T	0.820872	0.95618	D	0.370319	0.88067	D	0.294161	0.87916	D	0.972184110097132	0.69602	D	NULL	0.99641	.	.	.	.	.	.	.	4.001730	0.78674	27.0	3.862233	0.77499	26.6	0.99801264555154767	0.88639	0.97830	0.77447	D	AEFBCI	0.935538	0.93054	D	0.752124901589085	0.83044	7.914953	0.788938151857871	0.89012	9.804334	0.999999999989603	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.64	5.64	0.86480	9.602000	0.97623	1.172000	0.72986	0.672000	0.70159	1.000000	0.71638	0.998000	0.65909	0.995000	0.73285	0.0:0.0:1.0:0.0	18.7056	0.91599	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	243057	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A	criteria_provided,_single_submitter	NC_000001.11:g.11999009G>T	.	C4721887	609260	ORPHA99947	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11999009	G	T	V	L	rs879253777	1	12059066	1	11981653	244	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.730G>T	p.V244L	c.730G>T	p.Val244Leu	c.730G>T	p.Val244Leu	principal1	Y	2	.	+	GTG	1	0	G	G/G	G/G	G/G	0.0	0.91255	D	0.0	0.92824	D	0.941	0.52883	P	0.887	0.62952	P	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	V244L;V244L;.	1.575	0.39704	L	-3.5	0.94658	D	-2.65	0.56787	D	0.88	0.98065	0.8116	0.94554	D	0.8572	0.95244	D	10	0.204432	0.86930	D	0.830	0.94691	0.649	0.78639	O95140	V244L	Loss of methylation at K243 (P = 0.0807); Gain of helix (P = 0.0854); Loss of MoRF binding (P = 0.0954); Loss of loop (P = 0.1242); Gain of disorder (P = 0.1593)	0.960646269291	0.96023	NULL	0.91287	0.766544938087	0.76906	T	0.820872	0.95618	D	0.370319	0.88067	D	0.294161	0.87916	D	0.972184110097132	0.69602	D	0.999094	0.99641	D	.	.	.	.	.	.	4.001730	0.78674	27.0	3.862233	0.77499	26.6	0.99801264555154767	0.88639	0.97830	0.77447	D	AEFBCI	0.935538	0.93054	D	0.752124901589085	0.83044	7.914953	0.788938151857871	0.89012	9.804334	0.999999999989603	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.64	5.64	0.86480	9.602000	0.97623	1.172000	0.72986	0.672000	0.70159	1.000000	0.71638	0.998000	0.65909	0.995000	0.73285	0.0:0.0:1.0:0.0	18.7056	0.91599	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	243057	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A	criteria_provided,_single_submitter	NC_000001.11:g.11999009G>T	.	C4721887	609260	ORPHA99947	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11999025	C	T	S	F	rs794729198	1	12059082	1	11981669	249	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.746C>T	p.S249F	c.746C>T	p.Ser249Phe	c.746C>T	p.Ser249Phe	principal1	Y	1	YES	+	TCC	2	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.0	0.92824	D	0.975	0.58077	D	0.874	0.62049	P	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	S249F;S249F;.	2.565	0.75005	M	-4.48	0.97606	D	-5.43	0.85323	D	0.892	0.89131	1.0781	0.98822	D	0.9453	0.98211	D	10	0.414129	0.93660	D	0.943	0.98834	0.513	0.61140	O95140	S249F	Loss of sheet (P = 0.007); Loss of disorder (P = 0.0347); Loss of phosphorylation at S249 (P = 0.0384); Gain of loop (P = 0.0502); Loss of MoRF binding (P = 0.1111)	0.962009808031	0.96160	1.87457451814	0.92549	0.749428510666	0.74362	T	0.906471	0.98205	D	0.545828	0.95637	D	0.546268	0.95573	D	0.994116600677369	0.85224	D	NULL	0.99094	.	.	.	.	.	.	.	3.917271	0.75834	26.4	4.098431	0.85568	28.6	0.99852780809232367	0.93191	0.96221	0.68092	D	AEFBCI	0.913797	0.87627	D	0.875347149663497	0.90501	10.43248	0.851085173718902	0.93080	11.81128	0.999999999989603	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.64	5.64	0.86480	7.568000	0.81546	1.022000	0.39869	0.596000	0.33519	1.000000	0.71638	0.997000	0.62031	0.987000	0.62547	0.0:1.0:0.0:0.0	18.7056	0.91599	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	202171	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease	criteria_provided,_single_submitter	NC_000001.11:g.11999025C>T	.	C4721887|C0007959	609260	ORPHA99947|ORPHA166	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11999025	C	T	S	F	rs794729198	1	12059082	1	11981669	249	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.746C>T	p.S249F	c.746C>T	p.Ser249Phe	c.746C>T	p.Ser249Phe	principal1	Y	2	.	+	TCC	2	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.0	0.92824	D	0.975	0.58077	D	0.874	0.62049	P	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	S249F;S249F;.	2.565	0.75005	M	-4.48	0.97606	D	-5.43	0.85323	D	0.861	0.89131	1.0781	0.98822	D	0.9453	0.98211	D	10	0.414129	0.93660	D	0.943	0.98834	0.513	0.61140	O95140	S249F	Loss of sheet (P = 0.007); Loss of disorder (P = 0.0347); Loss of phosphorylation at S249 (P = 0.0384); Gain of loop (P = 0.0502); Loss of MoRF binding (P = 0.1111)	0.962009808031	0.96160	NULL	0.92549	0.749428510666	0.74362	T	0.906471	0.98205	D	0.545828	0.95637	D	0.546268	0.95573	D	0.994116600677369	0.85224	D	0.997863	0.99094	D	.	.	.	.	.	.	3.917271	0.75834	26.4	4.098431	0.85568	28.6	0.99852780809232367	0.93191	0.96221	0.68092	D	AEFBCI	0.913797	0.87627	D	0.875347149663497	0.90501	10.43248	0.851085173718902	0.93080	11.81128	0.999999999989603	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.64	5.64	0.86480	7.568000	0.81546	1.022000	0.39869	0.596000	0.33519	1.000000	0.71638	0.997000	0.62031	0.987000	0.62547	0.0:1.0:0.0:0.0	18.7056	0.91599	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	202171	Pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease	criteria_provided,_single_submitter	NC_000001.11:g.11999025C>T	.	C4721887|C0007959	609260	ORPHA99947|ORPHA166	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11999054	C	T	R	C	rs587777875	1	12059111	1	11981698	259	MFN2	ENSG00000116688	ENST00000235329	ENSP00000235329	MFN2_HUMAN	c.775C>T	p.R259C	c.775C>T	p.Arg259Cys	c.775C>T	p.Arg259Cys	principal1	Y	1	YES	+	CGC	1	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.0	0.92824	D	0.999	0.77913	D	0.958	0.70027	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	R259C;R259C;.	3.235	0.89610	M	-3.81	0.95728	D	-7.1	0.93974	D	0.982	0.99181	1.0649	0.98458	D	0.9324	0.97771	D	10	0.436451	0.94081	D	0.952	0.99138	0.782	0.90613	O95140	R259C	Loss of MoRF binding (P = 0.0187); Loss of disorder (P = 0.0447); Gain of catalytic residue at W260 (P = 0.0525); Loss of stability (P = 0.1563); Loss of phosphorylation at S263 (P = 0.1704)	0.978117000243	0.97787	2.08877544307	0.94702	0.926208019257	0.98759	D	0.906002	0.98193	D	0.545035	0.95624	D	0.545129	0.95560	D	0.999121129512787	0.96259	D	NULL	0.98010	.	.	.	.	.	.	.	4.430279	0.90507	31	4.571146	0.92136	32	0.99948802613594756	0.99931	0.96221	0.68092	D	AEFBCI	0.941856	0.94569	D	0.920507738062018	0.92727	11.59302	0.882833976174014	0.94778	13.03614	0.999999999989603	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.64	5.64	0.86480	7.568000	0.81546	1.022000	0.39869	0.596000	0.33519	1.000000	0.71638	1.000000	0.86279	0.993000	0.69303	0.0:1.0:0.0:0.0	18.7056	0.91599	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	155730	Pathogenic/Likely_pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11999054C>T	.	C4721887|C0007959|C0270914|CN517202	609260	ORPHA99947|ORPHA166|ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	11999054	C	T	R	C	rs587777875	1	12059111	1	11981698	259	MFN2	ENSG00000116688	ENST00000444836	ENSP00000416338	MFN2_HUMAN	c.775C>T	p.R259C	c.775C>T	p.Arg259Cys	c.775C>T	p.Arg259Cys	principal1	Y	2	.	+	CGC	1	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.0	0.92824	D	0.999	0.77913	D	0.958	0.70027	D	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	R259C;R259C;.	3.235	0.89610	M	-3.81	0.95728	D	-7.1	0.93974	D	0.96	0.99181	1.0649	0.98458	D	0.9324	0.97771	D	10	0.436451	0.94081	D	0.952	0.99138	0.782	0.90613	O95140	R259C	Loss of MoRF binding (P = 0.0187); Loss of disorder (P = 0.0447); Gain of catalytic residue at W260 (P = 0.0525); Loss of stability (P = 0.1563); Loss of phosphorylation at S263 (P = 0.1704)	0.978117000243	0.97787	NULL	0.94702	0.926208019257	0.98759	D	0.906002	0.98193	D	0.545035	0.95624	D	0.545129	0.95560	D	0.999121129512787	0.96259	D	0.993967	0.98010	D	.	.	.	.	.	.	4.430279	0.90507	31	4.571146	0.92136	32	0.99948802613594756	0.99931	0.96221	0.68092	D	AEFBCI	0.941856	0.94569	D	0.920507738062018	0.92727	11.59302	0.882833976174014	0.94778	13.03614	0.999999999989603	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.64	5.64	0.86480	7.568000	0.81546	1.022000	0.39869	0.596000	0.33519	1.000000	0.71638	1.000000	0.86279	0.993000	0.69303	0.0:1.0:0.0:0.0	18.7056	0.91599	784	0.47045	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	155730	Pathogenic/Likely_pathogenic	Charcot-Marie-Tooth_disease,_type_2A2A|Charcot-Marie-Tooth_disease|Charcot-Marie-Tooth_disease,_type_2|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.11999054C>T	.	C4721887|C0007959|C0270914|CN517202	609260	ORPHA99947|ORPHA166|ORPHA64746	Dynamin-type guanine nucleotide-binding (G) domain	.	. 	.
1	99875231	G	A	R	Q	rs17121464	1	100340787	1	100113375	371	AGL	ENSG00000162688	ENST00000370161	ENSP00000359180	GDE_HUMAN	c.1112G>A	p.R371Q	c.1112G>A	p.Arg371Gln	c.1112G>A	p.Arg371Gln	.	Y	5	.	+	CGA	2	0	G	G/G	G/G	G/G	0.81	0.03036	T	0.591	0.08189	T	0.001	0.07471	B	0.002	0.06944	B	0.172330	0.17338	N	0.604027	1;1;1;1;1;1;1	0.08975	P;P;P;P;P;P;P	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	R371Q;R370Q;R387Q;R371Q;R387Q;R387Q;R387Q	NULL	0.20815	.	-1.77	0.83660	D	-0.29	0.11728	N	0.024	0.02272	-1.0608	0.11557	T	0.1469	0.47183	T	9	NULL	NULL	.	0.198	0.48544	.	NULL	.	.	.	NULL	NULL	NULL	0.04870	0.22545593977	0.01649	T	NULL	0.22827	.	-0.580512	0.00191	T	-0.462822	0.26293	T	0.00153068324989613	0.00015	T	0.524448	0.17180	T	.	.	.	.	.	.	0.981801	0.14815	11.39	-0.276068	0.02476	0.431	0.37239413134539384	0.02442	0.08562	0.14474	N	AEFI	0.033358	0.03938	N	-1.42082456441782	0.02456	0.1084878	-1.39661612118613	0.03288	0.1530698	1.75861703584737E-5	0.02871	0.615465	0.37627	0	0.633656	0.55848	0	0.658983	0.55881	0	0.655142	0.61905	0	NULL	NULL	5.29	-2.41	0.06184	1.701000	0.37444	-1.834000	0.00832	-2.212000	0.00351	0.668000	0.28331	0.161000	0.21232	0.111000	0.18785	0.4114:0.0:0.5886:0.0	10.1791	0.42133	858	0.34001	399	0.07967252396166134	3	0.0022692889561270802	5	0.004970178926441352	77	0.11095100864553314	178	0.1765873015873016	136	0.1390593047034765	2	5.393743257820927E-4	6	0.0015568240788790867	8	0.0010579211848717272	14	0.0031774852473899226	17	0.0019767441860465114	5752	4.738e-02	5734	4.756e-02	37	3.717e-03	2048	1.777e-01	1533	1.777e-01	69	1.044e-02	183	2.753e-03	1832	1.112e-01	5515	5.193e-02	5497	5.215e-02	32	3.714e-03	2009	1.800e-01	1403	1.790e-01	69	1.044e-02	146	2.697e-03	1821	1.113e-01	5195	5.725e-02	5181	5.751e-02	37	3.724e-03	2047	1.778e-01	1078	1.917e-01	45	1.184e-02	117	2.783e-03	1832	1.113e-01	.	13144	250642	5.244133e-02	1085	54	15868	3.403075e-03	0	5715	34556	1.653837e-01	556	43	10070	4.270109e-03	0	3261	18382	1.774018e-01	284	217	21648	1.002402e-02	0	216	113420	1.904426e-03	1	3415	30600	1.116013e-01	236	3261	18382	1.774018e-01	284	6534	109376	5.973888e-02	548	19	7164	2.652150e-03	0	2885	17102	1.686937e-01	290	13	2320	5.603448e-03	0	1596	9036	1.766268e-01	130	124	13394	9.257877e-03	0	72	42764	1.683659e-03	0	1750	15682	1.115929e-01	126	1596	9036	1.766268e-01	130	.	2420	143250	1.689354e-02	153	156	42040	3.710752e-03	0	947	13652	6.936713e-02	58	14	3320	4.216867e-03	0	558	3126	1.785029e-01	57	121	10440	1.159004e-02	1	164	64570	2.539879e-03	0	391	3048	1.282808e-01	32	199034	Benign	Glycogen_storage_disease_type_III|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.99875231G>A	Illumina_Clinical_Services_Laboratory,Illumina:111868|UniProtKB_(protein):P35573#VAR_009621	C0017922|CN169374|CN517202	232400	ORPHA366	.	.	. 	.
1	99875231	G	A	R	Q	rs17121464	1	100340787	1	100113375	387	AGL	ENSG00000162688	ENST00000294724	ENSP00000294724	GDE_HUMAN	c.1160G>A	p.R387Q	c.1160G>A	p.Arg387Gln	c.1160G>A	p.Arg387Gln	principal1	Y	1	YES	+	CGA	2	0	G	G/G	G/G	G/G	0.851	0.03036	T	0.594	0.08189	T	0.0	0.07471	B	0.0	0.06944	B	0.172330	0.17338	N	0.604027	1;1;1;1;1;1;1	0.08975	P;P;P;P;P;P;P	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	R371Q;R370Q;R387Q;R371Q;R387Q;R387Q;R387Q	0.815	0.20815	L	-1.77	0.83660	D	-0.29	0.11728	N	0.042	0.02272	-1.0608	0.11557	T	0.1469	0.47183	T	9	NULL	NULL	.	0.198	0.48544	.	NULL	.	.	.	NULL	NULL	0.0450179926135	0.04870	0.22545593977	0.01649	T	0.033228	0.22827	T	-0.580512	0.00191	T	-0.462822	0.26293	T	0.00153068324989613	0.00015	T	NULL	0.17180	.	.	.	.	.	.	.	0.981801	0.14815	11.39	-0.276068	0.02476	0.431	0.37239413134539384	0.02442	0.08562	0.14474	N	AEFI	0.033358	0.03938	N	-1.42082456441782	0.02456	0.1084878	-1.39661612118613	0.03288	0.1530698	1.75861703584737E-5	0.02871	0.615465	0.37627	0	0.633656	0.55848	0	0.658983	0.55881	0	0.655142	0.61905	0	NULL	NULL	5.29	-2.41	0.06184	1.701000	0.37444	-1.834000	0.00832	-2.212000	0.00351	0.668000	0.28331	0.161000	0.21232	0.111000	0.18785	0.4114:0.0:0.5886:0.0	10.1791	0.42133	858	0.34001	399	0.07967252396166134	3	0.0022692889561270802	5	0.004970178926441352	77	0.11095100864553314	178	0.1765873015873016	136	0.1390593047034765	2	5.393743257820927E-4	6	0.0015568240788790867	8	0.0010579211848717272	14	0.0031774852473899226	17	0.0019767441860465114	5752	4.738e-02	5734	4.756e-02	37	3.717e-03	2048	1.777e-01	1533	1.777e-01	69	1.044e-02	183	2.753e-03	1832	1.112e-01	5515	5.193e-02	5497	5.215e-02	32	3.714e-03	2009	1.800e-01	1403	1.790e-01	69	1.044e-02	146	2.697e-03	1821	1.113e-01	5195	5.725e-02	5181	5.751e-02	37	3.724e-03	2047	1.778e-01	1078	1.917e-01	45	1.184e-02	117	2.783e-03	1832	1.113e-01	.	13144	250642	5.244133e-02	1085	54	15868	3.403075e-03	0	5715	34556	1.653837e-01	556	43	10070	4.270109e-03	0	3261	18382	1.774018e-01	284	217	21648	1.002402e-02	0	216	113420	1.904426e-03	1	3415	30600	1.116013e-01	236	3261	18382	1.774018e-01	284	6534	109376	5.973888e-02	548	19	7164	2.652150e-03	0	2885	17102	1.686937e-01	290	13	2320	5.603448e-03	0	1596	9036	1.766268e-01	130	124	13394	9.257877e-03	0	72	42764	1.683659e-03	0	1750	15682	1.115929e-01	126	1596	9036	1.766268e-01	130	.	2420	143250	1.689354e-02	153	156	42040	3.710752e-03	0	947	13652	6.936713e-02	58	14	3320	4.216867e-03	0	558	3126	1.785029e-01	57	121	10440	1.159004e-02	1	164	64570	2.539879e-03	0	391	3048	1.282808e-01	32	199034	Benign	Glycogen_storage_disease_type_III|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.99875231G>A	Illumina_Clinical_Services_Laboratory,Illumina:111868|UniProtKB_(protein):P35573#VAR_009621	C0017922|CN169374|CN517202	232400	ORPHA366	Glycogen debranching enzyme, glucanotransferase domain|Glycogen debranching enzyme, glucanotransferase domain	.	. 	.
1	99875231	G	A	R	Q	rs17121464	1	100340787	1	100113375	387	AGL	ENSG00000162688	ENST00000361915	ENSP00000355106	GDE_HUMAN	c.1160G>A	p.R387Q	c.1160G>A	p.Arg387Gln	c.1160G>A	p.Arg387Gln	principal1	Y	1	.	+	CGA	2	0	G	G/G	G/G	G/G	0.851	0.03036	T	0.594	0.08189	T	0.0	0.07471	B	0.0	0.06944	B	0.172330	0.17338	N	0.604027	1;1;1;1;1;1;1	0.08975	P;P;P;P;P;P;P	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	R371Q;R370Q;R387Q;R371Q;R387Q;R387Q;R387Q	0.815	0.20815	L	-1.77	0.83660	D	-0.29	0.11728	N	0.051	0.02272	-1.0608	0.11557	T	0.1469	0.47183	T	9	NULL	NULL	.	0.198	0.48544	.	NULL	.	.	.	NULL	NULL	NULL	0.04870	0.22545593977	0.01649	T	0.033228	0.22827	T	-0.580512	0.00191	T	-0.462822	0.26293	T	0.00153068324989613	0.00015	T	0.524448	0.17180	T	.	.	.	.	.	.	0.981801	0.14815	11.39	-0.276068	0.02476	0.431	0.37239413134539384	0.02442	0.08562	0.14474	N	AEFI	0.033358	0.03938	N	-1.42082456441782	0.02456	0.1084878	-1.39661612118613	0.03288	0.1530698	1.75861703584737E-5	0.02871	0.615465	0.37627	0	0.633656	0.55848	0	0.658983	0.55881	0	0.655142	0.61905	0	NULL	NULL	5.29	-2.41	0.06184	1.701000	0.37444	-1.834000	0.00832	-2.212000	0.00351	0.668000	0.28331	0.161000	0.21232	0.111000	0.18785	0.4114:0.0:0.5886:0.0	10.1791	0.42133	858	0.34001	399	0.07967252396166134	3	0.0022692889561270802	5	0.004970178926441352	77	0.11095100864553314	178	0.1765873015873016	136	0.1390593047034765	2	5.393743257820927E-4	6	0.0015568240788790867	8	0.0010579211848717272	14	0.0031774852473899226	17	0.0019767441860465114	5752	4.738e-02	5734	4.756e-02	37	3.717e-03	2048	1.777e-01	1533	1.777e-01	69	1.044e-02	183	2.753e-03	1832	1.112e-01	5515	5.193e-02	5497	5.215e-02	32	3.714e-03	2009	1.800e-01	1403	1.790e-01	69	1.044e-02	146	2.697e-03	1821	1.113e-01	5195	5.725e-02	5181	5.751e-02	37	3.724e-03	2047	1.778e-01	1078	1.917e-01	45	1.184e-02	117	2.783e-03	1832	1.113e-01	.	13144	250642	5.244133e-02	1085	54	15868	3.403075e-03	0	5715	34556	1.653837e-01	556	43	10070	4.270109e-03	0	3261	18382	1.774018e-01	284	217	21648	1.002402e-02	0	216	113420	1.904426e-03	1	3415	30600	1.116013e-01	236	3261	18382	1.774018e-01	284	6534	109376	5.973888e-02	548	19	7164	2.652150e-03	0	2885	17102	1.686937e-01	290	13	2320	5.603448e-03	0	1596	9036	1.766268e-01	130	124	13394	9.257877e-03	0	72	42764	1.683659e-03	0	1750	15682	1.115929e-01	126	1596	9036	1.766268e-01	130	.	2420	143250	1.689354e-02	153	156	42040	3.710752e-03	0	947	13652	6.936713e-02	58	14	3320	4.216867e-03	0	558	3126	1.785029e-01	57	121	10440	1.159004e-02	1	164	64570	2.539879e-03	0	391	3048	1.282808e-01	32	199034	Benign	Glycogen_storage_disease_type_III|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.99875231G>A	Illumina_Clinical_Services_Laboratory,Illumina:111868|UniProtKB_(protein):P35573#VAR_009621	C0017922|CN169374|CN517202	232400	ORPHA366	Glycogen debranching enzyme, glucanotransferase domain|Glycogen debranching enzyme, glucanotransferase domain	.	. 	.
1	99875231	G	A	R	Q	rs17121464	1	100340787	1	100113375	387	AGL	ENSG00000162688	ENST00000370163	ENSP00000359182	GDE_HUMAN	c.1160G>A	p.R387Q	c.1160G>A	p.Arg387Gln	c.1160G>A	p.Arg387Gln	principal1	Y	1	.	+	CGA	2	0	G	G/G	G/G	G/G	0.851	0.03036	T	0.594	0.08189	T	0.0	0.07471	B	0.0	0.06944	B	0.172330	0.17338	N	0.604027	1;1;1;1;1;1;1	0.08975	P;P;P;P;P;P;P	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	R371Q;R370Q;R387Q;R371Q;R387Q;R387Q;R387Q	0.815	0.20815	L	-1.77	0.83660	D	-0.29	0.11728	N	0.041	0.02272	-1.0608	0.11557	T	0.1469	0.47183	T	9	NULL	NULL	.	0.198	0.48544	.	NULL	.	.	.	NULL	NULL	NULL	0.04870	0.22545593977	0.01649	T	0.033228	0.22827	T	-0.580512	0.00191	T	-0.462822	0.26293	T	0.00153068324989613	0.00015	T	NULL	0.17180	.	.	.	.	.	.	.	0.981801	0.14815	11.39	-0.276068	0.02476	0.431	0.37239413134539384	0.02442	0.08562	0.14474	N	AEFI	0.033358	0.03938	N	-1.42082456441782	0.02456	0.1084878	-1.39661612118613	0.03288	0.1530698	1.75861703584737E-5	0.02871	0.615465	0.37627	0	0.633656	0.55848	0	0.658983	0.55881	0	0.655142	0.61905	0	NULL	NULL	5.29	-2.41	0.06184	1.701000	0.37444	-1.834000	0.00832	-2.212000	0.00351	0.668000	0.28331	0.161000	0.21232	0.111000	0.18785	0.4114:0.0:0.5886:0.0	10.1791	0.42133	858	0.34001	399	0.07967252396166134	3	0.0022692889561270802	5	0.004970178926441352	77	0.11095100864553314	178	0.1765873015873016	136	0.1390593047034765	2	5.393743257820927E-4	6	0.0015568240788790867	8	0.0010579211848717272	14	0.0031774852473899226	17	0.0019767441860465114	5752	4.738e-02	5734	4.756e-02	37	3.717e-03	2048	1.777e-01	1533	1.777e-01	69	1.044e-02	183	2.753e-03	1832	1.112e-01	5515	5.193e-02	5497	5.215e-02	32	3.714e-03	2009	1.800e-01	1403	1.790e-01	69	1.044e-02	146	2.697e-03	1821	1.113e-01	5195	5.725e-02	5181	5.751e-02	37	3.724e-03	2047	1.778e-01	1078	1.917e-01	45	1.184e-02	117	2.783e-03	1832	1.113e-01	.	13144	250642	5.244133e-02	1085	54	15868	3.403075e-03	0	5715	34556	1.653837e-01	556	43	10070	4.270109e-03	0	3261	18382	1.774018e-01	284	217	21648	1.002402e-02	0	216	113420	1.904426e-03	1	3415	30600	1.116013e-01	236	3261	18382	1.774018e-01	284	6534	109376	5.973888e-02	548	19	7164	2.652150e-03	0	2885	17102	1.686937e-01	290	13	2320	5.603448e-03	0	1596	9036	1.766268e-01	130	124	13394	9.257877e-03	0	72	42764	1.683659e-03	0	1750	15682	1.115929e-01	126	1596	9036	1.766268e-01	130	.	2420	143250	1.689354e-02	153	156	42040	3.710752e-03	0	947	13652	6.936713e-02	58	14	3320	4.216867e-03	0	558	3126	1.785029e-01	57	121	10440	1.159004e-02	1	164	64570	2.539879e-03	0	391	3048	1.282808e-01	32	199034	Benign	Glycogen_storage_disease_type_III|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.99875231G>A	Illumina_Clinical_Services_Laboratory,Illumina:111868|UniProtKB_(protein):P35573#VAR_009621	C0017922|CN169374|CN517202	232400	ORPHA366	Glycogen debranching enzyme, glucanotransferase domain|Glycogen debranching enzyme, glucanotransferase domain	.	. 	.
1	99875231	G	A	R	Q	rs17121464	1	100340787	1	100113375	387	AGL	ENSG00000162688	ENST00000370165	ENSP00000359184	GDE_HUMAN	c.1160G>A	p.R387Q	c.1160G>A	p.Arg387Gln	c.1160G>A	p.Arg387Gln	principal1	Y	1	.	+	CGA	2	0	G	G/G	G/G	G/G	0.851	0.03036	T	0.594	0.08189	T	0.0	0.07471	B	0.0	0.06944	B	0.172330	0.17338	N	0.604027	1;1;1;1;1;1;1	0.08975	P;P;P;P;P;P;P	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	R371Q;R370Q;R387Q;R371Q;R387Q;R387Q;R387Q	0.815	0.20815	L	-1.77	0.83660	D	-0.29	0.11728	N	0.04	0.02272	-1.0608	0.11557	T	0.1469	0.47183	T	9	NULL	NULL	.	0.198	0.48544	.	NULL	.	.	.	NULL	NULL	NULL	0.04870	0.22545593977	0.01649	T	0.033228	0.22827	T	-0.580512	0.00191	T	-0.462822	0.26293	T	0.00153068324989613	0.00015	T	NULL	0.17180	.	.	.	.	.	.	.	0.981801	0.14815	11.39	-0.276068	0.02476	0.431	0.37239413134539384	0.02442	0.08562	0.14474	N	AEFI	0.033358	0.03938	N	-1.42082456441782	0.02456	0.1084878	-1.39661612118613	0.03288	0.1530698	1.75861703584737E-5	0.02871	0.615465	0.37627	0	0.633656	0.55848	0	0.658983	0.55881	0	0.655142	0.61905	0	NULL	NULL	5.29	-2.41	0.06184	1.701000	0.37444	-1.834000	0.00832	-2.212000	0.00351	0.668000	0.28331	0.161000	0.21232	0.111000	0.18785	0.4114:0.0:0.5886:0.0	10.1791	0.42133	858	0.34001	399	0.07967252396166134	3	0.0022692889561270802	5	0.004970178926441352	77	0.11095100864553314	178	0.1765873015873016	136	0.1390593047034765	2	5.393743257820927E-4	6	0.0015568240788790867	8	0.0010579211848717272	14	0.0031774852473899226	17	0.0019767441860465114	5752	4.738e-02	5734	4.756e-02	37	3.717e-03	2048	1.777e-01	1533	1.777e-01	69	1.044e-02	183	2.753e-03	1832	1.112e-01	5515	5.193e-02	5497	5.215e-02	32	3.714e-03	2009	1.800e-01	1403	1.790e-01	69	1.044e-02	146	2.697e-03	1821	1.113e-01	5195	5.725e-02	5181	5.751e-02	37	3.724e-03	2047	1.778e-01	1078	1.917e-01	45	1.184e-02	117	2.783e-03	1832	1.113e-01	.	13144	250642	5.244133e-02	1085	54	15868	3.403075e-03	0	5715	34556	1.653837e-01	556	43	10070	4.270109e-03	0	3261	18382	1.774018e-01	284	217	21648	1.002402e-02	0	216	113420	1.904426e-03	1	3415	30600	1.116013e-01	236	3261	18382	1.774018e-01	284	6534	109376	5.973888e-02	548	19	7164	2.652150e-03	0	2885	17102	1.686937e-01	290	13	2320	5.603448e-03	0	1596	9036	1.766268e-01	130	124	13394	9.257877e-03	0	72	42764	1.683659e-03	0	1750	15682	1.115929e-01	126	1596	9036	1.766268e-01	130	.	2420	143250	1.689354e-02	153	156	42040	3.710752e-03	0	947	13652	6.936713e-02	58	14	3320	4.216867e-03	0	558	3126	1.785029e-01	57	121	10440	1.159004e-02	1	164	64570	2.539879e-03	0	391	3048	1.282808e-01	32	199034	Benign	Glycogen_storage_disease_type_III|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.99875231G>A	Illumina_Clinical_Services_Laboratory,Illumina:111868|UniProtKB_(protein):P35573#VAR_009621	C0017922|CN169374|CN517202	232400	ORPHA366	Glycogen debranching enzyme, glucanotransferase domain|Glycogen debranching enzyme, glucanotransferase domain	.	. 	.
1	100206250	C	A	G	W	rs796051945	1	100671806	1	100444394	421	DBT	ENSG00000137992	ENST00000370132	ENSP00000359151	.	c.1261G>T	p.G421W	c.1261G>T	p.Gly421Trp	c.1261G>T	p.Gly421Trp	principal1	Y	1	YES	-	GGG	1	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.002	0.79402	D	NULL	NULL	.	NULL	NULL	.	0.000000	0.84330	D	0.000000	1	0.81001	D	simple_aae	G421W	NULL	NULL	.	0.96	0.42888	T	-7.18	0.94171	D	0.853	0.84922	-0.2232	0.77066	T	0.3448	0.70996	T	10	0.085497	0.74545	D	0.539	0.80948	0.603	0.73456	P11182	G421W	Gain of MoRF binding (P = 0.076); Loss of catalytic residue at I420 (P = 0.097); Loss of helix (P = 0.3949); Loss of phosphorylation at S425 (P = 0.474); Loss of sheet (P = 0.5184)	0.808749858071	0.80695	1.14493569404	0.79046	0.805725812912	0.82836	D	NULL	NULL	.	0.132768	0.67630	D	0.128783	0.78811	D	0.997977316379547	0.92901	D	NULL	NULL	.	.	.	.	.	.	.	3.856495	0.73910	26.1	4.233837	0.88948	29.7	0.99401678567585472	0.62841	0.99453	0.96219	D	AEFBI	0.919975	0.89128	D	0.965419852007195	0.94576	12.86807	0.892900613947259	0.95255	13.45234	0.999999999661511	0.74766	0.732398	0.92422	0	0.708844	0.79440	0	0.724815	0.87919	0	0.727631	0.95156	0	NULL	NULL	5.97	5.97	0.96935	7.568000	0.81546	1.008000	0.37630	0.599000	0.40250	1.000000	0.71638	0.978000	0.47047	0.641000	0.32449	0.0:1.0:0.0:0.0	20.4388	0.99109	525	0.74024	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	2	251314	7.958172e-06	0	0	16246	0	0	2	34548	5.789047e-05	0	0	10076	0	0	0	18394	0	0	0	21640	0	0	0	113704	0	0	0	30574	0	0	2	34548	5.789047e-05	0	2	109350	1.828989e-05	0	0	7164	0	0	2	17080	1.170960e-04	0	0	2320	0	0	0	9046	0	0	0	13390	0	0	0	42760	0	0	0	15676	0	0	2	17080	1.170960e-04	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	203669	Uncertain_significance	Maple_syrup_urine_disease	criteria_provided,_single_submitter	NC_000001.11:g.100206250C>A	.	C0024776	248600	ORPHA511	.	.	. 	.
1	100206621	C	T	G	R	rs869312132	1	100672177	1	100444765	345	DBT	ENSG00000137992	ENST00000370132	ENSP00000359151	.	c.1033G>A	p.G345R	c.1033G>A	p.Gly345Arg	c.1033G>A	p.Gly345Arg	principal1	Y	1	YES	-	GGG	1	0	C	./.	./.	./.	0.003	0.68238	D	0.002	0.79402	D	NULL	NULL	.	NULL	NULL	.	0.000000	0.84330	D	0.000000	1	0.81001	D	simple_aae	G345R	NULL	NULL	.	0.28	0.59037	T	-6.01	0.89648	D	0.997	0.99973	0.5312	0.90980	D	0.5891	0.85285	D	10	0.119382	0.79967	D	0.646	0.86753	0.921	0.98604	P11182	G345R	Gain of catalytic residue at G345 (P = 0.0406); Loss of loop (P = 0.2237); Loss of sheet (P = 0.302); Loss of disorder (P = 0.5038); Gain of methylation at G345 (P = 0.511)	0.925323374927	0.92456	1.15447126358	0.79324	0.821252822876	0.85220	D	NULL	NULL	.	0.353828	0.86773	D	0.270473	0.86600	D	0.999543368816376	0.97846	D	NULL	NULL	.	.	.	.	.	.	.	4.315084	0.88560	29.7	4.606769	0.92270	32	0.99930008611936239	0.99334	0.99027	0.90159	D	AEFDBI	0.891302	0.82715	D	1.10091649871542	0.98150	17.54561	0.999778711083299	0.98623	18.82778	0.999999998797306	0.74766	0.6512	0.46895	0	0.708844	0.79440	0	0.608884	0.39905	0	0.635551	0.53088	0	NULL	NULL	5.74	5.74	0.90070	7.480000	0.80148	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	0.0:1.0:0.0:0.0	19.9185	0.97074	525	0.74024	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	224073	Pathogenic	Maple_syrup_urine_disease	criteria_provided,_single_submitter	NC_000001.11:g.100206621C>T	.	C0024776	248600	ORPHA511	.	.	. 	.
1	100214817	C	G	K	N	rs398123676	1	100680373	1	100452961	313	DBT	ENSG00000137992	ENST00000370131	ENSP00000359150	Q5VVL7_HUMAN	c.939G>C	p.K313N	c.939G>C	p.Lys313Asn	c.939G>C	p.Lys313Asn	.	Y	1	.	-	AAG	3	2	C	C/C	C/C	C/C	0.0	0.91255	D	0.0	0.92824	D	NULL	NULL	.	NULL	NULL	.	0.000000	0.84330	D	0.000000	0.999999;1	0.81001	D;D	simple_aae;simple_aae	K313N;K313N	NULL	NULL	.	0.45	0.56446	T	-3.02	0.80682	D	0.904	0.90476	0.1160	0.84465	D	0.4288	0.77134	T	9	0.138101	0.82060	D	0.586	0.83615	0.951	0.99429	P11182	K313N	Loss of ubiquitination at K313 (P = 0.0199); Loss of MoRF binding (P = 0.1864); Gain of catalytic residue at S316 (P = 0.2941); Loss of helix (P = 0.3949); Loss of sheet (P = 0.5184)	0.820746442501	0.81905	NULL	0.78998	0.76670306921	0.76930	T	NULL	NULL	.	-0.068484	0.41570	T	-0.133495	0.60677	T	0.999019622802734	0.95890	D	0.350665	0.07816	T	.	.	.	.	.	.	5.407998	0.94309	34	5.128517	0.93536	33	0.99796941377306481	0.88194	0.98806	0.87096	D	AEFDBI	0.825538	0.74521	D	0.685779192877958	0.78699	6.924812	0.554011158062273	0.71676	5.691412	0.974832623360693	0.29578	0.706548	0.73137	0	0.653731	0.59785	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	5.54	3.68	0.41359	5.859000	0.69288	0.129000	0.18587	-0.202000	0.08738	1.000000	0.71638	0.997000	0.62031	0.994000	0.71098	0.0:0.862:0.0:0.138	12.2028	0.53645	526	0.73951	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	3	2.471e-05	3	2.478e-05	0	0	0	0	0	0	0	0	0	0	3	1.820e-04	3	2.825e-05	3	2.830e-05	0	0	0	0	0	0	0	0	0	0	3	1.831e-04	3	3.306e-05	3	3.317e-05	0	0	0	0	0	0	0	0	0	0	3	1.821e-04	.	3	251402	1.193308e-05	0	0	16250	0	0	0	34592	0	0	0	10076	0	0	0	18392	0	0	0	21630	0	0	0	113716	0	0	3	30610	9.800719e-05	0	3	30610	9.800719e-05	0	2	109382	1.828454e-05	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9044	0	0	0	13376	0	0	0	42764	0	0	2	15688	1.274860e-04	0	2	15688	1.274860e-04	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	94017	Pathogenic/Likely_pathogenic	Maple_syrup_urine_disease|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.100214817C>G	HGMD:CM082593	C0024776|CN517202	248600	ORPHA511	2-oxoacid dehydrogenase acyltransferase, catalytic domain	.	. 	.
1	100214817	C	G	K	N	rs398123676	1	100680373	1	100452961	313	DBT	ENSG00000137992	ENST00000370132	ENSP00000359151	.	c.939G>C	p.K313N	c.939G>C	p.Lys313Asn	c.939G>C	p.Lys313Asn	principal1	Y	1	YES	-	AAG	3	2	C	C/C	C/C	C/C	0.0	0.91255	D	0.0	0.92824	D	NULL	NULL	.	NULL	NULL	.	0.000000	0.84330	D	0.000000	0.999999;1	0.81001	D;D	simple_aae;simple_aae	K313N;K313N	NULL	NULL	.	0.45	0.56446	T	-4.8	0.80682	D	0.884	0.90476	0.1160	0.84465	D	0.4288	0.77134	T	9	0.138101	0.82060	D	0.586	0.83615	0.951	0.99429	P11182	K313N	Loss of ubiquitination at K313 (P = 0.0199); Loss of MoRF binding (P = 0.1864); Gain of catalytic residue at S316 (P = 0.2941); Loss of helix (P = 0.3949); Loss of sheet (P = 0.5184)	0.820746442501	0.81905	1.14325732967	0.78998	0.76670306921	0.76930	T	NULL	NULL	.	-0.068484	0.41570	T	-0.133495	0.60677	T	0.999019622802734	0.95890	D	NULL	0.07816	.	.	.	.	.	.	.	5.407998	0.94309	34	5.128517	0.93536	33	0.99796941377306481	0.88194	0.98806	0.87096	D	AEFDBI	0.825538	0.74521	D	0.685779192877958	0.78699	6.924812	0.554011158062273	0.71676	5.691412	0.974832623360693	0.29578	0.706548	0.73137	0	0.653731	0.59785	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	5.54	3.68	0.41359	5.859000	0.69288	0.129000	0.18587	-0.202000	0.08738	1.000000	0.71638	0.997000	0.62031	0.994000	0.71098	0.0:0.862:0.0:0.138	12.2028	0.53645	526	0.73951	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	3	2.471e-05	3	2.478e-05	0	0	0	0	0	0	0	0	0	0	3	1.820e-04	3	2.825e-05	3	2.830e-05	0	0	0	0	0	0	0	0	0	0	3	1.831e-04	3	3.306e-05	3	3.317e-05	0	0	0	0	0	0	0	0	0	0	3	1.821e-04	.	3	251402	1.193308e-05	0	0	16250	0	0	0	34592	0	0	0	10076	0	0	0	18392	0	0	0	21630	0	0	0	113716	0	0	3	30610	9.800719e-05	0	3	30610	9.800719e-05	0	2	109382	1.828454e-05	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9044	0	0	0	13376	0	0	0	42764	0	0	2	15688	1.274860e-04	0	2	15688	1.274860e-04	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	94017	Pathogenic/Likely_pathogenic	Maple_syrup_urine_disease|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.100214817C>G	HGMD:CM082593	C0024776|CN517202	248600	ORPHA511	.	.	. 	.
1	100214855	G	A	R	C	rs185492864	1	100680411	1	100452999	301	DBT	ENSG00000137992	ENST00000370131	ENSP00000359150	Q5VVL7_HUMAN	c.901C>T	p.R301C	c.901C>T	p.Arg301Cys	c.901C>T	p.Arg301Cys	.	Y	1	.	-	CGT	1	0	G	G/G	G/G	G/G	0.001	0.78490	D	0.009	0.66756	D	NULL	NULL	.	NULL	NULL	.	0.000000	0.84330	D	0.000000	1;1	0.81001	D;D	simple_aae;simple_aae	R301C;R301C	NULL	NULL	.	0.88	0.46028	T	-5.0	0.85397	D	0.852	0.84817	-0.5866	0.65356	T	0.1945	0.54826	T	10	0.074418	0.72037	D	0.696	0.89147	.	NULL	.	.	.	0.640860639658	0.63789	NULL	0.47755	0.569589853287	0.48619	T	NULL	NULL	.	-0.00398048	0.51105	T	0.165158	0.81118	D	0.710987985134125	0.41248	D	0.969003	0.88824	D	.	.	.	.	.	.	3.887420	0.74882	26.3	3.891177	0.78487	26.8	0.9989443236167348	0.96742	0.99268	0.93707	D	AEFDBI	0.909449	0.86609	D	0.699361961224066	0.79588	7.109963	0.731715927105669	0.84787	8.390299	0.999999999209004	0.74766	0.706548	0.73137	0	0.708844	0.79440	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	5.44	5.44	0.79348	9.602000	0.97623	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	1.000000	0.86279	0.992000	0.67800	0.0:0.0:1.0:0.0	19.2747	0.94014	526	0.73951	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	2	2.3255813953488373E-4	97	7.990e-04	97	7.996e-04	1	9.628e-05	0	0	0	0	0	0	96	1.440e-03	0	0	93	8.756e-04	93	8.762e-04	1	1.105e-04	0	0	0	0	0	0	92	1.694e-03	0	0	14	1.543e-04	14	1.544e-04	1	9.645e-05	0	0	0	0	0	0	13	3.088e-04	0	0	.	129	251458	5.130081e-04	2	1	16256	6.151575e-05	0	3	34592	8.672525e-05	1	0	10080	0	0	0	18394	0	0	6	21646	2.771875e-04	0	118	113738	1.037472e-03	1	0	30612	0	0	118	113738	1.037472e-03	1	53	109402	4.844518e-04	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	5	13392	3.733572e-04	0	47	42766	1.099004e-03	0	0	15688	0	0	47	42766	1.099004e-03	0	.	35	143222	2.443759e-04	0	3	42016	7.140137e-05	0	3	13648	2.198124e-04	0	0	3320	0	0	0	3128	0	0	0	10462	0	0	27	64558	4.182286e-04	0	27	64558	4.182286e-04	0	94016	Pathogenic/Likely_pathogenic	Maple_syrup_urine_disease|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.100214855G>A	HGMD:CM104302	C0024776|CN517202	248600	ORPHA511	2-oxoacid dehydrogenase acyltransferase, catalytic domain	.	. 	.
1	100214855	G	A	R	C	rs185492864	1	100680411	1	100452999	301	DBT	ENSG00000137992	ENST00000370132	ENSP00000359151	.	c.901C>T	p.R301C	c.901C>T	p.Arg301Cys	c.901C>T	p.Arg301Cys	principal1	Y	1	YES	-	CGT	1	0	G	G/G	G/G	G/G	0.003	0.78490	D	0.045	0.66756	D	NULL	NULL	.	NULL	NULL	.	0.000000	0.84330	D	0.000000	1;1	0.81001	D;D	simple_aae;simple_aae	R301C;R301C	NULL	NULL	.	0.88	0.46028	T	-5.44	0.85397	D	0.707	0.84817	-0.5866	0.65356	T	0.1945	0.54826	T	10	0.074418	0.72037	D	0.696	0.89147	.	NULL	.	.	.	0.640860639658	0.63789	0.490150029755	0.47755	0.569589853287	0.48619	T	NULL	NULL	.	-0.00398048	0.51105	T	0.165158	0.81118	D	0.710987985134125	0.41248	D	NULL	0.88824	.	.	.	.	.	.	.	3.887420	0.74882	26.3	3.891177	0.78487	26.8	0.9989443236167348	0.96742	0.99268	0.93707	D	AEFDBI	0.909449	0.86609	D	0.699361961224066	0.79588	7.109963	0.731715927105669	0.84787	8.390299	0.999999999209004	0.74766	0.706548	0.73137	0	0.708844	0.79440	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	5.44	5.44	0.79348	9.602000	0.97623	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	1.000000	0.86279	0.992000	0.67800	0.0:0.0:1.0:0.0	19.2747	0.94014	526	0.73951	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	2	2.3255813953488373E-4	97	7.990e-04	97	7.996e-04	1	9.628e-05	0	0	0	0	0	0	96	1.440e-03	0	0	93	8.756e-04	93	8.762e-04	1	1.105e-04	0	0	0	0	0	0	92	1.694e-03	0	0	14	1.543e-04	14	1.544e-04	1	9.645e-05	0	0	0	0	0	0	13	3.088e-04	0	0	.	129	251458	5.130081e-04	2	1	16256	6.151575e-05	0	3	34592	8.672525e-05	1	0	10080	0	0	0	18394	0	0	6	21646	2.771875e-04	0	118	113738	1.037472e-03	1	0	30612	0	0	118	113738	1.037472e-03	1	53	109402	4.844518e-04	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	5	13392	3.733572e-04	0	47	42766	1.099004e-03	0	0	15688	0	0	47	42766	1.099004e-03	0	.	35	143222	2.443759e-04	0	3	42016	7.140137e-05	0	3	13648	2.198124e-04	0	0	3320	0	0	0	3128	0	0	0	10462	0	0	27	64558	4.182286e-04	0	27	64558	4.182286e-04	0	94016	Pathogenic/Likely_pathogenic	Maple_syrup_urine_disease|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.100214855G>A	HGMD:CM104302	C0024776|CN517202	248600	ORPHA511	.	.	. 	.
1	100214929	A	C	F	C	rs121964999	1	100680485	1	100453073	276	DBT	ENSG00000137992	ENST00000370131	ENSP00000359150	Q5VVL7_HUMAN	c.827T>G	p.F276C	c.827T>G	p.Phe276Cys	c.827T>G	p.Phe276Cys	.	Y	1	.	-	TTT	2	0	A	A/A	A/A	A/A	0.0	0.91255	D	0.0	0.92824	D	NULL	NULL	.	NULL	NULL	.	0.000000	0.84330	D	0.048727	1;1	0.81001	A;A	simple_aae;simple_aae	F276C;F276C	NULL	NULL	.	0.71	0.51228	T	-7.39	0.95102	D	0.952	0.96072	-0.1374	0.79228	T	0.3312	0.69885	T	9	0.146784	0.82886	D	0.842	0.95133	.	NULL	.	.	.	0.857982843109	0.85661	NULL	0.81487	0.712607264519	0.68972	T	NULL	NULL	.	0.12766	0.67132	D	0.235742	0.84946	D	0.971343278884888	0.69282	D	0.937706	0.76563	D	.	.	.	.	.	.	4.324906	0.88772	29.8	4.140790	0.86783	29.0	0.99369502520023612	0.61368	0.99191	0.92574	D	AEFDBI	0.902315	0.85006	D	0.929275328073261	0.93117	11.83278	0.855873552189179	0.93355	11.9877	0.999999125757386	0.74766	0.706548	0.73137	0	0.708844	0.79440	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	5.44	5.44	0.79348	8.947000	0.92735	1.312000	0.94714	0.756000	0.94297	1.000000	0.71638	0.997000	0.62031	0.995000	0.73285	1.0:0.0:0.0:0.0	15.511	0.75515	526	0.73951	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	2.6968716289104636E-4	0	0.0	1	1.322401481089659E-4	0	0.0	3	3.488372093023256E-4	12	9.884e-05	12	9.905e-05	0	0	0	0	0	0	0	0	12	1.802e-04	0	0	10	9.415e-05	10	9.432e-05	0	0	0	0	0	0	0	0	10	1.843e-04	0	0	8	8.815e-05	8	8.835e-05	0	0	0	0	0	0	0	0	8	1.902e-04	0	0	.	28	251448	1.113550e-04	0	0	16254	0	0	1	34592	2.890842e-05	0	0	10080	0	0	0	18394	0	0	2	21648	9.238729e-05	0	24	113730	2.110261e-04	0	0	30612	0	0	24	113730	2.110261e-04	0	10	109406	9.140267e-05	0	0	7164	0	0	1	17112	5.843852e-05	0	0	2320	0	0	0	9046	0	0	1	13394	7.466030e-05	0	8	42768	1.870557e-04	0	0	15688	0	0	8	42768	1.870557e-04	0	.	15	143318	1.046624e-04	0	1	42058	2.377669e-05	0	0	13660	0	0	0	3318	0	0	0	3132	0	0	0	10482	0	0	14	64572	2.168122e-04	0	14	64572	2.168122e-04	0	11943	Pathogenic/Likely_pathogenic	Maple_syrup_urine_disease|Maple_syrup_urine_disease,_thiamine-responsive,_type_II|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.100214929A>C	HGMD:CM910107|Illumina_Clinical_Services_Laboratory,Illumina:455954|OMIM_Allelic_Variant:248610.0002	C0024776|C4016440|CN517202	248600	ORPHA511	2-oxoacid dehydrogenase acyltransferase, catalytic domain	.	. 	.
1	100214929	A	C	F	C	rs121964999	1	100680485	1	100453073	276	DBT	ENSG00000137992	ENST00000370132	ENSP00000359151	.	c.827T>G	p.F276C	c.827T>G	p.Phe276Cys	c.827T>G	p.Phe276Cys	principal1	Y	1	YES	-	TTT	2	0	A	A/A	A/A	A/A	0.0	0.91255	D	0.0	0.92824	D	NULL	NULL	.	NULL	NULL	.	0.000000	0.84330	D	0.048727	1;1	0.81001	A;A	simple_aae;simple_aae	F276C;F276C	NULL	NULL	.	0.71	0.51228	T	-7.52	0.95102	D	0.914	0.96072	-0.1374	0.79228	T	0.3312	0.69885	T	9	0.146784	0.82886	D	0.842	0.95133	.	NULL	.	.	.	0.857982843109	0.85661	1.23657706264	0.81487	0.712607264519	0.68972	T	NULL	NULL	.	0.12766	0.67132	D	0.235742	0.84946	D	0.971343278884888	0.69282	D	NULL	0.76563	.	.	.	.	.	.	.	4.324906	0.88772	29.8	4.140790	0.86783	29.0	0.99369502520023612	0.61368	0.99191	0.92574	D	AEFDBI	0.902315	0.85006	D	0.929275328073261	0.93117	11.83278	0.855873552189179	0.93355	11.9877	0.999999125757386	0.74766	0.706548	0.73137	0	0.708844	0.79440	0	0.724815	0.87919	0	0.635551	0.53088	0	NULL	NULL	5.44	5.44	0.79348	8.947000	0.92735	1.312000	0.94714	0.756000	0.94297	1.000000	0.71638	0.997000	0.62031	0.995000	0.73285	1.0:0.0:0.0:0.0	15.511	0.75515	526	0.73951	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	2.6968716289104636E-4	0	0.0	1	1.322401481089659E-4	0	0.0	3	3.488372093023256E-4	12	9.884e-05	12	9.905e-05	0	0	0	0	0	0	0	0	12	1.802e-04	0	0	10	9.415e-05	10	9.432e-05	0	0	0	0	0	0	0	0	10	1.843e-04	0	0	8	8.815e-05	8	8.835e-05	0	0	0	0	0	0	0	0	8	1.902e-04	0	0	.	28	251448	1.113550e-04	0	0	16254	0	0	1	34592	2.890842e-05	0	0	10080	0	0	0	18394	0	0	2	21648	9.238729e-05	0	24	113730	2.110261e-04	0	0	30612	0	0	24	113730	2.110261e-04	0	10	109406	9.140267e-05	0	0	7164	0	0	1	17112	5.843852e-05	0	0	2320	0	0	0	9046	0	0	1	13394	7.466030e-05	0	8	42768	1.870557e-04	0	0	15688	0	0	8	42768	1.870557e-04	0	.	15	143318	1.046624e-04	0	1	42058	2.377669e-05	0	0	13660	0	0	0	3318	0	0	0	3132	0	0	0	10482	0	0	14	64572	2.168122e-04	0	14	64572	2.168122e-04	0	11943	Pathogenic/Likely_pathogenic	Maple_syrup_urine_disease|Maple_syrup_urine_disease,_thiamine-responsive,_type_II|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.100214929A>C	HGMD:CM910107|Illumina_Clinical_Services_Laboratory,Illumina:455954|OMIM_Allelic_Variant:248610.0002	C0024776|C4016440|CN517202	248600	ORPHA511	.	.	. 	.
1	100216031	A	G	S	P	rs146249007	1	100681587	1	100454175	242	DBT	ENSG00000137992	ENST00000370131	ENSP00000359150	Q5VVL7_HUMAN	c.724T>C	p.S242P	c.724T>C	p.Ser242Pro	c.724T>C	p.Ser242Pro	.	Y	1	.	-	TCA	1	0	A	A/A	A/A	G/G	0.262	0.16466	T	0.373	0.22962	T	NULL	NULL	.	NULL	NULL	.	0.233402	0.15869	N	0.655427	0.999999;0.999999	0.08975	N;N	simple_aae;simple_aae	S242P;S242P	NULL	NULL	.	1.47	0.31987	T	-0.1	0.08495	N	0.244	0.28498	-0.9484	0.41245	T	0.0149	0.05994	T	10	NULL	NULL	.	0.026	0.05840	.	NULL	.	.	.	0.18274738541	0.17906	NULL	0.50832	0.360091269016	0.19399	T	NULL	NULL	.	-0.632211	0.00093	T	-0.664648	0.07957	T	0.000309917408977404	0.00003	T	0.59724	0.22223	T	.	.	.	.	.	.	0.994471	0.14973	11.55	0.043335	0.05277	3.313	0.84317567664795934	0.15221	0.34859	0.25166	N	AEFDBI	0.088245	0.17890	N	-1.03815179980117	0.07821	0.3646864	-0.990087816733431	0.10007	0.5013103	0.00160025830155342	0.08681	0.732398	0.92422	0	0.708844	0.79440	0	0.743671	0.96076	0	0.683762	0.67416	0	NULL	NULL	5.66	0.236	0.14733	0.899000	0.28049	-0.155000	0.10715	-0.103000	0.15852	0.456000	0.26612	0.001000	0.05097	0.019000	0.11356	0.3275:0.4528:0.0:0.2197	8.6001	0.32902	527	0.73864	17	0.0033945686900958465	0	0.0	11	0.010934393638170975	5	0.007204610951008645	0	0.0	1	0.0010224948875255625	31	0.008360302049622438	49	0.012714063310845874	80	0.01057921184871727	5	0.0011348161597821154	89	0.010348837209302325	1165	9.595e-03	1165	9.596e-03	13	1.250e-03	45	3.887e-03	1	1.156e-04	56	8.467e-03	990	1.483e-02	46	2.786e-03	989	9.312e-03	989	9.312e-03	10	1.103e-03	44	3.923e-03	1	1.271e-04	56	8.467e-03	822	1.513e-02	46	2.804e-03	660	7.273e-03	660	7.273e-03	13	1.252e-03	45	3.891e-03	1	1.774e-04	31	8.154e-03	513	1.217e-02	46	2.788e-03	.	2151	251452	8.554317e-03	17	22	16256	1.353346e-03	0	163	34590	4.712345e-03	0	76	10076	7.542676e-03	0	1	18394	5.436555e-05	0	177	21646	8.177030e-03	1	1566	113740	1.376824e-02	16	79	30614	2.580519e-03	0	1566	113740	1.376824e-02	16	840	109406	7.677824e-03	6	10	7164	1.395868e-03	0	77	17110	4.500292e-03	0	19	2320	8.189655e-03	0	0	9046	0	0	100	13394	7.466030e-03	0	579	42768	1.353816e-02	6	37	15690	2.358190e-03	0	579	42768	1.353816e-02	6	.	1219	143126	8.516971e-03	9	79	41980	1.881848e-03	0	140	13636	1.026694e-02	0	26	3322	7.826610e-03	0	0	3128	0	0	82	10418	7.870993e-03	0	861	64546	1.333932e-02	8	9	3042	2.958580e-03	0	94011	Benign/Likely_benign	Maple_syrup_urine_disease|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.100216031A>G	Illumina_Clinical_Services_Laboratory,Illumina:1998	C0024776|CN169374|CN517202	248600	ORPHA511	.	SASS6|AGL|SASS6	Skin_Sun_Exposed_Lower_leg|Testis|Thyroid 	.
1	100216031	A	G	S	P	rs146249007	1	100681587	1	100454175	242	DBT	ENSG00000137992	ENST00000370132	ENSP00000359151	.	c.724T>C	p.S242P	c.724T>C	p.Ser242Pro	c.724T>C	p.Ser242Pro	principal1	Y	1	YES	-	TCA	1	0	A	A/A	A/A	G/G	0.327	0.16466	T	0.261	0.22962	T	NULL	NULL	.	NULL	NULL	.	0.233402	0.15869	N	0.655427	0.999999;0.999999	0.08975	N;N	simple_aae;simple_aae	S242P;S242P	NULL	NULL	.	1.5	0.31987	T	0.0	0.08495	N	0.252	0.28498	-0.9484	0.41245	T	0.0149	0.05994	T	10	NULL	NULL	.	0.026	0.05840	.	NULL	.	.	.	0.18274738541	0.17906	0.534135777531	0.50832	0.360091269016	0.19399	T	NULL	NULL	.	-0.632211	0.00093	T	-0.664648	0.07957	T	0.000309917408977404	0.00003	T	NULL	0.22223	.	.	.	.	.	.	.	0.994471	0.14973	11.55	0.043335	0.05277	3.313	0.84317567664795934	0.15221	0.34859	0.25166	N	AEFDBI	0.088245	0.17890	N	-1.03815179980117	0.07821	0.3646864	-0.990087816733431	0.10007	0.5013103	0.00160025830155342	0.08681	0.732398	0.92422	0	0.708844	0.79440	0	0.743671	0.96076	0	0.683762	0.67416	0	NULL	NULL	5.66	0.236	0.14733	0.899000	0.28049	-0.155000	0.10715	-0.103000	0.15852	0.456000	0.26612	0.001000	0.05097	0.019000	0.11356	0.3275:0.4528:0.0:0.2197	8.6001	0.32902	527	0.73864	17	0.0033945686900958465	0	0.0	11	0.010934393638170975	5	0.007204610951008645	0	0.0	1	0.0010224948875255625	31	0.008360302049622438	49	0.012714063310845874	80	0.01057921184871727	5	0.0011348161597821154	89	0.010348837209302325	1165	9.595e-03	1165	9.596e-03	13	1.250e-03	45	3.887e-03	1	1.156e-04	56	8.467e-03	990	1.483e-02	46	2.786e-03	989	9.312e-03	989	9.312e-03	10	1.103e-03	44	3.923e-03	1	1.271e-04	56	8.467e-03	822	1.513e-02	46	2.804e-03	660	7.273e-03	660	7.273e-03	13	1.252e-03	45	3.891e-03	1	1.774e-04	31	8.154e-03	513	1.217e-02	46	2.788e-03	.	2151	251452	8.554317e-03	17	22	16256	1.353346e-03	0	163	34590	4.712345e-03	0	76	10076	7.542676e-03	0	1	18394	5.436555e-05	0	177	21646	8.177030e-03	1	1566	113740	1.376824e-02	16	79	30614	2.580519e-03	0	1566	113740	1.376824e-02	16	840	109406	7.677824e-03	6	10	7164	1.395868e-03	0	77	17110	4.500292e-03	0	19	2320	8.189655e-03	0	0	9046	0	0	100	13394	7.466030e-03	0	579	42768	1.353816e-02	6	37	15690	2.358190e-03	0	579	42768	1.353816e-02	6	.	1219	143126	8.516971e-03	9	79	41980	1.881848e-03	0	140	13636	1.026694e-02	0	26	3322	7.826610e-03	0	0	3128	0	0	82	10418	7.870993e-03	0	861	64546	1.333932e-02	8	9	3042	2.958580e-03	0	94011	Benign/Likely_benign	Maple_syrup_urine_disease|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.100216031A>G	Illumina_Clinical_Services_Laboratory,Illumina:1998	C0024776|CN169374|CN517202	248600	ORPHA511	.	SASS6|AGL|SASS6	Skin_Sun_Exposed_Lower_leg|Testis|Thyroid 	.
1	100216040	T	C	I	V	rs72973763	1	100681596	1	100454184	239	DBT	ENSG00000137992	ENST00000370131	ENSP00000359150	Q5VVL7_HUMAN	c.715A>G	p.I239V	c.715A>G	p.Ile239Val	c.715A>G	p.Ile239Val	.	Y	1	.	-	ATA	1	0	T	C/C	T/T	T/T	1.0	0.00964	T	1.0	0.08390	T	NULL	NULL	.	NULL	NULL	.	0.934860	0.07557	N	1.025950	1;1	0.08975	N;N	simple_aae;simple_aae	I239V;I239V	NULL	NULL	.	1.7	0.27331	T	0.11	0.05706	N	0.128	0.19190	-0.9616	0.38877	T	0.0081	0.02842	T	10	NULL	NULL	.	0.029	0.06892	.	NULL	.	.	.	NULL	NULL	NULL	0.29064	0.231587871909	0.02088	T	NULL	NULL	.	-0.729186	0.00024	T	-0.723485	0.04629	T	0.00715198145188104	0.00082	T	0.562944	0.19809	T	.	.	.	.	.	.	0.163603	0.05596	2.719	-0.334919	0.02152	0.287	0.57737146437461961	0.05835	0.08582	0.14491	N	AEFDBI	0.067783	0.13341	N	-1.17123679742874	0.05439	0.2479779	-1.12122611743184	0.07295	0.3543186	0.00165446229360381	0.08750	0.732398	0.92422	0	0.708844	0.79440	0	0.743671	0.96076	0	0.683762	0.67416	0	NULL	NULL	5.66	0.647	0.16968	-0.079000	0.11321	1.138000	0.64695	0.665000	0.62972	0.000000	0.06391	0.006000	0.10312	0.122000	0.19250	0.126:0.289:0.1299:0.4551	1.8245	0.02929	527	0.73864	180	0.035942492012779555	172	0.13010590015128592	0	0.0	8	0.011527377521613832	0	0.0	0	0.0	2	5.393743257820927E-4	0	0.0	2	2.644802962179318E-4	492	0.11166591012256015	5	5.813953488372093E-4	1258	1.036e-02	1258	1.036e-02	1190	1.144e-01	40	3.455e-03	0	0	0	0	18	2.697e-04	3	1.817e-04	1106	1.041e-02	1106	1.041e-02	1045	1.153e-01	35	3.121e-03	0	0	0	0	16	2.944e-04	3	1.828e-04	1258	1.386e-02	1258	1.386e-02	1190	1.146e-01	40	3.458e-03	0	0	0	0	18	4.271e-04	3	1.818e-04	.	2094	251468	8.327103e-03	110	1885	16256	1.159572e-01	109	150	34592	4.336263e-03	0	15	10078	1.488391e-03	0	0	18394	0	0	0	21646	0	0	19	113750	1.670330e-04	0	4	30616	1.306506e-04	0	1885	16256	1.159572e-01	109	933	109408	8.527713e-03	51	841	7164	1.173925e-01	50	67	17112	3.915381e-03	0	6	2320	2.586207e-03	0	0	9046	0	0	0	13394	0	0	8	42768	1.870557e-04	0	4	15690	2.549395e-04	0	841	7164	1.173925e-01	50	.	4824	143184	3.369092e-02	288	4649	41964	1.107854e-01	283	107	13646	7.841126e-03	1	2	3318	6.027728e-04	0	0	3132	0	0	0	10468	0	0	14	64562	2.168458e-04	0	14	64562	2.168458e-04	0	94010	Benign	Maple_syrup_urine_disease|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.100216040T>C	Illumina_Clinical_Services_Laboratory,Illumina:584685	C0024776|CN169374	248600	ORPHA511	.	.	. 	.
1	100216040	T	C	I	V	rs72973763	1	100681596	1	100454184	239	DBT	ENSG00000137992	ENST00000370132	ENSP00000359151	.	c.715A>G	p.I239V	c.715A>G	p.Ile239Val	c.715A>G	p.Ile239Val	principal1	Y	1	YES	-	ATA	1	0	T	C/C	T/T	T/T	1.0	0.00964	T	0.584	0.08390	T	NULL	NULL	.	NULL	NULL	.	0.934860	0.07557	N	1.025950	1;1	0.08975	N;N	simple_aae;simple_aae	I239V;I239V	NULL	NULL	.	1.67	0.27331	T	0.16	0.05706	N	0.178	0.19190	-0.9616	0.38877	T	0.0081	0.02842	T	10	NULL	NULL	.	0.029	0.06892	.	NULL	.	.	.	NULL	NULL	0.265094830884	0.29064	0.231587871909	0.02088	T	NULL	NULL	.	-0.729186	0.00024	T	-0.723485	0.04629	T	0.00715198145188104	0.00082	T	NULL	0.19809	.	.	.	.	.	.	.	0.163603	0.05596	2.719	-0.334919	0.02152	0.287	0.57737146437461961	0.05835	0.08582	0.14491	N	AEFDBI	0.067783	0.13341	N	-1.17123679742874	0.05439	0.2479779	-1.12122611743184	0.07295	0.3543186	0.00165446229360381	0.08750	0.732398	0.92422	0	0.708844	0.79440	0	0.743671	0.96076	0	0.683762	0.67416	0	NULL	NULL	5.66	0.647	0.16968	-0.079000	0.11321	1.138000	0.64695	0.665000	0.62972	0.000000	0.06391	0.006000	0.10312	0.122000	0.19250	0.126:0.289:0.1299:0.4551	1.8245	0.02929	527	0.73864	180	0.035942492012779555	172	0.13010590015128592	0	0.0	8	0.011527377521613832	0	0.0	0	0.0	2	5.393743257820927E-4	0	0.0	2	2.644802962179318E-4	492	0.11166591012256015	5	5.813953488372093E-4	1258	1.036e-02	1258	1.036e-02	1190	1.144e-01	40	3.455e-03	0	0	0	0	18	2.697e-04	3	1.817e-04	1106	1.041e-02	1106	1.041e-02	1045	1.153e-01	35	3.121e-03	0	0	0	0	16	2.944e-04	3	1.828e-04	1258	1.386e-02	1258	1.386e-02	1190	1.146e-01	40	3.458e-03	0	0	0	0	18	4.271e-04	3	1.818e-04	.	2094	251468	8.327103e-03	110	1885	16256	1.159572e-01	109	150	34592	4.336263e-03	0	15	10078	1.488391e-03	0	0	18394	0	0	0	21646	0	0	19	113750	1.670330e-04	0	4	30616	1.306506e-04	0	1885	16256	1.159572e-01	109	933	109408	8.527713e-03	51	841	7164	1.173925e-01	50	67	17112	3.915381e-03	0	6	2320	2.586207e-03	0	0	9046	0	0	0	13394	0	0	8	42768	1.870557e-04	0	4	15690	2.549395e-04	0	841	7164	1.173925e-01	50	.	4824	143184	3.369092e-02	288	4649	41964	1.107854e-01	283	107	13646	7.841126e-03	1	2	3318	6.027728e-04	0	0	3132	0	0	0	10468	0	0	14	64562	2.168458e-04	0	14	64562	2.168458e-04	0	94010	Benign	Maple_syrup_urine_disease|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.100216040T>C	Illumina_Clinical_Services_Laboratory,Illumina:584685	C0024776|CN169374	248600	ORPHA511	.	.	. 	.
1	100240860	A	G	C	R	rs145674833	1	100706416	1	100479004	26	DBT	ENSG00000137992	ENST00000370131	ENSP00000359150	Q5VVL7_HUMAN	c.76T>C	p.C26R	c.76T>C	p.Cys26Arg	c.76T>C	p.Cys26Arg	.	Y	1	.	-	TGT	1	0	A	./.	./.	./.	0.07	0.35349	T	0.011	0.64786	D	NULL	NULL	.	NULL	NULL	.	0.015880	0.28130	N	0.472746	0.999969;0.999969	0.18878	N;N	simple_aae;simple_aae	C26R;C26R	NULL	NULL	.	1.55	0.29866	T	-2.36	0.52128	N	0.472	0.50778	-0.9900	0.32601	T	0.0184	0.07659	T	10	NULL	NULL	.	0.047	0.13297	.	NULL	.	.	.	0.370608029945	0.36667	NULL	0.52753	0.516384422779	0.41117	T	NULL	NULL	.	-0.545759	0.00309	T	-0.550182	0.17309	T	0.00841681485127588	0.00102	T	0.475652	0.14239	T	.	.	.	.	.	.	1.022254	0.15324	11.90	0.541522	0.11277	9.786	0.68621838315915518	0.08715	0.10397	0.15915	N	AEFDBI	0.116511	0.22863	N	-0.85660850153582	0.11888	0.5762576	-0.854206040552466	0.13186	0.6827118	0.00325969054306532	0.10018	0.706298	0.61202	0	0.709663	0.81188	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	5.49	1.94	0.25058	1.554000	0.35873	1.312000	0.94714	0.756000	0.94297	0.055000	0.21596	0.023000	0.14501	0.003000	0.05239	0.776:0.0:0.224:0.0	8.1137	0.30091	593	0.68665	25	0.0049920127795527154	25	0.018910741301059002	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	39	0.0088515660463005	1	1.1638733705772812E-4	107	8.815e-04	107	8.840e-04	98	9.509e-03	7	6.061e-04	0	0	0	0	2	3.005e-05	0	0	99	9.323e-04	99	9.334e-04	91	1.008e-02	6	5.359e-04	0	0	0	0	2	3.684e-05	0	0	107	1.179e-03	107	1.184e-03	98	9.526e-03	7	6.067e-04	0	0	0	0	2	4.767e-05	0	0	.	182	251018	7.250476e-04	0	150	16248	9.231905e-03	0	29	34558	8.391689e-04	0	0	10066	0	0	0	18390	0	0	0	21646	0	0	2	113432	1.763171e-05	0	0	30556	0	0	150	16248	9.231905e-03	0	83	109346	7.590584e-04	0	70	7160	9.776536e-03	0	13	17094	7.605008e-04	0	0	2318	0	0	0	9044	0	0	0	13394	0	0	0	42762	0	0	0	15660	0	0	70	7160	9.776536e-03	0	.	423	143312	2.951602e-03	3	386	42052	9.179112e-03	3	33	13664	2.415105e-03	0	0	3318	0	0	0	3134	0	0	0	10478	0	0	1	64562	1.548899e-05	0	1	64562	1.548899e-05	0	94013	Benign/Likely_benign	Maple_syrup_urine_disease|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.100240860A>G	.	C0024776|CN169374	248600	ORPHA511	.	.	. 	.
1	100240860	A	G	C	R	rs145674833	1	100706416	1	100479004	26	DBT	ENSG00000137992	ENST00000370132	ENSP00000359151	.	c.76T>C	p.C26R	c.76T>C	p.Cys26Arg	c.76T>C	p.Cys26Arg	principal1	Y	1	YES	-	TGT	1	0	A	./.	./.	./.	0.087	0.35349	T	0.015	0.64786	D	NULL	NULL	.	NULL	NULL	.	0.015880	0.28130	N	0.472746	0.999969;0.999969	0.18878	N;N	simple_aae;simple_aae	C26R;C26R	NULL	NULL	.	1.57	0.29866	T	-1.99	0.52128	N	0.465	0.50778	-0.9900	0.32601	T	0.0184	0.07659	T	10	NULL	NULL	.	0.047	0.13297	.	NULL	.	.	.	0.370608029945	0.36667	0.563021646235	0.52753	0.516384422779	0.41117	T	NULL	NULL	.	-0.545759	0.00309	T	-0.550182	0.17309	T	0.00841681485127588	0.00102	T	NULL	0.14239	.	.	.	.	.	.	.	1.022254	0.15324	11.90	0.541522	0.11277	9.786	0.68621838315915518	0.08715	0.10397	0.15915	N	AEFDBI	0.116511	0.22863	N	-0.85660850153582	0.11888	0.5762576	-0.854206040552466	0.13186	0.6827118	0.00325969054306532	0.10018	0.706298	0.61202	0	0.709663	0.81188	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	5.49	1.94	0.25058	1.554000	0.35873	1.312000	0.94714	0.756000	0.94297	0.055000	0.21596	0.023000	0.14501	0.003000	0.05239	0.776:0.0:0.224:0.0	8.1137	0.30091	593	0.68665	25	0.0049920127795527154	25	0.018910741301059002	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	39	0.0088515660463005	1	1.1638733705772812E-4	107	8.815e-04	107	8.840e-04	98	9.509e-03	7	6.061e-04	0	0	0	0	2	3.005e-05	0	0	99	9.323e-04	99	9.334e-04	91	1.008e-02	6	5.359e-04	0	0	0	0	2	3.684e-05	0	0	107	1.179e-03	107	1.184e-03	98	9.526e-03	7	6.067e-04	0	0	0	0	2	4.767e-05	0	0	.	182	251018	7.250476e-04	0	150	16248	9.231905e-03	0	29	34558	8.391689e-04	0	0	10066	0	0	0	18390	0	0	0	21646	0	0	2	113432	1.763171e-05	0	0	30556	0	0	150	16248	9.231905e-03	0	83	109346	7.590584e-04	0	70	7160	9.776536e-03	0	13	17094	7.605008e-04	0	0	2318	0	0	0	9044	0	0	0	13394	0	0	0	42762	0	0	0	15660	0	0	70	7160	9.776536e-03	0	.	423	143312	2.951602e-03	3	386	42052	9.179112e-03	3	33	13664	2.415105e-03	0	0	3318	0	0	0	3134	0	0	0	10478	0	0	1	64562	1.548899e-05	0	1	64562	1.548899e-05	0	94013	Benign/Likely_benign	Maple_syrup_urine_disease|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.100240860A>G	.	C0024776|CN169374	248600	ORPHA511	.	.	. 	.
1	102888579	G	C	P	A	rs139064549	1	103354135	1	103126723	1420	COL11A1	ENSG00000060718	ENST00000512756	ENSP00000426533	COBA1_HUMAN	c.4258C>G	p.P1420A	c.4258C>G	p.Pro1420Ala	c.4258C>G	p.Pro1420Ala	.	Y	1	.	-	CCA	1	0	G	G/G	G/G	G/G	0.0	0.91255	D	0.005	0.72224	D	NULL	0.90584	.	NULL	0.88582	.	0.000000	0.84330	D	0.000000	1;1;1;1	0.81001	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	P1536A;P1420A;P1548A;P1497A	NULL	0.56745	.	-2.31	0.87750	D	-6.84	0.93060	D	0.6	0.61849	0.6040	0.91953	D	0.7587	0.91781	D	10	NULL	NULL	.	0.597	0.84213	.	NULL	.	.	.	0.84505948143	0.84357	NULL	0.12810	0.707816421986	0.68277	T	NULL	0.97034	.	-0.221338	0.17811	T	-0.0770875	0.65116	T	0.0205891845536396	0.00759	T	0.813719	0.50110	T	.	.	.	.	.	.	4.308092	0.88411	29.6	4.358194	0.90727	31	0.98909183871360828	0.48345	0.99571	0.97563	D	AEFBI	0.925589	0.90539	D	0.892496565058651	0.91388	10.85819	0.881701707469779	0.94725	12.99049	0.999999693137499	0.74766	0.706298	0.61202	0	0.573888	0.26702	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	5.67	5.67	0.87673	9.537000	0.97144	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.972000	0.45474	0.854000	0.40426	0.0:0.0:1.0:0.0	19.7775	0.96396	928	0.17405	13	0.002595846645367412	0	0.0	9	0.008946322067594433	1	0.001440922190201729	0	0.0	3	0.003067484662576687	63	0.01699029126213592	56	0.014530358069538143	119	0.01573657762496694	10	0.0022696323195642307	113	0.013139534883720931	1029	8.476e-03	1025	8.516e-03	20	1.981e-03	27	2.378e-03	0	0	87	1.327e-02	812	1.223e-02	75	4.548e-03	862	8.117e-03	858	8.153e-03	13	1.483e-03	23	2.092e-03	0	0	87	1.327e-02	657	1.216e-02	75	4.577e-03	645	7.108e-03	642	7.151e-03	20	1.984e-03	27	2.381e-03	0	0	47	1.255e-02	471	1.126e-02	74	4.490e-03	.	2154	250618	8.594754e-03	15	33	16118	2.047400e-03	0	121	34494	3.507856e-03	1	17	10068	1.688518e-03	0	0	18368	0	0	249	21608	1.152351e-02	1	1578	113256	1.393304e-02	11	122	30614	3.985105e-03	2	1578	113256	1.393304e-02	11	875	109294	8.005929e-03	6	7	7158	9.779268e-04	0	65	17080	3.805621e-03	0	3	2320	1.293103e-03	0	0	9034	0	0	140	13382	1.046181e-02	1	588	42726	1.376211e-02	4	62	15688	3.952065e-03	1	588	42726	1.376211e-02	4	.	1263	143254	8.816508e-03	16	106	42028	2.522128e-03	0	83	13638	6.085936e-03	1	6	3322	1.806141e-03	0	0	3134	0	0	141	10464	1.347477e-02	5	878	64568	1.359807e-02	10	5	3050	1.639344e-03	0	235592	Benign/Likely_benign	Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.102888579G>C	Illumina_Clinical_Services_Laboratory,Illumina:47835	C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	102888579	G	C	P	A	rs139064549	1	103354135	1	103126723	1497	COL11A1	ENSG00000060718	ENST00000353414	ENSP00000302551	COBA1_HUMAN	c.4489C>G	p.P1497A	c.4489C>G	p.Pro1497Ala	c.4489C>G	p.Pro1497Ala	.	Y	5	.	-	CCA	1	0	G	G/G	G/G	G/G	0.002	0.91255	D	0.005	0.72224	D	1.0	0.90584	D	0.997	0.88582	D	0.000000	0.84330	D	0.000000	1;1;1;1	0.81001	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	P1536A;P1420A;P1548A;P1497A	NULL	0.56745	.	-2.31	0.87750	D	-6.38	0.93060	D	0.574	0.61849	0.6040	0.91953	D	0.7587	0.91781	D	10	NULL	NULL	.	0.597	0.84213	.	NULL	.	.	.	0.84505948143	0.84357	NULL	0.12810	0.707816421986	0.68277	T	NULL	0.97034	.	-0.221338	0.17811	T	-0.0770875	0.65116	T	0.0205891845536396	0.00759	T	0.807619	0.50110	T	.	.	.	.	.	.	4.308092	0.88411	29.6	4.358194	0.90727	31	0.98909183871360828	0.48345	0.99571	0.97563	D	AEFBI	0.925589	0.90539	D	0.892496565058651	0.91388	10.85819	0.881701707469779	0.94725	12.99049	0.999999693137499	0.74766	0.706298	0.61202	0	0.573888	0.26702	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	5.67	5.67	0.87673	9.537000	0.97144	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.972000	0.45474	0.854000	0.40426	0.0:0.0:1.0:0.0	19.7775	0.96396	928	0.17405	13	0.002595846645367412	0	0.0	9	0.008946322067594433	1	0.001440922190201729	0	0.0	3	0.003067484662576687	63	0.01699029126213592	56	0.014530358069538143	119	0.01573657762496694	10	0.0022696323195642307	113	0.013139534883720931	1029	8.476e-03	1025	8.516e-03	20	1.981e-03	27	2.378e-03	0	0	87	1.327e-02	812	1.223e-02	75	4.548e-03	862	8.117e-03	858	8.153e-03	13	1.483e-03	23	2.092e-03	0	0	87	1.327e-02	657	1.216e-02	75	4.577e-03	645	7.108e-03	642	7.151e-03	20	1.984e-03	27	2.381e-03	0	0	47	1.255e-02	471	1.126e-02	74	4.490e-03	.	2154	250618	8.594754e-03	15	33	16118	2.047400e-03	0	121	34494	3.507856e-03	1	17	10068	1.688518e-03	0	0	18368	0	0	249	21608	1.152351e-02	1	1578	113256	1.393304e-02	11	122	30614	3.985105e-03	2	1578	113256	1.393304e-02	11	875	109294	8.005929e-03	6	7	7158	9.779268e-04	0	65	17080	3.805621e-03	0	3	2320	1.293103e-03	0	0	9034	0	0	140	13382	1.046181e-02	1	588	42726	1.376211e-02	4	62	15688	3.952065e-03	1	588	42726	1.376211e-02	4	.	1263	143254	8.816508e-03	16	106	42028	2.522128e-03	0	83	13638	6.085936e-03	1	6	3322	1.806141e-03	0	0	3134	0	0	141	10464	1.347477e-02	5	878	64568	1.359807e-02	10	5	3050	1.639344e-03	0	235592	Benign/Likely_benign	Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.102888579G>C	Illumina_Clinical_Services_Laboratory,Illumina:47835	C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	102888579	G	C	P	A	rs139064549	1	103354135	1	103126723	1536	COL11A1	ENSG00000060718	ENST00000370096	ENSP00000359114	COBA1_HUMAN	c.4606C>G	p.P1536A	c.4606C>G	p.Pro1536Ala	c.4606C>G	p.Pro1536Ala	principal2	Y	1	YES	-	CCA	1	0	G	G/G	G/G	G/G	0.004	0.91255	D	0.005	0.72224	D	1.0	0.90584	D	0.998	0.88582	D	0.000000	0.84330	D	0.000000	1;1;1;1	0.81001	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	P1536A;P1420A;P1548A;P1497A	2.065	0.56745	M	-2.31	0.87750	D	-6.11	0.93060	D	0.582	0.61849	0.6040	0.91953	D	0.7587	0.91781	D	10	NULL	NULL	.	0.597	0.84213	.	NULL	.	.	.	0.84505948143	0.84357	0.113445622327	0.12810	0.707816421986	0.68277	T	0.864981	0.97034	D	-0.221338	0.17811	T	-0.0770875	0.65116	T	0.0205891845536396	0.00759	T	0.832517	0.50110	T	.	.	.	.	.	.	4.308092	0.88411	29.6	4.358194	0.90727	31	0.98909183871360828	0.48345	0.99571	0.97563	D	AEFBI	0.925589	0.90539	D	0.892496565058651	0.91388	10.85819	0.881701707469779	0.94725	12.99049	0.999999693137499	0.74766	0.706298	0.61202	0	0.573888	0.26702	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	5.67	5.67	0.87673	9.537000	0.97144	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.972000	0.45474	0.854000	0.40426	0.0:0.0:1.0:0.0	19.7775	0.96396	928	0.17405	13	0.002595846645367412	0	0.0	9	0.008946322067594433	1	0.001440922190201729	0	0.0	3	0.003067484662576687	63	0.01699029126213592	56	0.014530358069538143	119	0.01573657762496694	10	0.0022696323195642307	113	0.013139534883720931	1029	8.476e-03	1025	8.516e-03	20	1.981e-03	27	2.378e-03	0	0	87	1.327e-02	812	1.223e-02	75	4.548e-03	862	8.117e-03	858	8.153e-03	13	1.483e-03	23	2.092e-03	0	0	87	1.327e-02	657	1.216e-02	75	4.577e-03	645	7.108e-03	642	7.151e-03	20	1.984e-03	27	2.381e-03	0	0	47	1.255e-02	471	1.126e-02	74	4.490e-03	.	2154	250618	8.594754e-03	15	33	16118	2.047400e-03	0	121	34494	3.507856e-03	1	17	10068	1.688518e-03	0	0	18368	0	0	249	21608	1.152351e-02	1	1578	113256	1.393304e-02	11	122	30614	3.985105e-03	2	1578	113256	1.393304e-02	11	875	109294	8.005929e-03	6	7	7158	9.779268e-04	0	65	17080	3.805621e-03	0	3	2320	1.293103e-03	0	0	9034	0	0	140	13382	1.046181e-02	1	588	42726	1.376211e-02	4	62	15688	3.952065e-03	1	588	42726	1.376211e-02	4	.	1263	143254	8.816508e-03	16	106	42028	2.522128e-03	0	83	13638	6.085936e-03	1	6	3322	1.806141e-03	0	0	3134	0	0	141	10464	1.347477e-02	5	878	64568	1.359807e-02	10	5	3050	1.639344e-03	0	235592	Benign/Likely_benign	Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.102888579G>C	Illumina_Clinical_Services_Laboratory,Illumina:47835	C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	102888579	G	C	P	A	rs139064549	1	103354135	1	103126723	1548	COL11A1	ENSG00000060718	ENST00000358392	ENSP00000351163	COBA1_HUMAN	c.4642C>G	p.P1548A	c.4642C>G	p.Pro1548Ala	c.4642C>G	p.Pro1548Ala	alternative1	Y	5	.	-	CCA	1	0	G	G/G	G/G	G/G	0.003	0.91255	D	0.005	0.72224	D	1.0	0.90584	D	0.997	0.88582	D	0.000000	0.84330	D	0.000000	1;1;1;1	0.81001	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	P1536A;P1420A;P1548A;P1497A	NULL	0.56745	.	-2.31	0.87750	D	-6.12	0.93060	D	0.592	0.61849	0.6040	0.91953	D	0.7587	0.91781	D	10	NULL	NULL	.	0.597	0.84213	.	NULL	.	.	.	0.84505948143	0.84357	NULL	0.12810	0.707816421986	0.68277	T	NULL	0.97034	.	-0.221338	0.17811	T	-0.0770875	0.65116	T	0.0205891845536396	0.00759	T	0.807619	0.50110	T	.	.	.	.	.	.	4.308092	0.88411	29.6	4.358194	0.90727	31	0.98909183871360828	0.48345	0.99571	0.97563	D	AEFBI	0.925589	0.90539	D	0.892496565058651	0.91388	10.85819	0.881701707469779	0.94725	12.99049	0.999999693137499	0.74766	0.706298	0.61202	0	0.573888	0.26702	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	5.67	5.67	0.87673	9.537000	0.97144	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.972000	0.45474	0.854000	0.40426	0.0:0.0:1.0:0.0	19.7775	0.96396	928	0.17405	13	0.002595846645367412	0	0.0	9	0.008946322067594433	1	0.001440922190201729	0	0.0	3	0.003067484662576687	63	0.01699029126213592	56	0.014530358069538143	119	0.01573657762496694	10	0.0022696323195642307	113	0.013139534883720931	1029	8.476e-03	1025	8.516e-03	20	1.981e-03	27	2.378e-03	0	0	87	1.327e-02	812	1.223e-02	75	4.548e-03	862	8.117e-03	858	8.153e-03	13	1.483e-03	23	2.092e-03	0	0	87	1.327e-02	657	1.216e-02	75	4.577e-03	645	7.108e-03	642	7.151e-03	20	1.984e-03	27	2.381e-03	0	0	47	1.255e-02	471	1.126e-02	74	4.490e-03	.	2154	250618	8.594754e-03	15	33	16118	2.047400e-03	0	121	34494	3.507856e-03	1	17	10068	1.688518e-03	0	0	18368	0	0	249	21608	1.152351e-02	1	1578	113256	1.393304e-02	11	122	30614	3.985105e-03	2	1578	113256	1.393304e-02	11	875	109294	8.005929e-03	6	7	7158	9.779268e-04	0	65	17080	3.805621e-03	0	3	2320	1.293103e-03	0	0	9034	0	0	140	13382	1.046181e-02	1	588	42726	1.376211e-02	4	62	15688	3.952065e-03	1	588	42726	1.376211e-02	4	.	1263	143254	8.816508e-03	16	106	42028	2.522128e-03	0	83	13638	6.085936e-03	1	6	3322	1.806141e-03	0	0	3134	0	0	141	10464	1.347477e-02	5	878	64568	1.359807e-02	10	5	3050	1.639344e-03	0	235592	Benign/Likely_benign	Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.102888579G>C	Illumina_Clinical_Services_Laboratory,Illumina:47835	C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	102888916	T	C	I	V	rs145901197	1	103354472	1	103127060	1374	COL11A1	ENSG00000060718	ENST00000512756	ENSP00000426533	COBA1_HUMAN	c.4120A>G	p.I1374V	c.4120A>G	p.Ile1374Val	c.4120A>G	p.Ile1374Val	.	Y	1	.	-	ATT	1	0	T	T/T	T/T	T/T	0.627	0.06891	T	0.648	0.06788	T	NULL	0.07471	.	NULL	0.11217	.	0.000302	0.45977	D	0.220159	0.994928;0.991606;0.994928;0.994928	0.42472	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	I1490V;I1374V;I1502V;I1451V	NULL	0.04694	.	-3.23	0.93414	D	-0.14	0.09965	N	0.389	0.43029	-0.2386	0.76662	T	0.5086	0.81517	D	10	NULL	NULL	.	0.253	0.56695	.	NULL	.	.	.	0.54431890818	0.54086	NULL	0.10942	0.566077768803	0.48124	T	NULL	0.68040	.	-0.239227	0.15447	T	-0.10987	0.62623	T	0.018116875738121	0.00533	T	0.790321	0.44048	T	.	.	.	.	.	.	1.909571	0.28843	18.56	2.008568	0.33134	19.80	0.98274944222309724	0.39796	0.97144	0.72948	D	AEFBI	0.420401	0.48724	N	-0.120639584536358	0.36494	2.110245	0.0859902795780559	0.43841	2.677718	0.0133099011796512	0.12446	0.706298	0.61202	0	0.573888	0.26702	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	6.02	4.88	0.63131	4.215000	0.58331	1.138000	0.64695	0.665000	0.62972	1.000000	0.71638	0.998000	0.65909	0.992000	0.67800	0.0:0.0665:0.0:0.9335	12.3309	0.54364	928	0.17405	18	0.003594249201277955	17	0.012859304084720122	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	28	0.006354970494779845	0	0.0	96	7.907e-04	95	7.849e-04	85	8.337e-03	8	6.955e-04	0	0	0	0	1	1.500e-05	0	0	86	8.098e-04	85	8.030e-04	76	8.580e-03	7	6.284e-04	0	0	0	0	1	1.842e-05	0	0	96	1.058e-03	95	1.051e-03	85	8.351e-03	8	6.963e-04	0	0	0	0	1	2.377e-05	0	0	.	160	251044	6.373385e-04	1	138	16154	8.542776e-03	1	18	34536	5.211953e-04	0	0	10072	0	0	0	18388	0	0	0	21644	0	0	1	113522	8.808865e-06	0	0	30612	0	0	138	16154	8.542776e-03	1	64	109382	5.851054e-04	0	57	7162	7.958671e-03	0	7	17094	4.095004e-04	0	0	2320	0	0	0	9042	0	0	0	13394	0	0	0	42768	0	0	0	15688	0	0	57	7162	7.958671e-03	0	.	384	143278	2.680104e-03	6	374	42052	8.893751e-03	6	5	13646	3.664077e-04	0	0	3324	0	0	0	3132	0	0	0	10472	0	0	0	64554	0	0	5	13646	3.664077e-04	0	198301	Benign/Likely_benign	Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.102888916T>C	Illumina_Clinical_Services_Laboratory,Illumina:741843	C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	102888916	T	C	I	V	rs145901197	1	103354472	1	103127060	1451	COL11A1	ENSG00000060718	ENST00000353414	ENSP00000302551	COBA1_HUMAN	c.4351A>G	p.I1451V	c.4351A>G	p.Ile1451Val	c.4351A>G	p.Ile1451Val	.	Y	5	.	-	ATT	1	0	T	T/T	T/T	T/T	0.701	0.06891	T	0.778	0.06788	T	0.0	0.07471	B	0.002	0.11217	B	0.000302	0.45977	D	0.220159	0.994928;0.991606;0.994928;0.994928	0.42472	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	I1490V;I1374V;I1502V;I1451V	NULL	0.04694	.	-3.23	0.93414	D	-0.19	0.09965	N	0.326	0.43029	-0.2386	0.76662	T	0.5086	0.81517	D	10	NULL	NULL	.	0.253	0.56695	.	NULL	.	.	.	0.54431890818	0.54086	NULL	0.10942	0.566077768803	0.48124	T	NULL	0.68040	.	-0.239227	0.15447	T	-0.10987	0.62623	T	0.018116875738121	0.00533	T	0.79692	0.44048	T	.	.	.	.	.	.	1.909571	0.28843	18.56	2.008568	0.33134	19.80	0.98274944222309724	0.39796	0.97144	0.72948	D	AEFBI	0.420401	0.48724	N	-0.120639584536358	0.36494	2.110245	0.0859902795780559	0.43841	2.677718	0.0133099011796512	0.12446	0.706298	0.61202	0	0.573888	0.26702	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	6.02	4.88	0.63131	4.215000	0.58331	1.138000	0.64695	0.665000	0.62972	1.000000	0.71638	0.998000	0.65909	0.992000	0.67800	0.0:0.0665:0.0:0.9335	12.3309	0.54364	928	0.17405	18	0.003594249201277955	17	0.012859304084720122	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	28	0.006354970494779845	0	0.0	96	7.907e-04	95	7.849e-04	85	8.337e-03	8	6.955e-04	0	0	0	0	1	1.500e-05	0	0	86	8.098e-04	85	8.030e-04	76	8.580e-03	7	6.284e-04	0	0	0	0	1	1.842e-05	0	0	96	1.058e-03	95	1.051e-03	85	8.351e-03	8	6.963e-04	0	0	0	0	1	2.377e-05	0	0	.	160	251044	6.373385e-04	1	138	16154	8.542776e-03	1	18	34536	5.211953e-04	0	0	10072	0	0	0	18388	0	0	0	21644	0	0	1	113522	8.808865e-06	0	0	30612	0	0	138	16154	8.542776e-03	1	64	109382	5.851054e-04	0	57	7162	7.958671e-03	0	7	17094	4.095004e-04	0	0	2320	0	0	0	9042	0	0	0	13394	0	0	0	42768	0	0	0	15688	0	0	57	7162	7.958671e-03	0	.	384	143278	2.680104e-03	6	374	42052	8.893751e-03	6	5	13646	3.664077e-04	0	0	3324	0	0	0	3132	0	0	0	10472	0	0	0	64554	0	0	5	13646	3.664077e-04	0	198301	Benign/Likely_benign	Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.102888916T>C	Illumina_Clinical_Services_Laboratory,Illumina:741843	C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	102888916	T	C	I	V	rs145901197	1	103354472	1	103127060	1490	COL11A1	ENSG00000060718	ENST00000370096	ENSP00000359114	COBA1_HUMAN	c.4468A>G	p.I1490V	c.4468A>G	p.Ile1490Val	c.4468A>G	p.Ile1490Val	principal2	Y	1	YES	-	ATT	1	0	T	T/T	T/T	T/T	0.536	0.06891	T	1.0	0.06788	T	0.001	0.07471	B	0.005	0.11217	B	0.000302	0.45977	D	0.220159	0.994928;0.991606;0.994928;0.994928	0.42472	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	I1490V;I1374V;I1502V;I1451V	-0.1	0.04694	N	-3.23	0.93414	D	-0.15	0.09965	N	0.356	0.43029	-0.2386	0.76662	T	0.5086	0.81517	D	10	NULL	NULL	.	0.253	0.56695	.	NULL	.	.	.	0.54431890818	0.54086	0.0969139405913	0.10942	0.566077768803	0.48124	T	0.308297	0.68040	T	-0.239227	0.15447	T	-0.10987	0.62623	T	0.018116875738121	0.00533	T	0.79692	0.44048	T	.	.	.	.	.	.	1.909571	0.28843	18.56	2.008568	0.33134	19.80	0.98274944222309724	0.39796	0.97144	0.72948	D	AEFBI	0.420401	0.48724	N	-0.120639584536358	0.36494	2.110245	0.0859902795780559	0.43841	2.677718	0.0133099011796512	0.12446	0.706298	0.61202	0	0.573888	0.26702	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	6.02	4.88	0.63131	4.215000	0.58331	1.138000	0.64695	0.665000	0.62972	1.000000	0.71638	0.998000	0.65909	0.992000	0.67800	0.0:0.0665:0.0:0.9335	12.3309	0.54364	928	0.17405	18	0.003594249201277955	17	0.012859304084720122	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	28	0.006354970494779845	0	0.0	96	7.907e-04	95	7.849e-04	85	8.337e-03	8	6.955e-04	0	0	0	0	1	1.500e-05	0	0	86	8.098e-04	85	8.030e-04	76	8.580e-03	7	6.284e-04	0	0	0	0	1	1.842e-05	0	0	96	1.058e-03	95	1.051e-03	85	8.351e-03	8	6.963e-04	0	0	0	0	1	2.377e-05	0	0	.	160	251044	6.373385e-04	1	138	16154	8.542776e-03	1	18	34536	5.211953e-04	0	0	10072	0	0	0	18388	0	0	0	21644	0	0	1	113522	8.808865e-06	0	0	30612	0	0	138	16154	8.542776e-03	1	64	109382	5.851054e-04	0	57	7162	7.958671e-03	0	7	17094	4.095004e-04	0	0	2320	0	0	0	9042	0	0	0	13394	0	0	0	42768	0	0	0	15688	0	0	57	7162	7.958671e-03	0	.	384	143278	2.680104e-03	6	374	42052	8.893751e-03	6	5	13646	3.664077e-04	0	0	3324	0	0	0	3132	0	0	0	10472	0	0	0	64554	0	0	5	13646	3.664077e-04	0	198301	Benign/Likely_benign	Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.102888916T>C	Illumina_Clinical_Services_Laboratory,Illumina:741843	C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	102888916	T	C	I	V	rs145901197	1	103354472	1	103127060	1502	COL11A1	ENSG00000060718	ENST00000358392	ENSP00000351163	COBA1_HUMAN	c.4504A>G	p.I1502V	c.4504A>G	p.Ile1502Val	c.4504A>G	p.Ile1502Val	alternative1	Y	5	.	-	ATT	1	0	T	T/T	T/T	T/T	0.549	0.06891	T	1.0	0.06788	T	0.001	0.07471	B	0.003	0.11217	B	0.000302	0.45977	D	0.220159	0.994928;0.991606;0.994928;0.994928	0.42472	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	I1490V;I1374V;I1502V;I1451V	NULL	0.04694	.	-3.23	0.93414	D	-0.19	0.09965	N	0.353	0.43029	-0.2386	0.76662	T	0.5086	0.81517	D	10	NULL	NULL	.	0.253	0.56695	.	NULL	.	.	.	0.54431890818	0.54086	NULL	0.10942	0.566077768803	0.48124	T	NULL	0.68040	.	-0.239227	0.15447	T	-0.10987	0.62623	T	0.018116875738121	0.00533	T	0.79692	0.44048	T	.	.	.	.	.	.	1.909571	0.28843	18.56	2.008568	0.33134	19.80	0.98274944222309724	0.39796	0.97144	0.72948	D	AEFBI	0.420401	0.48724	N	-0.120639584536358	0.36494	2.110245	0.0859902795780559	0.43841	2.677718	0.0133099011796512	0.12446	0.706298	0.61202	0	0.573888	0.26702	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	6.02	4.88	0.63131	4.215000	0.58331	1.138000	0.64695	0.665000	0.62972	1.000000	0.71638	0.998000	0.65909	0.992000	0.67800	0.0:0.0665:0.0:0.9335	12.3309	0.54364	928	0.17405	18	0.003594249201277955	17	0.012859304084720122	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	28	0.006354970494779845	0	0.0	96	7.907e-04	95	7.849e-04	85	8.337e-03	8	6.955e-04	0	0	0	0	1	1.500e-05	0	0	86	8.098e-04	85	8.030e-04	76	8.580e-03	7	6.284e-04	0	0	0	0	1	1.842e-05	0	0	96	1.058e-03	95	1.051e-03	85	8.351e-03	8	6.963e-04	0	0	0	0	1	2.377e-05	0	0	.	160	251044	6.373385e-04	1	138	16154	8.542776e-03	1	18	34536	5.211953e-04	0	0	10072	0	0	0	18388	0	0	0	21644	0	0	1	113522	8.808865e-06	0	0	30612	0	0	138	16154	8.542776e-03	1	64	109382	5.851054e-04	0	57	7162	7.958671e-03	0	7	17094	4.095004e-04	0	0	2320	0	0	0	9042	0	0	0	13394	0	0	0	42768	0	0	0	15688	0	0	57	7162	7.958671e-03	0	.	384	143278	2.680104e-03	6	374	42052	8.893751e-03	6	5	13646	3.664077e-04	0	0	3324	0	0	0	3132	0	0	0	10472	0	0	0	64554	0	0	5	13646	3.664077e-04	0	198301	Benign/Likely_benign	Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.102888916T>C	Illumina_Clinical_Services_Laboratory,Illumina:741843	C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	102889503	G	T	D	E	rs55821405	1	103355059	1	103127647	1356	COL11A1	ENSG00000060718	ENST00000512756	ENSP00000426533	COBA1_HUMAN	c.4068C>A	p.D1356E	c.4068C>A	p.Asp1356Glu	c.4068C>A	p.Asp1356Glu	.	Y	1	.	-	GAC	3	2	G	G/G	G/G	G/G	0.099	0.31088	T	0.287	0.25061	T	NULL	0.70673	.	NULL	0.82059	.	0.000000	0.84330	D	0.000000	0.999989;0.999982;0.999989;0.999989	0.54805	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	D1472E;D1356E;D1484E;D1433E	NULL	0.01730	.	-3.23	0.93414	D	-3.57	0.69835	D	0.692	0.70527	0.3358	0.88119	D	0.6972	0.89565	D	10	0.112062	0.79008	D	0.552	0.81703	.	NULL	.	.	.	0.907785917712	0.90686	NULL	0.12296	0.824459969997	0.85713	D	NULL	0.94446	.	-0.170222	0.25199	T	-0.0135624	0.69451	D	0.02281865028848	0.01003	T	0.628437	0.24364	T	.	.	.	.	.	.	2.835280	0.48490	23.1	2.988389	0.54468	23.5	0.98851485639011649	0.47305	0.94042	0.59938	D	AEFBI	0.564315	0.57115	D	0.416438622550044	0.62327	4.446678	0.441024286526459	0.64141	4.662769	7.58905025739506E-4	0.07758	0.706298	0.61202	0	0.573888	0.26702	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	5.46	4.54	0.55220	2.536000	0.45351	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.903000	0.37846	0.451000	0.27917	0.2249:0.0:0.7751:0.0	7.9711	0.29289	928	0.17405	4	7.987220447284345E-4	0	0.0	1	9.940357852882703E-4	1	0.001440922190201729	0	0.0	2	0.002044989775051125	12	0.003236245954692557	8	0.0020757654385054488	20	0.0026448029621793175	2	4.5392646391284613E-4	35	0.004069767441860465	357	2.940e-03	357	2.943e-03	6	5.771e-04	32	2.774e-03	0	0	6	9.074e-04	278	4.168e-03	30	1.817e-03	296	2.787e-03	296	2.789e-03	5	5.521e-04	31	2.775e-03	0	0	6	9.074e-04	219	4.032e-03	30	1.828e-03	305	3.361e-03	305	3.365e-03	6	5.781e-04	32	2.777e-03	0	0	2	5.263e-04	230	5.463e-03	30	1.818e-03	.	848	251434	3.372654e-03	6	11	16252	6.768398e-04	0	83	34578	2.400370e-03	0	186	10078	1.845604e-02	1	0	18388	0	0	33	21646	1.524531e-03	0	424	113738	3.727866e-03	2	79	30614	2.580519e-03	2	424	113738	3.727866e-03	2	323	109398	2.952522e-03	3	3	7164	4.187605e-04	0	47	17106	2.747574e-03	0	45	2320	1.939655e-02	1	0	9042	0	0	22	13394	1.642527e-03	0	143	42768	3.343621e-03	1	52	15690	3.314213e-03	1	143	42768	3.343621e-03	1	.	406	142636	2.846406e-03	2	24	41814	5.739704e-04	0	52	13522	3.845585e-03	0	59	3318	1.778180e-02	0	0	3126	0	0	13	10332	1.258227e-03	0	219	64446	3.398194e-03	1	10	3036	3.293808e-03	0	198019	Conflicting_interpretations_of_pathogenicity	Connective_tissue_disease|Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.102889503G>T	Center_for_Human_Genetics,_Inc:COL11A1-A22|Illumina_Clinical_Services_Laboratory,Illumina:116936	C0009782|C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	102889503	G	T	D	E	rs55821405	1	103355059	1	103127647	1433	COL11A1	ENSG00000060718	ENST00000353414	ENSP00000302551	COBA1_HUMAN	c.4299C>A	p.D1433E	c.4299C>A	p.Asp1433Glu	c.4299C>A	p.Asp1433Glu	.	Y	5	.	-	GAC	3	2	G	G/G	G/G	G/G	0.145	0.31088	T	0.241	0.25061	T	0.99	0.70673	D	0.986	0.82059	D	0.000000	0.84330	D	0.000000	0.999989;0.999982;0.999989;0.999989	0.54805	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	D1472E;D1356E;D1484E;D1433E	NULL	0.01730	.	-3.23	0.93414	D	-3.64	0.69835	D	0.652	0.70527	0.3358	0.88119	D	0.6972	0.89565	D	10	0.112062	0.79008	D	0.552	0.81703	.	NULL	.	.	.	0.907785917712	0.90686	NULL	0.12296	0.824459969997	0.85713	D	NULL	0.94446	.	-0.170222	0.25199	T	-0.0135624	0.69451	D	0.02281865028848	0.01003	T	0.612939	0.24364	T	.	.	.	.	.	.	2.835280	0.48490	23.1	2.988389	0.54468	23.5	0.98851485639011649	0.47305	0.94042	0.59938	D	AEFBI	0.564315	0.57115	D	0.416438622550044	0.62327	4.446678	0.441024286526459	0.64141	4.662769	7.58905025739506E-4	0.07758	0.706298	0.61202	0	0.573888	0.26702	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	5.46	4.54	0.55220	2.536000	0.45351	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.903000	0.37846	0.451000	0.27917	0.2249:0.0:0.7751:0.0	7.9711	0.29289	928	0.17405	4	7.987220447284345E-4	0	0.0	1	9.940357852882703E-4	1	0.001440922190201729	0	0.0	2	0.002044989775051125	12	0.003236245954692557	8	0.0020757654385054488	20	0.0026448029621793175	2	4.5392646391284613E-4	35	0.004069767441860465	357	2.940e-03	357	2.943e-03	6	5.771e-04	32	2.774e-03	0	0	6	9.074e-04	278	4.168e-03	30	1.817e-03	296	2.787e-03	296	2.789e-03	5	5.521e-04	31	2.775e-03	0	0	6	9.074e-04	219	4.032e-03	30	1.828e-03	305	3.361e-03	305	3.365e-03	6	5.781e-04	32	2.777e-03	0	0	2	5.263e-04	230	5.463e-03	30	1.818e-03	.	848	251434	3.372654e-03	6	11	16252	6.768398e-04	0	83	34578	2.400370e-03	0	186	10078	1.845604e-02	1	0	18388	0	0	33	21646	1.524531e-03	0	424	113738	3.727866e-03	2	79	30614	2.580519e-03	2	424	113738	3.727866e-03	2	323	109398	2.952522e-03	3	3	7164	4.187605e-04	0	47	17106	2.747574e-03	0	45	2320	1.939655e-02	1	0	9042	0	0	22	13394	1.642527e-03	0	143	42768	3.343621e-03	1	52	15690	3.314213e-03	1	143	42768	3.343621e-03	1	.	406	142636	2.846406e-03	2	24	41814	5.739704e-04	0	52	13522	3.845585e-03	0	59	3318	1.778180e-02	0	0	3126	0	0	13	10332	1.258227e-03	0	219	64446	3.398194e-03	1	10	3036	3.293808e-03	0	198019	Conflicting_interpretations_of_pathogenicity	Connective_tissue_disease|Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.102889503G>T	Center_for_Human_Genetics,_Inc:COL11A1-A22|Illumina_Clinical_Services_Laboratory,Illumina:116936	C0009782|C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	102889503	G	T	D	E	rs55821405	1	103355059	1	103127647	1472	COL11A1	ENSG00000060718	ENST00000370096	ENSP00000359114	COBA1_HUMAN	c.4416C>A	p.D1472E	c.4416C>A	p.Asp1472Glu	c.4416C>A	p.Asp1472Glu	principal2	Y	1	YES	-	GAC	3	2	G	G/G	G/G	G/G	0.149	0.31088	T	0.244	0.25061	T	0.997	0.70673	D	0.994	0.82059	D	0.000000	0.84330	D	0.000000	0.999989;0.999982;0.999989;0.999989	0.54805	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	D1472E;D1356E;D1484E;D1433E	-0.75	0.01730	N	-3.23	0.93414	D	-3.5	0.69835	D	0.691	0.70527	0.3358	0.88119	D	0.6972	0.89565	D	10	0.112062	0.79008	D	0.552	0.81703	.	NULL	.	.	.	0.907785917712	0.90686	0.109054705777	0.12296	0.824459969997	0.85713	D	0.787476	0.94446	D	-0.170222	0.25199	T	-0.0135624	0.69451	D	0.02281865028848	0.01003	T	0.618838	0.24364	T	.	.	.	.	.	.	2.835280	0.48490	23.1	2.988389	0.54468	23.5	0.98851485639011649	0.47305	0.94042	0.59938	D	AEFBI	0.564315	0.57115	D	0.416438622550044	0.62327	4.446678	0.441024286526459	0.64141	4.662769	7.58905025739506E-4	0.07758	0.706298	0.61202	0	0.573888	0.26702	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	5.46	4.54	0.55220	2.536000	0.45351	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.903000	0.37846	0.451000	0.27917	0.2249:0.0:0.7751:0.0	7.9711	0.29289	928	0.17405	4	7.987220447284345E-4	0	0.0	1	9.940357852882703E-4	1	0.001440922190201729	0	0.0	2	0.002044989775051125	12	0.003236245954692557	8	0.0020757654385054488	20	0.0026448029621793175	2	4.5392646391284613E-4	35	0.004069767441860465	357	2.940e-03	357	2.943e-03	6	5.771e-04	32	2.774e-03	0	0	6	9.074e-04	278	4.168e-03	30	1.817e-03	296	2.787e-03	296	2.789e-03	5	5.521e-04	31	2.775e-03	0	0	6	9.074e-04	219	4.032e-03	30	1.828e-03	305	3.361e-03	305	3.365e-03	6	5.781e-04	32	2.777e-03	0	0	2	5.263e-04	230	5.463e-03	30	1.818e-03	.	848	251434	3.372654e-03	6	11	16252	6.768398e-04	0	83	34578	2.400370e-03	0	186	10078	1.845604e-02	1	0	18388	0	0	33	21646	1.524531e-03	0	424	113738	3.727866e-03	2	79	30614	2.580519e-03	2	424	113738	3.727866e-03	2	323	109398	2.952522e-03	3	3	7164	4.187605e-04	0	47	17106	2.747574e-03	0	45	2320	1.939655e-02	1	0	9042	0	0	22	13394	1.642527e-03	0	143	42768	3.343621e-03	1	52	15690	3.314213e-03	1	143	42768	3.343621e-03	1	.	406	142636	2.846406e-03	2	24	41814	5.739704e-04	0	52	13522	3.845585e-03	0	59	3318	1.778180e-02	0	0	3126	0	0	13	10332	1.258227e-03	0	219	64446	3.398194e-03	1	10	3036	3.293808e-03	0	198019	Conflicting_interpretations_of_pathogenicity	Connective_tissue_disease|Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.102889503G>T	Center_for_Human_Genetics,_Inc:COL11A1-A22|Illumina_Clinical_Services_Laboratory,Illumina:116936	C0009782|C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	102889503	G	T	D	E	rs55821405	1	103355059	1	103127647	1484	COL11A1	ENSG00000060718	ENST00000358392	ENSP00000351163	COBA1_HUMAN	c.4452C>A	p.D1484E	c.4452C>A	p.Asp1484Glu	c.4452C>A	p.Asp1484Glu	alternative1	Y	5	.	-	GAC	3	2	G	G/G	G/G	G/G	0.096	0.31088	T	0.231	0.25061	T	0.996	0.70673	D	0.99	0.82059	D	0.000000	0.84330	D	0.000000	0.999989;0.999982;0.999989;0.999989	0.54805	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	D1472E;D1356E;D1484E;D1433E	NULL	0.01730	.	-3.23	0.93414	D	-3.5	0.69835	D	0.701	0.70527	0.3358	0.88119	D	0.6972	0.89565	D	10	0.112062	0.79008	D	0.552	0.81703	.	NULL	.	.	.	0.907785917712	0.90686	NULL	0.12296	0.824459969997	0.85713	D	NULL	0.94446	.	-0.170222	0.25199	T	-0.0135624	0.69451	D	0.02281865028848	0.01003	T	0.615438	0.24364	T	.	.	.	.	.	.	2.835280	0.48490	23.1	2.988389	0.54468	23.5	0.98851485639011649	0.47305	0.94042	0.59938	D	AEFBI	0.564315	0.57115	D	0.416438622550044	0.62327	4.446678	0.441024286526459	0.64141	4.662769	7.58905025739506E-4	0.07758	0.706298	0.61202	0	0.573888	0.26702	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	5.46	4.54	0.55220	2.536000	0.45351	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.903000	0.37846	0.451000	0.27917	0.2249:0.0:0.7751:0.0	7.9711	0.29289	928	0.17405	4	7.987220447284345E-4	0	0.0	1	9.940357852882703E-4	1	0.001440922190201729	0	0.0	2	0.002044989775051125	12	0.003236245954692557	8	0.0020757654385054488	20	0.0026448029621793175	2	4.5392646391284613E-4	35	0.004069767441860465	357	2.940e-03	357	2.943e-03	6	5.771e-04	32	2.774e-03	0	0	6	9.074e-04	278	4.168e-03	30	1.817e-03	296	2.787e-03	296	2.789e-03	5	5.521e-04	31	2.775e-03	0	0	6	9.074e-04	219	4.032e-03	30	1.828e-03	305	3.361e-03	305	3.365e-03	6	5.781e-04	32	2.777e-03	0	0	2	5.263e-04	230	5.463e-03	30	1.818e-03	.	848	251434	3.372654e-03	6	11	16252	6.768398e-04	0	83	34578	2.400370e-03	0	186	10078	1.845604e-02	1	0	18388	0	0	33	21646	1.524531e-03	0	424	113738	3.727866e-03	2	79	30614	2.580519e-03	2	424	113738	3.727866e-03	2	323	109398	2.952522e-03	3	3	7164	4.187605e-04	0	47	17106	2.747574e-03	0	45	2320	1.939655e-02	1	0	9042	0	0	22	13394	1.642527e-03	0	143	42768	3.343621e-03	1	52	15690	3.314213e-03	1	143	42768	3.343621e-03	1	.	406	142636	2.846406e-03	2	24	41814	5.739704e-04	0	52	13522	3.845585e-03	0	59	3318	1.778180e-02	0	0	3126	0	0	13	10332	1.258227e-03	0	219	64446	3.398194e-03	1	10	3036	3.293808e-03	0	198019	Conflicting_interpretations_of_pathogenicity	Connective_tissue_disease|Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.102889503G>T	Center_for_Human_Genetics,_Inc:COL11A1-A22|Illumina_Clinical_Services_Laboratory,Illumina:116936	C0009782|C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	102979414	A	T	F	I	rs141548164	1	103444970	1	103217558	744	COL11A1	ENSG00000060718	ENST00000512756	ENSP00000426533	COBA1_HUMAN	c.2230T>A	p.F744I	c.2230T>A	p.Phe744Ile	c.2230T>A	p.Phe744Ile	.	Y	1	.	-	TTT	1	0	A	A/A	A/A	A/A	0.398	0.19430	T	0.243	0.24193	T	NULL	0.68779	.	NULL	0.78936	.	0.000000	0.84330	D	0.000000	1;1;1;1	0.81001	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	F860I;F744I;F872I;F821I	NULL	0.07966	.	-3.23	0.93414	D	-2.76	0.65742	D	0.532	0.58798	0.3924	0.88982	D	0.6971	0.89561	D	10	NULL	NULL	.	0.653	0.87099	.	NULL	.	.	.	0.6426644317	0.63971	NULL	0.18630	0.791092395782	0.80609	T	NULL	0.88659	.	-0.114007	0.34108	T	0.0871456	0.76054	D	0.0392798677672517	0.03561	T	0.926807	0.74183	D	.	.	.	.	.	.	3.461866	0.63118	24.6	3.447042	0.65753	24.8	0.98070656079945406	0.38023	0.99262	0.93620	D	AEFBI	0.888156	0.82101	D	0.41305981560501	0.62139	4.425081	0.491823572538103	0.67446	5.085271	0.995689001910527	0.34265	0.693126	0.56070	0	0.573888	0.26702	0	0.659464	0.59346	0	0.564101	0.26826	0	NULL	NULL	5.02	5.02	0.66742	8.850000	0.91815	1.288000	0.86526	0.756000	0.94297	1.000000	0.71638	0.997000	0.62031	0.998000	0.85391	1.0:0.0:0.0:0.0	14.9128	0.70414	857	0.34089	30	0.0059904153354632585	0	0.0	2	0.0019880715705765406	13	0.018731988472622477	15	0.01488095238095238	0	0.0	12	0.003236245954692557	12	0.0031136481577581734	24	0.003173763554615181	6	0.0013617793917385383	34	0.003953488372093023	784	6.457e-03	781	6.833e-03	12	1.279e-03	371	3.380e-02	111	1.310e-02	23	3.606e-03	258	4.126e-03	3	1.912e-04	721	6.789e-03	718	7.206e-03	11	1.363e-03	364	3.425e-02	104	1.344e-02	23	3.606e-03	210	4.151e-03	3	1.924e-04	624	6.876e-03	622	7.234e-03	12	1.282e-03	371	3.383e-02	78	1.419e-02	14	3.823e-03	141	3.514e-03	3	1.913e-04	.	1926	250608	7.685309e-03	29	17	16074	1.057609e-03	0	1083	34482	3.140769e-02	25	0	10062	0	0	251	18364	1.366805e-02	0	82	21610	3.794540e-03	0	450	113372	3.969234e-03	3	4	30540	1.309758e-04	0	1083	34482	3.140769e-02	25	891	109132	8.164425e-03	11	9	7128	1.262626e-03	0	523	17070	3.063855e-02	8	0	2306	0	0	129	9030	1.428571e-02	0	60	13384	4.482965e-03	0	162	42654	3.798003e-03	3	1	15648	6.390593e-05	0	523	17070	3.063855e-02	8	.	701	143316	4.891289e-03	6	52	42048	1.236682e-03	0	311	13658	2.277054e-02	5	0	3322	0	0	33	3134	1.052967e-02	0	24	10480	2.290076e-03	0	272	64574	4.212222e-03	1	2	3048	6.561680e-04	0	196779	Benign/Likely_benign	Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.102979414A>T	Illumina_Clinical_Services_Laboratory,Illumina:234873	C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	102979414	A	T	F	I	rs141548164	1	103444970	1	103217558	821	COL11A1	ENSG00000060718	ENST00000353414	ENSP00000302551	COBA1_HUMAN	c.2461T>A	p.F821I	c.2461T>A	p.Phe821Ile	c.2461T>A	p.Phe821Ile	.	Y	5	.	-	TTT	1	0	A	A/A	A/A	A/A	0.346	0.19430	T	0.29	0.24193	T	0.989	0.68779	D	0.985	0.78936	D	0.000000	0.84330	D	0.000000	1;1;1;1	0.81001	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	F860I;F744I;F872I;F821I	NULL	0.07966	.	-3.23	0.93414	D	-3.09	0.65742	D	0.564	0.58798	0.3924	0.88982	D	0.6971	0.89561	D	10	NULL	NULL	.	0.653	0.87099	.	NULL	.	.	.	0.6426644317	0.63971	NULL	0.18630	0.791092395782	0.80609	T	NULL	0.88659	.	-0.114007	0.34108	T	0.0871456	0.76054	D	0.0392798677672517	0.03561	T	0.930207	0.74183	D	.	.	.	.	.	.	3.461866	0.63118	24.6	3.447042	0.65753	24.8	0.98070656079945406	0.38023	0.99262	0.93620	D	AEFBI	0.888156	0.82101	D	0.41305981560501	0.62139	4.425081	0.491823572538103	0.67446	5.085271	0.995689001910527	0.34265	0.693126	0.56070	0	0.573888	0.26702	0	0.659464	0.59346	0	0.564101	0.26826	0	NULL	NULL	5.02	5.02	0.66742	8.850000	0.91815	1.288000	0.86526	0.756000	0.94297	1.000000	0.71638	0.997000	0.62031	0.998000	0.85391	1.0:0.0:0.0:0.0	14.9128	0.70414	857	0.34089	30	0.0059904153354632585	0	0.0	2	0.0019880715705765406	13	0.018731988472622477	15	0.01488095238095238	0	0.0	12	0.003236245954692557	12	0.0031136481577581734	24	0.003173763554615181	6	0.0013617793917385383	34	0.003953488372093023	784	6.457e-03	781	6.833e-03	12	1.279e-03	371	3.380e-02	111	1.310e-02	23	3.606e-03	258	4.126e-03	3	1.912e-04	721	6.789e-03	718	7.206e-03	11	1.363e-03	364	3.425e-02	104	1.344e-02	23	3.606e-03	210	4.151e-03	3	1.924e-04	624	6.876e-03	622	7.234e-03	12	1.282e-03	371	3.383e-02	78	1.419e-02	14	3.823e-03	141	3.514e-03	3	1.913e-04	.	1926	250608	7.685309e-03	29	17	16074	1.057609e-03	0	1083	34482	3.140769e-02	25	0	10062	0	0	251	18364	1.366805e-02	0	82	21610	3.794540e-03	0	450	113372	3.969234e-03	3	4	30540	1.309758e-04	0	1083	34482	3.140769e-02	25	891	109132	8.164425e-03	11	9	7128	1.262626e-03	0	523	17070	3.063855e-02	8	0	2306	0	0	129	9030	1.428571e-02	0	60	13384	4.482965e-03	0	162	42654	3.798003e-03	3	1	15648	6.390593e-05	0	523	17070	3.063855e-02	8	.	701	143316	4.891289e-03	6	52	42048	1.236682e-03	0	311	13658	2.277054e-02	5	0	3322	0	0	33	3134	1.052967e-02	0	24	10480	2.290076e-03	0	272	64574	4.212222e-03	1	2	3048	6.561680e-04	0	196779	Benign/Likely_benign	Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.102979414A>T	Illumina_Clinical_Services_Laboratory,Illumina:234873	C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	102979414	A	T	F	I	rs141548164	1	103444970	1	103217558	860	COL11A1	ENSG00000060718	ENST00000370096	ENSP00000359114	COBA1_HUMAN	c.2578T>A	p.F860I	c.2578T>A	p.Phe860Ile	c.2578T>A	p.Phe860Ile	principal2	Y	1	YES	-	TTT	1	0	A	A/A	A/A	A/A	0.222	0.19430	T	0.302	0.24193	T	0.981	0.68779	D	0.966	0.78936	D	0.000000	0.84330	D	0.000000	1;1;1;1	0.81001	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	F860I;F744I;F872I;F821I	0.015	0.07966	N	-3.23	0.93414	D	-2.96	0.65742	D	0.562	0.58798	0.3924	0.88982	D	0.6971	0.89561	D	10	NULL	NULL	.	0.653	0.87099	.	NULL	.	.	.	0.6426644317	0.63971	0.165154399423	0.18630	0.791092395782	0.80609	T	0.633234	0.88659	D	-0.114007	0.34108	T	0.0871456	0.76054	D	0.0392798677672517	0.03561	T	0.928457	0.74183	D	.	.	.	.	.	.	3.461866	0.63118	24.6	3.447042	0.65753	24.8	0.98070656079945406	0.38023	0.99262	0.93620	D	AEFBI	0.888156	0.82101	D	0.41305981560501	0.62139	4.425081	0.491823572538103	0.67446	5.085271	0.995689001910527	0.34265	0.693126	0.56070	0	0.573888	0.26702	0	0.659464	0.59346	0	0.564101	0.26826	0	NULL	NULL	5.02	5.02	0.66742	8.850000	0.91815	1.288000	0.86526	0.756000	0.94297	1.000000	0.71638	0.997000	0.62031	0.998000	0.85391	1.0:0.0:0.0:0.0	14.9128	0.70414	857	0.34089	30	0.0059904153354632585	0	0.0	2	0.0019880715705765406	13	0.018731988472622477	15	0.01488095238095238	0	0.0	12	0.003236245954692557	12	0.0031136481577581734	24	0.003173763554615181	6	0.0013617793917385383	34	0.003953488372093023	784	6.457e-03	781	6.833e-03	12	1.279e-03	371	3.380e-02	111	1.310e-02	23	3.606e-03	258	4.126e-03	3	1.912e-04	721	6.789e-03	718	7.206e-03	11	1.363e-03	364	3.425e-02	104	1.344e-02	23	3.606e-03	210	4.151e-03	3	1.924e-04	624	6.876e-03	622	7.234e-03	12	1.282e-03	371	3.383e-02	78	1.419e-02	14	3.823e-03	141	3.514e-03	3	1.913e-04	.	1926	250608	7.685309e-03	29	17	16074	1.057609e-03	0	1083	34482	3.140769e-02	25	0	10062	0	0	251	18364	1.366805e-02	0	82	21610	3.794540e-03	0	450	113372	3.969234e-03	3	4	30540	1.309758e-04	0	1083	34482	3.140769e-02	25	891	109132	8.164425e-03	11	9	7128	1.262626e-03	0	523	17070	3.063855e-02	8	0	2306	0	0	129	9030	1.428571e-02	0	60	13384	4.482965e-03	0	162	42654	3.798003e-03	3	1	15648	6.390593e-05	0	523	17070	3.063855e-02	8	.	701	143316	4.891289e-03	6	52	42048	1.236682e-03	0	311	13658	2.277054e-02	5	0	3322	0	0	33	3134	1.052967e-02	0	24	10480	2.290076e-03	0	272	64574	4.212222e-03	1	2	3048	6.561680e-04	0	196779	Benign/Likely_benign	Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.102979414A>T	Illumina_Clinical_Services_Laboratory,Illumina:234873	C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	102979414	A	T	F	I	rs141548164	1	103444970	1	103217558	872	COL11A1	ENSG00000060718	ENST00000358392	ENSP00000351163	COBA1_HUMAN	c.2614T>A	p.F872I	c.2614T>A	p.Phe872Ile	c.2614T>A	p.Phe872Ile	alternative1	Y	5	.	-	TTT	1	0	A	A/A	A/A	A/A	0.213	0.19430	T	0.3	0.24193	T	0.996	0.68779	D	0.99	0.78936	D	0.000000	0.84330	D	0.000000	1;1;1;1	0.81001	D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae	F860I;F744I;F872I;F821I	NULL	0.07966	.	-3.23	0.93414	D	-3.29	0.65742	D	0.54	0.58798	0.3924	0.88982	D	0.6971	0.89561	D	10	NULL	NULL	.	0.653	0.87099	.	NULL	.	.	.	0.6426644317	0.63971	NULL	0.18630	0.791092395782	0.80609	T	NULL	0.88659	.	-0.114007	0.34108	T	0.0871456	0.76054	D	0.0392798677672517	0.03561	T	0.927307	0.74183	D	.	.	.	.	.	.	3.461866	0.63118	24.6	3.447042	0.65753	24.8	0.98070656079945406	0.38023	0.99262	0.93620	D	AEFBI	0.888156	0.82101	D	0.41305981560501	0.62139	4.425081	0.491823572538103	0.67446	5.085271	0.995689001910527	0.34265	0.693126	0.56070	0	0.573888	0.26702	0	0.659464	0.59346	0	0.564101	0.26826	0	NULL	NULL	5.02	5.02	0.66742	8.850000	0.91815	1.288000	0.86526	0.756000	0.94297	1.000000	0.71638	0.997000	0.62031	0.998000	0.85391	1.0:0.0:0.0:0.0	14.9128	0.70414	857	0.34089	30	0.0059904153354632585	0	0.0	2	0.0019880715705765406	13	0.018731988472622477	15	0.01488095238095238	0	0.0	12	0.003236245954692557	12	0.0031136481577581734	24	0.003173763554615181	6	0.0013617793917385383	34	0.003953488372093023	784	6.457e-03	781	6.833e-03	12	1.279e-03	371	3.380e-02	111	1.310e-02	23	3.606e-03	258	4.126e-03	3	1.912e-04	721	6.789e-03	718	7.206e-03	11	1.363e-03	364	3.425e-02	104	1.344e-02	23	3.606e-03	210	4.151e-03	3	1.924e-04	624	6.876e-03	622	7.234e-03	12	1.282e-03	371	3.383e-02	78	1.419e-02	14	3.823e-03	141	3.514e-03	3	1.913e-04	.	1926	250608	7.685309e-03	29	17	16074	1.057609e-03	0	1083	34482	3.140769e-02	25	0	10062	0	0	251	18364	1.366805e-02	0	82	21610	3.794540e-03	0	450	113372	3.969234e-03	3	4	30540	1.309758e-04	0	1083	34482	3.140769e-02	25	891	109132	8.164425e-03	11	9	7128	1.262626e-03	0	523	17070	3.063855e-02	8	0	2306	0	0	129	9030	1.428571e-02	0	60	13384	4.482965e-03	0	162	42654	3.798003e-03	3	1	15648	6.390593e-05	0	523	17070	3.063855e-02	8	.	701	143316	4.891289e-03	6	52	42048	1.236682e-03	0	311	13658	2.277054e-02	5	0	3322	0	0	33	3134	1.052967e-02	0	24	10480	2.290076e-03	0	272	64574	4.212222e-03	1	2	3048	6.561680e-04	0	196779	Benign/Likely_benign	Marshall_syndrome|Fibrochondrogenesis_1|Stickler_syndrome_type_2|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.102979414A>T	Illumina_Clinical_Services_Laboratory,Illumina:234873	C0265235|C3278138|C1858084|CN169374|CN517202	154780|228520|604841	ORPHA560|ORPHA90654	.	.	. 	.
1	108897593	G	A	R	Q	rs41279678	1	109440215	1	109241738	127	GPSM2	ENSG00000121957	ENST00000264126	ENSP00000264126	GPSM2_HUMAN	c.380G>A	p.R127Q	c.380G>A	p.Arg127Gln	c.380G>A	p.Arg127Gln	principal1	Y	1	.	+	CGA	2	0	G	G/G	G/G	G/G	0.055	0.38407	T	0.131	0.34596	T	0.933	0.52105	P	0.242	0.38699	B	0.000002	0.62929	D	0.063176	1e-37;8.48961e-05;8.48961e-05	0.81001	P;P;P	without_aae;simple_aae;simple_aae	.;R127Q;R127Q	1.06	0.26948	L	-3.35	0.94022	D	-3.91	0.73684	D	0.233	0.26233	0.1028	0.84226	D	0.5861	0.85154	D	9	NULL	NULL	.	0.607	0.84747	.	NULL	.	.	.	NULL	NULL	NULL	0.72432	0.782829046249	0.79355	T	0.780377	0.94197	D	-0.23503	0.15989	T	-0.0235274	0.68797	D	0.0117389830241997	0.00181	T	0.962304	0.85835	D	.	.	.	.	.	.	3.437124	0.62477	24.5	2.841112	0.51192	23.2	0.99936145330492632	0.99621	0.98521	0.83668	D	AEFDBI	0.909387	0.86595	D	0.177747574575004	0.50130	3.206145	0.235647991853075	0.51836	3.362888	0.999999999623525	0.74766	0.706298	0.61202	0	0.709663	0.81188	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	5.93	5.01	0.66477	8.159000	0.89602	1.175000	0.73717	0.676000	0.76740	1.000000	0.71638	1.000000	0.86279	0.993000	0.69303	0.0:0.0:0.8681:0.1319	16.5133	0.84138	858	0.34001	345	0.06888977635782748	161	0.12178517397881997	99	0.09840954274353876	31	0.0446685878962536	2	0.001984126984126984	52	0.053169734151329244	319	0.0860302049622438	365	0.0947067981318111	684	0.09045226130653267	431	0.09782115297321833	844	0.09813953488372093	10475	8.628e-02	10472	8.648e-02	1016	9.809e-02	411	3.565e-02	2	2.325e-04	731	1.107e-01	7057	1.059e-01	1156	7.013e-02	9021	8.494e-02	9020	8.512e-02	891	9.867e-02	391	3.500e-02	2	2.558e-04	731	1.107e-01	5774	1.064e-01	1150	7.021e-02	7342	8.090e-02	7339	8.115e-02	1012	9.787e-02	411	3.568e-02	2	3.579e-04	390	1.028e-01	4297	1.023e-01	1156	7.017e-02	.	20917	251314	8.323054e-02	1040	1610	16254	9.905254e-02	74	1476	34584	4.267870e-02	30	1072	10076	1.063914e-01	69	4	18392	2.174859e-04	0	2408	21610	1.114299e-01	138	11620	113648	1.022455e-01	614	2143	30616	6.999608e-02	88	11620	113648	1.022455e-01	614	8810	109346	8.056993e-02	404	694	7162	9.690031e-02	28	725	17106	4.238279e-02	16	263	2320	1.133621e-01	18	1	9044	1.105705e-04	0	1451	13360	1.086078e-01	78	4338	42750	1.014737e-01	216	1154	15690	7.355003e-02	44	4338	42750	1.014737e-01	216	.	13723	142902	9.603085e-02	696	4173	41884	9.963232e-02	206	944	13606	6.938116e-02	34	363	3324	1.092058e-01	19	0	3132	0	0	1148	10328	1.111541e-01	66	6623	64542	1.026154e-01	348	197	3038	6.484529e-02	6	45568	Benign/Likely_benign	Chudley-McCullough_syndrome|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.108897593G>A	Illumina_Clinical_Services_Laboratory,Illumina:2082	C1858695|CN169374	604213	ORPHA314597	Tetratricopeptide repeat-containing domain	CLCC1|GPSM2|GPSM2|CLCC1|GPSM2|GPSM2|CLCC1|GPSM2|WDR47|GPSM2|GPSM2|SPATA42|AKNAD1|GPSM2	Adipose_Visceral_Omentum|Artery_Tibial|Cells_Cultured_fibroblasts|Cells_Cultured_fibroblasts|Esophagus_Mucosa|Lung|Lung|Nerve_Tibial|Nerve_Tibial|Skin_Not_Sun_Exposed_Suprapubic|Skin_Sun_Exposed_Lower_leg|Testis|Testis|Testis 	.
1	108897593	G	A	R	Q	rs41279678	1	109440215	1	109241738	127	GPSM2	ENSG00000121957	ENST00000406462	ENSP00000385510	GPSM2_HUMAN	c.380G>A	p.R127Q	c.380G>A	p.Arg127Gln	c.380G>A	p.Arg127Gln	principal1	Y	5	YES	+	CGA	2	0	G	G/G	G/G	G/G	0.055	0.38407	T	0.131	0.34596	T	0.933	0.52105	P	0.242	0.38699	B	0.000002	0.62929	D	0.063176	1e-37;8.48961e-05;8.48961e-05	0.81001	P;P;P	without_aae;simple_aae;simple_aae	.;R127Q;R127Q	1.06	0.26948	L	-3.35	0.94022	D	-3.91	0.73684	D	0.178	0.26233	0.1028	0.84226	D	0.5861	0.85154	D	9	NULL	NULL	.	0.607	0.84747	.	NULL	.	.	.	NULL	NULL	0.946565603157	0.72432	0.782829046249	0.79355	T	0.780377	0.94197	D	-0.23503	0.15989	T	-0.0235274	0.68797	D	0.0117389830241997	0.00181	T	NULL	0.85835	.	.	.	.	.	.	.	3.437124	0.62477	24.5	2.841112	0.51192	23.2	0.99936145330492632	0.99621	0.98521	0.83668	D	AEFDBI	0.909387	0.86595	D	0.177747574575004	0.50130	3.206145	0.235647991853075	0.51836	3.362888	0.999999999623525	0.74766	0.706298	0.61202	0	0.709663	0.81188	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	5.93	5.01	0.66477	8.159000	0.89602	1.175000	0.73717	0.676000	0.76740	1.000000	0.71638	1.000000	0.86279	0.993000	0.69303	0.0:0.0:0.8681:0.1319	16.5133	0.84138	858	0.34001	345	0.06888977635782748	161	0.12178517397881997	99	0.09840954274353876	31	0.0446685878962536	2	0.001984126984126984	52	0.053169734151329244	319	0.0860302049622438	365	0.0947067981318111	684	0.09045226130653267	431	0.09782115297321833	844	0.09813953488372093	10475	8.628e-02	10472	8.648e-02	1016	9.809e-02	411	3.565e-02	2	2.325e-04	731	1.107e-01	7057	1.059e-01	1156	7.013e-02	9021	8.494e-02	9020	8.512e-02	891	9.867e-02	391	3.500e-02	2	2.558e-04	731	1.107e-01	5774	1.064e-01	1150	7.021e-02	7342	8.090e-02	7339	8.115e-02	1012	9.787e-02	411	3.568e-02	2	3.579e-04	390	1.028e-01	4297	1.023e-01	1156	7.017e-02	.	20917	251314	8.323054e-02	1040	1610	16254	9.905254e-02	74	1476	34584	4.267870e-02	30	1072	10076	1.063914e-01	69	4	18392	2.174859e-04	0	2408	21610	1.114299e-01	138	11620	113648	1.022455e-01	614	2143	30616	6.999608e-02	88	11620	113648	1.022455e-01	614	8810	109346	8.056993e-02	404	694	7162	9.690031e-02	28	725	17106	4.238279e-02	16	263	2320	1.133621e-01	18	1	9044	1.105705e-04	0	1451	13360	1.086078e-01	78	4338	42750	1.014737e-01	216	1154	15690	7.355003e-02	44	4338	42750	1.014737e-01	216	.	13723	142902	9.603085e-02	696	4173	41884	9.963232e-02	206	944	13606	6.938116e-02	34	363	3324	1.092058e-01	19	0	3132	0	0	1148	10328	1.111541e-01	66	6623	64542	1.026154e-01	348	197	3038	6.484529e-02	6	45568	Benign/Likely_benign	Chudley-McCullough_syndrome|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.108897593G>A	Illumina_Clinical_Services_Laboratory,Illumina:2082	C1858695|CN169374	604213	ORPHA314597	Tetratricopeptide repeat-containing domain	CLCC1|GPSM2|GPSM2|CLCC1|GPSM2|GPSM2|CLCC1|GPSM2|WDR47|GPSM2|GPSM2|SPATA42|AKNAD1|GPSM2	Adipose_Visceral_Omentum|Artery_Tibial|Cells_Cultured_fibroblasts|Cells_Cultured_fibroblasts|Esophagus_Mucosa|Lung|Lung|Nerve_Tibial|Nerve_Tibial|Skin_Not_Sun_Exposed_Suprapubic|Skin_Sun_Exposed_Lower_leg|Testis|Testis|Testis 	.
1	108897593	G	A	R	Q	rs41279678	1	109440215	1	109241738	127	GPSM2	ENSG00000121957	ENST00000435987	ENSP00000408664	Q5T1N9_HUMAN	.	.	c.380G>A	p.Arg127Gln	c.380G>A	p.Arg127Gln	.	.	3	.	+	CGA	2	0	G	G/G	G/G	G/G	0.262	0.38407	T	0.357	0.34596	T	NULL	0.52105	.	NULL	0.38699	.	0.000002	0.62929	D	0.063176	1e-37;8.48961e-05;8.48961e-05	0.81001	P;P;P	without_aae;simple_aae;simple_aae	.;R127Q;R127Q	NULL	0.26948	.	-3.35	0.94022	D	-3.97	0.73684	D	NULL	0.26233	0.1028	0.84226	D	0.5861	0.85154	D	9	NULL	NULL	.	0.607	0.84747	.	NULL	.	.	.	NULL	NULL	NULL	0.72432	0.782829046249	0.79355	T	NULL	0.94197	.	-0.23503	0.15989	T	-0.0235274	0.68797	D	0.0117389830241997	0.00181	T	0.962104	0.85835	D	.	.	.	.	.	.	3.437124	0.62477	24.5	2.841112	0.51192	23.2	0.99936145330492632	0.99621	0.98521	0.83668	D	AEFDBI	0.909387	0.86595	D	0.177747574575004	0.50130	3.206145	0.235647991853075	0.51836	3.362888	0.999999999623525	0.74766	0.706298	0.61202	0	0.709663	0.81188	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	5.93	5.01	0.66477	8.159000	0.89602	1.175000	0.73717	0.676000	0.76740	1.000000	0.71638	1.000000	0.86279	0.993000	0.69303	0.0:0.0:0.8681:0.1319	16.5133	0.84138	858	0.34001	345	0.06888977635782748	161	0.12178517397881997	99	0.09840954274353876	31	0.0446685878962536	2	0.001984126984126984	52	0.053169734151329244	319	0.0860302049622438	365	0.0947067981318111	684	0.09045226130653267	431	0.09782115297321833	844	0.09813953488372093	10475	8.628e-02	10472	8.648e-02	1016	9.809e-02	411	3.565e-02	2	2.325e-04	731	1.107e-01	7057	1.059e-01	1156	7.013e-02	9021	8.494e-02	9020	8.512e-02	891	9.867e-02	391	3.500e-02	2	2.558e-04	731	1.107e-01	5774	1.064e-01	1150	7.021e-02	7342	8.090e-02	7339	8.115e-02	1012	9.787e-02	411	3.568e-02	2	3.579e-04	390	1.028e-01	4297	1.023e-01	1156	7.017e-02	.	20917	251314	8.323054e-02	1040	1610	16254	9.905254e-02	74	1476	34584	4.267870e-02	30	1072	10076	1.063914e-01	69	4	18392	2.174859e-04	0	2408	21610	1.114299e-01	138	11620	113648	1.022455e-01	614	2143	30616	6.999608e-02	88	11620	113648	1.022455e-01	614	8810	109346	8.056993e-02	404	694	7162	9.690031e-02	28	725	17106	4.238279e-02	16	263	2320	1.133621e-01	18	1	9044	1.105705e-04	0	1451	13360	1.086078e-01	78	4338	42750	1.014737e-01	216	1154	15690	7.355003e-02	44	4338	42750	1.014737e-01	216	.	13723	142902	9.603085e-02	696	4173	41884	9.963232e-02	206	944	13606	6.938116e-02	34	363	3324	1.092058e-01	19	0	3132	0	0	1148	10328	1.111541e-01	66	6623	64542	1.026154e-01	348	197	3038	6.484529e-02	6	45568	Benign/Likely_benign	Chudley-McCullough_syndrome|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.108897593G>A	Illumina_Clinical_Services_Laboratory,Illumina:2082	C1858695|CN169374	604213	ORPHA314597	Tetratricopeptide repeat-containing domain	CLCC1|GPSM2|GPSM2|CLCC1|GPSM2|GPSM2|CLCC1|GPSM2|WDR47|GPSM2|GPSM2|SPATA42|AKNAD1|GPSM2	Adipose_Visceral_Omentum|Artery_Tibial|Cells_Cultured_fibroblasts|Cells_Cultured_fibroblasts|Esophagus_Mucosa|Lung|Lung|Nerve_Tibial|Nerve_Tibial|Skin_Not_Sun_Exposed_Suprapubic|Skin_Sun_Exposed_Lower_leg|Testis|Testis|Testis 	.
1	108897593	G	A	R	Q	rs41279678	1	109440215	1	109241738	127	GPSM2	ENSG00000121957	ENST00000642355	ENSP00000496104	GPSM2_HUMAN	.	.	.	.	c.380G>A	p.Arg127Gln	principal1	Y	.	.	+	CGA	2	0	G	G/G	G/G	G/G	NULL	0.38407	.	NULL	0.34596	.	0.933	0.52105	P	0.242	0.38699	B	0.000002	0.62929	D	0.063176	1e-37;8.48961e-05;8.48961e-05	0.81001	P;P;P	without_aae;simple_aae;simple_aae	.;R127Q;R127Q	1.06	0.26948	L	NULL	0.94022	.	NULL	0.73684	.	NULL	0.26233	0.1028	0.84226	D	0.5861	0.85154	D	9	NULL	NULL	.	0.607	0.84747	.	NULL	.	.	.	NULL	NULL	NULL	0.72432	0.782829046249	0.79355	T	0.780377	0.94197	D	-0.23503	0.15989	T	-0.0235274	0.68797	D	0.0117389830241997	0.00181	T	NULL	0.85835	.	.	.	.	.	.	.	3.437124	0.62477	24.5	2.841112	0.51192	23.2	0.99936145330492632	0.99621	0.98521	0.83668	D	AEFDBI	0.909387	0.86595	D	0.177747574575004	0.50130	3.206145	0.235647991853075	0.51836	3.362888	0.999999999623525	0.74766	0.706298	0.61202	0	0.709663	0.81188	0	0.709663	0.75317	0	0.613276	0.41899	0	NULL	NULL	5.93	5.01	0.66477	8.159000	0.89602	1.175000	0.73717	0.676000	0.76740	1.000000	0.71638	1.000000	0.86279	0.993000	0.69303	0.0:0.0:0.8681:0.1319	16.5133	0.84138	858	0.34001	345	0.06888977635782748	161	0.12178517397881997	99	0.09840954274353876	31	0.0446685878962536	2	0.001984126984126984	52	0.053169734151329244	319	0.0860302049622438	365	0.0947067981318111	684	0.09045226130653267	431	0.09782115297321833	844	0.09813953488372093	10475	8.628e-02	10472	8.648e-02	1016	9.809e-02	411	3.565e-02	2	2.325e-04	731	1.107e-01	7057	1.059e-01	1156	7.013e-02	9021	8.494e-02	9020	8.512e-02	891	9.867e-02	391	3.500e-02	2	2.558e-04	731	1.107e-01	5774	1.064e-01	1150	7.021e-02	7342	8.090e-02	7339	8.115e-02	1012	9.787e-02	411	3.568e-02	2	3.579e-04	390	1.028e-01	4297	1.023e-01	1156	7.017e-02	.	20917	251314	8.323054e-02	1040	1610	16254	9.905254e-02	74	1476	34584	4.267870e-02	30	1072	10076	1.063914e-01	69	4	18392	2.174859e-04	0	2408	21610	1.114299e-01	138	11620	113648	1.022455e-01	614	2143	30616	6.999608e-02	88	11620	113648	1.022455e-01	614	8810	109346	8.056993e-02	404	694	7162	9.690031e-02	28	725	17106	4.238279e-02	16	263	2320	1.133621e-01	18	1	9044	1.105705e-04	0	1451	13360	1.086078e-01	78	4338	42750	1.014737e-01	216	1154	15690	7.355003e-02	44	4338	42750	1.014737e-01	216	.	13723	142902	9.603085e-02	696	4173	41884	9.963232e-02	206	944	13606	6.938116e-02	34	363	3324	1.092058e-01	19	0	3132	0	0	1148	10328	1.111541e-01	66	6623	64542	1.026154e-01	348	197	3038	6.484529e-02	6	45568	Benign/Likely_benign	Chudley-McCullough_syndrome|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.108897593G>A	Illumina_Clinical_Services_Laboratory,Illumina:2082	C1858695|CN169374	604213	ORPHA314597	Tetratricopeptide repeat-containing domain	CLCC1|GPSM2|GPSM2|CLCC1|GPSM2|GPSM2|CLCC1|GPSM2|WDR47|GPSM2|GPSM2|SPATA42|AKNAD1|GPSM2	Adipose_Visceral_Omentum|Artery_Tibial|Cells_Cultured_fibroblasts|Cells_Cultured_fibroblasts|Esophagus_Mucosa|Lung|Lung|Nerve_Tibial|Nerve_Tibial|Skin_Not_Sun_Exposed_Suprapubic|Skin_Sun_Exposed_Lower_leg|Testis|Testis|Testis 	.
1	108904128	G	A	G	R	rs61754640	1	109446750	1	109248273	356	GPSM2	ENSG00000121957	ENST00000264126	ENSP00000264126	GPSM2_HUMAN	c.1066G>A	p.G356R	c.1066G>A	p.Gly356Arg	c.1066G>A	p.Gly356Arg	principal1	Y	1	.	+	GGG	1	0	G	G/G	G/G	G/G	0.02	0.49613	D	0.007	0.69154	D	0.994	0.66517	D	0.807	0.58472	P	0.000001	0.84330	D	0.056584	1;0.999945;0.999945	0.81001	D;D;D	without_aae;simple_aae;simple_aae	.;G356R;G356R	2.39	0.68882	M	-1.0	0.76037	T	-6.41	0.91226	D	0.707	0.71055	-0.0626	0.80938	T	0.4562	0.78825	T	10	NULL	NULL	.	0.470	0.76685	.	NULL	.	.	.	NULL	NULL	NULL	0.71029	0.783422529697	0.79445	T	0.509338	0.82621	D	-0.2574	0.13205	T	-0.117447	0.62011	T	0.0288951857825697	0.01821	T	0.90421	0.66396	D	.	.	.	.	.	.	4.483674	0.91091	32	4.337730	0.90502	31	0.99836871223436541	0.91800	0.99020	0.90058	D	AEFBI	0.899119	0.84316	D	0.845355429267861	0.88841	9.732992	0.844022690097737	0.92662	11.55723	0.999999999999553	0.74766	0.706298	0.61202	0	0.708844	0.79440	0	0.658983	0.55881	0	0.613276	0.41899	0	NULL	NULL	5.51	5.51	0.81769	9.559000	0.97245	1.154000	0.70595	0.674000	0.70861	1.000000	0.71638	1.000000	0.86279	0.995000	0.73285	0.0:0.0:1.0:0.0	17.5977	0.87916	859	0.33891	59	0.01178115015974441	2	0.0015128593040847202	36	0.03578528827037773	17	0.024495677233429394	0	0.0	4	0.00408997955010225	127	0.03425026968716289	130	0.033731188375713546	257	0.03398571806400423	26	0.005901044030866999	283	0.032906976744186044	2652	2.184e-02	2648	2.208e-02	62	6.070e-03	248	2.178e-02	0	0	160	2.432e-02	2077	3.152e-02	82	5.019e-03	2220	2.090e-02	2218	2.115e-02	53	5.962e-03	241	2.184e-02	0	0	160	2.432e-02	1671	3.117e-02	81	4.990e-03	1931	2.128e-02	1927	2.149e-02	62	6.080e-03	248	2.180e-02	0	0	97	2.567e-02	1421	3.408e-02	82	5.022e-03	.	5667	251176	2.256187e-02	85	99	16234	6.098312e-03	0	650	34550	1.881331e-02	8	213	10074	2.114354e-02	1	0	18390	0	0	532	21642	2.458183e-02	6	3801	113564	3.347011e-02	68	189	30596	6.177278e-03	0	3801	113564	3.347011e-02	68	2279	109320	2.084705e-02	33	41	7152	5.732662e-03	0	330	17082	1.931858e-02	4	45	2318	1.941329e-02	0	0	9046	0	0	320	13392	2.389486e-02	3	1394	42734	3.262040e-02	25	95	15684	6.057128e-03	0	1394	42734	3.262040e-02	25	.	3222	143100	2.251572e-02	51	255	41984	6.073742e-03	0	302	13634	2.215051e-02	9	59	3324	1.774970e-02	0	0	3132	0	0	273	10400	2.625000e-02	6	2189	64528	3.392326e-02	31	24	3048	7.874016e-03	0	45563	Conflicting_interpretations_of_pathogenicity	Chudley-McCullough_syndrome|not_specified|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.108904128G>A	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:81686|Illumina_Clinical_Services_Laboratory,Illumina:47942	C1858695|CN169374|CN517202	604213	ORPHA314597	.	GPSM2|GPSM2	Adrenal_Gland|Thyroid 	.
1	108904128	G	A	G	R	rs61754640	1	109446750	1	109248273	356	GPSM2	ENSG00000121957	ENST00000406462	ENSP00000385510	GPSM2_HUMAN	c.1066G>A	p.G356R	c.1066G>A	p.Gly356Arg	c.1066G>A	p.Gly356Arg	principal1	Y	5	YES	+	GGG	1	0	G	G/G	G/G	G/G	0.02	0.49613	D	0.007	0.69154	D	0.994	0.66517	D	0.807	0.58472	P	0.000001	0.84330	D	0.056584	1;0.999945;0.999945	0.81001	D;D;D	without_aae;simple_aae;simple_aae	.;G356R;G356R	2.39	0.68882	M	-1.0	0.76037	T	-6.41	0.91226	D	0.314	0.71055	-0.0626	0.80938	T	0.4562	0.78825	T	10	NULL	NULL	.	0.470	0.76685	.	NULL	.	.	.	NULL	NULL	0.910207131385	0.71029	0.783422529697	0.79445	T	0.509338	0.82621	D	-0.2574	0.13205	T	-0.117447	0.62011	T	0.0288951857825697	0.01821	T	NULL	0.66396	.	.	.	.	.	.	.	4.483674	0.91091	32	4.337730	0.90502	31	0.99836871223436541	0.91800	0.99020	0.90058	D	AEFBI	0.899119	0.84316	D	0.845355429267861	0.88841	9.732992	0.844022690097737	0.92662	11.55723	0.999999999999553	0.74766	0.706298	0.61202	0	0.708844	0.79440	0	0.658983	0.55881	0	0.613276	0.41899	0	NULL	NULL	5.51	5.51	0.81769	9.559000	0.97245	1.154000	0.70595	0.674000	0.70861	1.000000	0.71638	1.000000	0.86279	0.995000	0.73285	0.0:0.0:1.0:0.0	17.5977	0.87916	859	0.33891	59	0.01178115015974441	2	0.0015128593040847202	36	0.03578528827037773	17	0.024495677233429394	0	0.0	4	0.00408997955010225	127	0.03425026968716289	130	0.033731188375713546	257	0.03398571806400423	26	0.005901044030866999	283	0.032906976744186044	2652	2.184e-02	2648	2.208e-02	62	6.070e-03	248	2.178e-02	0	0	160	2.432e-02	2077	3.152e-02	82	5.019e-03	2220	2.090e-02	2218	2.115e-02	53	5.962e-03	241	2.184e-02	0	0	160	2.432e-02	1671	3.117e-02	81	4.990e-03	1931	2.128e-02	1927	2.149e-02	62	6.080e-03	248	2.180e-02	0	0	97	2.567e-02	1421	3.408e-02	82	5.022e-03	.	5667	251176	2.256187e-02	85	99	16234	6.098312e-03	0	650	34550	1.881331e-02	8	213	10074	2.114354e-02	1	0	18390	0	0	532	21642	2.458183e-02	6	3801	113564	3.347011e-02	68	189	30596	6.177278e-03	0	3801	113564	3.347011e-02	68	2279	109320	2.084705e-02	33	41	7152	5.732662e-03	0	330	17082	1.931858e-02	4	45	2318	1.941329e-02	0	0	9046	0	0	320	13392	2.389486e-02	3	1394	42734	3.262040e-02	25	95	15684	6.057128e-03	0	1394	42734	3.262040e-02	25	.	3222	143100	2.251572e-02	51	255	41984	6.073742e-03	0	302	13634	2.215051e-02	9	59	3324	1.774970e-02	0	0	3132	0	0	273	10400	2.625000e-02	6	2189	64528	3.392326e-02	31	24	3048	7.874016e-03	0	45563	Conflicting_interpretations_of_pathogenicity	Chudley-McCullough_syndrome|not_specified|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.108904128G>A	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:81686|Illumina_Clinical_Services_Laboratory,Illumina:47942	C1858695|CN169374|CN517202	604213	ORPHA314597	.	GPSM2|GPSM2	Adrenal_Gland|Thyroid 	.
1	108904128	G	A	G	R	rs61754640	1	109446750	1	109248273	356	GPSM2	ENSG00000121957	ENST00000642355	ENSP00000496104	GPSM2_HUMAN	.	.	.	.	c.1066G>A	p.Gly356Arg	principal1	Y	.	.	+	GGG	1	0	G	G/G	G/G	G/G	NULL	0.49613	.	NULL	0.69154	.	0.994	0.66517	D	0.807	0.58472	P	0.000001	0.84330	D	0.056584	1;0.999945;0.999945	0.81001	D;D;D	without_aae;simple_aae;simple_aae	.;G356R;G356R	2.39	0.68882	M	NULL	0.76037	.	NULL	0.91226	.	NULL	0.71055	-0.0626	0.80938	T	0.4562	0.78825	T	10	NULL	NULL	.	0.470	0.76685	.	NULL	.	.	.	NULL	NULL	NULL	0.71029	0.783422529697	0.79445	T	0.509338	0.82621	D	-0.2574	0.13205	T	-0.117447	0.62011	T	0.0288951857825697	0.01821	T	NULL	0.66396	.	.	.	.	.	.	.	4.483674	0.91091	32	4.337730	0.90502	31	0.99836871223436541	0.91800	0.99020	0.90058	D	AEFBI	0.899119	0.84316	D	0.845355429267861	0.88841	9.732992	0.844022690097737	0.92662	11.55723	0.999999999999553	0.74766	0.706298	0.61202	0	0.708844	0.79440	0	0.658983	0.55881	0	0.613276	0.41899	0	NULL	NULL	5.51	5.51	0.81769	9.559000	0.97245	1.154000	0.70595	0.674000	0.70861	1.000000	0.71638	1.000000	0.86279	0.995000	0.73285	0.0:0.0:1.0:0.0	17.5977	0.87916	859	0.33891	59	0.01178115015974441	2	0.0015128593040847202	36	0.03578528827037773	17	0.024495677233429394	0	0.0	4	0.00408997955010225	127	0.03425026968716289	130	0.033731188375713546	257	0.03398571806400423	26	0.005901044030866999	283	0.032906976744186044	2652	2.184e-02	2648	2.208e-02	62	6.070e-03	248	2.178e-02	0	0	160	2.432e-02	2077	3.152e-02	82	5.019e-03	2220	2.090e-02	2218	2.115e-02	53	5.962e-03	241	2.184e-02	0	0	160	2.432e-02	1671	3.117e-02	81	4.990e-03	1931	2.128e-02	1927	2.149e-02	62	6.080e-03	248	2.180e-02	0	0	97	2.567e-02	1421	3.408e-02	82	5.022e-03	.	5667	251176	2.256187e-02	85	99	16234	6.098312e-03	0	650	34550	1.881331e-02	8	213	10074	2.114354e-02	1	0	18390	0	0	532	21642	2.458183e-02	6	3801	113564	3.347011e-02	68	189	30596	6.177278e-03	0	3801	113564	3.347011e-02	68	2279	109320	2.084705e-02	33	41	7152	5.732662e-03	0	330	17082	1.931858e-02	4	45	2318	1.941329e-02	0	0	9046	0	0	320	13392	2.389486e-02	3	1394	42734	3.262040e-02	25	95	15684	6.057128e-03	0	1394	42734	3.262040e-02	25	.	3222	143100	2.251572e-02	51	255	41984	6.073742e-03	0	302	13634	2.215051e-02	9	59	3324	1.774970e-02	0	0	3132	0	0	273	10400	2.625000e-02	6	2189	64528	3.392326e-02	31	24	3048	7.874016e-03	0	45563	Conflicting_interpretations_of_pathogenicity	Chudley-McCullough_syndrome|not_specified|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.108904128G>A	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:81686|Illumina_Clinical_Services_Laboratory,Illumina:47942	C1858695|CN169374|CN517202	604213	ORPHA314597	.	GPSM2|GPSM2	Adrenal_Gland|Thyroid 	.
1	108918719	C	T	T	M	rs35089879	1	109461341	1	109262864	457	GPSM2	ENSG00000121957	ENST00000264126	ENSP00000264126	GPSM2_HUMAN	c.1370C>T	p.T457M	c.1370C>T	p.Thr457Met	c.1370C>T	p.Thr457Met	principal1	Y	1	.	+	ACG	2	0	C	C/C	C/C	C/C	0.081	0.33418	T	0.083	0.41405	T	0.239	0.30839	B	0.031	0.21939	B	0.823282	0.06897	N	1.071430	0.928254;1;1	0.27125	N;N;N	without_aae;simple_aae;simple_aae	.;T457M;T457M	0.345	0.11182	N	-3.17	0.93054	D	-0.78	0.21644	N	0.153	0.15749	-0.6075	0.64507	T	0.3406	0.70656	T	10	NULL	NULL	.	0.161	0.42115	.	NULL	.	.	.	NULL	NULL	NULL	0.27649	0.388738006353	0.23491	T	0.055023	0.29890	T	-0.355302	0.04402	T	-0.226438	0.52115	T	0.00452091597082243	0.00048	T	0.868113	0.56980	D	.	.	.	.	.	.	1.452425	0.21169	15.43	1.410701	0.22531	15.77	0.97077605707594516	0.32264	0.08961	0.14809	N	AEFBI	0.076824	0.15464	N	-0.665347120418366	0.17014	0.8719716	-0.578868078540076	0.20044	1.078193	0.00881666599860214	0.11746	0.732398	0.92422	0	0.743671	0.97443	0	0.658983	0.55881	0	0.613276	0.41899	0	NULL	NULL	5.91	1.38	0.21262	0.277000	0.18496	0.074000	0.15429	0.599000	0.40250	0.019000	0.19563	0.686000	0.30623	0.975000	0.56047	0.3964:0.2909:0.3127:0.0	7.9942	0.29419	860	0.33753	202	0.04033546325878594	100	0.07564296520423601	8	0.007952286282306162	12	0.01729106628242075	13	0.012896825396825396	69	0.0705521472392638	36	0.009708737864077669	49	0.012714063310845874	85	0.0112404125892621	328	0.07444394008170677	85	0.009883720930232558	2742	2.258e-02	2740	2.258e-02	828	7.971e-02	119	1.028e-02	147	1.700e-02	11	1.664e-03	719	1.077e-02	895	5.421e-02	2452	2.309e-02	2450	2.308e-02	716	7.913e-02	113	1.008e-02	134	1.705e-02	11	1.664e-03	572	1.053e-02	888	5.413e-02	2531	2.789e-02	2529	2.788e-02	827	7.975e-02	119	1.029e-02	100	1.774e-02	4	1.053e-03	567	1.346e-02	895	5.424e-02	.	5258	251392	2.091554e-02	140	1238	16250	7.618462e-02	49	367	34592	1.060939e-02	5	307	10080	3.045635e-02	5	313	18392	1.701827e-02	3	33	21640	1.524954e-03	0	1191	113698	1.047512e-02	10	1686	30608	5.508364e-02	65	1238	16250	7.618462e-02	49	2286	109394	2.089694e-02	55	549	7160	7.667598e-02	16	177	17112	1.034362e-02	2	74	2320	3.189655e-02	0	148	9046	1.636082e-02	2	20	13388	1.493875e-03	0	415	42766	9.703970e-03	3	869	15688	5.539266e-02	32	549	7160	7.667598e-02	16	.	4595	143190	3.209023e-02	154	3269	41992	7.784816e-02	135	227	13644	1.663735e-02	0	98	3320	2.951807e-02	5	41	3130	1.309904e-02	0	23	10458	2.199273e-03	1	676	64554	1.047185e-02	5	198	3040	6.513158e-02	7	45564	Benign/Likely_benign	Chudley-McCullough_syndrome|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.108918719C>T	Illumina_Clinical_Services_Laboratory,Illumina:139773	C1858695|CN169374|CN517202	604213	ORPHA314597	.	.	. 	.
1	108918719	C	T	T	M	rs35089879	1	109461341	1	109262864	457	GPSM2	ENSG00000121957	ENST00000406462	ENSP00000385510	GPSM2_HUMAN	c.1370C>T	p.T457M	c.1370C>T	p.Thr457Met	c.1370C>T	p.Thr457Met	principal1	Y	5	YES	+	ACG	2	0	C	C/C	C/C	C/C	0.081	0.33418	T	0.083	0.41405	T	0.239	0.30839	B	0.031	0.21939	B	0.823282	0.06897	N	1.071430	0.928254;1;1	0.27125	N;N;N	without_aae;simple_aae;simple_aae	.;T457M;T457M	0.345	0.11182	N	-3.17	0.93054	D	-0.78	0.21644	N	0.07	0.15749	-0.6075	0.64507	T	0.3406	0.70656	T	10	NULL	NULL	.	0.161	0.42115	.	NULL	.	.	.	NULL	NULL	0.250755808032	0.27649	0.388738006353	0.23491	T	0.055023	0.29890	T	-0.355302	0.04402	T	-0.226438	0.52115	T	0.00452091597082243	0.00048	T	NULL	0.56980	.	.	.	.	.	.	.	1.452425	0.21169	15.43	1.410701	0.22531	15.77	0.97077605707594516	0.32264	0.08961	0.14809	N	AEFBI	0.076824	0.15464	N	-0.665347120418366	0.17014	0.8719716	-0.578868078540076	0.20044	1.078193	0.00881666599860214	0.11746	0.732398	0.92422	0	0.743671	0.97443	0	0.658983	0.55881	0	0.613276	0.41899	0	NULL	NULL	5.91	1.38	0.21262	0.277000	0.18496	0.074000	0.15429	0.599000	0.40250	0.019000	0.19563	0.686000	0.30623	0.975000	0.56047	0.3964:0.2909:0.3127:0.0	7.9942	0.29419	860	0.33753	202	0.04033546325878594	100	0.07564296520423601	8	0.007952286282306162	12	0.01729106628242075	13	0.012896825396825396	69	0.0705521472392638	36	0.009708737864077669	49	0.012714063310845874	85	0.0112404125892621	328	0.07444394008170677	85	0.009883720930232558	2742	2.258e-02	2740	2.258e-02	828	7.971e-02	119	1.028e-02	147	1.700e-02	11	1.664e-03	719	1.077e-02	895	5.421e-02	2452	2.309e-02	2450	2.308e-02	716	7.913e-02	113	1.008e-02	134	1.705e-02	11	1.664e-03	572	1.053e-02	888	5.413e-02	2531	2.789e-02	2529	2.788e-02	827	7.975e-02	119	1.029e-02	100	1.774e-02	4	1.053e-03	567	1.346e-02	895	5.424e-02	.	5258	251392	2.091554e-02	140	1238	16250	7.618462e-02	49	367	34592	1.060939e-02	5	307	10080	3.045635e-02	5	313	18392	1.701827e-02	3	33	21640	1.524954e-03	0	1191	113698	1.047512e-02	10	1686	30608	5.508364e-02	65	1238	16250	7.618462e-02	49	2286	109394	2.089694e-02	55	549	7160	7.667598e-02	16	177	17112	1.034362e-02	2	74	2320	3.189655e-02	0	148	9046	1.636082e-02	2	20	13388	1.493875e-03	0	415	42766	9.703970e-03	3	869	15688	5.539266e-02	32	549	7160	7.667598e-02	16	.	4595	143190	3.209023e-02	154	3269	41992	7.784816e-02	135	227	13644	1.663735e-02	0	98	3320	2.951807e-02	5	41	3130	1.309904e-02	0	23	10458	2.199273e-03	1	676	64554	1.047185e-02	5	198	3040	6.513158e-02	7	45564	Benign/Likely_benign	Chudley-McCullough_syndrome|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.108918719C>T	Illumina_Clinical_Services_Laboratory,Illumina:139773	C1858695|CN169374|CN517202	604213	ORPHA314597	.	.	. 	.
1	108918719	C	T	T	M	rs35089879	1	109461341	1	109262864	457	GPSM2	ENSG00000121957	ENST00000642355	ENSP00000496104	GPSM2_HUMAN	.	.	.	.	c.1370C>T	p.Thr457Met	principal1	Y	.	.	+	ACG	2	0	C	C/C	C/C	C/C	NULL	0.33418	.	NULL	0.41405	.	0.239	0.30839	B	0.031	0.21939	B	0.823282	0.06897	N	1.071430	0.928254;1;1	0.27125	N;N;N	without_aae;simple_aae;simple_aae	.;T457M;T457M	0.345	0.11182	N	NULL	0.93054	.	NULL	0.21644	.	NULL	0.15749	-0.6075	0.64507	T	0.3406	0.70656	T	10	NULL	NULL	.	0.161	0.42115	.	NULL	.	.	.	NULL	NULL	NULL	0.27649	0.388738006353	0.23491	T	0.055023	0.29890	T	-0.355302	0.04402	T	-0.226438	0.52115	T	0.00452091597082243	0.00048	T	NULL	0.56980	.	.	.	.	.	.	.	1.452425	0.21169	15.43	1.410701	0.22531	15.77	0.97077605707594516	0.32264	0.08961	0.14809	N	AEFBI	0.076824	0.15464	N	-0.665347120418366	0.17014	0.8719716	-0.578868078540076	0.20044	1.078193	0.00881666599860214	0.11746	0.732398	0.92422	0	0.743671	0.97443	0	0.658983	0.55881	0	0.613276	0.41899	0	NULL	NULL	5.91	1.38	0.21262	0.277000	0.18496	0.074000	0.15429	0.599000	0.40250	0.019000	0.19563	0.686000	0.30623	0.975000	0.56047	0.3964:0.2909:0.3127:0.0	7.9942	0.29419	860	0.33753	202	0.04033546325878594	100	0.07564296520423601	8	0.007952286282306162	12	0.01729106628242075	13	0.012896825396825396	69	0.0705521472392638	36	0.009708737864077669	49	0.012714063310845874	85	0.0112404125892621	328	0.07444394008170677	85	0.009883720930232558	2742	2.258e-02	2740	2.258e-02	828	7.971e-02	119	1.028e-02	147	1.700e-02	11	1.664e-03	719	1.077e-02	895	5.421e-02	2452	2.309e-02	2450	2.308e-02	716	7.913e-02	113	1.008e-02	134	1.705e-02	11	1.664e-03	572	1.053e-02	888	5.413e-02	2531	2.789e-02	2529	2.788e-02	827	7.975e-02	119	1.029e-02	100	1.774e-02	4	1.053e-03	567	1.346e-02	895	5.424e-02	.	5258	251392	2.091554e-02	140	1238	16250	7.618462e-02	49	367	34592	1.060939e-02	5	307	10080	3.045635e-02	5	313	18392	1.701827e-02	3	33	21640	1.524954e-03	0	1191	113698	1.047512e-02	10	1686	30608	5.508364e-02	65	1238	16250	7.618462e-02	49	2286	109394	2.089694e-02	55	549	7160	7.667598e-02	16	177	17112	1.034362e-02	2	74	2320	3.189655e-02	0	148	9046	1.636082e-02	2	20	13388	1.493875e-03	0	415	42766	9.703970e-03	3	869	15688	5.539266e-02	32	549	7160	7.667598e-02	16	.	4595	143190	3.209023e-02	154	3269	41992	7.784816e-02	135	227	13644	1.663735e-02	0	98	3320	2.951807e-02	5	41	3130	1.309904e-02	0	23	10458	2.199273e-03	1	676	64554	1.047185e-02	5	198	3040	6.513158e-02	7	45564	Benign/Likely_benign	Chudley-McCullough_syndrome|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.108918719C>T	Illumina_Clinical_Services_Laboratory,Illumina:139773	C1858695|CN169374|CN517202	604213	ORPHA314597	.	.	. 	.
1	108924138	C	T	S	L	rs79730689	1	109466760	1	109268283	580	GPSM2	ENSG00000121957	ENST00000264126	ENSP00000264126	GPSM2_HUMAN	c.1739C>T	p.S580L	c.1739C>T	p.Ser580Leu	c.1739C>T	p.Ser580Leu	principal1	Y	1	.	+	TCG	2	0	C	C/C	C/C	C/C	0.234	0.18061	T	0.068	0.44106	T	0.103	0.25884	B	0.01	0.14941	B	0.029684	0.25417	N	0.435283	1;0.997463;0.997463	0.81001	D;D;D	without_aae;simple_aae;simple_aae	.;S580L;S580L	1.78	0.46185	L	-3.23	0.93414	D	-1.15	0.29525	N	0.471	0.52208	0.0058	0.82375	D	0.6167	0.86468	D	10	0.049899	0.64009	D	0.466	0.76421	.	NULL	.	.	.	0.924117231453	0.92334	NULL	0.24879	0.376377284527	0.21742	T	0.102713	0.41069	T	-0.159172	0.26888	T	-0.00046299	0.70306	D	0.0238433641103516	0.01125	T	0.944206	0.78893	D	.	.	.	.	.	.	2.599304	0.43415	22.6	2.528963	0.44369	22.6	0.9896838679583253	0.49481	0.97374	0.74345	D	AEFDBI	0.475228	0.51916	N	-0.0698072759732775	0.38721	2.272308	0.0533494119979812	0.42233	2.551021	0.999784343268559	0.43007	0.706298	0.61202	0	0.653731	0.59785	0	0.709663	0.75317	0	0.635551	0.53088	0	NULL	NULL	5.62	5.62	0.85714	5.619000	0.67408	1.025000	0.40714	0.599000	0.40250	1.000000	0.71638	0.326000	0.24477	0.969000	0.54022	0.0:1.0:0.0:0.0	19.6528	0.95819	861	0.33516	10	0.001996805111821086	9	0.00680786686838124	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	19	0.004312301407172038	0	0.0	59	4.859e-04	59	4.862e-04	54	5.190e-03	3	2.599e-04	2	2.311e-04	0	0	0	0	0	0	50	4.708e-04	50	4.710e-04	45	4.965e-03	3	2.683e-04	2	2.543e-04	0	0	0	0	0	0	58	6.391e-04	58	6.396e-04	54	5.199e-03	3	2.601e-04	1	1.774e-04	0	0	0	0	0	0	.	106	251288	4.218267e-04	0	82	16256	5.044291e-03	0	18	34576	5.205923e-04	0	0	10076	0	0	3	18390	1.631321e-04	0	0	21648	0	0	0	113600	0	0	1	30614	3.266479e-05	0	82	16256	5.044291e-03	0	46	109398	4.204830e-04	0	33	7164	4.606365e-03	0	10	17104	5.846586e-04	0	0	2320	0	0	2	9044	2.211411e-04	0	0	13394	0	0	0	42768	0	0	1	15690	6.373486e-05	0	33	7164	4.606365e-03	0	.	203	143156	1.418033e-03	1	193	41974	4.598085e-03	1	8	13654	5.859089e-04	0	0	3324	0	0	0	3130	0	0	0	10446	0	0	1	64550	1.549187e-05	0	1	64550	1.549187e-05	0	178376	Conflicting_interpretations_of_pathogenicity	Chudley-McCullough_syndrome|not_specified|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.108924138C>T	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:174019|Illumina_Clinical_Services_Laboratory,Illumina:730016	C1858695|CN169374|CN517202	604213	ORPHA314597	.	.	. 	.
1	108924138	C	T	S	L	rs79730689	1	109466760	1	109268283	580	GPSM2	ENSG00000121957	ENST00000406462	ENSP00000385510	GPSM2_HUMAN	c.1739C>T	p.S580L	c.1739C>T	p.Ser580Leu	c.1739C>T	p.Ser580Leu	principal1	Y	5	YES	+	TCG	2	0	C	C/C	C/C	C/C	0.234	0.18061	T	0.068	0.44106	T	0.103	0.25884	B	0.01	0.14941	B	0.029684	0.25417	N	0.435283	1;0.997463;0.997463	0.81001	D;D;D	without_aae;simple_aae;simple_aae	.;S580L;S580L	1.78	0.46185	L	-3.23	0.93414	D	-1.15	0.29525	N	0.488	0.52208	0.0058	0.82375	D	0.6167	0.86468	D	10	0.049899	0.64009	D	0.466	0.76421	.	NULL	.	.	.	0.924117231453	0.92334	0.223555790711	0.24879	0.376377284527	0.21742	T	0.102713	0.41069	T	-0.159172	0.26888	T	-0.00046299	0.70306	D	0.0238433641103516	0.01125	T	NULL	0.78893	.	.	.	.	.	.	.	2.599304	0.43415	22.6	2.528963	0.44369	22.6	0.9896838679583253	0.49481	0.97374	0.74345	D	AEFDBI	0.475228	0.51916	N	-0.0698072759732775	0.38721	2.272308	0.0533494119979812	0.42233	2.551021	0.999784343268559	0.43007	0.706298	0.61202	0	0.653731	0.59785	0	0.709663	0.75317	0	0.635551	0.53088	0	NULL	NULL	5.62	5.62	0.85714	5.619000	0.67408	1.025000	0.40714	0.599000	0.40250	1.000000	0.71638	0.326000	0.24477	0.969000	0.54022	0.0:1.0:0.0:0.0	19.6528	0.95819	861	0.33516	10	0.001996805111821086	9	0.00680786686838124	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	19	0.004312301407172038	0	0.0	59	4.859e-04	59	4.862e-04	54	5.190e-03	3	2.599e-04	2	2.311e-04	0	0	0	0	0	0	50	4.708e-04	50	4.710e-04	45	4.965e-03	3	2.683e-04	2	2.543e-04	0	0	0	0	0	0	58	6.391e-04	58	6.396e-04	54	5.199e-03	3	2.601e-04	1	1.774e-04	0	0	0	0	0	0	.	106	251288	4.218267e-04	0	82	16256	5.044291e-03	0	18	34576	5.205923e-04	0	0	10076	0	0	3	18390	1.631321e-04	0	0	21648	0	0	0	113600	0	0	1	30614	3.266479e-05	0	82	16256	5.044291e-03	0	46	109398	4.204830e-04	0	33	7164	4.606365e-03	0	10	17104	5.846586e-04	0	0	2320	0	0	2	9044	2.211411e-04	0	0	13394	0	0	0	42768	0	0	1	15690	6.373486e-05	0	33	7164	4.606365e-03	0	.	203	143156	1.418033e-03	1	193	41974	4.598085e-03	1	8	13654	5.859089e-04	0	0	3324	0	0	0	3130	0	0	0	10446	0	0	1	64550	1.549187e-05	0	1	64550	1.549187e-05	0	178376	Conflicting_interpretations_of_pathogenicity	Chudley-McCullough_syndrome|not_specified|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.108924138C>T	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:174019|Illumina_Clinical_Services_Laboratory,Illumina:730016	C1858695|CN169374|CN517202	604213	ORPHA314597	.	.	. 	.
1	108924138	C	T	S	L	rs79730689	1	109466760	1	109268283	580	GPSM2	ENSG00000121957	ENST00000642355	ENSP00000496104	GPSM2_HUMAN	.	.	.	.	c.1739C>T	p.Ser580Leu	principal1	Y	.	.	+	TCG	2	0	C	C/C	C/C	C/C	NULL	0.18061	.	NULL	0.44106	.	0.103	0.25884	B	0.01	0.14941	B	0.029684	0.25417	N	0.435283	1;0.997463;0.997463	0.81001	D;D;D	without_aae;simple_aae;simple_aae	.;S580L;S580L	1.78	0.46185	L	NULL	0.93414	.	NULL	0.29525	.	NULL	0.52208	0.0058	0.82375	D	0.6167	0.86468	D	10	0.049899	0.64009	D	0.466	0.76421	.	NULL	.	.	.	NULL	0.92334	NULL	0.24879	0.376377284527	0.21742	T	0.102713	0.41069	T	-0.159172	0.26888	T	-0.00046299	0.70306	D	0.0238433641103516	0.01125	T	NULL	0.78893	.	.	.	.	.	.	.	2.599304	0.43415	22.6	2.528963	0.44369	22.6	0.9896838679583253	0.49481	0.97374	0.74345	D	AEFDBI	0.475228	0.51916	N	-0.0698072759732775	0.38721	2.272308	0.0533494119979812	0.42233	2.551021	0.999784343268559	0.43007	0.706298	0.61202	0	0.653731	0.59785	0	0.709663	0.75317	0	0.635551	0.53088	0	NULL	NULL	5.62	5.62	0.85714	5.619000	0.67408	1.025000	0.40714	0.599000	0.40250	1.000000	0.71638	0.326000	0.24477	0.969000	0.54022	0.0:1.0:0.0:0.0	19.6528	0.95819	861	0.33516	10	0.001996805111821086	9	0.00680786686838124	0	0.0	1	0.001440922190201729	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	19	0.004312301407172038	0	0.0	59	4.859e-04	59	4.862e-04	54	5.190e-03	3	2.599e-04	2	2.311e-04	0	0	0	0	0	0	50	4.708e-04	50	4.710e-04	45	4.965e-03	3	2.683e-04	2	2.543e-04	0	0	0	0	0	0	58	6.391e-04	58	6.396e-04	54	5.199e-03	3	2.601e-04	1	1.774e-04	0	0	0	0	0	0	.	106	251288	4.218267e-04	0	82	16256	5.044291e-03	0	18	34576	5.205923e-04	0	0	10076	0	0	3	18390	1.631321e-04	0	0	21648	0	0	0	113600	0	0	1	30614	3.266479e-05	0	82	16256	5.044291e-03	0	46	109398	4.204830e-04	0	33	7164	4.606365e-03	0	10	17104	5.846586e-04	0	0	2320	0	0	2	9044	2.211411e-04	0	0	13394	0	0	0	42768	0	0	1	15690	6.373486e-05	0	33	7164	4.606365e-03	0	.	203	143156	1.418033e-03	1	193	41974	4.598085e-03	1	8	13654	5.859089e-04	0	0	3324	0	0	0	3130	0	0	0	10446	0	0	1	64550	1.549187e-05	0	1	64550	1.549187e-05	0	178376	Conflicting_interpretations_of_pathogenicity	Chudley-McCullough_syndrome|not_specified|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.108924138C>T	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:174019|Illumina_Clinical_Services_Laboratory,Illumina:730016	C1858695|CN169374|CN517202	604213	ORPHA314597	.	.	. 	.
1	108929705	C	T	S	F	rs35322815	1	109472327	1	109273850	607	GPSM2	ENSG00000121957	ENST00000264126	ENSP00000264126	GPSM2_HUMAN	c.1820C>T	p.S607F	c.1820C>T	p.Ser607Phe	c.1820C>T	p.Ser607Phe	principal1	Y	1	.	+	TCC	2	0	C	C/C	C/C	C/C	0.001	0.78490	D	0.001	0.83351	D	0.999	0.77913	D	0.983	0.75793	D	0.000000	0.84330	D	0.053767	1;1;1;1;1;1;1;1	0.81001	D;D;D;D;D;D;D;D	without_aae;without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae;simple_aae	.;.;.;.;.;.;S607F;S607F	3.175	0.88760	M	-3.52	0.94729	D	-4.72	0.79998	D	0.752	0.80767	1.0143	0.97432	D	0.9167	0.97240	D	10	NULL	NULL	.	0.836	0.94913	.	NULL	.	.	.	0.993241518062	0.99316	NULL	0.71571	0.616739332676	0.55268	T	0.624171	0.88264	D	-0.112055	0.34428	T	0.0858606	0.75969	D	0.0278651169423726	0.01668	T	0.987501	0.95747	D	.	.	.	.	.	.	4.283542	0.87827	29.4	4.505208	0.91835	32	0.9978482479902383	0.87131	0.99057	0.90596	D	AEFBI	0.871912	0.79352	D	0.928112828802992	0.93067	11.80099	0.896342888548824	0.95412	13.59639	0.99999999812227	0.74766	0.6512	0.46895	0	0.653731	0.59785	0	0.65145	0.50148	0	0.635551	0.53088	0	NULL	NULL	5.79	5.79	0.91751	7.568000	0.81546	1.025000	0.40714	0.599000	0.40250	1.000000	0.71638	0.997000	0.62031	0.989000	0.64315	0.0:1.0:0.0:0.0	19.6367	0.95731	861	0.33516	36	0.00718849840255591	33	0.024962178517397883	0	0.0	3	0.004322766570605188	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	113	0.025646845211075804	0	0.0	283	2.331e-03	280	2.332e-03	270	2.682e-02	8	6.974e-04	0	0	0	0	1	1.515e-05	1	6.095e-05	243	2.288e-03	243	2.294e-03	234	2.603e-02	8	7.175e-04	0	0	0	0	0	0	1	6.131e-05	283	3.118e-03	280	3.132e-03	270	2.687e-02	8	6.981e-04	0	0	0	0	1	2.415e-05	1	6.099e-05	.	435	249668	1.742314e-03	5	398	16084	2.474509e-02	5	27	34528	7.819741e-04	0	0	10012	0	0	0	18364	0	0	0	21646	0	0	3	112390	2.669277e-05	0	3	30556	9.818039e-05	0	398	16084	2.474509e-02	5	170	109274	1.555722e-03	3	155	7128	2.174523e-02	3	13	17084	7.609459e-04	0	0	2320	0	0	0	9040	0	0	0	13394	0	0	1	42762	2.338525e-05	0	0	15634	0	0	155	7128	2.174523e-02	3	.	1122	143246	7.832679e-03	12	1070	42020	2.546406e-02	12	32	13650	2.344322e-03	0	0	3320	0	0	0	3132	0	0	0	10460	0	0	3	64572	4.645977e-05	0	3	64572	4.645977e-05	0	163642	Benign/Likely_benign	not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.108929705C>T	.	CN169374|CN517202	.	.	GoLoco motif|GoLoco motif|GoLoco motif	.	. 	.
1	108929705	C	T	S	F	rs35322815	1	109472327	1	109273850	607	GPSM2	ENSG00000121957	ENST00000406462	ENSP00000385510	GPSM2_HUMAN	c.1820C>T	p.S607F	c.1820C>T	p.Ser607Phe	c.1820C>T	p.Ser607Phe	principal1	Y	5	YES	+	TCC	2	0	C	C/C	C/C	C/C	0.001	0.78490	D	0.001	0.83351	D	0.999	0.77913	D	0.983	0.75793	D	0.000000	0.84330	D	0.053767	1;1;1;1;1;1;1;1	0.81001	D;D;D;D;D;D;D;D	without_aae;without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae;simple_aae	.;.;.;.;.;.;S607F;S607F	3.175	0.88760	M	-3.52	0.94729	D	-4.72	0.79998	D	0.812	0.80767	1.0143	0.97432	D	0.9167	0.97240	D	10	NULL	NULL	.	0.836	0.94913	.	NULL	.	.	.	0.993241518062	0.99316	0.924097085248	0.71571	0.616739332676	0.55268	T	0.624171	0.88264	D	-0.112055	0.34428	T	0.0858606	0.75969	D	0.0278651169423726	0.01668	T	NULL	0.95747	.	.	.	.	.	.	.	4.283542	0.87827	29.4	4.505208	0.91835	32	0.9978482479902383	0.87131	0.99057	0.90596	D	AEFBI	0.871912	0.79352	D	0.928112828802992	0.93067	11.80099	0.896342888548824	0.95412	13.59639	0.99999999812227	0.74766	0.6512	0.46895	0	0.653731	0.59785	0	0.65145	0.50148	0	0.635551	0.53088	0	NULL	NULL	5.79	5.79	0.91751	7.568000	0.81546	1.025000	0.40714	0.599000	0.40250	1.000000	0.71638	0.997000	0.62031	0.989000	0.64315	0.0:1.0:0.0:0.0	19.6367	0.95731	861	0.33516	36	0.00718849840255591	33	0.024962178517397883	0	0.0	3	0.004322766570605188	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	113	0.025646845211075804	0	0.0	283	2.331e-03	280	2.332e-03	270	2.682e-02	8	6.974e-04	0	0	0	0	1	1.515e-05	1	6.095e-05	243	2.288e-03	243	2.294e-03	234	2.603e-02	8	7.175e-04	0	0	0	0	0	0	1	6.131e-05	283	3.118e-03	280	3.132e-03	270	2.687e-02	8	6.981e-04	0	0	0	0	1	2.415e-05	1	6.099e-05	.	435	249668	1.742314e-03	5	398	16084	2.474509e-02	5	27	34528	7.819741e-04	0	0	10012	0	0	0	18364	0	0	0	21646	0	0	3	112390	2.669277e-05	0	3	30556	9.818039e-05	0	398	16084	2.474509e-02	5	170	109274	1.555722e-03	3	155	7128	2.174523e-02	3	13	17084	7.609459e-04	0	0	2320	0	0	0	9040	0	0	0	13394	0	0	1	42762	2.338525e-05	0	0	15634	0	0	155	7128	2.174523e-02	3	.	1122	143246	7.832679e-03	12	1070	42020	2.546406e-02	12	32	13650	2.344322e-03	0	0	3320	0	0	0	3132	0	0	0	10460	0	0	3	64572	4.645977e-05	0	3	64572	4.645977e-05	0	163642	Benign/Likely_benign	not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.108929705C>T	.	CN169374|CN517202	.	.	GoLoco motif|GoLoco motif|GoLoco motif	.	. 	.
1	108929705	C	T	S	F	rs35322815	1	109472327	1	109273850	607	GPSM2	ENSG00000121957	ENST00000642355	ENSP00000496104	GPSM2_HUMAN	.	.	.	.	c.1820C>T	p.Ser607Phe	principal1	Y	.	.	+	TCC	2	0	C	C/C	C/C	C/C	NULL	0.78490	.	NULL	0.83351	.	0.999	0.77913	D	0.983	0.75793	D	0.000000	0.84330	D	0.053767	1;1;1;1;1;1;1;1	0.81001	D;D;D;D;D;D;D;D	without_aae;without_aae;without_aae;without_aae;without_aae;without_aae;simple_aae;simple_aae	.;.;.;.;.;.;S607F;S607F	3.175	0.88760	M	NULL	0.94729	.	NULL	0.79998	.	NULL	0.80767	1.0143	0.97432	D	0.9167	0.97240	D	10	NULL	NULL	.	0.836	0.94913	.	NULL	.	.	.	NULL	0.99316	NULL	0.71571	0.616739332676	0.55268	T	0.624171	0.88264	D	-0.112055	0.34428	T	0.0858606	0.75969	D	0.0278651169423726	0.01668	T	NULL	0.95747	.	.	.	.	.	.	.	4.283542	0.87827	29.4	4.505208	0.91835	32	0.9978482479902383	0.87131	0.99057	0.90596	D	AEFBI	0.871912	0.79352	D	0.928112828802992	0.93067	11.80099	0.896342888548824	0.95412	13.59639	0.99999999812227	0.74766	0.6512	0.46895	0	0.653731	0.59785	0	0.65145	0.50148	0	0.635551	0.53088	0	NULL	NULL	5.79	5.79	0.91751	7.568000	0.81546	1.025000	0.40714	0.599000	0.40250	1.000000	0.71638	0.997000	0.62031	0.989000	0.64315	0.0:1.0:0.0:0.0	19.6367	0.95731	861	0.33516	36	0.00718849840255591	33	0.024962178517397883	0	0.0	3	0.004322766570605188	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	113	0.025646845211075804	0	0.0	283	2.331e-03	280	2.332e-03	270	2.682e-02	8	6.974e-04	0	0	0	0	1	1.515e-05	1	6.095e-05	243	2.288e-03	243	2.294e-03	234	2.603e-02	8	7.175e-04	0	0	0	0	0	0	1	6.131e-05	283	3.118e-03	280	3.132e-03	270	2.687e-02	8	6.981e-04	0	0	0	0	1	2.415e-05	1	6.099e-05	.	435	249668	1.742314e-03	5	398	16084	2.474509e-02	5	27	34528	7.819741e-04	0	0	10012	0	0	0	18364	0	0	0	21646	0	0	3	112390	2.669277e-05	0	3	30556	9.818039e-05	0	398	16084	2.474509e-02	5	170	109274	1.555722e-03	3	155	7128	2.174523e-02	3	13	17084	7.609459e-04	0	0	2320	0	0	0	9040	0	0	0	13394	0	0	1	42762	2.338525e-05	0	0	15634	0	0	155	7128	2.174523e-02	3	.	1122	143246	7.832679e-03	12	1070	42020	2.546406e-02	12	32	13650	2.344322e-03	0	0	3320	0	0	0	3132	0	0	0	10460	0	0	3	64572	4.645977e-05	0	3	64572	4.645977e-05	0	163642	Benign/Likely_benign	not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.108929705C>T	.	CN169374|CN517202	.	.	GoLoco motif|GoLoco motif|GoLoco motif	.	. 	.
1	109548838	G	C	G	R	rs387907178	1	110091460	1	109892983	40	GNAI3	ENSG00000065135	ENST00000369851	ENSP00000358867	GNAI3_HUMAN	c.118G>C	p.G40R	c.118G>C	p.Gly40Arg	c.118G>C	p.Gly40Arg	principal1	Y	1	YES	+	GGT	1	0	G	G/G	G/G	G/G	0.0	0.91255	D	0.004	0.74150	D	1.0	0.90584	D	0.999	0.92359	D	0.000000	0.84330	D	0.000000	1	0.81001	D	simple_aae	G40R	4.425	0.98735	H	-4.75	0.98096	D	-6.26	0.90608	D	0.973	0.98368	1.0547	0.98219	D	0.9801	0.99388	D	10	0.76891	0.98172	D	0.976	0.99786	0.867	0.96158	P08754	G40R	Gain of MoRF binding (P = 0.0045); Loss of ubiquitination at K35 (P = 0.0396); Loss of catalytic residue at A41 (P = 0.2144); Gain of disorder (P = 0.2157); Gain of helix (P = 0.2684)	0.991456739636	0.99136	1.73859626385	0.90843	0.933438777924	0.99170	D	0.976787	0.99781	D	0.592348	0.97373	D	0.613091	0.97331	D	0.999816119670868	0.99146	D	0.976002	0.91601	D	.	.	.	.	.	.	6.120003	0.95909	35	5.913885	0.95467	35	0.99925886786695983	0.99042	0.98667	0.85343	D	AEFDGBHCI	0.939470	0.94012	D	1.12291941301461	0.98536	18.56284	1.01337406999017	0.98869	19.68254	1.0	0.98316	0.441713	0.08003	0	0.52208	0.09955	0	0.52208	0.10781	0	0.56214	0.19341	0	NULL	NULL	5.82	5.82	0.92740	9.725000	0.98015	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.700000	0.30932	0.745000	0.35611	0.0:0.0:1.0:0.0	19.7034	0.96060	607	0.67291	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	31636	Pathogenic	Auriculocondylar_syndrome_1	criteria_provided,_single_submitter	NC_000001.11:g.109548838G>C	OMIM_Allelic_Variant:139370.0001	C4551996	602483	.	.	.	. 	.
1	109608722	C	T	V	M	rs41280330	1	110151344	1	109952867	124	GNAT2	ENSG00000134183	ENST00000351050	ENSP00000251337	GNAT2_HUMAN	c.370G>A	p.V124M	c.370G>A	p.Val124Met	c.370G>A	p.Val124Met	principal1	Y	1	YES	-	GTG	1	0	C	C/C	C/C	C/C	0.046	0.40573	D	0.065	0.44702	T	0.99	0.63424	D	0.738	0.55619	P	0.005516	0.32736	N	0.287924	0.868387	0.35516	D	simple_aae	V124M	1.63	0.41750	L	-2.43	0.88689	D	-0.41	0.14000	N	0.426	0.46555	0.5298	0.90961	D	0.7144	0.90196	D	10	0.044655	0.61597	D	0.335	0.66064	.	NULL	.	.	.	0.921974883161	0.92118	0.354423072536	0.37217	0.497574865818	0.38490	T	0.423673	0.77435	T	-0.23169	0.16426	T	-0.096188	0.63691	T	0.0494856905650249	0.05409	T	0.973003	0.90263	D	.	.	.	.	.	.	2.696698	0.45523	22.8	3.095923	0.56970	23.8	0.99895602382781312	0.96895	0.91798	0.54285	D	AEFBI	0.437475	0.49726	N	0.562450296784154	0.70845	5.56152	0.525014713537541	0.69678	5.394781	0.99998920776304	0.51787	0.421363	0.06395	0	0.550933	0.16991	0	0.491513	0.07944	0	0.664235	0.64389	0	NULL	NULL	4.69	4.69	0.58546	2.020000	0.40630	1.026000	0.45946	0.599000	0.40250	0.897000	0.31356	0.323000	0.24426	0.842000	0.39752	0.0:1.0:0.0:0.0	17.7737	0.88411	851	0.35303	13	0.002595846645367412	0	0.0	7	0.006958250497017893	2	0.002881844380403458	0	0.0	4	0.00408997955010225	24	0.006472491909385114	30	0.007784120394395433	54	0.007140967997884158	4	9.078529278256923E-4	54	0.006279069767441861	661	5.444e-03	661	5.445e-03	9	8.651e-04	24	2.074e-03	0	0	21	3.176e-03	500	7.493e-03	101	6.117e-03	570	5.367e-03	570	5.367e-03	8	8.826e-04	24	2.141e-03	0	0	21	3.176e-03	412	7.582e-03	101	6.156e-03	412	4.540e-03	412	4.541e-03	9	8.666e-04	24	2.076e-03	0	0	11	2.895e-03	263	6.242e-03	101	6.120e-03	.	1295	251464	5.149843e-03	1	14	16254	8.613264e-04	0	85	34588	2.457500e-03	0	42	10078	4.167494e-03	0	0	18394	0	0	77	21646	3.557239e-03	0	862	113752	7.577889e-03	1	177	30616	5.781291e-03	0	862	113752	7.577889e-03	1	519	109400	4.744059e-03	0	7	7164	9.771078e-04	0	40	17108	2.338087e-03	0	7	2320	3.017241e-03	0	0	9046	0	0	37	13392	2.762843e-03	0	312	42766	7.295515e-03	0	101	15690	6.437221e-03	0	312	42766	7.295515e-03	0	.	625	143270	4.362393e-03	4	53	42036	1.260824e-03	0	43	13650	3.150183e-03	0	8	3322	2.408188e-03	0	0	3132	0	0	32	10466	3.057520e-03	2	454	64572	7.030911e-03	2	25	3042	8.218277e-03	0	197251	Likely_benign	Achromatopsia_4|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.109608722C>T	Illumina_Clinical_Services_Laboratory,Illumina:230517|UniProtKB_(protein):P19087#VAR_047624	C1841721|CN169374|CN517202	613856	.	.	.	. 	.
1	109627794	G	C	R	P	rs746332433	1	110170416	1	109971939	259	AMPD2	ENSG00000116337	ENST00000393688	ENSP00000377292	AMPD2_HUMAN	c.776G>C	p.R259P	c.776G>C	p.Arg259Pro	c.776G>C	p.Arg259Pro	.	Y	1	.	+	CGG	2	0	G	G/G	G/G	G/G	0.001	0.78490	D	0.001	0.83351	D	1.0	0.90584	D	1.0	0.97372	D	0.000000	0.84330	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	R297P;R378P;R378P;R303P;R260P;R259P	NULL	0.97316	.	-2.44	0.88767	D	-5.57	0.91353	D	0.981	0.99863	0.9660	0.96638	D	0.8733	0.95790	D	10	0.556689	0.95936	D	0.956	0.99265	0.863	0.95939	Q01433	R378P	Loss of MoRF binding (P = 0.0203); Loss of catalytic residue at R378 (P = 0.0412); Loss of stability (P = 0.0717); Loss of helix (P = 0.1299); Gain of glycosylation at R378 (P = 0.2676)	0.967615550514	0.96726	NULL	0.94091	0.887371480465	0.94929	D	NULL	0.96551	.	0.490761	0.94031	D	0.467168	0.93954	D	0.999334633350372	0.97004	D	0.99594	0.98606	D	.	.	.	.	.	.	4.821215	0.92782	33	4.663641	0.92456	32	0.99767115683378949	0.85583	0.98515	0.83602	D	AEFGBCI	0.973324	0.99486	D	1.0353080252836	0.96730	15.06781	0.952749716031071	0.97485	16.21073	0.999999999999344	0.74766	0.719381	0.83141	0	0.697927	0.68747	0	0.724815	0.87919	0	0.733575	0.97253	0	NULL	NULL	5.17	5.17	0.70848	9.884000	0.98542	1.157000	0.71077	0.654000	0.53741	1.000000	0.71638	1.000000	0.86279	0.995000	0.73285	0.0:0.0:1.0:0.0	17.6075	0.87943	846	0.36215	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	8.236e-06	1	8.253e-06	0	0	0	0	0	0	0	0	1	1.502e-05	0	0	1	9.415e-06	1	9.435e-06	0	0	0	0	0	0	0	0	1	1.845e-05	0	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251326	3.978896e-06	0	0	16252	0	0	0	34558	0	0	0	10068	0	0	0	18392	0	0	0	21644	0	0	1	113666	8.797706e-06	0	0	30616	0	0	1	113666	8.797706e-06	0	0	109386	0	0	0	7164	0	0	0	17096	0	0	0	2320	0	0	0	9046	0	0	0	13392	0	0	0	42764	0	0	0	15690	0	0	0	0	0	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	224991	Likely_pathogenic	Inborn_genetic_diseases	criteria_provided,_single_submitter	NC_000001.11:g.109627794G>C	.	C0950123	.	.	.	.	. 	.
1	109627794	G	C	R	P	rs746332433	1	110170416	1	109971939	260	AMPD2	ENSG00000116337	ENST00000528454	ENSP00000437164	AMPD2_HUMAN	c.779G>C	p.R260P	c.779G>C	p.Arg260Pro	c.779G>C	p.Arg260Pro	.	Y	2	.	+	CGG	2	0	G	G/G	G/G	G/G	0.001	0.78490	D	0.001	0.83351	D	NULL	0.90584	.	NULL	0.97372	.	0.000000	0.84330	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	R297P;R378P;R378P;R303P;R260P;R259P	NULL	0.97316	.	-2.44	0.88767	D	-5.57	0.91353	D	0.969	0.99863	0.9660	0.96638	D	0.8733	0.95790	D	10	0.556689	0.95936	D	0.956	0.99265	0.863	0.95939	Q01433	R378P	Loss of MoRF binding (P = 0.0203); Loss of catalytic residue at R378 (P = 0.0412); Loss of stability (P = 0.0717); Loss of helix (P = 0.1299); Gain of glycosylation at R378 (P = 0.2676)	0.967615550514	0.96726	NULL	0.94091	0.887371480465	0.94929	D	NULL	0.96551	.	0.490761	0.94031	D	0.467168	0.93954	D	0.999334633350372	0.97004	D	0.99594	0.98606	D	.	.	.	.	.	.	4.821215	0.92782	33	4.663641	0.92456	32	0.99767115683378949	0.85583	0.98515	0.83602	D	AEFGBCI	0.973324	0.99486	D	1.0353080252836	0.96730	15.06781	0.952749716031071	0.97485	16.21073	0.999999999999344	0.74766	0.719381	0.83141	0	0.697927	0.68747	0	0.724815	0.87919	0	0.733575	0.97253	0	NULL	NULL	5.17	5.17	0.70848	9.884000	0.98542	1.157000	0.71077	0.654000	0.53741	1.000000	0.71638	1.000000	0.86279	0.995000	0.73285	0.0:0.0:1.0:0.0	17.6075	0.87943	846	0.36215	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	8.236e-06	1	8.253e-06	0	0	0	0	0	0	0	0	1	1.502e-05	0	0	1	9.415e-06	1	9.435e-06	0	0	0	0	0	0	0	0	1	1.845e-05	0	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251326	3.978896e-06	0	0	16252	0	0	0	34558	0	0	0	10068	0	0	0	18392	0	0	0	21644	0	0	1	113666	8.797706e-06	0	0	30616	0	0	1	113666	8.797706e-06	0	0	109386	0	0	0	7164	0	0	0	17096	0	0	0	2320	0	0	0	9046	0	0	0	13392	0	0	0	42764	0	0	0	15690	0	0	0	0	0	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	224991	Likely_pathogenic	Inborn_genetic_diseases	criteria_provided,_single_submitter	NC_000001.11:g.109627794G>C	.	C0950123	.	.	.	.	. 	.
1	109627794	G	C	R	P	rs746332433	1	110170416	1	109971939	297	AMPD2	ENSG00000116337	ENST00000342115	ENSP00000345498	AMPD2_HUMAN	c.890G>C	p.R297P	c.890G>C	p.Arg297Pro	c.890G>C	p.Arg297Pro	alternative1	Y	1	.	+	CGG	2	0	G	G/G	G/G	G/G	0.001	0.78490	D	0.001	0.83351	D	1.0	0.90584	D	1.0	0.97372	D	0.000000	0.84330	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	R297P;R378P;R378P;R303P;R260P;R259P	NULL	0.97316	.	-2.44	0.88767	D	-5.57	0.91353	D	0.99	0.99863	0.9660	0.96638	D	0.8733	0.95790	D	10	0.556689	0.95936	D	0.956	0.99265	0.863	0.95939	Q01433	R378P	Loss of MoRF binding (P = 0.0203); Loss of catalytic residue at R378 (P = 0.0412); Loss of stability (P = 0.0717); Loss of helix (P = 0.1299); Gain of glycosylation at R378 (P = 0.2676)	0.967615550514	0.96726	NULL	0.94091	0.887371480465	0.94929	D	NULL	0.96551	.	0.490761	0.94031	D	0.467168	0.93954	D	0.999334633350372	0.97004	D	0.99594	0.98606	D	.	.	.	.	.	.	4.821215	0.92782	33	4.663641	0.92456	32	0.99767115683378949	0.85583	0.98515	0.83602	D	AEFGBCI	0.973324	0.99486	D	1.0353080252836	0.96730	15.06781	0.952749716031071	0.97485	16.21073	0.999999999999344	0.74766	0.719381	0.83141	0	0.697927	0.68747	0	0.724815	0.87919	0	0.733575	0.97253	0	NULL	NULL	5.17	5.17	0.70848	9.884000	0.98542	1.157000	0.71077	0.654000	0.53741	1.000000	0.71638	1.000000	0.86279	0.995000	0.73285	0.0:0.0:1.0:0.0	17.6075	0.87943	846	0.36215	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	8.236e-06	1	8.253e-06	0	0	0	0	0	0	0	0	1	1.502e-05	0	0	1	9.415e-06	1	9.435e-06	0	0	0	0	0	0	0	0	1	1.845e-05	0	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251326	3.978896e-06	0	0	16252	0	0	0	34558	0	0	0	10068	0	0	0	18392	0	0	0	21644	0	0	1	113666	8.797706e-06	0	0	30616	0	0	1	113666	8.797706e-06	0	0	109386	0	0	0	7164	0	0	0	17096	0	0	0	2320	0	0	0	9046	0	0	0	13392	0	0	0	42764	0	0	0	15690	0	0	0	0	0	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	224991	Likely_pathogenic	Inborn_genetic_diseases	criteria_provided,_single_submitter	NC_000001.11:g.109627794G>C	.	C0950123	.	.	.	.	. 	.
1	109627794	G	C	R	P	rs746332433	1	110170416	1	109971939	303	AMPD2	ENSG00000116337	ENST00000358729	ENSP00000351573	AMPD2_HUMAN	c.908G>C	p.R303P	c.908G>C	p.Arg303Pro	c.908G>C	p.Arg303Pro	.	Y	2	.	+	CGG	2	0	G	G/G	G/G	G/G	0.001	0.78490	D	0.001	0.83351	D	1.0	0.90584	D	1.0	0.97372	D	0.000000	0.84330	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	R297P;R378P;R378P;R303P;R260P;R259P	NULL	0.97316	.	-2.44	0.88767	D	-5.57	0.91353	D	0.993	0.99863	0.9660	0.96638	D	0.8733	0.95790	D	10	0.556689	0.95936	D	0.956	0.99265	0.863	0.95939	Q01433	R378P	Loss of MoRF binding (P = 0.0203); Loss of catalytic residue at R378 (P = 0.0412); Loss of stability (P = 0.0717); Loss of helix (P = 0.1299); Gain of glycosylation at R378 (P = 0.2676)	0.967615550514	0.96726	NULL	0.94091	0.887371480465	0.94929	D	NULL	0.96551	.	0.490761	0.94031	D	0.467168	0.93954	D	0.999334633350372	0.97004	D	0.99594	0.98606	D	.	.	.	.	.	.	4.821215	0.92782	33	4.663641	0.92456	32	0.99767115683378949	0.85583	0.98515	0.83602	D	AEFGBCI	0.973324	0.99486	D	1.0353080252836	0.96730	15.06781	0.952749716031071	0.97485	16.21073	0.999999999999344	0.74766	0.719381	0.83141	0	0.697927	0.68747	0	0.724815	0.87919	0	0.733575	0.97253	0	NULL	NULL	5.17	5.17	0.70848	9.884000	0.98542	1.157000	0.71077	0.654000	0.53741	1.000000	0.71638	1.000000	0.86279	0.995000	0.73285	0.0:0.0:1.0:0.0	17.6075	0.87943	846	0.36215	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	8.236e-06	1	8.253e-06	0	0	0	0	0	0	0	0	1	1.502e-05	0	0	1	9.415e-06	1	9.435e-06	0	0	0	0	0	0	0	0	1	1.845e-05	0	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251326	3.978896e-06	0	0	16252	0	0	0	34558	0	0	0	10068	0	0	0	18392	0	0	0	21644	0	0	1	113666	8.797706e-06	0	0	30616	0	0	1	113666	8.797706e-06	0	0	109386	0	0	0	7164	0	0	0	17096	0	0	0	2320	0	0	0	9046	0	0	0	13392	0	0	0	42764	0	0	0	15690	0	0	0	0	0	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	224991	Likely_pathogenic	Inborn_genetic_diseases	criteria_provided,_single_submitter	NC_000001.11:g.109627794G>C	.	C0950123	.	.	.	.	. 	.
1	109627794	G	C	R	P	rs746332433	1	110170416	1	109971939	378	AMPD2	ENSG00000116337	ENST00000256578	ENSP00000256578	AMPD2_HUMAN	c.1133G>C	p.R378P	c.1133G>C	p.Arg378Pro	c.1133G>C	p.Arg378Pro	principal4	Y	5	YES	+	CGG	2	0	G	G/G	G/G	G/G	0.001	0.78490	D	0.001	0.83351	D	1.0	0.90584	D	1.0	0.97372	D	0.000000	0.84330	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	R297P;R378P;R378P;R303P;R260P;R259P	4.1	0.97316	H	-2.44	0.88767	D	-6.44	0.91353	D	0.992	0.99863	0.9660	0.96638	D	0.8733	0.95790	D	10	0.556689	0.95936	D	0.956	0.99265	0.863	0.95939	Q01433	R378P	Loss of MoRF binding (P = 0.0203); Loss of catalytic residue at R378 (P = 0.0412); Loss of stability (P = 0.0717); Loss of helix (P = 0.1299); Gain of glycosylation at R378 (P = 0.2676)	0.967615550514	0.96726	2.0305426451	0.94091	0.887371480465	0.94929	D	0.849159	0.96551	D	0.490761	0.94031	D	0.467168	0.93954	D	0.999334633350372	0.97004	D	0.99594	0.98606	D	.	.	.	.	.	.	4.821215	0.92782	33	4.663641	0.92456	32	0.99767115683378949	0.85583	0.98515	0.83602	D	AEFGBCI	0.973324	0.99486	D	1.0353080252836	0.96730	15.06781	0.952749716031071	0.97485	16.21073	0.999999999999344	0.74766	0.719381	0.83141	0	0.697927	0.68747	0	0.724815	0.87919	0	0.733575	0.97253	0	NULL	NULL	5.17	5.17	0.70848	9.884000	0.98542	1.157000	0.71077	0.654000	0.53741	1.000000	0.71638	1.000000	0.86279	0.995000	0.73285	0.0:0.0:1.0:0.0	17.6075	0.87943	846	0.36215	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	8.236e-06	1	8.253e-06	0	0	0	0	0	0	0	0	1	1.502e-05	0	0	1	9.415e-06	1	9.435e-06	0	0	0	0	0	0	0	0	1	1.845e-05	0	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251326	3.978896e-06	0	0	16252	0	0	0	34558	0	0	0	10068	0	0	0	18392	0	0	0	21644	0	0	1	113666	8.797706e-06	0	0	30616	0	0	1	113666	8.797706e-06	0	0	109386	0	0	0	7164	0	0	0	17096	0	0	0	2320	0	0	0	9046	0	0	0	13392	0	0	0	42764	0	0	0	15690	0	0	0	0	0	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	224991	Likely_pathogenic	Inborn_genetic_diseases	criteria_provided,_single_submitter	NC_000001.11:g.109627794G>C	.	C0950123	.	.	.	.	. 	.
1	109627794	G	C	R	P	rs746332433	1	110170416	1	109971939	378	AMPD2	ENSG00000116337	ENST00000528667	ENSP00000436541	AMPD2_HUMAN	c.1133G>C	p.R378P	c.1133G>C	p.Arg378Pro	c.1133G>C	p.Arg378Pro	principal4	Y	1	.	+	CGG	2	0	G	G/G	G/G	G/G	0.001	0.78490	D	0.001	0.83351	D	1.0	0.90584	D	1.0	0.97372	D	0.000000	0.84330	D	0.000000	1;1;1;1;1;1	0.81001	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	R297P;R378P;R378P;R303P;R260P;R259P	4.1	0.97316	H	-2.44	0.88767	D	-6.44	0.91353	D	0.991	0.99863	0.9660	0.96638	D	0.8733	0.95790	D	10	0.556689	0.95936	D	0.956	0.99265	0.863	0.95939	Q01433	R378P	Loss of MoRF binding (P = 0.0203); Loss of catalytic residue at R378 (P = 0.0412); Loss of stability (P = 0.0717); Loss of helix (P = 0.1299); Gain of glycosylation at R378 (P = 0.2676)	0.967615550514	0.96726	NULL	0.94091	0.887371480465	0.94929	D	0.849159	0.96551	D	0.490761	0.94031	D	0.467168	0.93954	D	0.999334633350372	0.97004	D	NULL	0.98606	.	.	.	.	.	.	.	4.821215	0.92782	33	4.663641	0.92456	32	0.99767115683378949	0.85583	0.98515	0.83602	D	AEFGBCI	0.973324	0.99486	D	1.0353080252836	0.96730	15.06781	0.952749716031071	0.97485	16.21073	0.999999999999344	0.74766	0.719381	0.83141	0	0.697927	0.68747	0	0.724815	0.87919	0	0.733575	0.97253	0	NULL	NULL	5.17	5.17	0.70848	9.884000	0.98542	1.157000	0.71077	0.654000	0.53741	1.000000	0.71638	1.000000	0.86279	0.995000	0.73285	0.0:0.0:1.0:0.0	17.6075	0.87943	846	0.36215	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	8.236e-06	1	8.253e-06	0	0	0	0	0	0	0	0	1	1.502e-05	0	0	1	9.415e-06	1	9.435e-06	0	0	0	0	0	0	0	0	1	1.845e-05	0	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251326	3.978896e-06	0	0	16252	0	0	0	34558	0	0	0	10068	0	0	0	18392	0	0	0	21644	0	0	1	113666	8.797706e-06	0	0	30616	0	0	1	113666	8.797706e-06	0	0	109386	0	0	0	7164	0	0	0	17096	0	0	0	2320	0	0	0	9046	0	0	0	13392	0	0	0	42764	0	0	0	15690	0	0	0	0	0	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	224991	Likely_pathogenic	Inborn_genetic_diseases	criteria_provided,_single_submitter	NC_000001.11:g.109627794G>C	.	C0950123	.	.	.	.	. 	.
1	109627893	A	G	N	S	rs869312928	1	110170515	1	109972038	292	AMPD2	ENSG00000116337	ENST00000393688	ENSP00000377292	AMPD2_HUMAN	c.875A>G	p.N292S	c.875A>G	p.Asn292Ser	c.875A>G	p.Asn292Ser	.	Y	1	.	+	AAC	2	0	A	A/A	A/A	A/A	0.0	0.91255	D	0.0	0.92824	D	0.967	0.68779	D	0.846	0.70482	P	0.000000	0.84330	D	0.000000	0.999995;0.999995;0.999995;0.999995;0.999995;0.999995	0.58761	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	N330S;N411S;N411S;N336S;N293S;N292S	NULL	0.93507	.	-3.99	0.96308	D	-4.07	0.80256	D	0.942	0.99481	1.0763	0.98767	D	0.9386	0.97982	D	10	0.325593	0.91603	D	0.873	0.96262	0.581	0.70722	Q01433	N411S	Gain of phosphorylation at N411 (P = 0.0789); Loss of helix (P = 0.1299); Gain of MoRF binding (P = 0.1382); Loss of methylation at K414 (P = 0.1542); Gain of disorder (P = 0.1778)	0.936812336596	0.93616	NULL	0.87103	0.763066649437	0.76387	T	NULL	0.95139	.	0.258083	0.79352	D	0.132942	0.79085	D	0.993635296821594	0.84513	D	0.991784	0.98830	D	.	.	.	.	.	.	3.825628	0.72963	26.0	3.702919	0.72538	25.8	0.99891507569959304	0.96513	0.99892	0.99958	D	AEFBI	0.945469	0.95381	D	0.868237734905267	0.90121	10.26189	0.816117269016198	0.90890	10.61772	0.999999997074967	0.74766	0.706548	0.73137	0	0.702456	0.74545	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.25	5.25	0.73169	9.260000	0.94752	1.312000	0.94714	0.756000	0.94297	1.000000	0.71638	0.998000	0.65909	0.993000	0.69303	1.0:0.0:0.0:0.0	14.2686	0.65687	846	0.36215	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	225018	Likely_pathogenic	Inborn_genetic_diseases	criteria_provided,_single_submitter	NC_000001.11:g.109627893A>G	.	C0950123	.	.	.	.	. 	.
1	109627893	A	G	N	S	rs869312928	1	110170515	1	109972038	293	AMPD2	ENSG00000116337	ENST00000528454	ENSP00000437164	AMPD2_HUMAN	c.878A>G	p.N293S	c.878A>G	p.Asn293Ser	c.878A>G	p.Asn293Ser	.	Y	2	.	+	AAC	2	0	A	A/A	A/A	A/A	0.0	0.91255	D	0.0	0.92824	D	NULL	0.68779	.	NULL	0.70482	.	0.000000	0.84330	D	0.000000	0.999995;0.999995;0.999995;0.999995;0.999995;0.999995	0.58761	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	N330S;N411S;N411S;N336S;N293S;N292S	NULL	0.93507	.	-3.99	0.96308	D	-4.07	0.80256	D	0.927	0.99481	1.0763	0.98767	D	0.9386	0.97982	D	10	0.325593	0.91603	D	0.873	0.96262	0.581	0.70722	Q01433	N411S	Gain of phosphorylation at N411 (P = 0.0789); Loss of helix (P = 0.1299); Gain of MoRF binding (P = 0.1382); Loss of methylation at K414 (P = 0.1542); Gain of disorder (P = 0.1778)	0.936812336596	0.93616	NULL	0.87103	0.763066649437	0.76387	T	NULL	0.95139	.	0.258083	0.79352	D	0.132942	0.79085	D	0.993635296821594	0.84513	D	0.991784	0.98830	D	.	.	.	.	.	.	3.825628	0.72963	26.0	3.702919	0.72538	25.8	0.99891507569959304	0.96513	0.99892	0.99958	D	AEFBI	0.945469	0.95381	D	0.868237734905267	0.90121	10.26189	0.816117269016198	0.90890	10.61772	0.999999997074967	0.74766	0.706548	0.73137	0	0.702456	0.74545	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.25	5.25	0.73169	9.260000	0.94752	1.312000	0.94714	0.756000	0.94297	1.000000	0.71638	0.998000	0.65909	0.993000	0.69303	1.0:0.0:0.0:0.0	14.2686	0.65687	846	0.36215	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	225018	Likely_pathogenic	Inborn_genetic_diseases	criteria_provided,_single_submitter	NC_000001.11:g.109627893A>G	.	C0950123	.	.	.	.	. 	.
1	109627893	A	G	N	S	rs869312928	1	110170515	1	109972038	330	AMPD2	ENSG00000116337	ENST00000342115	ENSP00000345498	AMPD2_HUMAN	c.989A>G	p.N330S	c.989A>G	p.Asn330Ser	c.989A>G	p.Asn330Ser	alternative1	Y	1	.	+	AAC	2	0	A	A/A	A/A	A/A	0.0	0.91255	D	0.0	0.92824	D	0.967	0.68779	D	0.846	0.70482	P	0.000000	0.84330	D	0.000000	0.999995;0.999995;0.999995;0.999995;0.999995;0.999995	0.58761	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	N330S;N411S;N411S;N336S;N293S;N292S	NULL	0.93507	.	-3.99	0.96308	D	-4.07	0.80256	D	0.986	0.99481	1.0763	0.98767	D	0.9386	0.97982	D	10	0.325593	0.91603	D	0.873	0.96262	0.581	0.70722	Q01433	N411S	Gain of phosphorylation at N411 (P = 0.0789); Loss of helix (P = 0.1299); Gain of MoRF binding (P = 0.1382); Loss of methylation at K414 (P = 0.1542); Gain of disorder (P = 0.1778)	0.936812336596	0.93616	NULL	0.87103	0.763066649437	0.76387	T	NULL	0.95139	.	0.258083	0.79352	D	0.132942	0.79085	D	0.993635296821594	0.84513	D	0.991784	0.98830	D	.	.	.	.	.	.	3.825628	0.72963	26.0	3.702919	0.72538	25.8	0.99891507569959304	0.96513	0.99892	0.99958	D	AEFBI	0.945469	0.95381	D	0.868237734905267	0.90121	10.26189	0.816117269016198	0.90890	10.61772	0.999999997074967	0.74766	0.706548	0.73137	0	0.702456	0.74545	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.25	5.25	0.73169	9.260000	0.94752	1.312000	0.94714	0.756000	0.94297	1.000000	0.71638	0.998000	0.65909	0.993000	0.69303	1.0:0.0:0.0:0.0	14.2686	0.65687	846	0.36215	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	225018	Likely_pathogenic	Inborn_genetic_diseases	criteria_provided,_single_submitter	NC_000001.11:g.109627893A>G	.	C0950123	.	.	.	.	. 	.
1	109627893	A	G	N	S	rs869312928	1	110170515	1	109972038	336	AMPD2	ENSG00000116337	ENST00000358729	ENSP00000351573	AMPD2_HUMAN	c.1007A>G	p.N336S	c.1007A>G	p.Asn336Ser	c.1007A>G	p.Asn336Ser	.	Y	2	.	+	AAC	2	0	A	A/A	A/A	A/A	0.0	0.91255	D	0.0	0.92824	D	0.996	0.68779	D	0.961	0.70482	D	0.000000	0.84330	D	0.000000	0.999995;0.999995;0.999995;0.999995;0.999995;0.999995	0.58761	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	N330S;N411S;N411S;N336S;N293S;N292S	NULL	0.93507	.	-3.99	0.96308	D	-4.07	0.80256	D	0.986	0.99481	1.0763	0.98767	D	0.9386	0.97982	D	10	0.325593	0.91603	D	0.873	0.96262	0.581	0.70722	Q01433	N411S	Gain of phosphorylation at N411 (P = 0.0789); Loss of helix (P = 0.1299); Gain of MoRF binding (P = 0.1382); Loss of methylation at K414 (P = 0.1542); Gain of disorder (P = 0.1778)	0.936812336596	0.93616	NULL	0.87103	0.763066649437	0.76387	T	NULL	0.95139	.	0.258083	0.79352	D	0.132942	0.79085	D	0.993635296821594	0.84513	D	0.991784	0.98830	D	.	.	.	.	.	.	3.825628	0.72963	26.0	3.702919	0.72538	25.8	0.99891507569959304	0.96513	0.99892	0.99958	D	AEFBI	0.945469	0.95381	D	0.868237734905267	0.90121	10.26189	0.816117269016198	0.90890	10.61772	0.999999997074967	0.74766	0.706548	0.73137	0	0.702456	0.74545	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.25	5.25	0.73169	9.260000	0.94752	1.312000	0.94714	0.756000	0.94297	1.000000	0.71638	0.998000	0.65909	0.993000	0.69303	1.0:0.0:0.0:0.0	14.2686	0.65687	846	0.36215	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	225018	Likely_pathogenic	Inborn_genetic_diseases	criteria_provided,_single_submitter	NC_000001.11:g.109627893A>G	.	C0950123	.	.	.	.	. 	.
1	109627893	A	G	N	S	rs869312928	1	110170515	1	109972038	411	AMPD2	ENSG00000116337	ENST00000256578	ENSP00000256578	AMPD2_HUMAN	c.1232A>G	p.N411S	c.1232A>G	p.Asn411Ser	c.1232A>G	p.Asn411Ser	principal4	Y	5	YES	+	AAC	2	0	A	A/A	A/A	A/A	0.0	0.91255	D	0.0	0.92824	D	0.936	0.68779	P	0.906	0.70482	P	0.000000	0.84330	D	0.000000	0.999995;0.999995;0.999995;0.999995;0.999995;0.999995	0.58761	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	N330S;N411S;N411S;N336S;N293S;N292S	3.575	0.93507	H	-3.99	0.96308	D	-4.75	0.80256	D	0.955	0.99481	1.0763	0.98767	D	0.9386	0.97982	D	10	0.325593	0.91603	D	0.873	0.96262	0.581	0.70722	Q01433	N411S	Gain of phosphorylation at N411 (P = 0.0789); Loss of helix (P = 0.1299); Gain of MoRF binding (P = 0.1382); Loss of methylation at K414 (P = 0.1542); Gain of disorder (P = 0.1778)	0.936812336596	0.93616	1.50458477683	0.87103	0.763066649437	0.76387	T	0.807092	0.95139	D	0.258083	0.79352	D	0.132942	0.79085	D	0.993635296821594	0.84513	D	0.996967	0.98830	D	.	.	.	.	.	.	3.825628	0.72963	26.0	3.702919	0.72538	25.8	0.99891507569959304	0.96513	0.99892	0.99958	D	AEFBI	0.945469	0.95381	D	0.868237734905267	0.90121	10.26189	0.816117269016198	0.90890	10.61772	0.999999997074967	0.74766	0.706548	0.73137	0	0.702456	0.74545	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.25	5.25	0.73169	9.260000	0.94752	1.312000	0.94714	0.756000	0.94297	1.000000	0.71638	0.998000	0.65909	0.993000	0.69303	1.0:0.0:0.0:0.0	14.2686	0.65687	846	0.36215	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	225018	Likely_pathogenic	Inborn_genetic_diseases	criteria_provided,_single_submitter	NC_000001.11:g.109627893A>G	.	C0950123	.	.	Adenosine/AMP deaminase domain	.	. 	.
1	109627893	A	G	N	S	rs869312928	1	110170515	1	109972038	411	AMPD2	ENSG00000116337	ENST00000528667	ENSP00000436541	AMPD2_HUMAN	c.1232A>G	p.N411S	c.1232A>G	p.Asn411Ser	c.1232A>G	p.Asn411Ser	principal4	Y	1	.	+	AAC	2	0	A	A/A	A/A	A/A	0.0	0.91255	D	0.0	0.92824	D	0.936	0.68779	P	0.906	0.70482	P	0.000000	0.84330	D	0.000000	0.999995;0.999995;0.999995;0.999995;0.999995;0.999995	0.58761	D;D;D;D;D;D	simple_aae;simple_aae;simple_aae;simple_aae;simple_aae;simple_aae	N330S;N411S;N411S;N336S;N293S;N292S	3.575	0.93507	H	-3.99	0.96308	D	-4.75	0.80256	D	0.954	0.99481	1.0763	0.98767	D	0.9386	0.97982	D	10	0.325593	0.91603	D	0.873	0.96262	0.581	0.70722	Q01433	N411S	Gain of phosphorylation at N411 (P = 0.0789); Loss of helix (P = 0.1299); Gain of MoRF binding (P = 0.1382); Loss of methylation at K414 (P = 0.1542); Gain of disorder (P = 0.1778)	0.936812336596	0.93616	NULL	0.87103	0.763066649437	0.76387	T	0.807092	0.95139	D	0.258083	0.79352	D	0.132942	0.79085	D	0.993635296821594	0.84513	D	NULL	0.98830	.	.	.	.	.	.	.	3.825628	0.72963	26.0	3.702919	0.72538	25.8	0.99891507569959304	0.96513	0.99892	0.99958	D	AEFBI	0.945469	0.95381	D	0.868237734905267	0.90121	10.26189	0.816117269016198	0.90890	10.61772	0.999999997074967	0.74766	0.706548	0.73137	0	0.702456	0.74545	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.25	5.25	0.73169	9.260000	0.94752	1.312000	0.94714	0.756000	0.94297	1.000000	0.71638	0.998000	0.65909	0.993000	0.69303	1.0:0.0:0.0:0.0	14.2686	0.65687	846	0.36215	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	225018	Likely_pathogenic	Inborn_genetic_diseases	criteria_provided,_single_submitter	NC_000001.11:g.109627893A>G	.	C0950123	.	.	Adenosine/AMP deaminase domain	.	. 	.
1	110061017	G	C	P	A	rs145995775	1	110603639	1	110405162	107	ALX3	ENSG00000156150	ENST00000649954	ENSP00000497035	A0A3B3IS30_HUMAN	.	.	.	.	c.319C>G	p.Pro107Ala	.	Y	.	.	-	CCA	1	0	G	G/G	G/G	G/G	NULL	0.43393	.	NULL	0.14284	.	NULL	0.12183	.	NULL	0.06944	.	0.009764	0.30209	N	0.316339	0.999559	0.20991	N	simple_aae	P250A	NULL	0.23182	.	NULL	0.92721	.	NULL	0.34397	.	NULL	0.04188	-0.6163	0.64143	T	0.4494	0.78425	T	10	NULL	NULL	.	0.195	0.48053	.	NULL	.	.	.	NULL	0.93297	NULL	0.27649	0.370616316795	0.20921	T	NULL	0.44830	.	-0.330732	0.06057	T	-0.237462	0.51047	T	0.00561785466641775	0.00061	T	0.574243	0.20591	T	.	.	.	.	.	.	0.891668	0.13701	10.35	1.362958	0.21820	15.52	0.96364256291883565	0.29560	0.17333	0.19791	N	AEFBCI	0.043999	0.07024	N	-0.533948200246842	0.20990	1.110631	-0.463641320952862	0.23162	1.261765	0.998642798377056	0.37371	0.6512	0.46895	0	0.379588	0.06130	0	0.643519	0.47002	0	0.683762	0.67416	0	NULL	NULL	5.51	3.62	0.40616	0.256000	0.18120	1.176000	0.78918	0.676000	0.76740	0.038000	0.20882	0.132000	0.20446	0.806000	0.37994	0.0749:0.0:0.7843:0.1409	9.6526	0.39070	430	0.80826	11	0.002196485623003195	11	0.00832072617246596	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	39	0.009228584950307619	1	1.1859582542694497E-4	92	7.616e-04	79	9.419e-04	77	1.252e-02	2	2.614e-04	0	0	0	0	0	0	0	0	81	7.665e-04	71	9.581e-04	69	1.271e-02	2	2.686e-04	0	0	0	0	0	0	0	0	92	1.020e-03	79	1.251e-03	77	1.255e-02	2	2.616e-04	0	0	0	0	0	0	0	0	.	155	236576	6.551806e-04	0	147	14038	1.047158e-02	0	8	33736	2.371354e-04	0	0	9684	0	0	0	17776	0	0	0	20312	0	0	0	105464	0	0	0	29834	0	0	147	14038	1.047158e-02	0	72	105620	6.816891e-04	0	67	6596	1.015767e-02	0	5	16652	3.002642e-04	0	0	2230	0	0	0	8638	0	0	0	13214	0	0	0	41210	0	0	0	15250	0	0	67	6596	1.015767e-02	0	.	509	143288	3.552286e-03	4	487	42042	1.158365e-02	4	15	13660	1.098097e-03	0	0	3324	0	0	0	3132	0	0	0	10482	0	0	3	64552	4.647416e-05	0	3	64552	4.647416e-05	0	210134	Benign/Likely_benign	not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.110061017G>C	.	CN169374|CN517202	.	.	.	.	. 	.
1	110061017	G	C	P	A	rs145995775	1	110603639	1	110405162	250	ALX3	ENSG00000156150	ENST00000369792	ENSP00000358807	ALX3_HUMAN	c.748C>G	p.P250A	c.748C>G	p.Pro250Ala	c.748C>G	p.Pro250Ala	principal1	Y	1	YES	-	CCA	1	0	G	G/G	G/G	G/G	0.036	0.43393	D	0.416	0.14284	T	0.004	0.12183	B	0.002	0.06944	B	0.009764	0.30209	N	0.316339	0.999559	0.20991	N	simple_aae	P250A	0.9	0.23182	L	-3.11	0.92721	D	-1.39	0.34397	N	0.069	0.04188	-0.6163	0.64143	T	0.4494	0.78425	T	10	NULL	NULL	.	0.195	0.48053	.	NULL	.	.	.	0.933661607158	0.93297	0.250718495106	0.27649	0.370616316795	0.20921	T	0.123729	0.44830	T	-0.330732	0.06057	T	-0.237462	0.51047	T	0.00561785466641775	0.00061	T	0.573243	0.20591	T	.	.	.	.	.	.	0.891668	0.13701	10.35	1.362958	0.21820	15.52	0.96364256291883565	0.29560	0.17333	0.19791	N	AEFBCI	0.043999	0.07024	N	-0.533948200246842	0.20990	1.110631	-0.463641320952862	0.23162	1.261765	0.998642798377056	0.37371	0.6512	0.46895	0	0.379588	0.06130	0	0.643519	0.47002	0	0.683762	0.67416	0	NULL	NULL	5.51	3.62	0.40616	0.256000	0.18120	1.176000	0.78918	0.676000	0.76740	0.038000	0.20882	0.132000	0.20446	0.806000	0.37994	0.0749:0.0:0.7843:0.1409	9.6526	0.39070	430	0.80826	11	0.002196485623003195	11	0.00832072617246596	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	39	0.009228584950307619	1	1.1859582542694497E-4	92	7.616e-04	79	9.419e-04	77	1.252e-02	2	2.614e-04	0	0	0	0	0	0	0	0	81	7.665e-04	71	9.581e-04	69	1.271e-02	2	2.686e-04	0	0	0	0	0	0	0	0	92	1.020e-03	79	1.251e-03	77	1.255e-02	2	2.616e-04	0	0	0	0	0	0	0	0	.	155	236576	6.551806e-04	0	147	14038	1.047158e-02	0	8	33736	2.371354e-04	0	0	9684	0	0	0	17776	0	0	0	20312	0	0	0	105464	0	0	0	29834	0	0	147	14038	1.047158e-02	0	72	105620	6.816891e-04	0	67	6596	1.015767e-02	0	5	16652	3.002642e-04	0	0	2230	0	0	0	8638	0	0	0	13214	0	0	0	41210	0	0	0	15250	0	0	67	6596	1.015767e-02	0	.	509	143288	3.552286e-03	4	487	42042	1.158365e-02	4	15	13660	1.098097e-03	0	0	3324	0	0	0	3132	0	0	0	10482	0	0	3	64552	4.647416e-05	0	3	64552	4.647416e-05	0	210134	Benign/Likely_benign	not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.110061017G>C	.	CN169374|CN517202	.	.	.	.	. 	.
1	110061017	G	C	P	A	rs145995775	1	110603639	1	110405162	250	ALX3	ENSG00000156150	ENST00000647563	ENSP00000497310	ALX3_HUMAN	.	.	.	.	c.748C>G	p.Pro250Ala	principal1	Y	.	.	-	CCA	1	0	G	G/G	G/G	G/G	NULL	0.43393	.	NULL	0.14284	.	0.004	0.12183	B	0.002	0.06944	B	0.009764	0.30209	N	0.316339	0.999559	0.20991	N	simple_aae	P250A	0.9	0.23182	L	NULL	0.92721	.	NULL	0.34397	.	NULL	0.04188	-0.6163	0.64143	T	0.4494	0.78425	T	10	NULL	NULL	.	0.195	0.48053	.	NULL	.	.	.	NULL	0.93297	NULL	0.27649	0.370616316795	0.20921	T	0.123729	0.44830	T	-0.330732	0.06057	T	-0.237462	0.51047	T	0.00561785466641775	0.00061	T	NULL	0.20591	.	.	.	.	.	.	.	0.891668	0.13701	10.35	1.362958	0.21820	15.52	0.96364256291883565	0.29560	0.17333	0.19791	N	AEFBCI	0.043999	0.07024	N	-0.533948200246842	0.20990	1.110631	-0.463641320952862	0.23162	1.261765	0.998642798377056	0.37371	0.6512	0.46895	0	0.379588	0.06130	0	0.643519	0.47002	0	0.683762	0.67416	0	NULL	NULL	5.51	3.62	0.40616	0.256000	0.18120	1.176000	0.78918	0.676000	0.76740	0.038000	0.20882	0.132000	0.20446	0.806000	0.37994	0.0749:0.0:0.7843:0.1409	9.6526	0.39070	430	0.80826	11	0.002196485623003195	11	0.00832072617246596	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	39	0.009228584950307619	1	1.1859582542694497E-4	92	7.616e-04	79	9.419e-04	77	1.252e-02	2	2.614e-04	0	0	0	0	0	0	0	0	81	7.665e-04	71	9.581e-04	69	1.271e-02	2	2.686e-04	0	0	0	0	0	0	0	0	92	1.020e-03	79	1.251e-03	77	1.255e-02	2	2.616e-04	0	0	0	0	0	0	0	0	.	155	236576	6.551806e-04	0	147	14038	1.047158e-02	0	8	33736	2.371354e-04	0	0	9684	0	0	0	17776	0	0	0	20312	0	0	0	105464	0	0	0	29834	0	0	147	14038	1.047158e-02	0	72	105620	6.816891e-04	0	67	6596	1.015767e-02	0	5	16652	3.002642e-04	0	0	2230	0	0	0	8638	0	0	0	13214	0	0	0	41210	0	0	0	15250	0	0	67	6596	1.015767e-02	0	.	509	143288	3.552286e-03	4	487	42042	1.158365e-02	4	15	13660	1.098097e-03	0	0	3324	0	0	0	3132	0	0	0	10482	0	0	3	64552	4.647416e-05	0	3	64552	4.647416e-05	0	210134	Benign/Likely_benign	not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.110061017G>C	.	CN169374|CN517202	.	.	.	.	. 	.
1	111120671	T	A	H	L	rs786205664	1	111663293	1	111464816	121	DRAM2	ENSG00000156171	ENST00000286692	ENSP00000286692	DRAM2_HUMAN	c.362A>T	p.H121L	c.362A>T	p.His121Leu	c.362A>T	p.His121Leu	principal1	Y	1	YES	-	CAT	2	0	T	T/T	T/T	T/T	0.0	0.91255	D	0.0	0.92824	D	1.0	0.90584	D	0.999	0.92359	D	0.000000	0.84330	D	0.000000	1;1	0.81001	D;D	simple_aae;simple_aae	H121L;H121L	3.03	0.86425	M	-3.59	0.94975	D	-10.61	0.99112	D	0.948	0.95608	1.0401	0.97913	D	0.9116	0.97070	D	10	0.471385	0.94686	D	0.918	0.97923	0.906	0.98028	Q6UX65	H121L	Gain of sheet (P = 0.1451); Loss of catalytic residue at H121 (P = 0.1877); Gain of helix (P = 0.2059); Loss of glycosylation at S123 (P = 0.2201); Gain of loop (P = 0.4248)	0.903085138499	0.90212	0.67947272554	0.59938	0.538072943687	0.44173	T	0.860142	0.96890	D	0.517367	0.94813	D	0.505386	0.94736	D	0.999752700328827	0.98831	D	NULL	0.28920	.	.	.	.	.	.	.	4.140925	0.83504	28.1	4.070690	0.84688	28.3	0.97548079413192179	0.34550	0.96257	0.68261	D	AEFBI	0.636649	0.61572	D	0.866426973273146	0.90023	10.21916	0.815807366584519	0.90869	10.60797	0.999999994176395	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.87	5.87	0.94266	5.831000	0.69032	1.138000	0.64695	0.665000	0.62972	1.000000	0.71638	0.977000	0.46756	0.985000	0.61073	0.0:0.0:0.0:1.0	12.9575	0.57836	861	0.33516	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	192237	Pathogenic	Retinal_dystrophy|Cone-rod_dystrophy_21	criteria_provided,_single_submitter	NC_000001.11:g.111120671T>A	Leeds_Vision_Research_Group,University_of_Leeds:GC4728|OMIM_Allelic_Variant:613360.0005|UniProtKB_(protein):Q6UX65#VAR_075077	C0854723|C4049066	616502	ORPHA71862	.	.	. 	.
1	111120671	T	A	H	L	rs786205664	1	111663293	1	111464816	121	DRAM2	ENSG00000156171	ENST00000539140	ENSP00000437718	DRAM2_HUMAN	c.362A>T	p.H121L	c.362A>T	p.His121Leu	c.362A>T	p.His121Leu	principal1	Y	1	.	-	CAT	2	0	T	T/T	T/T	T/T	0.0	0.91255	D	0.0	0.92824	D	1.0	0.90584	D	0.999	0.92359	D	0.000000	0.84330	D	0.000000	1;1	0.81001	D;D	simple_aae;simple_aae	H121L;H121L	3.03	0.86425	M	-3.59	0.94975	D	-10.61	0.99112	D	0.948	0.95608	1.0401	0.97913	D	0.9116	0.97070	D	10	0.471385	0.94686	D	0.918	0.97923	0.906	0.98028	Q6UX65	H121L	Gain of sheet (P = 0.1451); Loss of catalytic residue at H121 (P = 0.1877); Gain of helix (P = 0.2059); Loss of glycosylation at S123 (P = 0.2201); Gain of loop (P = 0.4248)	0.903085138499	0.90212	NULL	0.59938	0.538072943687	0.44173	T	0.860142	0.96890	D	0.517367	0.94813	D	0.505386	0.94736	D	0.999752700328827	0.98831	D	0.680532	0.28920	T	.	.	.	.	.	.	4.140925	0.83504	28.1	4.070690	0.84688	28.3	0.97548079413192179	0.34550	0.96257	0.68261	D	AEFBI	0.636649	0.61572	D	0.866426973273146	0.90023	10.21916	0.815807366584519	0.90869	10.60797	0.999999994176395	0.74766	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.87	5.87	0.94266	5.831000	0.69032	1.138000	0.64695	0.665000	0.62972	1.000000	0.71638	0.977000	0.46756	0.985000	0.61073	0.0:0.0:0.0:1.0	12.9575	0.57836	861	0.33516	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	192237	Pathogenic	Retinal_dystrophy|Cone-rod_dystrophy_21	criteria_provided,_single_submitter	NC_000001.11:g.111120671T>A	Leeds_Vision_Research_Group,University_of_Leeds:GC4728|OMIM_Allelic_Variant:613360.0005|UniProtKB_(protein):Q6UX65#VAR_075077	C0854723|C4049066	616502	ORPHA71862	.	.	. 	.
1	111131424	C	T	S	N	rs786205665	1	111674046	1	111475569	44	DRAM2	ENSG00000156171	ENST00000286692	ENSP00000286692	DRAM2_HUMAN	c.131G>A	p.S44N	c.131G>A	p.Ser44Asn	c.131G>A	p.Ser44Asn	principal1	Y	1	YES	-	AGT	2	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.005	0.72224	D	1.0	0.90584	D	0.999	0.92359	D	0.000000	0.84330	D	0.000000	1;1	0.81001	D;D	simple_aae;simple_aae	S44N;S44N	3.02	0.86243	M	-1.36	0.80125	T	-2.65	0.56787	D	0.99	0.99725	0.5047	0.90613	D	0.6912	0.89345	D	9	0.20269	0.86834	D	0.627	0.85792	0.879	0.96785	Q6UX65	S44N	Loss of glycosylation at S44 (P = 0.0061); Loss of sheet (P = 0.0315); Gain of relative solvent accessibility (P = 0.09); Loss of stability (P = 0.133); Gain of solvent accessibility (P = 0.1422)	0.90078472887	0.89979	0.57446744646	0.53476	0.685432195663	0.65050	T	0.858085	0.96827	D	0.159642	0.70166	D	-0.0084613	0.69785	D	0.997390329837799	0.91454	D	NULL	0.68156	.	.	.	.	.	.	.	4.629972	0.92093	32	4.803546	0.92821	33	0.99662774546695621	0.78074	0.89911	0.50691	D	AEFGBCI	0.796466	0.72359	D	0.870125839990261	0.90220	10.30663	0.803041630943727	0.90005	10.21438	0.999999999721401	0.74766	0.732398	0.92422	0	0.719019	0.82233	0	0.743671	0.96076	0	0.714379	0.83352	0	NULL	NULL	5.4	5.4	0.77957	6.319000	0.72833	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	0.999000	0.70432	0.973000	0.55318	0.0:1.0:0.0:0.0	15.0274	0.71341	818	0.41518	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	143178	6.984313e-06	0	0	41972	0	0	0	13644	0	0	0	3320	0	0	0	3128	0	0	0	10442	0	0	1	64572	1.548659e-05	0	1	64572	1.548659e-05	0	192238	Pathogenic	Retinal_dystrophy|Cone-rod_dystrophy_21	criteria_provided,_single_submitter	NC_000001.11:g.111131424C>T	Leeds_Vision_Research_Group,University_of_Leeds:1325-1|OMIM_Allelic_Variant:613360.0003|UniProtKB_(protein):Q6UX65#VAR_075075	C0854723|C4049066	616502	ORPHA71862	.	.	. 	.
1	111131424	C	T	S	N	rs786205665	1	111674046	1	111475569	44	DRAM2	ENSG00000156171	ENST00000539140	ENSP00000437718	DRAM2_HUMAN	c.131G>A	p.S44N	c.131G>A	p.Ser44Asn	c.131G>A	p.Ser44Asn	principal1	Y	1	.	-	AGT	2	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.005	0.72224	D	1.0	0.90584	D	0.999	0.92359	D	0.000000	0.84330	D	0.000000	1;1	0.81001	D;D	simple_aae;simple_aae	S44N;S44N	3.02	0.86243	M	-1.36	0.80125	T	-2.65	0.56787	D	0.99	0.99725	0.5047	0.90613	D	0.6912	0.89345	D	9	0.20269	0.86834	D	0.627	0.85792	0.879	0.96785	Q6UX65	S44N	Loss of glycosylation at S44 (P = 0.0061); Loss of sheet (P = 0.0315); Gain of relative solvent accessibility (P = 0.09); Loss of stability (P = 0.133); Gain of solvent accessibility (P = 0.1422)	0.90078472887	0.89979	NULL	0.53476	0.685432195663	0.65050	T	0.858085	0.96827	D	0.159642	0.70166	D	-0.0084613	0.69785	D	0.997390329837799	0.91454	D	0.910209	0.68156	D	.	.	.	.	.	.	4.629972	0.92093	32	4.803546	0.92821	33	0.99662774546695621	0.78074	0.89911	0.50691	D	AEFGBCI	0.796466	0.72359	D	0.870125839990261	0.90220	10.30663	0.803041630943727	0.90005	10.21438	0.999999999721401	0.74766	0.732398	0.92422	0	0.719019	0.82233	0	0.743671	0.96076	0	0.714379	0.83352	0	NULL	NULL	5.4	5.4	0.77957	6.319000	0.72833	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	0.999000	0.70432	0.973000	0.55318	0.0:1.0:0.0:0.0	15.0274	0.71341	818	0.41518	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	143178	6.984313e-06	0	0	41972	0	0	0	13644	0	0	0	3320	0	0	0	3128	0	0	0	10442	0	0	1	64572	1.548659e-05	0	1	64572	1.548659e-05	0	192238	Pathogenic	Retinal_dystrophy|Cone-rod_dystrophy_21	criteria_provided,_single_submitter	NC_000001.11:g.111131424C>T	Leeds_Vision_Research_Group,University_of_Leeds:1325-1|OMIM_Allelic_Variant:613360.0003|UniProtKB_(protein):Q6UX65#VAR_075075	C0854723|C4049066	616502	ORPHA71862	.	.	. 	.
1	111131476	A	G	Y	H	rs786205662	1	111674098	1	111475621	27	DRAM2	ENSG00000156171	ENST00000286692	ENSP00000286692	DRAM2_HUMAN	c.79T>C	p.Y27H	c.79T>C	p.Tyr27His	c.79T>C	p.Tyr27His	principal1	Y	1	YES	-	TAC	1	0	A	A/A	A/A	A/A	0.0	0.91255	D	0.001	0.83351	D	1.0	0.90584	D	1.0	0.97372	D	0.000000	0.84330	D	0.000000	0.999999;0.999999	0.58761	D;D	simple_aae;simple_aae	Y27H;Y27H	3.02	0.86243	M	0.64	0.52867	T	-4.03	0.74348	D	0.952	0.96072	-0.3607	0.73242	T	0.2837	0.65557	T	10	0.031468	0.53543	D	0.540	0.81006	0.742	0.87396	Q6UX65	Y27H	Gain of helix (P = 0.0861); Loss of stability (P = 0.0962); Gain of glycosylation at T29 (P = 0.1115); Gain of relative solvent accessibility (P = 0.2363); Gain of solvent accessibility (P = 0.3089)	0.834805913023	0.83323	0.695537818122	0.60814	0.753253161907	0.74927	T	0.845487	0.96434	D	0.327591	0.85002	D	0.232785	0.84806	D	0.999332249164581	0.97004	D	NULL	0.76702	.	.	.	.	.	.	.	4.069688	0.81026	27.5	3.891917	0.78524	26.8	0.99868381712755028	0.94637	0.93656	0.58818	D	AEFBCI	0.701573	0.65822	D	0.86821933353603	0.90121	10.26146	0.820155985813845	0.91157	10.74718	0.999999999742492	0.74766	0.732398	0.92422	0	0.719019	0.82233	0	0.743671	0.96076	0	0.714379	0.83352	0	NULL	NULL	5.64	5.64	0.86480	7.472000	0.79998	1.312000	0.94714	0.756000	0.94297	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	1.0:0.0:0.0:0.0	12.53	0.55455	813	0.42397	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	192235	Pathogenic	Retinal_dystrophy	criteria_provided,_single_submitter	NC_000001.11:g.111131476A>G	Leeds_Vision_Research_Group,University_of_Leeds:GC17004-1|UniProtKB_(protein):Q6UX65#VAR_075074	C0854723	.	ORPHA71862	.	.	. 	.
1	111131476	A	G	Y	H	rs786205662	1	111674098	1	111475621	27	DRAM2	ENSG00000156171	ENST00000539140	ENSP00000437718	DRAM2_HUMAN	c.79T>C	p.Y27H	c.79T>C	p.Tyr27His	c.79T>C	p.Tyr27His	principal1	Y	1	.	-	TAC	1	0	A	A/A	A/A	A/A	0.0	0.91255	D	0.001	0.83351	D	1.0	0.90584	D	1.0	0.97372	D	0.000000	0.84330	D	0.000000	0.999999;0.999999	0.58761	D;D	simple_aae;simple_aae	Y27H;Y27H	3.02	0.86243	M	0.64	0.52867	T	-4.03	0.74348	D	0.952	0.96072	-0.3607	0.73242	T	0.2837	0.65557	T	10	0.031468	0.53543	D	0.540	0.81006	0.742	0.87396	Q6UX65	Y27H	Gain of helix (P = 0.0861); Loss of stability (P = 0.0962); Gain of glycosylation at T29 (P = 0.1115); Gain of relative solvent accessibility (P = 0.2363); Gain of solvent accessibility (P = 0.3089)	0.834805913023	0.83323	NULL	0.60814	0.753253161907	0.74927	T	0.845487	0.96434	D	0.327591	0.85002	D	0.232785	0.84806	D	0.999332249164581	0.97004	D	0.937906	0.76702	D	.	.	.	.	.	.	4.069688	0.81026	27.5	3.891917	0.78524	26.8	0.99868381712755028	0.94637	0.93656	0.58818	D	AEFBCI	0.701573	0.65822	D	0.86821933353603	0.90121	10.26146	0.820155985813845	0.91157	10.74718	0.999999999742492	0.74766	0.732398	0.92422	0	0.719019	0.82233	0	0.743671	0.96076	0	0.714379	0.83352	0	NULL	NULL	5.64	5.64	0.86480	7.472000	0.79998	1.312000	0.94714	0.756000	0.94297	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	1.0:0.0:0.0:0.0	12.53	0.55455	813	0.42397	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	192235	Pathogenic	Retinal_dystrophy	criteria_provided,_single_submitter	NC_000001.11:g.111131476A>G	Leeds_Vision_Research_Group,University_of_Leeds:GC17004-1|UniProtKB_(protein):Q6UX65#VAR_075074	C0854723	.	ORPHA71862	.	.	. 	.
1	111981693	C	A	G	V	rs797045634	1	112524315	1	112325838	345	KCND3	ENSG00000171385	ENST00000302127	ENSP00000306923	KCND3_HUMAN	c.1034G>T	p.G345V	c.1034G>T	p.Gly345Val	c.1034G>T	p.Gly345Val	alternative1	Y	5	.	-	GGC	2	0	C	C/C	C/C	C/C	0.056	0.40832	T	0.084	0.41239	T	NULL	0.36006	.	NULL	0.48916	.	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	G345V;G345V;G345V	2.02	0.55341	M	-5.21	0.98866	D	-4.47	0.78388	D	0.98	0.99015	1.1314	0.99926	D	0.9506	0.98392	D	10	0.843627	0.98792	D	0.862	0.95863	0.545	0.65861	Q9UK17	G345V	Loss of disorder (P = 0.036); Loss of ubiquitination at K344 (P = 0.0373); Gain of methylation at K344 (P = 0.0566); Gain of helix (P = 0.2294); Loss of phosphorylation at S347 (P = 0.2659)	0.99138326699	0.99129	NULL	0.91093	0.840152561665	0.88118	D	NULL	0.98456	.	0.477599	0.93612	D	0.448262	0.93532	D	0.987830340862274	0.78258	D	0.944006	0.78847	D	.	.	.	.	.	.	3.479931	0.63579	24.6	3.766274	0.74421	26.1	0.99515482828554191	0.68919	0.92220	0.55214	D	AEFDBCI	0.864671	0.78353	D	0.579323672827583	0.71886	5.71945	0.623475592080914	0.76648	6.529943	0.999999999999831	0.74766	0.497415	0.19182	0	0.59043	0.45803	0	0.578056	0.29568	0	0.542086	0.14980	0	NULL	NULL	5.49	5.49	0.81022	6.170000	0.71810	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	1.000000	0.97212	0.0:1.0:0.0:0.0	18.9601	0.92650	622	0.65860	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	211216	Pathogenic	Spinocerebellar_ataxia_type_19/22	criteria_provided,_single_submitter	NC_000001.11:g.111981693C>A	UniProtKB_(protein):Q9UK17#VAR_070787	C1846367	607346	ORPHA98772	Ion transport domain	.	. 	.
1	111981693	C	A	G	V	rs797045634	1	112524315	1	112325838	345	KCND3	ENSG00000171385	ENST00000315987	ENSP00000319591	KCND3_HUMAN	c.1034G>T	p.G345V	c.1034G>T	p.Gly345Val	c.1034G>T	p.Gly345Val	principal4	Y	1	YES	-	GGC	2	0	C	C/C	C/C	C/C	0.045	0.40832	D	0.086	0.41239	T	0.447	0.36006	B	0.542	0.48916	P	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	G345V;G345V;G345V	2.02	0.55341	M	-5.21	0.98866	D	-4.53	0.78388	D	0.959	0.99015	1.1314	0.99926	D	0.9506	0.98392	D	10	0.843627	0.98792	D	0.862	0.95863	0.545	0.65861	Q9UK17	G345V	Loss of disorder (P = 0.036); Loss of ubiquitination at K344 (P = 0.0373); Gain of methylation at K344 (P = 0.0566); Gain of helix (P = 0.2294); Loss of phosphorylation at S347 (P = 0.2659)	0.99138326699	0.99129	1.75885429192	0.91093	0.840152561665	0.88118	D	0.915952	0.98456	D	0.477599	0.93612	D	0.448262	0.93532	D	0.987830340862274	0.78258	D	0.943706	0.78847	D	.	.	.	.	.	.	3.479931	0.63579	24.6	3.766274	0.74421	26.1	0.99515482828554191	0.68919	0.92220	0.55214	D	AEFDBCI	0.864671	0.78353	D	0.579323672827583	0.71886	5.71945	0.623475592080914	0.76648	6.529943	0.999999999999831	0.74766	0.497415	0.19182	0	0.59043	0.45803	0	0.578056	0.29568	0	0.542086	0.14980	0	NULL	NULL	5.49	5.49	0.81022	6.170000	0.71810	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	1.000000	0.97212	0.0:1.0:0.0:0.0	18.9601	0.92650	622	0.65860	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	211216	Pathogenic	Spinocerebellar_ataxia_type_19/22	criteria_provided,_single_submitter	NC_000001.11:g.111981693C>A	UniProtKB_(protein):Q9UK17#VAR_070787	C1846367	607346	ORPHA98772	Ion transport domain	.	. 	.
1	111981693	C	A	G	V	rs797045634	1	112524315	1	112325838	345	KCND3	ENSG00000171385	ENST00000369697	ENSP00000358711	KCND3_HUMAN	c.1034G>T	p.G345V	c.1034G>T	p.Gly345Val	c.1034G>T	p.Gly345Val	alternative1	Y	1	.	-	GGC	2	0	C	C/C	C/C	C/C	0.056	0.40832	T	0.084	0.41239	T	NULL	0.36006	.	NULL	0.48916	.	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	G345V;G345V;G345V	2.02	0.55341	M	-5.21	0.98866	D	-4.47	0.78388	D	0.98	0.99015	1.1314	0.99926	D	0.9506	0.98392	D	10	0.843627	0.98792	D	0.862	0.95863	0.545	0.65861	Q9UK17	G345V	Loss of disorder (P = 0.036); Loss of ubiquitination at K344 (P = 0.0373); Gain of methylation at K344 (P = 0.0566); Gain of helix (P = 0.2294); Loss of phosphorylation at S347 (P = 0.2659)	0.99138326699	0.99129	NULL	0.91093	0.840152561665	0.88118	D	NULL	0.98456	.	0.477599	0.93612	D	0.448262	0.93532	D	0.987830340862274	0.78258	D	NULL	0.78847	.	.	.	.	.	.	.	3.479931	0.63579	24.6	3.766274	0.74421	26.1	0.99515482828554191	0.68919	0.92220	0.55214	D	AEFDBCI	0.864671	0.78353	D	0.579323672827583	0.71886	5.71945	0.623475592080914	0.76648	6.529943	0.999999999999831	0.74766	0.497415	0.19182	0	0.59043	0.45803	0	0.578056	0.29568	0	0.542086	0.14980	0	NULL	NULL	5.49	5.49	0.81022	6.170000	0.71810	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	1.000000	0.97212	0.0:1.0:0.0:0.0	18.9601	0.92650	622	0.65860	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	211216	Pathogenic	Spinocerebellar_ataxia_type_19/22	criteria_provided,_single_submitter	NC_000001.11:g.111981693C>A	UniProtKB_(protein):Q9UK17#VAR_070787	C1846367	607346	ORPHA98772	Ion transport domain	.	. 	.
1	111982086	T	C	K	R	rs142744204	1	112524708	1	112326231	214	KCND3	ENSG00000171385	ENST00000302127	ENSP00000306923	KCND3_HUMAN	c.641A>G	p.K214R	c.641A>G	p.Lys214Arg	c.641A>G	p.Lys214Arg	alternative1	Y	5	.	-	AAG	2	0	T	T/T	T/T	T/T	0.344	0.13306	T	0.456	0.12740	T	NULL	0.02946	.	NULL	0.04355	.	0.000000	0.84330	D	0.042956	0.999589;0.999589;0.999589	0.47691	D;D;D	simple_aae;simple_aae;simple_aae	K214R;K214R;K214R	0.435	0.12660	N	-4.13	0.96772	D	-0.89	0.26200	N	0.176	0.19055	0.0037	0.82333	D	0.6164	0.86456	D	10	0.01877	0.40941	T	0.319	0.64468	.	NULL	.	.	.	0.784856537408	0.78286	NULL	0.80639	0.72260081768	0.70425	T	NULL	0.88184	.	-0.208996	0.19521	T	-0.230568	0.51717	T	0.0343845129055515	0.02703	T	0.79652	0.44001	T	.	.	.	.	.	.	2.444025	0.40013	22.3	2.089680	0.34795	20.5	0.97904527311393907	0.36766	0.85178	0.44289	D	AEFDBCI	0.594686	0.58952	D	-0.139642275392839	0.35676	2.052294	0.0751741420622725	0.43305	2.634954	0.998135974104661	0.36473	0.516011	0.20929	0	0.59043	0.45803	0	0.577349	0.28860	0	0.542086	0.14980	0	NULL	NULL	5.51	5.51	0.81769	4.904000	0.62975	1.138000	0.64695	0.665000	0.62972	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	0.0:0.0767:0.0:0.9233	10.5038	0.44008	621	0.65931	1	1.9968051118210862E-4	0	0.0	1	9.940357852882703E-4	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	4	4.6511627906976747E-4	29	2.389e-04	28	2.352e-04	0	0	1	8.708e-05	1	1.168e-04	0	0	26	3.983e-04	0	0	22	2.072e-04	21	2.007e-04	0	0	1	8.972e-05	1	1.278e-04	0	0	19	3.550e-04	0	0	24	2.646e-04	23	2.592e-04	0	0	1	8.717e-05	0	0	0	0	22	5.398e-04	0	0	.	49	249806	1.961522e-04	0	0	15974	0	0	5	34540	1.447597e-04	0	0	10010	0	0	1	18334	5.454347e-05	0	0	21510	0	0	40	112740	3.547987e-04	0	1	30596	3.268401e-05	0	40	112740	3.547987e-04	0	18	109092	1.649984e-04	0	0	7120	0	0	3	17092	1.755207e-04	0	0	2298	0	0	1	9024	1.108156e-04	0	0	13364	0	0	12	42612	2.816108e-04	0	1	15678	6.378365e-05	0	12	42612	2.816108e-04	0	.	48	143150	3.353126e-04	1	2	41980	4.764173e-05	0	3	13656	2.196837e-04	0	0	3320	0	0	0	3130	0	0	0	10472	0	0	28	64516	4.340009e-04	0	14	900	1.555556e-02	1	222665	Conflicting_interpretations_of_pathogenicity	Spinocerebellar_ataxia_type_19/22|not_specified|Cardiovascular_phenotype	criteria_provided,_conflicting_interpretations	NC_000001.11:g.111982086T>C	.	C1846367|CN169374|CN230736	607346	ORPHA98772	Ion transport domain	.	. 	.
1	111982086	T	C	K	R	rs142744204	1	112524708	1	112326231	214	KCND3	ENSG00000171385	ENST00000315987	ENSP00000319591	KCND3_HUMAN	c.641A>G	p.K214R	c.641A>G	p.Lys214Arg	c.641A>G	p.Lys214Arg	principal4	Y	1	YES	-	AAG	2	0	T	T/T	T/T	T/T	0.326	0.13306	T	0.458	0.12740	T	0.0	0.02946	B	0.001	0.04355	B	0.000000	0.84330	D	0.042956	0.999589;0.999589;0.999589	0.47691	D;D;D	simple_aae;simple_aae;simple_aae	K214R;K214R;K214R	0.435	0.12660	N	-4.14	0.96772	D	-0.99	0.26200	N	0.148	0.19055	0.0037	0.82333	D	0.6164	0.86456	D	10	0.01877	0.40941	T	0.319	0.64468	.	NULL	.	.	.	0.784856537408	0.78286	1.20430854673	0.80639	0.72260081768	0.70425	T	0.62242	0.88184	D	-0.208996	0.19521	T	-0.230568	0.51717	T	0.0343845129055515	0.02703	T	0.79652	0.44001	T	.	.	.	.	.	.	2.444025	0.40013	22.3	2.089680	0.34795	20.5	0.97904527311393907	0.36766	0.85178	0.44289	D	AEFDBCI	0.594686	0.58952	D	-0.139642275392839	0.35676	2.052294	0.0751741420622725	0.43305	2.634954	0.998135974104661	0.36473	0.516011	0.20929	0	0.59043	0.45803	0	0.577349	0.28860	0	0.542086	0.14980	0	NULL	NULL	5.51	5.51	0.81769	4.904000	0.62975	1.138000	0.64695	0.665000	0.62972	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	0.0:0.0767:0.0:0.9233	10.5038	0.44008	621	0.65931	1	1.9968051118210862E-4	0	0.0	1	9.940357852882703E-4	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	4	4.6511627906976747E-4	29	2.389e-04	28	2.352e-04	0	0	1	8.708e-05	1	1.168e-04	0	0	26	3.983e-04	0	0	22	2.072e-04	21	2.007e-04	0	0	1	8.972e-05	1	1.278e-04	0	0	19	3.550e-04	0	0	24	2.646e-04	23	2.592e-04	0	0	1	8.717e-05	0	0	0	0	22	5.398e-04	0	0	.	49	249806	1.961522e-04	0	0	15974	0	0	5	34540	1.447597e-04	0	0	10010	0	0	1	18334	5.454347e-05	0	0	21510	0	0	40	112740	3.547987e-04	0	1	30596	3.268401e-05	0	40	112740	3.547987e-04	0	18	109092	1.649984e-04	0	0	7120	0	0	3	17092	1.755207e-04	0	0	2298	0	0	1	9024	1.108156e-04	0	0	13364	0	0	12	42612	2.816108e-04	0	1	15678	6.378365e-05	0	12	42612	2.816108e-04	0	.	48	143150	3.353126e-04	1	2	41980	4.764173e-05	0	3	13656	2.196837e-04	0	0	3320	0	0	0	3130	0	0	0	10472	0	0	28	64516	4.340009e-04	0	14	900	1.555556e-02	1	222665	Conflicting_interpretations_of_pathogenicity	Spinocerebellar_ataxia_type_19/22|not_specified|Cardiovascular_phenotype	criteria_provided,_conflicting_interpretations	NC_000001.11:g.111982086T>C	.	C1846367|CN169374|CN230736	607346	ORPHA98772	Ion transport domain	.	. 	.
1	111982086	T	C	K	R	rs142744204	1	112524708	1	112326231	214	KCND3	ENSG00000171385	ENST00000369697	ENSP00000358711	KCND3_HUMAN	c.641A>G	p.K214R	c.641A>G	p.Lys214Arg	c.641A>G	p.Lys214Arg	alternative1	Y	1	.	-	AAG	2	0	T	T/T	T/T	T/T	0.344	0.13306	T	0.456	0.12740	T	NULL	0.02946	.	NULL	0.04355	.	0.000000	0.84330	D	0.042956	0.999589;0.999589;0.999589	0.47691	D;D;D	simple_aae;simple_aae;simple_aae	K214R;K214R;K214R	0.435	0.12660	N	-4.13	0.96772	D	-0.89	0.26200	N	0.177	0.19055	0.0037	0.82333	D	0.6164	0.86456	D	10	0.01877	0.40941	T	0.319	0.64468	.	NULL	.	.	.	0.784856537408	0.78286	NULL	0.80639	0.72260081768	0.70425	T	NULL	0.88184	.	-0.208996	0.19521	T	-0.230568	0.51717	T	0.0343845129055515	0.02703	T	NULL	0.44001	.	.	.	.	.	.	.	2.444025	0.40013	22.3	2.089680	0.34795	20.5	0.97904527311393907	0.36766	0.85178	0.44289	D	AEFDBCI	0.594686	0.58952	D	-0.139642275392839	0.35676	2.052294	0.0751741420622725	0.43305	2.634954	0.998135974104661	0.36473	0.516011	0.20929	0	0.59043	0.45803	0	0.577349	0.28860	0	0.542086	0.14980	0	NULL	NULL	5.51	5.51	0.81769	4.904000	0.62975	1.138000	0.64695	0.665000	0.62972	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	0.0:0.0767:0.0:0.9233	10.5038	0.44008	621	0.65931	1	1.9968051118210862E-4	0	0.0	1	9.940357852882703E-4	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	4	4.6511627906976747E-4	29	2.389e-04	28	2.352e-04	0	0	1	8.708e-05	1	1.168e-04	0	0	26	3.983e-04	0	0	22	2.072e-04	21	2.007e-04	0	0	1	8.972e-05	1	1.278e-04	0	0	19	3.550e-04	0	0	24	2.646e-04	23	2.592e-04	0	0	1	8.717e-05	0	0	0	0	22	5.398e-04	0	0	.	49	249806	1.961522e-04	0	0	15974	0	0	5	34540	1.447597e-04	0	0	10010	0	0	1	18334	5.454347e-05	0	0	21510	0	0	40	112740	3.547987e-04	0	1	30596	3.268401e-05	0	40	112740	3.547987e-04	0	18	109092	1.649984e-04	0	0	7120	0	0	3	17092	1.755207e-04	0	0	2298	0	0	1	9024	1.108156e-04	0	0	13364	0	0	12	42612	2.816108e-04	0	1	15678	6.378365e-05	0	12	42612	2.816108e-04	0	.	48	143150	3.353126e-04	1	2	41980	4.764173e-05	0	3	13656	2.196837e-04	0	0	3320	0	0	0	3130	0	0	0	10472	0	0	28	64516	4.340009e-04	0	14	900	1.555556e-02	1	222665	Conflicting_interpretations_of_pathogenicity	Spinocerebellar_ataxia_type_19/22|not_specified|Cardiovascular_phenotype	criteria_provided,_conflicting_interpretations	NC_000001.11:g.111982086T>C	.	C1846367|CN169374|CN230736	607346	ORPHA98772	Ion transport domain	.	. 	.
1	112913924	A	T	D	E	rs1049434	1	113456546	1	113258069	490	SLC16A1	ENSG00000155380	ENST00000369626	ENSP00000358640	MOT1_HUMAN	c.1470T>A	p.D490E	c.1470T>A	p.Asp490Glu	c.1470T>A	p.Asp490Glu	principal1	Y	1	.	-	GAT	3	2	T	T/T	T/T	T/T	1.0	0.00964	T	1.0	0.01155	T	0.0	0.02946	B	0.0	0.01387	B	0.937885	0.07576	N	1.028960	0.999994;0.999994	0.08975	P;P	simple_aae;simple_aae	D490E;D490E	-0.345	0.03330	N	2.08	0.20255	T	0.49	0.02993	N	0.066	0.03841	-0.9392	0.42743	T	0.0051	0.01688	T	9	NULL	NULL	.	0.035	0.09032	.	NULL	.	.	.	NULL	NULL	NULL	0.33496	0.295026123524	0.09662	T	0.071274	0.34167	T	-0.810056	0.00006	T	-0.792545	0.02096	T	0.00573044940384483	0.00063	T	NULL	NULL	.	.	.	.	.	.	.	0.025213	0.04374	1.501	0.340926	0.08880	7.727	0.15334841120252185	0.00371	0.00759	0.03145	N	AEFBI	0.050167	0.08742	N	-1.35570649420175	0.03066	0.1363909	-1.27409764056245	0.04783	0.2264697	0.86056853965934	0.25217	0.722319	0.85440	0	0.724815	0.89359	0	0.698795	0.65105	0	0.714379	0.83352	0	NULL	NULL	5.06	2.74	0.31352	-0.105000	0.10876	-0.210000	0.09518	-0.111000	0.15049	0.287000	0.25205	0.119000	0.20051	0.785000	0.37106	0.1437:0.083:0.1728:0.6005	2.5356	0.04426	822	0.40702	3389	0.6767172523961661	1201	0.9084720121028744	566	0.562624254473161	383	0.5518731988472623	670	0.6646825396825397	569	0.581799591002045	2096	0.5652642934196332	2189	0.5679813181110535	4285	0.5666490346469188	3721	0.8445301861098502	4944	0.5748837209302325	72494	5.971e-01	72494	5.972e-01	8953	8.604e-01	6003	5.186e-01	5736	6.633e-01	3794	5.738e-01	38487	5.767e-01	8981	5.441e-01	63285	5.958e-01	63285	5.960e-01	7808	8.612e-01	5801	5.173e-01	5215	6.635e-01	3794	5.738e-01	31331	5.766e-01	8927	5.443e-01	54756	6.034e-01	54756	6.034e-01	8943	8.609e-01	5995	5.184e-01	3745	6.642e-01	2191	5.766e-01	24479	5.809e-01	8976	5.441e-01	.	148782	251466	5.916585e-01	45046	14019	16254	8.624954e-01	6052	18043	34588	5.216549e-01	4748	6357	10078	6.307799e-01	1990	12328	18394	6.702185e-01	4137	12508	21648	5.777901e-01	3589	65130	113752	5.725614e-01	18771	16762	30612	5.475630e-01	4669	14019	16254	8.624954e-01	6052	64489	109404	5.894574e-01	19450	6210	7164	8.668342e-01	2705	8903	17110	5.203390e-01	2326	1469	2320	6.331897e-01	465	6030	9046	6.665930e-01	2017	7665	13394	5.722712e-01	2170	24492	42766	5.726979e-01	7054	8597	15690	5.479286e-01	2373	6210	7164	8.668342e-01	2705	.	94281	143018	6.592247e-01	32343	35853	41976	8.541309e-01	15354	7693	13632	5.643339e-01	2207	2112	3320	6.361446e-01	657	2060	3110	6.623794e-01	680	6099	10404	5.862168e-01	1795	36832	64492	5.711096e-01	10563	1747	3034	5.758075e-01	510	130315	Benign	Exercise-induced_hyperinsulinism|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.112913924A>T	Illumina_Clinical_Services_Laboratory,Illumina:2056|UniProtKB_(protein):P53985#VAR_010436	C1864902|CN169374	610021	ORPHA165991	.	SLC16A1|SLC16A1|SLC16A1|LRIG2|SLC16A1-AS1|SLC16A1|LRIG2-DT|LRIG2-DT|SLC16A1-AS1|SLC16A1-AS1|SLC16A1|SLC16A1-AS1|LRIG2-DT|SLC16A1-AS1|AKR7A2P1|SLC16A1|SLC16A1-AS1|LRIG2-DT|SLC16A1-AS1|LRIG2-DT|LRIG2-DT|SLC16A1|SLC16A1|SLC16A1|LRIG2-DT|AL357055.2|LRIG2-DT|SLC16A1-AS1	Adipose_Subcutaneous|Adrenal_Gland|Artery_Tibial|Brain_Cerebellum|Brain_Hypothalamus|Breast_Mammary_Tissue|Cells_Cultured_fibroblasts|Colon_Sigmoid|Esophagus_Gastroesophageal_Junction|Esophagus_Mucosa|Esophagus_Muscularis|Esophagus_Muscularis|Esophagus_Muscularis|Heart_Atrial_Appendage|Heart_Left_Ventricle|Heart_Left_Ventricle|Heart_Left_Ventricle|Lung|Nerve_Tibial|Nerve_Tibial|Pituitary|Skin_Not_Sun_Exposed_Suprapubic|Skin_Sun_Exposed_Lower_leg|Spleen|Spleen|Testis|Thyroid|Whole_Blood 	ENSG00000238198
1	112913924	A	T	D	E	rs1049434	1	113456546	1	113258069	490	SLC16A1	ENSG00000155380	ENST00000538576	ENSP00000441065	MOT1_HUMAN	c.1470T>A	p.D490E	c.1470T>A	p.Asp490Glu	c.1470T>A	p.Asp490Glu	principal1	Y	2	YES	-	GAT	3	2	T	T/T	T/T	T/T	1.0	0.00964	T	1.0	0.01155	T	0.0	0.02946	B	0.0	0.01387	B	0.937885	0.07576	N	1.028960	0.999994;0.999994	0.08975	P;P	simple_aae;simple_aae	D490E;D490E	-0.345	0.03330	N	2.08	0.20255	T	0.49	0.02993	N	0.021	0.03841	-0.9392	0.42743	T	0.0051	0.01688	T	9	NULL	NULL	.	0.035	0.09032	.	NULL	.	.	.	NULL	NULL	0.311953951144	0.33496	0.295026123524	0.09662	T	0.071274	0.34167	T	-0.810056	0.00006	T	-0.792545	0.02096	T	0.00573044940384483	0.00063	T	NULL	NULL	.	.	.	.	.	.	.	0.025213	0.04374	1.501	0.340926	0.08880	7.727	0.15334841120252185	0.00371	0.00759	0.03145	N	AEFBI	0.050167	0.08742	N	-1.35570649420175	0.03066	0.1363909	-1.27409764056245	0.04783	0.2264697	0.86056853965934	0.25217	0.722319	0.85440	0	0.724815	0.89359	0	0.698795	0.65105	0	0.714379	0.83352	0	NULL	NULL	5.06	2.74	0.31352	-0.105000	0.10876	-0.210000	0.09518	-0.111000	0.15049	0.287000	0.25205	0.119000	0.20051	0.785000	0.37106	0.1437:0.083:0.1728:0.6005	2.5356	0.04426	822	0.40702	3389	0.6767172523961661	1201	0.9084720121028744	566	0.562624254473161	383	0.5518731988472623	670	0.6646825396825397	569	0.581799591002045	2096	0.5652642934196332	2189	0.5679813181110535	4285	0.5666490346469188	3721	0.8445301861098502	4944	0.5748837209302325	72494	5.971e-01	72494	5.972e-01	8953	8.604e-01	6003	5.186e-01	5736	6.633e-01	3794	5.738e-01	38487	5.767e-01	8981	5.441e-01	63285	5.958e-01	63285	5.960e-01	7808	8.612e-01	5801	5.173e-01	5215	6.635e-01	3794	5.738e-01	31331	5.766e-01	8927	5.443e-01	54756	6.034e-01	54756	6.034e-01	8943	8.609e-01	5995	5.184e-01	3745	6.642e-01	2191	5.766e-01	24479	5.809e-01	8976	5.441e-01	.	148782	251466	5.916585e-01	45046	14019	16254	8.624954e-01	6052	18043	34588	5.216549e-01	4748	6357	10078	6.307799e-01	1990	12328	18394	6.702185e-01	4137	12508	21648	5.777901e-01	3589	65130	113752	5.725614e-01	18771	16762	30612	5.475630e-01	4669	14019	16254	8.624954e-01	6052	64489	109404	5.894574e-01	19450	6210	7164	8.668342e-01	2705	8903	17110	5.203390e-01	2326	1469	2320	6.331897e-01	465	6030	9046	6.665930e-01	2017	7665	13394	5.722712e-01	2170	24492	42766	5.726979e-01	7054	8597	15690	5.479286e-01	2373	6210	7164	8.668342e-01	2705	.	94281	143018	6.592247e-01	32343	35853	41976	8.541309e-01	15354	7693	13632	5.643339e-01	2207	2112	3320	6.361446e-01	657	2060	3110	6.623794e-01	680	6099	10404	5.862168e-01	1795	36832	64492	5.711096e-01	10563	1747	3034	5.758075e-01	510	130315	Benign	Exercise-induced_hyperinsulinism|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.112913924A>T	Illumina_Clinical_Services_Laboratory,Illumina:2056|UniProtKB_(protein):P53985#VAR_010436	C1864902|CN169374	610021	ORPHA165991	.	SLC16A1|SLC16A1|SLC16A1|LRIG2|SLC16A1-AS1|SLC16A1|LRIG2-DT|LRIG2-DT|SLC16A1-AS1|SLC16A1-AS1|SLC16A1|SLC16A1-AS1|LRIG2-DT|SLC16A1-AS1|AKR7A2P1|SLC16A1|SLC16A1-AS1|LRIG2-DT|SLC16A1-AS1|LRIG2-DT|LRIG2-DT|SLC16A1|SLC16A1|SLC16A1|LRIG2-DT|AL357055.2|LRIG2-DT|SLC16A1-AS1	Adipose_Subcutaneous|Adrenal_Gland|Artery_Tibial|Brain_Cerebellum|Brain_Hypothalamus|Breast_Mammary_Tissue|Cells_Cultured_fibroblasts|Colon_Sigmoid|Esophagus_Gastroesophageal_Junction|Esophagus_Mucosa|Esophagus_Muscularis|Esophagus_Muscularis|Esophagus_Muscularis|Heart_Atrial_Appendage|Heart_Left_Ventricle|Heart_Left_Ventricle|Heart_Left_Ventricle|Lung|Nerve_Tibial|Nerve_Tibial|Pituitary|Skin_Not_Sun_Exposed_Suprapubic|Skin_Sun_Exposed_Lower_leg|Spleen|Spleen|Testis|Thyroid|Whole_Blood 	ENSG00000238198
1	114678495	C	A	M	I	rs61752478	1	115221116	1	115022639	339	AMPD1	ENSG00000116748	ENST00000369538	ENSP00000358551	AMPD1_HUMAN	c.1017G>T	p.M339I	c.1017G>T	p.Met339Ile	c.1017G>T	p.Met339Ile	alternative2	Y	2	.	-	ATG	3	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.001	0.92824	D	NULL	NULL	.	NULL	NULL	.	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	M343I;M339I;M310I	NULL	0.74443	.	-3.72	0.95422	D	-3.44	0.67477	D	0.874	0.87157	1.0432	0.97976	D	0.9205	0.97369	D	10	0.549985	0.95847	D	0.960	0.99386	.	NULL	.	.	.	0.981770038479	0.98157	NULL	0.37948	0.81819999218	0.84753	D	NULL	0.96981	.	0.179706	0.72015	D	0.488387	0.94376	D	0.035392518300413	0.02875	T	0.845215	0.52386	T	.	.	.	.	.	.	3.702459	0.69421	25.4	3.943428	0.80321	27.2	0.99741771044736893	0.83555	0.98534	0.83810	D	AEFDBI	0.923019	0.89887	D	0.756356871615182	0.83319	7.986292	0.740929807000276	0.85479	8.592591	0.999999926094186	0.74766	0.487112	0.14033	0	0.573888	0.26702	0	0.573888	0.23631	0	0.530356	0.10902	0	NULL	NULL	5.1	5.1	0.68917	7.905000	0.86479	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	0.999000	0.91618	0.0:1.0:0.0:0.0	18.8767	0.92311	814	0.42100	13	0.002595846645367412	1	7.564296520423601E-4	7	0.006958250497017893	5	0.007204610951008645	0	0.0	0	0.0	24	0.006472491909385114	17	0.0044110015568240785	41	0.0054218460724676015	4	9.078529278256923E-4	46	0.005348837209302326	380	3.130e-03	380	3.133e-03	13	1.257e-03	37	3.197e-03	0	0	4	6.050e-04	318	4.766e-03	3	1.817e-04	317	2.985e-03	317	2.987e-03	12	1.333e-03	37	3.300e-03	0	0	4	6.050e-04	259	4.768e-03	3	1.829e-04	313	3.449e-03	313	3.453e-03	13	1.260e-03	37	3.200e-03	0	0	3	7.895e-04	253	6.006e-03	3	1.818e-04	.	829	251424	3.297219e-03	3	20	16252	1.230618e-03	0	167	34590	4.827985e-03	0	64	10080	6.349206e-03	1	0	18394	0	0	8	21632	3.698225e-04	0	543	113724	4.774718e-03	2	3	30616	9.798798e-05	0	167	34590	4.827985e-03	0	294	109392	2.687582e-03	1	11	7164	1.535455e-03	0	79	17112	4.616643e-03	0	16	2320	6.896552e-03	0	0	9046	0	0	5	13378	3.737479e-04	0	173	42768	4.045080e-03	1	1	15690	6.373486e-05	0	79	17112	4.616643e-03	0	.	539	143282	3.761812e-03	2	52	42032	1.237153e-03	0	151	13654	1.105903e-02	1	21	3320	6.325301e-03	0	0	3134	0	0	5	10478	4.771903e-04	0	287	64570	4.444789e-03	1	287	64570	4.444789e-03	1	92330	Conflicting_interpretations_of_pathogenicity	Muscle_AMP_deaminase_deficiency|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.114678495C>A	HGMD:CM041236	C3714933|CN517202	615511	.	.	.	. 	.
1	114678495	C	A	M	I	rs61752478	1	115221116	1	115022639	343	AMPD1	ENSG00000116748	ENST00000520113	ENSP00000430075	AMPD1_HUMAN	c.1029G>T	p.M343I	c.1029G>T	p.Met343Ile	c.1029G>T	p.Met343Ile	principal3	Y	1	YES	-	ATG	3	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.0	0.92824	D	NULL	NULL	.	NULL	NULL	.	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	M343I;M339I;M310I	2.55	0.74443	M	-3.72	0.95422	D	-3.44	0.67477	D	0.868	0.87157	1.0432	0.97976	D	0.9205	0.97369	D	10	0.549985	0.95847	D	0.960	0.99386	.	NULL	.	.	.	0.981770038479	0.98157	0.363144066244	0.37948	0.81819999218	0.84753	D	0.86317	0.96981	D	0.179706	0.72015	D	0.488387	0.94376	D	0.035392518300413	0.02875	T	0.845215	0.52386	T	.	.	.	.	.	.	3.702459	0.69421	25.4	3.943428	0.80321	27.2	0.99741771044736893	0.83555	0.98534	0.83810	D	AEFDBI	0.923019	0.89887	D	0.756356871615182	0.83319	7.986292	0.740929807000276	0.85479	8.592591	0.999999926094186	0.74766	0.487112	0.14033	0	0.573888	0.26702	0	0.573888	0.23631	0	0.530356	0.10902	0	NULL	NULL	5.1	5.1	0.68917	7.905000	0.86479	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	0.999000	0.91618	0.0:1.0:0.0:0.0	18.8767	0.92311	814	0.42100	13	0.002595846645367412	1	7.564296520423601E-4	7	0.006958250497017893	5	0.007204610951008645	0	0.0	0	0.0	24	0.006472491909385114	17	0.0044110015568240785	41	0.0054218460724676015	4	9.078529278256923E-4	46	0.005348837209302326	380	3.130e-03	380	3.133e-03	13	1.257e-03	37	3.197e-03	0	0	4	6.050e-04	318	4.766e-03	3	1.817e-04	317	2.985e-03	317	2.987e-03	12	1.333e-03	37	3.300e-03	0	0	4	6.050e-04	259	4.768e-03	3	1.829e-04	313	3.449e-03	313	3.453e-03	13	1.260e-03	37	3.200e-03	0	0	3	7.895e-04	253	6.006e-03	3	1.818e-04	.	829	251424	3.297219e-03	3	20	16252	1.230618e-03	0	167	34590	4.827985e-03	0	64	10080	6.349206e-03	1	0	18394	0	0	8	21632	3.698225e-04	0	543	113724	4.774718e-03	2	3	30616	9.798798e-05	0	167	34590	4.827985e-03	0	294	109392	2.687582e-03	1	11	7164	1.535455e-03	0	79	17112	4.616643e-03	0	16	2320	6.896552e-03	0	0	9046	0	0	5	13378	3.737479e-04	0	173	42768	4.045080e-03	1	1	15690	6.373486e-05	0	79	17112	4.616643e-03	0	.	539	143282	3.761812e-03	2	52	42032	1.237153e-03	0	151	13654	1.105903e-02	1	21	3320	6.325301e-03	0	0	3134	0	0	5	10478	4.771903e-04	0	287	64570	4.444789e-03	1	287	64570	4.444789e-03	1	92330	Conflicting_interpretations_of_pathogenicity	Muscle_AMP_deaminase_deficiency|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.114678495C>A	HGMD:CM041236	C3714933|CN517202	615511	.	Adenosine/AMP deaminase domain	.	. 	.
1	114679616	T	A	K	I	rs34526199	1	115222237	1	115023760	316	AMPD1	ENSG00000116748	ENST00000369538	ENSP00000358551	AMPD1_HUMAN	c.947A>T	p.K316I	c.947A>T	p.Lys316Ile	c.947A>T	p.Lys316Ile	alternative2	Y	2	.	-	AAA	2	0	T	A/A	T/T	A/A	0.0	0.91255	D	0.0	0.92824	D	NULL	NULL	.	NULL	NULL	.	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	K287I;K320I;K316I	NULL	0.95479	.	-1.99	0.85320	D	-6.86	0.93135	D	0.392	0.43320	0.8307	0.94790	D	0.7984	0.93174	D	10	NULL	NULL	.	0.881	0.96553	.	NULL	.	.	.	NULL	NULL	NULL	0.55159	0.770982503891	0.77572	T	NULL	0.94587	.	-0.0477223	0.44792	T	0.18795	0.82454	D	0.867863833904266	0.51786	D	0.777722	0.41106	T	.	.	.	.	.	.	4.335282	0.88993	29.9	4.248161	0.89205	29.8	0.99566596249392691	0.72136	0.98422	0.82613	D	AEFBI	0.925823	0.90596	D	0.954341640209264	0.94156	12.54345	0.889445809054819	0.95096	13.3077	0.99997604940268	0.50053	0.487112	0.14033	0	0.573888	0.26702	0	0.573888	0.23631	0	0.530356	0.10902	0	NULL	NULL	5.63	5.63	0.86108	8.017000	0.88732	1.138000	0.64695	0.665000	0.62972	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	0.0:0.0:0.0:1.0	16.1485	0.81406	809	0.43032	55	0.010982428115015975	0	0.0	37	0.036779324055666	12	0.01729106628242075	0	0.0	6	0.006134969325153374	138	0.0372168284789644	136	0.03528801245459263	274	0.03623380058185665	18	0.0040853381752156154	296	0.03441860465116279	3425	2.821e-02	3425	2.822e-02	47	4.527e-03	164	1.416e-02	0	0	581	8.784e-02	2334	3.498e-02	262	1.587e-02	2974	2.800e-02	2974	2.801e-02	40	4.423e-03	161	1.435e-02	0	0	581	8.784e-02	1901	3.498e-02	259	1.578e-02	2195	2.419e-02	2195	2.420e-02	47	4.535e-03	164	1.418e-02	0	0	351	9.232e-02	1347	3.197e-02	262	1.588e-02	.	7112	251474	2.828125e-02	153	71	16256	4.367618e-03	1	537	34592	1.552382e-02	11	243	10080	2.410714e-02	3	0	18394	0	0	1797	21644	8.302532e-02	71	3809	113754	3.348454e-02	58	473	30614	1.545045e-02	6	3809	113754	3.348454e-02	58	3242	109404	2.963329e-02	82	32	7164	4.466778e-03	1	251	17112	1.466807e-02	6	57	2320	2.456897e-02	1	0	9046	0	0	1117	13390	8.342046e-02	53	1498	42768	3.502619e-02	17	230	15690	1.465902e-02	2	1498	42768	3.502619e-02	17	.	3837	142144	2.699375e-02	88	234	41522	5.635567e-03	0	227	13578	1.671822e-02	6	79	3300	2.393939e-02	1	0	3108	0	0	873	10408	8.387779e-02	23	2236	64216	3.481998e-02	45	35	2974	1.176866e-02	2	92338	Conflicting_interpretations_of_pathogenicity	Muscle_AMP_deaminase_deficiency|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.114679616T>A	HGMD:CM041235	C3714933|CN517202	615511	.	.	TSPAN2|NRAS|DENND2C	Artery_Tibial|Esophagus_Mucosa|Testis 	.
1	114679616	T	A	K	I	rs34526199	1	115222237	1	115023760	320	AMPD1	ENSG00000116748	ENST00000520113	ENSP00000430075	AMPD1_HUMAN	c.959A>T	p.K320I	c.959A>T	p.Lys320Ile	c.959A>T	p.Lys320Ile	principal3	Y	1	YES	-	AAA	2	0	T	A/A	T/T	A/A	0.0	0.91255	D	0.0	0.92824	D	NULL	NULL	.	NULL	NULL	.	0.000000	0.84330	D	0.000000	1;1;1	0.81001	D;D;D	simple_aae;simple_aae;simple_aae	K287I;K320I;K316I	3.81	0.95479	H	-1.99	0.85320	D	-6.86	0.93135	D	0.351	0.43320	0.8307	0.94790	D	0.7984	0.93174	D	10	NULL	NULL	.	0.881	0.96553	.	NULL	.	.	.	NULL	NULL	0.601013901406	0.55159	0.770982503891	0.77572	T	0.791477	0.94587	D	-0.0477223	0.44792	T	0.18795	0.82454	D	0.867863833904266	0.51786	D	0.757724	0.41106	T	.	.	.	.	.	.	4.335282	0.88993	29.9	4.248161	0.89205	29.8	0.99566596249392691	0.72136	0.98422	0.82613	D	AEFBI	0.925823	0.90596	D	0.954341640209264	0.94156	12.54345	0.889445809054819	0.95096	13.3077	0.99997604940268	0.50053	0.487112	0.14033	0	0.573888	0.26702	0	0.573888	0.23631	0	0.530356	0.10902	0	NULL	NULL	5.63	5.63	0.86108	8.017000	0.88732	1.138000	0.64695	0.665000	0.62972	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	0.0:0.0:0.0:1.0	16.1485	0.81406	809	0.43032	55	0.010982428115015975	0	0.0	37	0.036779324055666	12	0.01729106628242075	0	0.0	6	0.006134969325153374	138	0.0372168284789644	136	0.03528801245459263	274	0.03623380058185665	18	0.0040853381752156154	296	0.03441860465116279	3425	2.821e-02	3425	2.822e-02	47	4.527e-03	164	1.416e-02	0	0	581	8.784e-02	2334	3.498e-02	262	1.587e-02	2974	2.800e-02	2974	2.801e-02	40	4.423e-03	161	1.435e-02	0	0	581	8.784e-02	1901	3.498e-02	259	1.578e-02	2195	2.419e-02	2195	2.420e-02	47	4.535e-03	164	1.418e-02	0	0	351	9.232e-02	1347	3.197e-02	262	1.588e-02	.	7112	251474	2.828125e-02	153	71	16256	4.367618e-03	1	537	34592	1.552382e-02	11	243	10080	2.410714e-02	3	0	18394	0	0	1797	21644	8.302532e-02	71	3809	113754	3.348454e-02	58	473	30614	1.545045e-02	6	3809	113754	3.348454e-02	58	3242	109404	2.963329e-02	82	32	7164	4.466778e-03	1	251	17112	1.466807e-02	6	57	2320	2.456897e-02	1	0	9046	0	0	1117	13390	8.342046e-02	53	1498	42768	3.502619e-02	17	230	15690	1.465902e-02	2	1498	42768	3.502619e-02	17	.	3837	142144	2.699375e-02	88	234	41522	5.635567e-03	0	227	13578	1.671822e-02	6	79	3300	2.393939e-02	1	0	3108	0	0	873	10408	8.387779e-02	23	2236	64216	3.481998e-02	45	35	2974	1.176866e-02	2	92338	Conflicting_interpretations_of_pathogenicity	Muscle_AMP_deaminase_deficiency|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.114679616T>A	HGMD:CM041235	C3714933|CN517202	615511	.	.	TSPAN2|NRAS|DENND2C	Artery_Tibial|Esophagus_Mucosa|Testis 	.
1	114684278	C	A	Q	H	rs139582106	1	115226899	1	115028422	185	AMPD1	ENSG00000116748	ENST00000369538	ENSP00000358551	AMPD1_HUMAN	c.555G>T	p.Q185H	c.555G>T	p.Gln185His	c.555G>T	p.Gln185His	alternative2	Y	2	.	-	CAG	3	2	C	C/C	C/C	C/C	0.291	0.15458	T	0.263	0.22828	T	NULL	NULL	.	NULL	NULL	.	0.000000	0.84330	D	0.053896	0.999999;0.999999;0.999999	0.58761	D;D;D	simple_aae;simple_aae;simple_aae	Q189H;Q185H;Q156H	NULL	0.35535	.	2.83	0.10771	T	-1.34	0.33401	N	0.714	0.78832	-1.1307	0.01749	T	0.0318	0.13679	T	10	0.01556	0.36360	T	0.164	0.42668	.	NULL	.	.	.	0.445910236696	0.44209	NULL	0.41434	0.58066868782	0.50180	T	NULL	0.75813	.	-0.346513	0.04949	T	-0.340678	0.40267	T	0.813956022262573	0.47330	D	0.822518	0.48242	T	.	.	.	.	.	.	1.881353	0.28310	18.34	1.112903	0.18386	14.15	0.72074072311449633	0.09847	0.90480	0.51691	D	AEFBI	0.422013	0.48819	N	-0.22351373765485	0.32170	1.811457	-0.210164991641147	0.31170	1.761514	1.37643061281839E-4	0.05486	0.487112	0.14033	0	0.573888	0.26702	0	0.573888	0.23631	0	0.542086	0.14980	0	NULL	NULL	5.72	2.88	0.32617	2.085000	0.41258	-0.238000	0.08574	-0.176000	0.10722	1.000000	0.71638	0.966000	0.44233	0.510000	0.29244	0.0:0.798:0.0:0.202	10.9182	0.46359	823	0.40596	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	2	5.393743257820927E-4	1	2.594706798131811E-4	3	3.9672044432689763E-4	0	0.0	8	9.302325581395349E-4	54	4.448e-04	54	4.448e-04	1	9.610e-05	1	8.640e-05	0	0	1	1.512e-04	51	7.643e-04	0	0	36	3.390e-04	36	3.390e-04	1	1.103e-04	1	8.919e-05	0	0	1	1.512e-04	33	6.073e-04	0	0	51	5.620e-04	51	5.620e-04	1	9.626e-05	1	8.649e-05	0	0	1	2.630e-04	48	1.139e-03	0	0	.	135	251484	5.368135e-04	0	1	16256	6.151575e-05	0	25	34592	7.227105e-04	0	0	10080	0	0	0	18394	0	0	2	21648	9.238729e-05	0	104	113762	9.141893e-04	0	0	30614	0	0	104	113762	9.141893e-04	0	51	109406	4.661536e-04	0	1	7164	1.395868e-04	0	6	17112	3.506311e-04	0	0	2320	0	0	0	9046	0	0	1	13394	7.466030e-05	0	43	42768	1.005425e-03	0	0	15688	0	0	43	42768	1.005425e-03	0	.	134	143176	9.359110e-04	0	7	41988	1.667143e-04	0	55	13644	4.031076e-03	0	0	3320	0	0	0	3132	0	0	1	10448	9.571210e-05	0	70	64556	1.084330e-03	0	70	64556	1.084330e-03	0	197620	Conflicting_interpretations_of_pathogenicity	Muscle_AMP_deaminase_deficiency|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.114684278C>A	.	C3714933|CN517202	615511	.	.	.	. 	.
1	114684278	C	A	Q	H	rs139582106	1	115226899	1	115028422	189	AMPD1	ENSG00000116748	ENST00000520113	ENSP00000430075	AMPD1_HUMAN	c.567G>T	p.Q189H	c.567G>T	p.Gln189His	c.567G>T	p.Gln189His	principal3	Y	1	YES	-	CAG	3	2	C	C/C	C/C	C/C	0.281	0.15458	T	0.303	0.22828	T	NULL	NULL	.	NULL	NULL	.	0.000000	0.84330	D	0.053896	0.999999;0.999999;0.999999	0.58761	D;D;D	simple_aae;simple_aae;simple_aae	Q189H;Q185H;Q156H	1.41	0.35535	L	2.83	0.10771	T	-1.34	0.33401	N	0.792	0.78832	-1.1307	0.01749	T	0.0318	0.13679	T	10	0.01556	0.36360	T	0.164	0.42668	.	NULL	.	.	.	0.445910236696	0.44209	0.405371340211	0.41434	0.58066868782	0.50180	T	0.4006	0.75813	T	-0.346513	0.04949	T	-0.340678	0.40267	T	0.813956022262573	0.47330	D	0.822518	0.48242	T	.	.	.	.	.	.	1.881353	0.28310	18.34	1.112903	0.18386	14.15	0.72074072311449633	0.09847	0.90480	0.51691	D	AEFBI	0.422013	0.48819	N	-0.22351373765485	0.32170	1.811457	-0.210164991641147	0.31170	1.761514	1.37643061281839E-4	0.05486	0.487112	0.14033	0	0.573888	0.26702	0	0.573888	0.23631	0	0.542086	0.14980	0	NULL	NULL	5.72	2.88	0.32617	2.085000	0.41258	-0.238000	0.08574	-0.176000	0.10722	1.000000	0.71638	0.966000	0.44233	0.510000	0.29244	0.0:0.798:0.0:0.202	10.9182	0.46359	823	0.40596	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	2	5.393743257820927E-4	1	2.594706798131811E-4	3	3.9672044432689763E-4	0	0.0	8	9.302325581395349E-4	54	4.448e-04	54	4.448e-04	1	9.610e-05	1	8.640e-05	0	0	1	1.512e-04	51	7.643e-04	0	0	36	3.390e-04	36	3.390e-04	1	1.103e-04	1	8.919e-05	0	0	1	1.512e-04	33	6.073e-04	0	0	51	5.620e-04	51	5.620e-04	1	9.626e-05	1	8.649e-05	0	0	1	2.630e-04	48	1.139e-03	0	0	.	135	251484	5.368135e-04	0	1	16256	6.151575e-05	0	25	34592	7.227105e-04	0	0	10080	0	0	0	18394	0	0	2	21648	9.238729e-05	0	104	113762	9.141893e-04	0	0	30614	0	0	104	113762	9.141893e-04	0	51	109406	4.661536e-04	0	1	7164	1.395868e-04	0	6	17112	3.506311e-04	0	0	2320	0	0	0	9046	0	0	1	13394	7.466030e-05	0	43	42768	1.005425e-03	0	0	15688	0	0	43	42768	1.005425e-03	0	.	134	143176	9.359110e-04	0	7	41988	1.667143e-04	0	55	13644	4.031076e-03	0	0	3320	0	0	0	3132	0	0	1	10448	9.571210e-05	0	70	64556	1.084330e-03	0	70	64556	1.084330e-03	0	197620	Conflicting_interpretations_of_pathogenicity	Muscle_AMP_deaminase_deficiency|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.114684278C>A	.	C3714933|CN517202	615511	.	.	.	. 	.
1	114686902	C	T	R	H	rs61738827	1	115229523	1	115031046	104	AMPD1	ENSG00000116748	ENST00000369538	ENSP00000358551	AMPD1_HUMAN	c.311G>A	p.R104H	c.311G>A	p.Arg104His	c.311G>A	p.Arg104His	alternative2	Y	2	.	-	CGT	2	0	C	./.	./.	./.	0.025	0.47320	D	0.106	0.37872	T	NULL	NULL	.	NULL	NULL	.	0.002416	0.00885	U	11.368800	0.987684;0.987684;0.987684	0.40632	D;D;D	simple_aae;simple_aae;simple_aae	R108H;R104H;R75H	NULL	0.56016	.	0.97	0.42502	T	-0.18	0.09796	N	0.291	0.32921	-0.9990	0.30199	T	0.1094	0.39509	T	10	NULL	NULL	.	0.093	0.27331	.	NULL	.	.	.	0.71889551114	0.71642	NULL	0.11892	0.356991648674	0.18946	T	NULL	0.73350	.	-0.485421	0.00689	T	-0.459019	0.26707	T	0.0192262107775266	0.00628	T	0.70223	0.31206	T	.	.	.	.	.	.	2.331170	0.37534	21.8	2.381038	0.41091	22.3	0.99748629097363373	0.84077	0.92457	0.55756	D	AEFBI	0.120830	0.23519	N	0.219453574693732	0.52143	3.390361	0.254924878545914	0.52931	3.464669	0.0102450568174137	0.11992	0.553676	0.25195	0	0.588015	0.36545	0	0.573888	0.23631	0	0.530356	0.10902	0	NULL	NULL	5.41	4.5	0.54382	2.272000	0.43032	1.026000	0.45946	0.599000	0.40250	0.972000	0.34453	0.997000	0.62031	0.997000	0.79791	0.0:0.9199:0.0:0.0801	12.2919	0.54142	825	0.40060	24	0.004792332268370607	2	0.0015128593040847202	3	0.002982107355864811	3	0.004322766570605188	0	0.0	16	0.016359918200409	10	0.002696871628910464	12	0.0031136481577581734	22	0.0029092832583972493	5	0.0011348161597821154	33	0.0038372093023255815	614	5.057e-03	614	5.059e-03	17	1.637e-03	42	3.631e-03	3	3.467e-04	3	4.536e-04	337	5.050e-03	200	1.212e-02	547	5.150e-03	547	5.153e-03	13	1.437e-03	40	3.570e-03	3	3.815e-04	3	4.536e-04	276	5.080e-03	200	1.219e-02	554	6.105e-03	554	6.108e-03	17	1.640e-03	42	3.634e-03	2	3.547e-04	1	2.630e-04	288	6.836e-03	199	1.206e-02	.	1257	251430	4.999403e-03	12	19	16256	1.168799e-03	0	114	34588	3.295941e-03	0	236	10078	2.341734e-02	4	3	18394	1.630967e-04	0	6	21648	2.771619e-04	0	456	113716	4.009990e-03	2	387	30616	1.264045e-02	5	387	30616	1.264045e-02	5	463	109404	4.232021e-03	4	6	7164	8.375209e-04	0	49	17108	2.864157e-03	0	51	2320	2.198276e-02	0	1	9046	1.105461e-04	0	2	13394	1.493206e-04	0	150	42768	3.507295e-03	2	197	15690	1.255577e-02	2	197	15690	1.255577e-02	2	.	494	143276	3.447891e-03	2	42	42046	9.989060e-04	0	63	13638	4.619446e-03	1	82	3324	2.466907e-02	1	0	3132	0	0	2	10468	1.910585e-04	0	251	64566	3.887495e-03	0	43	3048	1.410761e-02	0	166684	Conflicting_interpretations_of_pathogenicity	Muscle_AMP_deaminase_deficiency|not_specified	criteria_provided,_conflicting_interpretations	NC_000001.11:g.114686902C>T	Illumina_Clinical_Services_Laboratory,Illumina:222569	C3714933|CN169374	615511	.	.	.	. 	.
1	114686902	C	T	R	H	rs61738827	1	115229523	1	115031046	108	AMPD1	ENSG00000116748	ENST00000520113	ENSP00000430075	AMPD1_HUMAN	c.323G>A	p.R108H	c.323G>A	p.Arg108His	c.323G>A	p.Arg108His	principal3	Y	1	YES	-	CGT	2	0	C	./.	./.	./.	0.028	0.47320	D	0.109	0.37872	T	NULL	NULL	.	NULL	NULL	.	0.002416	0.00885	U	11.368800	0.987684;0.987684;0.987684	0.40632	D;D;D	simple_aae;simple_aae;simple_aae	R108H;R104H;R75H	2.045	0.56016	M	0.97	0.42502	T	-0.15	0.09796	N	0.289	0.32921	-0.9990	0.30199	T	0.1094	0.39509	T	10	NULL	NULL	.	0.093	0.27331	.	NULL	.	.	.	0.71889551114	0.71642	0.105181179434	0.11892	0.356991648674	0.18946	T	0.368652	0.73350	T	-0.485421	0.00689	T	-0.459019	0.26707	T	0.0192262107775266	0.00628	T	0.70223	0.31206	T	.	.	.	.	.	.	2.331170	0.37534	21.8	2.381038	0.41091	22.3	0.99748629097363373	0.84077	0.92457	0.55756	D	AEFBI	0.120830	0.23519	N	0.219453574693732	0.52143	3.390361	0.254924878545914	0.52931	3.464669	0.0102450568174137	0.11992	0.553676	0.25195	0	0.588015	0.36545	0	0.573888	0.23631	0	0.530356	0.10902	0	NULL	NULL	5.41	4.5	0.54382	2.272000	0.43032	1.026000	0.45946	0.599000	0.40250	0.972000	0.34453	0.997000	0.62031	0.997000	0.79791	0.0:0.9199:0.0:0.0801	12.2919	0.54142	825	0.40060	24	0.004792332268370607	2	0.0015128593040847202	3	0.002982107355864811	3	0.004322766570605188	0	0.0	16	0.016359918200409	10	0.002696871628910464	12	0.0031136481577581734	22	0.0029092832583972493	5	0.0011348161597821154	33	0.0038372093023255815	614	5.057e-03	614	5.059e-03	17	1.637e-03	42	3.631e-03	3	3.467e-04	3	4.536e-04	337	5.050e-03	200	1.212e-02	547	5.150e-03	547	5.153e-03	13	1.437e-03	40	3.570e-03	3	3.815e-04	3	4.536e-04	276	5.080e-03	200	1.219e-02	554	6.105e-03	554	6.108e-03	17	1.640e-03	42	3.634e-03	2	3.547e-04	1	2.630e-04	288	6.836e-03	199	1.206e-02	.	1257	251430	4.999403e-03	12	19	16256	1.168799e-03	0	114	34588	3.295941e-03	0	236	10078	2.341734e-02	4	3	18394	1.630967e-04	0	6	21648	2.771619e-04	0	456	113716	4.009990e-03	2	387	30616	1.264045e-02	5	387	30616	1.264045e-02	5	463	109404	4.232021e-03	4	6	7164	8.375209e-04	0	49	17108	2.864157e-03	0	51	2320	2.198276e-02	0	1	9046	1.105461e-04	0	2	13394	1.493206e-04	0	150	42768	3.507295e-03	2	197	15690	1.255577e-02	2	197	15690	1.255577e-02	2	.	494	143276	3.447891e-03	2	42	42046	9.989060e-04	0	63	13638	4.619446e-03	1	82	3324	2.466907e-02	1	0	3132	0	0	2	10468	1.910585e-04	0	251	64566	3.887495e-03	0	43	3048	1.410761e-02	0	166684	Conflicting_interpretations_of_pathogenicity	Muscle_AMP_deaminase_deficiency|not_specified	criteria_provided,_conflicting_interpretations	NC_000001.11:g.114686902C>T	Illumina_Clinical_Services_Laboratory,Illumina:222569	C3714933|CN169374	615511	.	.	.	. 	.
1	114708552	G	A	P	S	rs374061873	1	115251173	1	115052696	185	NRAS	ENSG00000213281	ENST00000369535	ENSP00000358548	RASN_HUMAN	c.553C>T	p.P185S	c.553C>T	p.Pro185Ser	c.553C>T	p.Pro185Ser	principal1	Y	1	YES	-	CCA	1	0	G	G/G	G/G	G/G	0.534	0.06935	T	0.695	0.05825	T	0.0	0.02946	B	0.001	0.04355	B	0.008519	0.30805	U	0.131887	0.999152	0.21565	N	simple_aae	P185S	0	0.06538	N	-0.18	0.65747	T	0.58	0.02598	N	0.22	0.24634	-1.0512	0.14064	T	0.0422	0.18160	T	10	0.005289	0.13525	T	0.051	0.14679	.	NULL	.	.	.	0.245697971988	0.24196	0.931234632884	0.71824	0.440081655979	0.30587	T	0.065054	0.32592	T	-0.385634	0.02870	T	-0.566011	0.15816	T	0.025668783321723	0.01362	T	0.661834	0.27067	T	.	.	.	.	.	.	1.915997	0.28962	18.61	1.596724	0.25451	16.83	0.96440858735114376	0.29827	0.83902	0.42993	D	AEFDBI	0.156272	0.28160	N	-0.374962286186295	0.26365	1.438294	-0.160835965810692	0.32992	1.882696	0.993824551401294	0.33371	0.706548	0.73137	0	0.724815	0.89359	0	0.724815	0.87919	0	0.711	0.71501	0	NULL	NULL	5.76	3.86	0.43689	1.877000	0.39234	1.176000	0.78918	0.676000	0.76740	0.991000	0.37257	0.983000	0.48746	0.995000	0.73285	0.2459:0.0:0.7541:0.0	9.4643	0.37967	819	0.41190	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	1	1.1627906976744187E-4	7	5.765e-05	7	5.765e-05	0	0	1	8.637e-05	0	0	0	0	6	8.990e-05	0	0	7	6.591e-05	7	6.591e-05	0	0	1	8.916e-05	0	0	0	0	6	1.104e-04	0	0	5	5.510e-05	5	5.510e-05	0	0	1	8.646e-05	0	0	0	0	4	9.492e-05	0	0	.	17	251444	6.760949e-05	0	0	16256	0	0	3	34592	8.672525e-05	0	0	10080	0	0	0	18394	0	0	0	21642	0	0	13	113728	1.143078e-04	0	0	30616	0	0	13	113728	1.143078e-04	0	4	109404	3.656173e-05	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13390	0	0	4	42768	9.352787e-05	0	0	15690	0	0	4	42768	9.352787e-05	0	.	10	143224	6.982070e-05	0	1	42028	2.379366e-05	0	4	13636	2.933412e-04	0	0	3320	0	0	0	3128	0	0	0	10456	0	0	5	64566	7.744014e-05	0	5	64566	7.744014e-05	0	179025	Conflicting_interpretations_of_pathogenicity	Noonan_syndrome_6|Rasopathy|not_specified	criteria_provided,_conflicting_interpretations	NC_000001.11:g.114708552G>A	Illumina_Clinical_Services_Laboratory,Illumina:203251	C2750732|CN166718|CN169374	613224	ORPHA536391	.	.	. 	.
1	114713908	T	C	Q	R	rs11554290	1	115256529	1	115058052	61	NRAS	ENSG00000213281	ENST00000369535	ENSP00000358548	RASN_HUMAN	c.182A>G	p.Q61R	c.182A>G	p.Gln61Arg	c.182A>G	p.Gln61Arg	principal1	Y	1	YES	-	CAA	2	0	T	T/T	T/T	T/T	0.029	0.45756	D	0.048	0.48594	D	0.214	0.30086	B	0.304	0.41178	B	0.000043	0.53742	U	0.000000	1	0.81001	D	simple_aae	Q61R	3.275	0.90144	M	-1.75	0.83495	D	-3.38	0.66780	D	0.795	0.79118	0.2919	0.87428	D	0.5945	0.85521	D	10	0.112085	0.79010	D	0.888	0.96810	0.752	0.88232	P01111	Q61R	Loss of glycosylation at T58 (P = 0.1035); Gain of phosphorylation at T58 (P = 0.1219); Loss of helix (P = 0.1299); Loss of disorder (P = 0.2229); Gain of loop (P = 0.2754)	0.96560272545	0.96523	0.993306901932	0.74149	0.881335020065	0.94139	D	0.690506	0.90997	D	0.429126	0.91488	D	0.378634	0.91382	D	0.983227014541626	0.74971	D	0.918008	0.70480	D	.	.	.	.	.	.	2.826369	0.48298	23.1	2.676457	0.47605	22.9	0.99698018450626236	0.80385	0.98635	0.84961	D	AEFDBI	0.911730	0.87139	D	0.46116955412125	0.64838	4.747765	0.512587548564142	0.68837	5.275368	0.999999999990908	0.74766	0.722319	0.85440	0	0.581341	0.33841	0	0.702456	0.68683	0	0.735409	0.98432	0	NULL	NULL	5.08	5.08	0.68373	7.911000	0.86862	1.138000	0.64695	0.665000	0.62972	1.000000	0.71638	1.000000	0.86279	0.999000	0.91618	0.0:0.0:0.0:1.0	15.0132	0.71224	829	0.39537	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	13900	Pathogenic	Hepatocellular_carcinoma|Acute_myeloid_leukemia|Chronic_lymphocytic_leukemia|Renal_cell_carcinoma,_papillary,_1|Large_congenital_melanocytic_nevus|Follicular_thyroid_carcinoma|Transitional_cell_carcinoma_of_the_bladder|Adrenocortical_carcinoma|Multiple_myeloma|Epidermal_nevus|Cutaneous_melanoma|Lung_adenocarcinoma|Non-small_cell_lung_cancer|Neoplasm_of_brain|Neoplasm_of_the_large_intestine|Adenocarcinoma_of_stomach|Ovarian_Serous_Cystadenocarcinoma|Neurocutaneous_melanocytosis|Glioblastoma|Malignant_melanoma_of_skin|Nasopharyngeal_Neoplasms|Malignant_neoplasm_of_body_of_uterus|Epidermal_nevus_syndrome|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.114713908T>C	OMIM_Allelic_Variant:164790.0002|UniProtKB_(protein):P01111#VAR_006847	C2239176|C0023467|C0023434|C0007134|C1842036|C4225426|C0279680|C0206686|C0026764|C0334082|C0025202|C0152013|C0007131|C0006118|C0009404|C0278701|C0279663|C0544862|C0017636|C0151779|C0027439|C0153574|C0265318|CN517202	114550|601626|151400|605074|137550|188470|254500|162900|249400|163200	ORPHA88673|ORPHA519|ORPHA67038|ORPHA217071|ORPHA626|ORPHA1501|ORPHA29073|ORPHA35125|ORPHA2481|ORPHA360|ORPHA213569	Small GTP-binding protein domain	.	. 	.
1	114713911	C	T	G	E	rs267606920	1	115256532	1	115058055	60	NRAS	ENSG00000213281	ENST00000369535	ENSP00000358548	RASN_HUMAN	c.179G>A	p.G60E	c.179G>A	p.Gly60Glu	c.179G>A	p.Gly60Glu	principal1	Y	1	YES	-	GGA	2	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.0	0.92824	D	1.0	0.90584	D	1.0	0.97372	D	0.000033	0.55875	U	0.000000	1	0.81001	D	simple_aae	G60E	4.065	0.97128	H	-3.26	0.93587	D	-7.49	0.95015	D	0.955	0.96416	1.1014	0.99717	D	0.9449	0.98198	D	10	0.603849	0.96520	D	0.958	0.99326	0.922	0.98639	P01111	G60E	Loss of catalytic residue at A59 (P = 0.038); Gain of disorder (P = 0.0681); Loss of loop (P = 0.0986); Gain of helix (P = 0.132); Gain of phosphorylation at T58 (P = 0.1467)	0.959995843908	0.95957	2.32877253769	0.96663	0.937324464321	0.99349	D	0.860794	0.96910	D	0.539472	0.95453	D	0.537137	0.95385	D	0.999893307685852	0.99577	D	0.885311	0.61048	D	.	.	.	.	.	.	3.920837	0.75952	26.5	4.077245	0.84895	28.4	0.9980826571228133	0.89264	0.98737	0.86207	D	AEFDBI	0.892748	0.83000	D	1.0699318946503	0.97537	16.29875	0.953413541574111	0.97506	16.24476	0.999999999999996	0.74766	0.722319	0.85440	0	0.581341	0.33841	0	0.702456	0.68683	0	0.735409	0.98432	0	NULL	NULL	5.08	5.08	0.68373	7.801000	0.84525	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	1.000000	0.97212	0.0:1.0:0.0:0.0	18.6626	0.91435	829	0.39537	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	143112	6.987534e-06	0	0	41936	0	0	0	13630	0	0	0	3324	0	0	0	3132	0	0	0	10436	0	0	1	64562	1.548899e-05	0	1	64562	1.548899e-05	0	13903	Pathogenic	Noonan_syndrome_1|Noonan_syndrome_6|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.114713911C>T	OMIM_Allelic_Variant:164790.0005|UniProtKB_(protein):P01111#VAR_063086	C4551602|C2750732|CN517202	163950|613224	.	Small GTP-binding protein domain	.	. 	.
1	114713915	C	T	A	T	rs730880965	1	115256536	1	115058059	59	NRAS	ENSG00000213281	ENST00000369535	ENSP00000358548	RASN_HUMAN	c.175G>A	p.A59T	c.175G>A	p.Ala59Thr	c.175G>A	p.Ala59Thr	principal1	Y	1	YES	-	GCT	1	0	C	C/C	C/C	C/C	0.065	0.36310	T	0.028	0.54934	D	0.875	0.48103	P	0.745	0.55870	P	0.000035	0.55875	U	0.000000	1	0.81001	D	simple_aae	A59T	3.385	0.91502	M	-2.42	0.88611	D	-3.59	0.69236	D	0.928	0.93252	0.9091	0.95802	D	0.8410	0.94687	D	10	0.271865	0.89909	D	0.873	0.96262	0.783	0.90689	P01111	A59T	Gain of glycosylation at T58 (P = 0.0656); Loss of helix (P = 0.1299); Loss of catalytic residue at A59 (P = 0.1404); Gain of disorder (P = 0.1568); Gain of phosphorylation at A59 (P = 0.1632)	0.861110126379	0.85976	0.90173056081	0.70663	0.887578964233	0.94956	D	0.731183	0.92478	D	0.312162	0.83907	D	0.210622	0.83697	D	0.988155841827393	0.78526	D	0.884911	0.60954	D	.	.	.	.	.	.	3.352548	0.60339	24.3	3.504870	0.67237	25.0	0.99883841960746622	0.95970	0.98737	0.86207	D	AEFDBI	0.859840	0.77759	D	0.887515922248404	0.91135	10.73253	0.829003760662022	0.91732	11.03868	0.999999999999996	0.74766	0.722319	0.85440	0	0.581341	0.33841	0	0.702456	0.68683	0	0.735409	0.98432	0	NULL	NULL	5.08	5.08	0.68373	7.801000	0.84525	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	0.999000	0.91618	0.0:1.0:0.0:0.0	18.6626	0.91435	829	0.39537	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	40473	Likely_pathogenic	not_provided	criteria_provided,_single_submitter	NC_000001.11:g.114713915C>T	.	CN517202	.	.	Small GTP-binding protein domain	.	. 	.
1	114713941	G	A	T	I	rs267606921	1	115256562	1	115058085	50	NRAS	ENSG00000213281	ENST00000369535	ENSP00000358548	RASN_HUMAN	c.149C>T	p.T50I	c.149C>T	p.Thr50Ile	c.149C>T	p.Thr50Ile	principal1	Y	1	YES	-	ACC	2	0	G	G/G	G/G	G/G	0.054	0.38633	T	0.222	0.25748	T	0.185	0.29232	B	0.074	0.28220	B	0.000021	0.55875	U	0.000000	1	0.81001	D	simple_aae	T50I	0.665	0.16292	N	-1.11	0.77466	T	-3.68	0.70314	D	0.897	0.89689	-0.7414	0.58381	T	0.1746	0.51816	T	10	0.01925	0.41561	T	0.693	0.89009	0.782	0.90613	P01111	T50I	Loss of sheet (P = 0.1158); Gain of stability (P = 0.1205); Loss of loop (P = 0.2897); Gain of catalytic residue at T50 (P = 0.3058); Loss of phosphorylation at T50 (P = 0.3452)	0.957862757569	0.95741	2.12843697498	0.95139	0.844822645187	0.88830	D	0.630061	0.88523	D	0.310656	0.83794	D	0.20846	0.83584	D	0.965212643146515	0.67198	D	0.939106	0.77081	D	.	.	.	.	.	.	2.818372	0.48135	23.1	2.430887	0.42182	22.4	0.99709942651562078	0.81283	0.99312	0.94338	D	AEFDBI	0.897995	0.84080	D	0.073355479729284	0.45222	2.782433	0.241349555971424	0.52158	3.392622	0.999999994863916	0.74766	0.722319	0.85440	0	0.581341	0.33841	0	0.702456	0.68683	0	0.735409	0.98432	0	NULL	NULL	5.08	4.16	0.48138	9.865000	0.98453	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	1.000000	0.86279	1.000000	0.97212	0.0:0.0:0.8575:0.1425	15.1124	0.72042	829	0.39537	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	13902	Pathogenic	Noonan_syndrome_1|Noonan_syndrome_6|Noonan_syndrome|Rasopathy	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.114713941G>A	OMIM_Allelic_Variant:164790.0004|UniProtKB_(protein):P01111#VAR_063085	C4551602|C2750732|C0028326|CN166718	163950|613224	ORPHA648|ORPHA536391	Small GTP-binding protein domain	.	. 	.
1	114716126	C	A	G	V	rs121913237	1	115258747	1	115060270	12	NRAS	ENSG00000213281	ENST00000369535	ENSP00000358548	RASN_HUMAN	c.35G>T	p.G12V	c.35G>T	p.Gly12Val	c.35G>T	p.Gly12Val	principal1	Y	1	YES	-	GGT	2	0	C	C/C	C/C	C/C	0.008	0.58626	D	0.001	0.83351	D	0.613	0.39753	P	0.52	0.48197	P	0.000025	0.55875	U	0.000000	1	0.81001	D	simple_aae	G12V	2.7	0.79018	M	-1.2	0.78537	T	-7.05	0.93856	D	0.935	0.94077	0.1431	0.84937	D	0.5454	0.83289	D	10	0.145241	0.82745	D	0.787	0.93044	0.896	0.97596	P01111	G12V	Loss of ubiquitination at K16 (P = 0.1037); Loss of methylation at K16 (P = 0.1769); Loss of disorder (P = 0.1841); Loss of sheet (P = 0.302); Loss of relative solvent accessibility (P = 0.3919)	0.911938280075	0.91105	2.18632837919	0.95598	0.90135371685	0.96589	D	0.659086	0.89747	D	0.38474	0.89010	D	0.314876	0.88872	D	0.994645953178406	0.86061	D	0.344566	0.07542	T	.	.	.	.	.	.	3.928735	0.76215	26.5	4.121058	0.86239	28.8	0.99665088774568356	0.78202	0.92468	0.55782	D	AEFDGBHCI	0.944304	0.95122	D	0.717393462304464	0.80773	7.369016	0.746575241810132	0.85902	8.720751	1.0	0.98316	0.627647	0.40530	0	0.672317	0.65289	0	0.685571	0.62057	0	0.657601	0.63696	0	NULL	NULL	5.58	5.58	0.84361	7.905000	0.86479	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	0.0:1.0:0.0:0.0	19.3769	0.94504	835	0.38313	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	40470	Pathogenic	Acute_myeloid_leukemia|Multiple_myeloma|Cutaneous_melanoma|Neoplasm_of_the_large_intestine|Adenocarcinoma_of_stomach|Myelodysplastic_syndrome|Noonan_syndrome|Malignant_melanoma_of_skin|Malignant_neoplasm_of_body_of_uterus|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.114716126C>A	.	C0023467|C0026764|C0025202|C0009404|C0278701|C3463824|C0028326|C0151779|C0153574|CN517202	601626|254500|614286	ORPHA519|ORPHA29073|ORPHA52688|ORPHA648|ORPHA213569	Small GTP-binding protein domain	.	. 	.
1	114716126	C	G	G	A	rs121913237	1	115258747	1	115060270	12	NRAS	ENSG00000213281	ENST00000369535	ENSP00000358548	RASN_HUMAN	c.35G>C	p.G12A	c.35G>C	p.Gly12Ala	c.35G>C	p.Gly12Ala	principal1	Y	1	YES	-	GGT	2	0	C	C/C	C/C	C/C	0.032	0.44694	D	0.019	0.59159	D	0.775	0.44108	P	0.589	0.50435	P	0.000025	0.55875	U	0.000000	1	0.81001	D	simple_aae	G12A	1.525	0.38595	L	-1.14	0.77843	T	-4.62	0.79143	D	0.825	0.82057	-0.0449	0.81314	T	0.4694	0.79562	T	10	0.07578	0.72372	D	0.689	0.88823	0.919	0.98533	P01111	G12A	Loss of ubiquitination at K16 (P = 0.1191); Loss of methylation at K16 (P = 0.1351); Loss of stability (P = 0.2599); Loss of sheet (P = 0.302); Loss of disorder (P = 0.3361)	0.868011717979	0.86673	1.28737985253	0.82694	0.894870460033	0.95852	D	0.632111	0.88611	D	0.219032	0.75682	D	0.0768482	0.75366	D	0.99155068397522	0.81865	D	0.912709	0.68911	D	.	.	.	.	.	.	3.849125	0.73674	26.1	3.958571	0.80850	27.3	0.99789383741208892	0.87484	0.92782	0.56532	D	AEFDGBHCI	0.938409	0.93756	D	0.693895945561063	0.79233	7.034521	0.736286919424017	0.85131	8.489467	1.0	0.98316	0.627647	0.40530	0	0.672317	0.65289	0	0.685571	0.62057	0	0.657601	0.63696	0	NULL	NULL	5.58	5.58	0.84361	7.905000	0.86479	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	0.0:1.0:0.0:0.0	19.3769	0.94504	835	0.38313	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	219097	Pathogenic	Acute_myeloid_leukemia|Multiple_myeloma|Cutaneous_melanoma|Non-small_cell_lung_cancer|Neoplasm_of_the_large_intestine|Adenocarcinoma_of_stomach|Myelodysplastic_syndrome|Malignant_melanoma_of_skin|Malignant_neoplasm_of_body_of_uterus|Myelodysplastic_syndrome_progressed_to_acute_myeloid_leukemia|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.114716126C>G	.	C0023467|C0026764|C0025202|C0007131|C0009404|C0278701|C3463824|C0151779|C0153574|CN234857|CN517202	601626|254500|614286	ORPHA519|ORPHA29073|ORPHA52688|ORPHA213569	Small GTP-binding protein domain	.	. 	.
1	114716126	C	T	G	D	rs121913237	1	115258747	1	115060270	12	NRAS	ENSG00000213281	ENST00000369535	ENSP00000358548	RASN_HUMAN	c.35G>A	p.G12D	c.35G>A	p.Gly12Asp	c.35G>A	p.Gly12Asp	principal1	Y	1	YES	-	GGT	2	0	C	C/C	C/C	C/C	0.011	0.55530	D	0.0	0.92824	D	0.372	0.34134	B	0.399	0.44455	B	0.000025	0.55875	U	0.000000	1	0.81001	D	simple_aae	G12D	3.105	0.87672	M	-1.19	0.78427	T	-5.35	0.84742	D	0.908	0.90932	0.1601	0.85230	D	0.5654	0.84226	D	10	0.148573	0.83047	D	0.783	0.92884	.	NULL	.	.	.	0.932073475879	0.93137	2.03506070386	0.94168	0.931540608406	0.99072	D	0.649478	0.89345	D	0.39426	0.89578	D	0.328551	0.89447	D	0.989752411842346	0.79975	D	0.311569	0.06072	T	.	.	.	.	.	.	3.486984	0.63763	24.7	3.692044	0.72231	25.7	0.99807341351654988	0.89174	0.91067	0.52795	D	AEFDGBHCI	0.930340	0.91749	D	0.646495593583447	0.76141	6.432235	0.69509339068702	0.82003	7.661363	1.0	0.98316	0.627647	0.40530	0	0.672317	0.65289	0	0.685571	0.62057	0	0.657601	0.63696	0	NULL	NULL	5.58	5.58	0.84361	7.905000	0.86479	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	0.0:1.0:0.0:0.0	19.3769	0.94504	835	0.38313	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	1	1.1627906976744187E-4	2	1.647e-05	1	8.237e-06	0	0	0	0	0	0	0	0	1	1.498e-05	0	0	2	1.883e-05	1	9.415e-06	0	0	0	0	0	0	0	0	1	1.840e-05	0	0	2	2.204e-05	1	1.102e-05	0	0	0	0	0	0	0	0	1	2.373e-05	0	0	.	2	251484	7.952792e-06	0	0	16256	0	0	0	34592	0	0	0	10078	0	0	0	18392	0	0	1	21648	4.619364e-05	0	1	113762	8.790281e-06	0	0	30616	0	0	1	113762	8.790281e-06	0	0	109406	0	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42766	0	0	0	15690	0	0	0	0	0	0	.	2	143254	1.396122e-05	0	0	42008	0	0	0	13658	0	0	0	3320	0	0	0	3132	0	0	0	10478	0	0	2	64560	3.097893e-05	0	2	64560	3.097893e-05	0	39648	Pathogenic	Acute_myeloid_leukemia|Multiple_myeloma|Epidermal_nevus|Cutaneous_melanoma|Juvenile_myelomonocytic_leukemia|Non-small_cell_lung_cancer|Neoplasm_of_the_large_intestine|Adenocarcinoma_of_stomach|Myelodysplastic_syndrome|Malignant_melanoma_of_skin|Malignant_neoplasm_of_body_of_uterus|not_provided	criteria_provided,_single_submitter	NC_000001.11:g.114716126C>T	OMIM_Allelic_Variant:164790.0007|UniProtKB_(protein):P01111#VAR_071129	C0023467|C0026764|C0334082|C0025202|C0349639|C0007131|C0009404|C0278701|C3463824|C0151779|C0153574|CN517202	601626|254500|162900|607785|614286	ORPHA519|ORPHA29073|ORPHA35125|ORPHA86834|ORPHA52688|ORPHA213569	Small GTP-binding protein domain	.	. 	.
1	114716127	C	A	G	C	rs121913250	1	115258748	1	115060271	12	NRAS	ENSG00000213281	ENST00000369535	ENSP00000358548	RASN_HUMAN	c.34G>T	p.G12C	c.34G>T	p.Gly12Cys	c.34G>T	p.Gly12Cys	principal1	Y	1	YES	-	GGT	1	0	C	C/C	C/C	C/C	0.065	0.36310	T	0.025	0.56192	D	0.675	0.41275	P	0.605	0.50945	P	0.000025	0.55875	U	0.000000	1	0.81001	D	simple_aae	G12C	2.995	0.85803	M	-1.24	0.78967	T	-7.09	0.93950	D	0.903	0.90363	0.2221	0.86285	D	0.5787	0.84827	D	10	0.098678	0.76981	D	0.773	0.92480	0.916	0.98422	P01111	G12C	Loss of disorder (P = 0.1073); Loss of ubiquitination at K16 (P = 0.1191); Loss of methylation at K16 (P = 0.1292); Loss of sheet (P = 0.302); Loss of relative solvent accessibility (P = 0.3919)	0.893071272495	0.89201	2.08749244515	0.94684	0.918128013611	0.98178	D	0.677554	0.90497	D	0.373122	0.88262	D	0.298187	0.88113	D	0.994021117687225	0.85086	D	0.306369	0.05889	T	.	.	.	.	.	.	4.178600	0.84766	28.5	4.368268	0.90837	31	0.99238574094862264	0.56469	0.92468	0.55782	D	AEFDGBHCI	0.950478	0.96414	D	0.76614373024068	0.83952	8.1541	0.780616321411702	0.88412	9.573273	1.0	0.98316	0.627647	0.40530	0	0.672317	0.65289	0	0.685571	0.62057	0	0.657601	0.63696	0	NULL	NULL	5.58	5.58	0.84361	7.905000	0.86479	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	0.0:1.0:0.0:0.0	19.3769	0.94504	835	0.38313	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	40468	Pathogenic	Acute_myeloid_leukemia|Multiple_myeloma|Cutaneous_melanoma|Non-small_cell_lung_cancer|Neoplasm_of_the_large_intestine|Adenocarcinoma_of_stomach|Myelodysplastic_syndrome|Malignant_melanoma_of_skin|Malignant_neoplasm_of_body_of_uterus|not_provided	criteria_provided,_single_submitter	NC_000001.11:g.114716127C>A	UniProtKB_(protein):P01111#VAR_021194	C0023467|C0026764|C0025202|C0007131|C0009404|C0278701|C3463824|C0151779|C0153574|CN517202	601626|254500|614286	ORPHA519|ORPHA29073|ORPHA52688|ORPHA213569	Small GTP-binding protein domain	.	. 	.
1	114716127	C	G	G	R	rs121913250	1	115258748	1	115060271	12	NRAS	ENSG00000213281	ENST00000369535	ENSP00000358548	RASN_HUMAN	c.34G>C	p.G12R	c.34G>C	p.Gly12Arg	c.34G>C	p.Gly12Arg	principal1	Y	1	YES	-	GGT	1	0	C	C/C	C/C	C/C	0.021	0.49117	D	0.005	0.72224	D	0.613	0.39753	P	0.602	0.50862	P	0.000025	0.55875	U	0.000000	1	0.81001	D	simple_aae	G12R	2.275	0.64647	M	-1.16	0.78082	T	-6.14	0.90140	D	0.905	0.90590	-0.0808	0.80536	T	0.4794	0.80083	T	10	0.070588	0.71044	D	0.713	0.89918	0.816	0.93058	P01111	G12R	Gain of MoRF binding (P = 0.0105); Gain of methylation at G12 (P = 0.0143); Gain of ubiquitination at K16 (P = 0.0522); Loss of catalytic residue at V9 (P = 0.1294); Gain of solvent accessibility (P = 0.1846)	0.913944370528	0.91308	2.16590570783	0.95413	0.928321123123	0.98889	D	0.658688	0.89731	D	0.350859	0.86564	D	0.266208	0.86388	D	0.995882391929626	0.88250	D	0.820618	0.47957	T	.	.	.	.	.	.	4.086874	0.81638	27.6	4.250396	0.89243	29.8	0.9991926512018755	0.98654	0.92782	0.56532	D	AEFDGBHCI	0.945956	0.95486	D	0.633275570982752	0.75291	6.279957	0.694134486763439	0.81933	7.643967	1.0	0.98316	0.627647	0.40530	0	0.672317	0.65289	0	0.685571	0.62057	0	0.657601	0.63696	0	NULL	NULL	5.58	5.58	0.84361	7.905000	0.86479	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	0.0:1.0:0.0:0.0	19.3769	0.94504	835	0.38313	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	40469	Pathogenic	Acute_myeloid_leukemia|Chronic_myelogenous_leukemia,_BCR-ABL1_positive|Multiple_myeloma|Cutaneous_melanoma|Non-small_cell_lung_cancer|Neoplasm_of_the_large_intestine|Adenocarcinoma_of_stomach|Myelodysplastic_syndrome|Malignant_melanoma_of_skin|Malignant_neoplasm_of_body_of_uterus|not_provided	criteria_provided,_single_submitter	NC_000001.11:g.114716127C>G	.	C0023467|C0023473|C0026764|C0025202|C0007131|C0009404|C0278701|C3463824|C0151779|C0153574|CN517202	601626|608232|254500|614286	ORPHA519|ORPHA521|ORPHA29073|ORPHA52688|ORPHA213569	Small GTP-binding protein domain	.	. 	.
1	114716127	C	T	G	S	rs121913250	1	115258748	1	115060271	12	NRAS	ENSG00000213281	ENST00000369535	ENSP00000358548	RASN_HUMAN	c.34G>A	p.G12S	c.34G>A	p.Gly12Ser	c.34G>A	p.Gly12Ser	principal1	Y	1	YES	-	GGT	1	0	C	C/C	C/C	C/C	0.029	0.45756	D	0.014	0.62352	D	0.329	0.33227	B	0.431	0.45421	B	0.000025	0.55875	U	0.000000	1	0.81001	D	simple_aae	G12S	0.79	0.19579	N	-1.01	0.76168	T	-4.44	0.77637	D	0.825	0.82057	-0.3770	0.72745	T	0.3554	0.71827	T	10	0.028066	0.50797	D	0.612	0.85012	0.896	0.97596	P01111	G12S	Gain of glycosylation at G12 (P = 0.0044); Loss of ubiquitination at K16 (P = 0.1037); Loss of sheet (P = 0.1158); Gain of methylation at K16 (P = 0.1763); Gain of disorder (P = 0.2179)	0.931994663837	0.93129	1.05385522469	0.76257	0.89466381073	0.95828	D	0.632111	0.88611	D	0.302595	0.83175	D	0.196881	0.82957	D	0.988803207874298	0.79093	D	0.69993	0.30971	T	.	.	.	.	.	.	3.548009	0.65336	24.9	3.748883	0.73898	26.0	0.99829667439660452	0.91112	0.91067	0.52795	D	AEFDGBHCI	0.932376	0.92263	D	0.398404321116823	0.61335	4.333256	0.534743777096971	0.70343	5.491296	1.0	0.98316	0.627647	0.40530	0	0.672317	0.65289	0	0.685571	0.62057	0	0.657601	0.63696	0	NULL	NULL	5.58	5.58	0.84361	7.905000	0.86479	1.026000	0.45946	0.599000	0.40250	1.000000	0.71638	1.000000	0.86279	0.998000	0.85391	0.0:1.0:0.0:0.0	19.3769	0.94504	835	0.38313	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	177778	Pathogenic	Acute_myeloid_leukemia|Multiple_myeloma|Cutaneous_melanoma|Juvenile_myelomonocytic_leukemia|Non-small_cell_lung_cancer|Neoplasm_of_the_large_intestine|Adenocarcinoma_of_stomach|Myelodysplastic_syndrome|Noonan_syndrome|Rasopathy|Malignant_melanoma_of_skin|Malignant_neoplasm_of_body_of_uterus|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.114716127C>T	.	C0023467|C0026764|C0025202|C0349639|C0007131|C0009404|C0278701|C3463824|C0028326|CN166718|C0151779|C0153574|CN517202	601626|254500|607785|614286	ORPHA519|ORPHA29073|ORPHA86834|ORPHA52688|ORPHA648|ORPHA536391|ORPHA213569	Small GTP-binding protein domain	.	. 	.
1	115701307	A	T	D	E	rs150486780	1	116243928	1	116045451	378	CASQ2	ENSG00000118729	ENST00000261448	ENSP00000261448	CASQ2_HUMAN	c.1134T>A	p.D378E	c.1134T>A	p.Asp378Glu	c.1134T>A	p.Asp378Glu	principal1	Y	1	YES	-	GAT	3	2	A	./.	./.	./.	0.566	0.06262	T	0.132	0.34477	T	0.006	0.13644	B	0.007	0.12992	B	0.467849	0.12313	N	0.787417	0.999707;0.994699	0.23463	N;N	simple_aae;simple_aae	D378E;D307E	1.635	0.41844	L	2.16	0.19166	T	-1.63	0.39119	N	0.166	0.17553	-0.9964	0.30919	T	0.0121	0.04653	T	10	0.017879	0.39748	T	0.060	0.17682	.	NULL	.	.	.	0.242825505644	0.23883	0.0444491111685	0.04800	0.384276866913	0.22861	T	0.197247	0.55387	T	-0.288475	0.09790	T	-0.652151	0.08803	T	0.0331868012679771	0.02502	T	0.294271	0.05429	T	.	.	.	.	.	.	0.602053	0.10279	7.532	-1.492367	0.00097	0.001	0.46657837621379838	0.03754	0.11334	0.16565	N	AEFGBI	0.484345	0.52440	N	-1.94333410594468	0.00279	0.01197282	-2.0867969717898	0.00199	0.008765347	0.999989575976358	0.51787	0.525926	0.21836	0	0.547309	0.14657	0	0.615948	0.41167	0	0.530356	0.10902	0	NULL	NULL	5.21	-10.4	0.00257	-0.282000	0.08478	-2.399000	0.00435	-3.022000	0.00137	0.884000	0.31069	0.000000	0.01923	0.001000	0.02609	0.5911:0.1674:0.2415:0.0	10.2589	0.42593	810	0.42761	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	2.2696323195642307E-4	0	0.0	1	8.237e-06	1	8.256e-06	0	0	0	0	0	0	0	0	1	1.501e-05	0	0	1	9.416e-06	1	9.439e-06	0	0	0	0	0	0	0	0	1	1.843e-05	0	0	1	1.102e-05	1	1.105e-05	0	0	0	0	0	0	0	0	1	2.378e-05	0	0	lcr	1	251052	3.983239e-06	0	0	16244	0	0	0	34576	0	0	0	10072	0	0	0	18372	0	0	0	21640	0	0	1	113426	8.816321e-06	0	0	30596	0	0	1	113426	8.816321e-06	0	1	109344	9.145449e-06	0	0	7154	0	0	0	17104	0	0	0	2320	0	0	0	9034	0	0	0	13394	0	0	1	42742	2.339619e-05	0	0	15684	0	0	1	42742	2.339619e-05	0	lcr	3	143184	2.095206e-05	0	3	42006	7.141837e-05	0	0	13640	0	0	0	3318	0	0	0	3134	0	0	0	10458	0	0	0	64546	0	0	3	42006	7.141837e-05	0	227209	Likely_benign	not_specified	criteria_provided,_single_submitter	NC_000001.11:g.115701307A>T	.	CN169374	.	.	.	.	. 	.
1	115701359	C	G	W	S	rs786205792	1	116243980	1	116045503	361	CASQ2	ENSG00000118729	ENST00000261448	ENSP00000261448	CASQ2_HUMAN	c.1082G>C	p.W361S	c.1082G>C	p.Trp361Ser	c.1082G>C	p.Trp361Ser	principal1	Y	1	YES	-	TGG	2	0	C	C/C	C/C	C/C	0.0	0.91255	D	0.107	0.37730	T	1.0	0.90584	D	1.0	0.97372	D	0.000000	0.84330	D	0.000000	1;1	0.81001	D;D	simple_aae;simple_aae	W361S;W290S	2.685	0.78553	M	-1.28	0.79376	T	-11.15	0.99356	D	0.85	0.84609	0.4826	0.90301	D	0.7133	0.90156	D	10	0.074624	0.72086	D	0.830	0.94691	0.686	0.82359	O14958	W361S	Gain of phosphorylation at W361 (P = 0.0073); Loss of stability (P = 0.0618); Gain of disorder (P = 0.092); Gain of glycosylation at W361 (P = 0.0981); Loss of helix (P = 0.4763)	0.997480251415	0.99745	0.387562673612	0.40033	0.768356025219	0.77179	T	0.678955	0.90552	D	0.404113	0.90148	D	0.342704	0.90025	D	0.999797999858856	0.99036	D	0.960304	0.85063	D	.	.	.	.	.	.	4.315615	0.88580	29.7	4.528404	0.91953	32	0.99107804209874506	0.52648	0.99588	0.97739	D	AEFGBI	0.961465	0.98271	D	0.964050146375356	0.94525	12.8273	0.930037553368404	0.96754	15.1005	0.999999999899491	0.74766	0.603402	0.35316	0	0.588066	0.40923	0	0.615948	0.41167	0	0.663205	0.64265	0	NULL	NULL	5.86	5.86	0.93936	7.425000	0.79444	1.016000	0.38774	0.587000	0.30956	1.000000	0.71638	1.000000	0.86279	0.995000	0.73285	0.0:1.0:0.0:0.0	20.1735	0.98171	810	0.42761	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	190748	Likely_pathogenic	not_provided	criteria_provided,_single_submitter	NC_000001.11:g.115701359C>G	.	CN517202	.	.	Calsequestrin, conserved site	.	. 	.
1	115705208	G	A	P	L	rs139228801	1	116247829	1	116049352	308	CASQ2	ENSG00000118729	ENST00000261448	ENSP00000261448	CASQ2_HUMAN	c.923C>T	p.P308L	c.923C>T	p.Pro308Leu	c.923C>T	p.Pro308Leu	principal1	Y	1	YES	-	CCG	2	0	G	G/G	G/G	G/G	0.0	0.91255	D	0.016	0.60972	D	1.0	0.90584	D	1.0	0.97372	D	0.000000	0.84330	D	0.000000	1;1	0.81001	D;D	simple_aae;simple_aae	P308L;P237L	2.78	0.81115	M	-1.42	0.80645	T	-8.14	0.96736	D	0.974	0.98466	0.4215	0.89419	D	0.6942	0.89455	D	10	0.161198	0.84104	D	0.853	0.95535	.	NULL	.	.	.	0.998169679838	0.99815	0.323843627622	0.34541	0.728167057037	0.71239	T	0.669233	0.90163	D	0.28558	0.81788	D	0.353968	0.90473	D	0.995888292789459	0.88250	D	0.969903	0.89155	D	.	.	.	.	.	.	4.472574	0.90986	32	4.367164	0.90826	31	0.99919682197309856	0.98654	0.99025	0.90130	D	AEFBI	0.970092	0.99241	D	0.958882162721832	0.94332	12.67598	0.913633643495081	0.96138	14.34678	0.999999999999894	0.74766	0.497415	0.19182	0	0.59043	0.45803	0	0.573078	0.19857	0	0.542086	0.14980	0	NULL	NULL	5.58	5.58	0.84361	9.594000	0.97423	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.801000	0.33537	0.609000	0.31615	0.0:0.0:1.0:0.0	19.1719	0.93567	814	0.42100	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	2	4.5392646391284613E-4	0	0.0	5	4.118e-05	5	4.119e-05	2	1.922e-04	0	0	0	0	0	0	3	4.495e-05	0	0	4	3.766e-05	4	3.767e-05	2	2.206e-04	0	0	0	0	0	0	2	3.680e-05	0	0	5	5.510e-05	5	5.512e-05	2	1.925e-04	0	0	0	0	0	0	3	7.120e-05	0	0	.	8	251362	3.182661e-05	0	2	16254	1.230466e-04	0	0	34592	0	0	0	10070	0	0	0	18386	0	0	0	21648	0	0	6	113660	5.278902e-05	0	0	30614	0	0	2	16254	1.230466e-04	0	3	109400	2.742230e-05	0	1	7164	1.395868e-04	0	0	17112	0	0	0	2320	0	0	0	9040	0	0	0	13394	0	0	2	42768	4.676394e-05	0	0	15688	0	0	1	7164	1.395868e-04	0	.	6	143324	4.186319e-05	0	3	42054	7.133685e-05	0	0	13664	0	0	0	3322	0	0	0	3132	0	0	0	10472	0	0	3	64580	4.645401e-05	0	3	64580	4.645401e-05	0	190755	Pathogenic/Likely_pathogenic	Catecholaminergic_polymorphic_ventricular_tachycardia|Cardiovascular_phenotype|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.115705208G>A	.	C1631597|CN230736|CN517202	.	ORPHA3286	.	.	. 	.
1	115717869	A	G	I	T	rs762381137	1	116260490	1	116062013	270	CASQ2	ENSG00000118729	ENST00000261448	ENSP00000261448	CASQ2_HUMAN	c.809T>C	p.I270T	c.809T>C	p.Ile270Thr	c.809T>C	p.Ile270Thr	principal1	Y	1	YES	-	ATT	2	0	A	A/A	A/A	A/A	0.001	0.78490	D	0.018	0.59732	D	0.991	0.64070	D	0.882	0.62632	P	0.000002	0.62929	D	0.100018	1;1	0.81001	D;D	simple_aae;simple_aae	I270T;I199T	2.675	0.78361	M	-1.09	0.77206	T	-3.72	0.70793	D	0.845	0.84090	0.3055	0.87645	D	0.5837	0.85048	D	10	0.119483	0.79980	D	0.785	0.92964	0.813	0.92855	O14958	I270T	Gain of disorder (P = 0.0736); Loss of catalytic residue at V271 (P = 0.1647); Loss of stability (P = 0.2156); Gain of phosphorylation at I270 (P = 0.2652); Loss of sheet (P = 0.302)	0.99822581921	0.99821	0.236820913855	0.26224	0.781349301338	0.79130	T	0.694958	0.91165	D	0.127636	0.67131	D	-0.0544365	0.66718	D	0.995009303092957	0.86667	D	0.957704	0.84069	D	.	.	.	.	.	.	4.167124	0.84381	28.4	3.809171	0.75768	26.3	0.99864928990206714	0.94276	0.95435	0.64709	D	AEFBHCI	0.939966	0.94127	D	0.827646257700678	0.87802	9.345503	0.781011562221186	0.88444	9.584052	0.999999998709636	0.74766	0.525926	0.21836	0	0.600433	0.49495	0	0.596394	0.31383	0	0.584449	0.35598	0	NULL	NULL	5.15	5.15	0.70287	8.331000	0.89933	1.312000	0.94714	0.756000	0.94297	1.000000	0.71638	1.000000	0.86279	0.995000	0.73285	1.0:0.0:0.0:0.0	14.9551	0.70757	813	0.42397	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	8.236e-06	1	8.237e-06	0	0	0	0	0	0	0	0	1	1.498e-05	0	0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	1.102e-05	1	1.102e-05	0	0	0	0	0	0	0	0	1	2.373e-05	0	0	.	1	251314	3.979086e-06	0	0	16256	0	0	0	34590	0	0	0	10078	0	0	0	18390	0	0	0	21600	0	0	1	113650	8.798944e-06	0	0	30616	0	0	1	113650	8.798944e-06	0	0	109356	0	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9044	0	0	0	13346	0	0	0	42766	0	0	0	15690	0	0	0	0	0	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	190745	Likely_pathogenic	not_provided	criteria_provided,_single_submitter	NC_000001.11:g.115717869A>G	.	CN517202	.	.	.	.	. 	.
1	115726999	G	A	H	Y	rs142036299	1	116269620	1	116071143	244	CASQ2	ENSG00000118729	ENST00000261448	ENSP00000261448	CASQ2_HUMAN	c.730C>T	p.H244Y	c.730C>T	p.His244Tyr	c.730C>T	p.His244Tyr	principal1	Y	1	YES	-	CAC	1	0	G	G/G	G/G	G/G	0.001	0.78490	D	0.002	0.79402	D	0.993	0.65571	D	0.869	0.61749	P	0.000000	0.84330	D	0.044047	1;1	0.81001	D;D	simple_aae;simple_aae	H244Y;H173Y	2.49	0.72568	M	-1.18	0.78314	T	-3.87	0.72594	D	0.759	0.75742	0.1710	0.85416	D	0.6208	0.86638	D	10	0.067661	0.70230	D	0.656	0.87247	.	NULL	.	.	.	0.98247088746	0.98228	0.287521967924	0.31153	0.585388422012	0.50844	T	0.686682	0.90852	D	-0.230681	0.16560	T	-0.109992	0.62612	T	0.0808079625311049	0.10091	T	0.973903	0.90628	D	.	.	.	.	.	.	3.096542	0.54190	23.6	3.932341	0.79905	27.1	0.99737143836108033	0.83192	0.97864	0.77703	D	AEFBI	0.955446	0.97328	D	0.855862429741219	0.89440	9.972421	0.833567758838507	0.92021	11.19301	0.999999999999957	0.74766	0.487112	0.14033	0	0.547309	0.14657	0	0.573888	0.23631	0	0.564101	0.26826	0	NULL	NULL	5.75	5.75	0.90390	5.275000	0.65386	0.225000	0.25044	-0.107000	0.15377	1.000000	0.71638	0.987000	0.50568	0.807000	0.38039	0.0:0.0:1.0:0.0	19.6103	0.95596	780	0.47616	7	0.0013977635782747603	7	0.00529500756429652	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	26	2.141e-04	26	2.327e-04	25	2.653e-03	1	9.320e-05	0	0	0	0	0	0	0	0	23	2.166e-04	23	2.362e-04	22	2.704e-03	1	9.623e-05	0	0	0	0	0	0	0	0	26	2.865e-04	26	3.111e-04	25	2.658e-03	1	9.328e-05	0	0	0	0	0	0	0	0	.	47	250308	1.877687e-04	0	38	16158	2.351776e-03	0	8	34526	2.317094e-04	0	0	10042	0	0	0	18330	0	0	0	21566	0	0	0	113154	0	0	0	30424	0	0	38	16158	2.351776e-03	0	23	109004	2.110014e-04	0	18	7082	2.541655e-03	0	5	17070	2.929115e-04	0	0	2292	0	0	0	9008	0	0	0	13380	0	0	0	42664	0	0	0	15598	0	0	18	7082	2.541655e-03	0	.	107	143000	7.482517e-04	0	97	41928	2.313490e-03	0	8	13628	5.870267e-04	0	0	3322	0	0	0	3128	0	0	0	10394	0	0	1	64520	1.549907e-05	0	1	64520	1.549907e-05	0	227210	Conflicting_interpretations_of_pathogenicity	Ventricular_tachycardia,_catecholaminergic_polymorphic,_2|not_specified|Cardiovascular_phenotype	criteria_provided,_conflicting_interpretations	NC_000001.11:g.115726999G>A	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2315256	C2677794|CN169374|CN230736	611938	.	.	.	. 	.
1	115738253	A	G	I	T	rs148057999	1	116280874	1	116082397	168	CASQ2	ENSG00000118729	ENST00000261448	ENSP00000261448	CASQ2_HUMAN	c.503T>C	p.I168T	c.503T>C	p.Ile168Thr	c.503T>C	p.Ile168Thr	principal1	Y	1	YES	-	ATT	2	0	A	A/A	A/A	A/A	0.001	0.78490	D	0.002	0.79402	D	0.922	0.51142	P	0.821	0.59116	P	0.000171	0.48594	D	0.215200	0.999931;1	0.81001	D;D	simple_aae;without_aae	I168T;.	2.415	0.69758	M	-1.63	0.82440	D	-3.47	0.67824	D	0.915	0.91736	0.4215	0.89419	D	0.6399	0.87411	D	10	0.111431	0.78921	D	0.716	0.90052	.	NULL	.	.	.	0.981871880158	0.98167	0.308157786748	0.33120	0.632216513157	0.57459	T	0.664794	0.89983	D	0.16661	0.70812	D	0.0844129	0.75872	D	0.983997821807861	0.75459	D	0.966703	0.87848	D	.	.	.	.	.	.	4.046158	0.80211	27.3	3.718904	0.73005	25.9	0.99837074106062096	0.91800	0.97472	0.74969	D	AEFBI	0.939513	0.94021	D	0.756362489516662	0.83319	7.986395	0.738096760712536	0.85266	8.529331	0.999991063083309	0.74766	0.487112	0.14033	0	0.563428	0.19063	0	0.573888	0.23631	0	0.564101	0.26826	0	NULL	NULL	6.03	6.03	0.97798	7.922000	0.86947	1.312000	0.94714	0.756000	0.94297	1.000000	0.71638	0.934000	0.40176	0.780000	0.36908	1.0:0.0:0.0:0.0	14.788	0.69444	764	0.49969	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	1	1.1627906976744187E-4	2	1.647e-05	2	1.647e-05	0	0	0	0	0	0	0	0	1	1.498e-05	0	0	2	1.883e-05	2	1.883e-05	0	0	0	0	0	0	0	0	1	1.840e-05	0	0	2	2.204e-05	2	2.204e-05	0	0	0	0	0	0	0	0	1	2.373e-05	0	0	.	3	251436	1.193147e-05	0	0	16256	0	0	2	34592	5.781684e-05	0	0	10078	0	0	0	18392	0	0	0	21648	0	0	1	113718	8.793683e-06	0	0	30616	0	0	2	34592	5.781684e-05	0	1	109406	9.140267e-06	0	0	7164	0	0	1	17112	5.843852e-05	0	0	2320	0	0	0	9044	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	1	17112	5.843852e-05	0	.	10	143312	6.977783e-05	0	0	42054	0	0	9	13654	6.591475e-04	0	0	3322	0	0	0	3130	0	0	0	10480	0	0	1	64572	1.548659e-05	0	1	64572	1.548659e-05	0	190741	Conflicting_interpretations_of_pathogenicity	Catecholaminergic_polymorphic_ventricular_tachycardia|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.115738253A>G	.	C1631597|CN517202	.	ORPHA3286	.	.	. 	.
1	115768316	C	T	V	M	rs10801999	1	116310937	1	116112460	76	CASQ2	ENSG00000118729	ENST00000261448	ENSP00000261448	CASQ2_HUMAN	c.226G>A	p.V76M	c.226G>A	p.Val76Met	c.226G>A	p.Val76Met	principal1	Y	1	YES	-	GTG	1	0	C	C/C	C/C	C/C	0.445	0.09128	T	0.324	0.18903	T	0.82	0.45712	P	0.225	0.38015	B	0.000000	0.84330	D	0.000000	1;0.909869	0.81001	D;D	simple_aae;simple_aae	V76M;V76M	2.39	0.68882	M	-1.08	0.77078	T	-0.69	0.19720	N	0.225	0.25253	-0.0533	0.81136	T	0.5343	0.82757	D	10	NULL	NULL	.	0.254	0.56829	.	NULL	.	.	.	NULL	NULL	0.318348307855	0.34060	0.726589262486	0.71009	T	0.179829	0.53096	T	-0.367888	0.03702	T	-0.158945	0.58447	T	0.021491189331824	0.00853	T	0.956004	0.83260	D	.	.	.	.	.	.	2.162303	0.33910	20.6	2.160442	0.36293	21.1	0.99757804262724925	0.84772	0.97069	0.72509	D	AEFDBIJ	0.876064	0.79987	D	0.42412596621924	0.62752	4.496358	0.417288619866744	0.62641	4.483031	0.999999999999976	0.74766	0.497415	0.19182	0	0.59043	0.45803	0	0.547309	0.15389	0	0.542086	0.14980	0	NULL	NULL	5.49	5.49	0.81022	5.855000	0.69252	1.026000	0.45946	0.549000	0.26987	1.000000	0.71638	0.729000	0.31609	0.433000	0.27516	0.0:1.0:0.0:0.0	19.3685	0.94465	783	0.47268	152	0.03035143769968051	2	0.0015128593040847202	3	0.002982107355864811	68	0.09798270893371758	61	0.060515873015873016	18	0.018404907975460124	NULL	NULL	NULL	NULL	NULL	NULL	13	0.0029505220154334997	6	6.976744186046512E-4	3042	2.506e-02	3042	2.506e-02	24	2.306e-03	1936	1.672e-01	564	6.529e-02	157	2.374e-02	152	2.277e-03	191	1.157e-02	2932	2.761e-02	2932	2.761e-02	17	1.875e-03	1894	1.689e-01	526	6.701e-02	157	2.374e-02	132	2.429e-03	191	1.164e-02	2721	2.998e-02	2721	2.999e-02	24	2.310e-03	1935	1.673e-01	401	7.133e-02	95	2.499e-02	61	1.447e-03	191	1.157e-02	.	7968	251022	3.174224e-02	544	36	16256	2.214567e-03	0	5473	34588	1.582341e-01	481	1	10074	9.926544e-05	0	1210	18384	6.581810e-02	48	564	21646	2.605562e-02	7	156	113330	1.376511e-03	1	383	30616	1.250980e-02	5	5473	34588	1.582341e-01	481	4010	109396	3.665582e-02	269	14	7164	1.954216e-03	0	2728	17112	1.594203e-01	242	0	2320	0	0	597	9036	6.606906e-02	23	359	13392	2.680705e-02	1	57	42768	1.332772e-03	1	199	15690	1.268324e-02	1	2728	17112	1.594203e-01	242	.	1875	143262	1.308791e-02	67	132	42026	3.140913e-03	0	1073	13648	7.861958e-02	54	1	3324	3.008424e-04	0	197	3130	6.293930e-02	7	287	10460	2.743786e-02	4	79	64576	1.223365e-03	0	68	3050	2.229508e-02	2	44162	Benign/Likely_benign	Cardiomyopathy|Ventricular_tachycardia,_catecholaminergic_polymorphic,_2|Catecholaminergic_polymorphic_ventricular_tachycardia|not_specified|Cardiovascular_phenotype	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.115768316C>T	Illumina_Clinical_Services_Laboratory,Illumina:78500|UniProtKB_(protein):O14958#VAR_023693	C0878544|C2677794|C1631597|CN169374|CN230736	611938	ORPHA167848|ORPHA3286	.	.	. 	.
1	115768346	T	C	T	A	rs4074536	1	116310967	1	116112490	66	CASQ2	ENSG00000118729	ENST00000261448	ENSP00000261448	CASQ2_HUMAN	c.196A>G	p.T66A	c.196A>G	p.Thr66Ala	c.196A>G	p.Thr66Ala	principal1	Y	1	YES	-	ACG	1	0	C	C/C	T/T	C/C	0.943	0.02181	T	1.0	0.01155	T	0.0	0.02946	B	0.0	0.01387	B	0.025162	0.26135	N	0.442334	1;1	0.08975	P;P	simple_aae;simple_aae	T66A;T66A	-1.7	0.00354	N	1.18	0.37746	T	0.49	0.02993	N	0.01	0.00095	-0.9393	0.42727	T	0.0064	0.02168	T	9	NULL	NULL	.	0.086	0.25457	.	NULL	.	.	.	NULL	NULL	0.0457679641949	0.04968	0.300364643335	0.10455	T	0.08587	0.37599	T	-0.797124	0.00008	T	-0.77397	0.02640	T	0.000220162258131143	0.00001	T	0.00779922	0.00034	T	.	.	.	.	.	.	0.102400	0.05034	2.113	-0.001783	0.04759	2.597	0.18263294931457388	0.00567	0.07724	0.13725	N	AEFDBIJ	0.082735	0.16756	N	-1.33178622643283	0.03317	0.1479811	-1.17295485904305	0.06364	0.3061405	0.999475944543718	0.39898	0.497415	0.19182	0	0.59043	0.45803	0	0.547309	0.15389	0	0.542086	0.14980	0	NULL	NULL	5.49	3.44	0.38486	1.629000	0.36683	-1.586000	0.01114	-0.230000	0.07744	0.308000	0.25396	0.001000	0.05097	0.005000	0.06747	0.3705:0.5482:0.0:0.0813	8.6205	0.33019	783	0.47268	2009	0.40115814696485624	642	0.4856278366111952	294	0.2922465208747515	255	0.36743515850144093	520	0.5158730158730159	298	0.3047034764826176	1077	0.290453074433657	1149	0.2981318111053451	2226	0.2943665696905581	1928	0.4375851112119837	2486	0.28906976744186047	39634	3.264e-01	39634	3.265e-01	4722	4.538e-01	4208	3.635e-01	4735	5.483e-01	1806	2.731e-01	18935	2.837e-01	4952	2.999e-01	34996	3.295e-01	34996	3.296e-01	4153	4.581e-01	4064	3.624e-01	4351	5.544e-01	1806	2.731e-01	15476	2.848e-01	4929	3.004e-01	30510	3.362e-01	30510	3.362e-01	4715	4.539e-01	4202	3.634e-01	3059	5.430e-01	1072	2.820e-01	12285	2.915e-01	4949	2.999e-01	.	82656	251288	3.289294e-01	14499	7384	16256	4.542323e-01	1668	12439	34590	3.596126e-01	2215	2627	10078	2.606668e-01	347	10095	18394	5.488203e-01	2822	6000	21648	2.771619e-01	887	32849	113574	2.892299e-01	4746	9260	30616	3.024562e-01	1476	10095	18394	5.488203e-01	2822	36553	109408	3.340981e-01	6515	3223	7164	4.498883e-01	732	6177	17112	3.609748e-01	1125	601	2320	2.590517e-01	73	5005	9046	5.532832e-01	1402	3750	13394	2.799761e-01	540	12416	42768	2.903105e-01	1764	4758	15690	3.032505e-01	760	5005	9046	5.532832e-01	1402	.	49192	142964	3.440866e-01	8973	18696	41876	4.464610e-01	4204	4691	13630	3.441673e-01	813	831	3322	2.501505e-01	100	1679	3116	5.388318e-01	446	2988	10422	2.867012e-01	438	18183	64514	2.818458e-01	2578	937	3036	3.086298e-01	167	44160	Benign	Ventricular_tachycardia,_catecholaminergic_polymorphic,_2|not_specified|Cardiovascular_phenotype	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.115768346T>C	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:49998|Illumina_Clinical_Services_Laboratory,Illumina:2219|UniProtKB_(protein):O14958#VAR_023692	C2677794|CN169374|CN230736	611938	.	.	CASQ2|VANGL1|CASQ2|CASQ2|VANGL1|CASQ2|CASQ2	Artery_Coronary|Artery_Tibial|Artery_Tibial|Colon_Transverse|Esophagus_Muscularis|Heart_Atrial_Appendage|Heart_Left_Ventricle 	.
1	115768448	C	T	D	N	rs147941846	1	116311069	1	116112592	32	CASQ2	ENSG00000118729	ENST00000261448	ENSP00000261448	CASQ2_HUMAN	c.94G>A	p.D32N	c.94G>A	p.Asp32Asn	c.94G>A	p.Asp32Asn	principal1	Y	1	YES	-	GAC	1	0	C	C/C	C/C	C/C	0.008	0.58626	D	0.0	0.92824	D	1.0	0.90584	D	1.0	0.97372	D	0.000000	0.84330	D	0.000000	1;0.996702	0.81001	D;D	simple_aae;simple_aae	D32N;D32N	2.78	0.81115	M	-1.33	0.79854	T	-3.26	0.65397	D	0.586	0.60664	0.5168	0.90781	D	0.7014	0.89720	D	10	0.153056	0.83438	D	0.657	0.87296	0.734	0.86714	O14958	D32N	Gain of MoRF binding (P = 0.0698); Loss of stability (P = 0.1033); Loss of sheet (P = 0.1398); Loss of disorder (P = 0.1665); Gain of methylation at K31 (P = 0.1818)	0.997908391905	0.99788	0.307859778024	0.33085	0.709800183773	0.68565	T	0.593832	0.86882	D	-0.029305	0.47517	T	-0.279871	0.46816	T	0.996400117874146	0.89278	D	0.987001	0.95549	D	.	.	.	.	.	.	4.242499	0.86739	29.1	4.148529	0.86986	29.0	0.9991792034223258	0.98518	0.98239	0.80830	D	AEFDBI	0.971282	0.99338	D	0.90743156547456	0.92119	11.24353	0.862785031967211	0.93741	12.24742	0.999999999999976	0.74766	0.497415	0.19182	0	0.59043	0.45803	0	0.547309	0.15389	0	0.542086	0.14980	0	NULL	NULL	5.49	5.49	0.81022	7.568000	0.81546	1.026000	0.45946	0.549000	0.26987	1.000000	0.71638	0.998000	0.65909	0.998000	0.85391	0.0:1.0:0.0:0.0	19.3685	0.94465	783	0.47268	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	68878	Likely_pathogenic	not_provided	criteria_provided,_single_submitter	NC_000001.11:g.115768448C>T	.	CN517202	.	.	Calsequestrin, conserved site	.	. 	.
1	115768523	A	G	F	L	rs727502911	1	116311144	1	116112667	7	CASQ2	ENSG00000118729	ENST00000261448	ENSP00000261448	CASQ2_HUMAN	c.19T>C	p.F7L	c.19T>C	p.Phe7Leu	c.19T>C	p.Phe7Leu	principal1	Y	1	YES	-	TTT	1	0	A	A/A	A/A	A/A	0.662	0.04671	T	1.0	0.01155	T	0.0	0.02946	B	0.001	0.04355	B	0.423476	0.12840	N	0.755486	0.999966;0.999975	0.18878	N;N	simple_aae;simple_aae	F7L;F7L	-0.68	0.02027	N	-0.69	0.72678	T	0.41	0.03407	N	0.074	0.04790	-1.0058	0.28216	T	0.0296	0.12717	T	10	0.007944	0.21059	T	0.126	0.35136	0.572	0.69552	O14958	F7L	Loss of MoRF binding (P = 0.1121); Gain of disorder (P = 0.1394); Loss of methylation at R3 (P = 0.1406); Gain of loop (P = 0.2045); Gain of helix (P = 0.2294)	0.476445137733	0.47274	0.0516909325249	0.05692	0.377955555916	0.21965	T	0.068045	0.33357	T	-0.259149	0.13000	T	-0.610026	0.11983	T	0.0615713594653259	0.07414	T	0.572743	0.20478	T	.	.	.	.	.	.	1.620724	0.23772	16.51	0.719132	0.13421	11.31	0.84740584752255976	0.15470	0.43885	0.27197	N	AEFBI	0.112794	0.22281	N	-0.834840453000632	0.12427	0.6056315	-0.655000404054399	0.18090	0.9648755	0.998032538123321	0.36340	0.497415	0.19182	0	0.59043	0.45803	0	0.547309	0.15389	0	0.542086	0.14980	0	NULL	NULL	5.64	2.19	0.26890	1.591000	0.36275	-0.043000	0.13315	0.691000	0.84096	1.000000	0.71638	0.213000	0.22414	0.856000	0.40543	0.3395:0.1586:0.3247:0.1772	0.9164	0.01223	783	0.47268	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	162823	Likely_benign	not_specified	criteria_provided,_single_submitter	NC_000001.11:g.115768523A>G	.	CN169374	.	.	.	.	. 	.
1	119033203	T	C	Y	C	rs139194636	1	119575826	1	119377349	264	WARS2	ENSG00000116874	ENST00000235521	ENSP00000235521	SYWM_HUMAN	c.791A>G	p.Y264C	c.791A>G	p.Tyr264Cys	c.791A>G	p.Tyr264Cys	principal1	Y	1	YES	-	TAT	2	0	T	T/T	T/T	T/T	0.001	0.78490	D	0.004	0.74150	D	1.0	0.90584	D	0.999	0.92359	D	0.000204	0.47681	D	0.226336	0.999998;0.999998;1	0.81001	D;D;D	simple_aae;simple_aae;without_aae	Y264C;Y170C;.	3.295	0.90403	M	1.41	0.33412	T	-8.06	0.96621	D	0.552	0.57775	-0.3754	0.72795	T	0.2248	0.58919	T	10	0.059493	0.67683	D	0.338	0.66354	.	NULL	.	.	.	0.364535869594	0.36064	1.4025835623	0.85236	0.590684890747	0.51590	T	0.472234	0.80460	T	-0.230203	0.16621	T	-0.172269	0.57235	T	0.993008017539978	0.83645	D	0.987201	0.95630	D	.	.	.	.	.	.	3.557845	0.65591	24.9	3.574540	0.69045	25.2	0.99780161106117304	0.86693	0.90722	0.52138	D	AEFGBI	0.360528	0.45046	N	0.70297126095245	0.79826	7.16076	0.582649072922155	0.73698	6.012985	0.042531792859288	0.14530	0.693126	0.56070	0	0.659464	0.62310	0	0.658983	0.55881	0	0.655142	0.61905	0	NULL	NULL	5.87	4.71	0.59010	2.857000	0.48048	1.138000	0.64695	0.665000	0.62972	0.998000	0.41325	0.807000	0.33722	0.462000	0.28163	0.1278:0.0:0.0:0.8722	12.2177	0.53728	842	0.36989	1	1.9968051118210862E-4	1	7.564296520423601E-4	0	0.0	0	0.0	0	0.0	0	0.0	NULL	NULL	NULL	NULL	NULL	NULL	1	2.2696323195642307E-4	0	0.0	6	4.942e-05	6	4.943e-05	4	3.844e-04	0	0	0	0	0	0	1	1.499e-05	0	0	6	5.649e-05	6	5.650e-05	4	4.412e-04	0	0	0	0	0	0	1	1.840e-05	0	0	5	5.510e-05	5	5.511e-05	4	3.851e-04	0	0	0	0	0	0	0	0	0	0	.	16	250944	6.375925e-05	0	15	16256	9.227362e-04	0	0	34592	0	0	0	10076	0	0	0	18394	0	0	0	21636	0	0	1	113238	8.830958e-06	0	0	30616	0	0	15	16256	9.227362e-04	0	8	109396	7.312882e-05	0	8	7164	1.116695e-03	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13382	0	0	0	42768	0	0	0	15690	0	0	8	7164	1.116695e-03	0	.	33	143364	2.301833e-04	0	30	42064	7.131989e-04	0	2	13664	1.463700e-04	0	0	3324	0	0	0	3134	0	0	0	10484	0	0	1	64590	1.548227e-05	0	1	64590	1.548227e-05	0	224151	Likely_pathogenic	not_provided	criteria_provided,_single_submitter	NC_000001.11:g.119033203T>C	.	CN517202	.	.	.	.	. 	.
1	119727010	G	A	G	R	rs587777770	1	120269633	1	120071156	118	PHGDH	ENSG00000092621	ENST00000641272	ENSP00000493432	A0A286YFM8_HUMAN	.	.	.	.	c.352G>A	p.Gly118Arg	.	.	.	.	+	GGA	1	0	G	G/G	G/G	G/G	NULL	0.91255	.	NULL	0.92824	.	NULL	0.90584	.	NULL	0.97372	.	0.000000	0.84330	D	0.048251	1;1	0.81001	D;D	simple_aae;simple_aae	G140R;G106R	NULL	0.83555	.	NULL	0.81987	.	NULL	0.96368	.	NULL	0.94904	0.6611	0.92684	D	0.7557	0.91675	D	10	0.464384	0.94570	D	0.975	0.99765	0.849	0.95142	O43175	G140R	Loss of sheet (P = 0.007); Gain of MoRF binding (P = 0.0148); Gain of loop (P = 0.0435); Gain of methylation at G140 (P = 0.0524); Gain of disorder (P = 0.1923)	NULL	0.97344	NULL	0.73431	0.747325539589	0.74052	T	NULL	0.98525	.	0.449794	0.92474	D	0.408322	0.92381	D	0.998413443565369	0.94084	D	0.992526	0.97582	D	.	.	.	.	.	.	4.102972	0.82187	27.8	4.331031	0.90425	31	0.99934140671338501	0.99535	0.95568	0.65241	D	AEFDBCI	0.954402	0.97148	D	0.972684274158569	0.94842	13.08549	0.925335415902816	0.96585	14.87952	1.0	0.98316	0.722319	0.85440	0	0.724815	0.89359	0	0.702456	0.68683	0	0.735409	0.98432	0	NULL	NULL	5.68	5.68	0.88021	8.017000	0.88732	1.172000	0.72986	0.672000	0.70159	1.000000	0.71638	0.996000	0.59523	0.995000	0.73285	0.0:0.0:1.0:0.0	18.3597	0.90314	753	0.51500	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251474	3.976554e-06	0	1	16256	6.151575e-05	0	0	34590	0	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	0	113752	0	0	0	30614	0	0	1	16256	6.151575e-05	0	1	109408	9.140099e-06	0	1	7164	1.395868e-04	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	1	7164	1.395868e-04	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	139534	Pathogenic/Likely_pathogenic	Neu-Laxova_syndrome_1|not_provided	no_assertion_criteria_provided	NC_000001.11:g.119727010G>A	OMIM_Allelic_Variant:606879.0007|UniProtKB_(protein):O43175#VAR_071819	C4551478|CN517202	256520	.	D-isomer specific 2-hydroxyacid dehydrogenase, NAD-binding domain	.	. 	.
1	119727010	G	A	G	R	rs587777770	1	120269633	1	120071156	140	PHGDH	ENSG00000092621	ENST00000369409	ENSP00000358417	A0A2C9F2M7_HUMAN	c.418G>A	p.G140R	c.418G>A	p.Gly140Arg	c.418G>A	p.Gly140Arg	.	Y	1	.	+	GGA	1	0	G	G/G	G/G	G/G	0.0	0.91255	D	0.0	0.92824	D	NULL	0.90584	.	NULL	0.97372	.	0.000000	0.84330	D	0.048251	1;1	0.81001	D;D	simple_aae;simple_aae	G140R;G106R	NULL	0.83555	.	-1.58	0.81987	D	-7.97	0.96368	D	0.942	0.94904	0.6611	0.92684	D	0.7557	0.91675	D	10	0.464384	0.94570	D	0.975	0.99765	0.849	0.95142	O43175	G140R	Loss of sheet (P = 0.007); Gain of MoRF binding (P = 0.0148); Gain of loop (P = 0.0435); Gain of methylation at G140 (P = 0.0524); Gain of disorder (P = 0.1923)	0.97372677379	0.97344	0.972712254251	0.73431	0.747325539589	0.74052	T	NULL	0.98525	.	0.449794	0.92474	D	0.408322	0.92381	D	0.998413443565369	0.94084	D	0.965303	0.97582	D	.	.	.	.	.	.	4.102972	0.82187	27.8	4.331031	0.90425	31	0.99934140671338501	0.99535	0.95568	0.65241	D	AEFDBCI	0.954402	0.97148	D	0.972684274158569	0.94842	13.08549	0.925335415902816	0.96585	14.87952	1.0	0.98316	0.722319	0.85440	0	0.724815	0.89359	0	0.702456	0.68683	0	0.735409	0.98432	0	NULL	NULL	5.68	5.68	0.88021	8.017000	0.88732	1.172000	0.72986	0.672000	0.70159	1.000000	0.71638	0.996000	0.59523	0.995000	0.73285	0.0:0.0:1.0:0.0	18.3597	0.90314	753	0.51500	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251474	3.976554e-06	0	1	16256	6.151575e-05	0	0	34590	0	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	0	113752	0	0	0	30614	0	0	1	16256	6.151575e-05	0	1	109408	9.140099e-06	0	1	7164	1.395868e-04	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	1	7164	1.395868e-04	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	139534	Pathogenic/Likely_pathogenic	Neu-Laxova_syndrome_1|not_provided	no_assertion_criteria_provided	NC_000001.11:g.119727010G>A	OMIM_Allelic_Variant:606879.0007|UniProtKB_(protein):O43175#VAR_071819	C4551478|CN517202	256520	.	D-isomer specific 2-hydroxyacid dehydrogenase, catalytic domain|D-isomer specific 2-hydroxyacid dehydrogenase, NAD-binding domain	.	. 	.
1	119727010	G	A	G	R	rs587777770	1	120269633	1	120071156	140	PHGDH	ENSG00000092621	ENST00000641023	ENSP00000493175	SERA_HUMAN	.	.	.	.	c.418G>A	p.Gly140Arg	principal1	Y	.	.	+	GGA	1	0	G	G/G	G/G	G/G	NULL	0.91255	.	NULL	0.92824	.	1.0	0.90584	D	1.0	0.97372	D	0.000000	0.84330	D	0.048251	1;1	0.81001	D;D	simple_aae;simple_aae	G140R;G106R	2.885	0.83555	M	NULL	0.81987	.	NULL	0.96368	.	NULL	0.94904	0.6611	0.92684	D	0.7557	0.91675	D	10	0.464384	0.94570	D	0.975	0.99765	0.849	0.95142	O43175	G140R	Loss of sheet (P = 0.007); Gain of MoRF binding (P = 0.0148); Gain of loop (P = 0.0435); Gain of methylation at G140 (P = 0.0524); Gain of disorder (P = 0.1923)	NULL	0.97344	NULL	0.73431	0.747325539589	0.74052	T	0.918608	0.98525	D	0.449794	0.92474	D	0.408322	0.92381	D	0.998413443565369	0.94084	D	0.957038	0.97582	D	.	.	.	.	.	.	4.102972	0.82187	27.8	4.331031	0.90425	31	0.99934140671338501	0.99535	0.95568	0.65241	D	AEFDBCI	0.954402	0.97148	D	0.972684274158569	0.94842	13.08549	0.925335415902816	0.96585	14.87952	1.0	0.98316	0.722319	0.85440	0	0.724815	0.89359	0	0.702456	0.68683	0	0.735409	0.98432	0	NULL	NULL	5.68	5.68	0.88021	8.017000	0.88732	1.172000	0.72986	0.672000	0.70159	1.000000	0.71638	0.996000	0.59523	0.995000	0.73285	0.0:0.0:1.0:0.0	18.3597	0.90314	753	0.51500	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251474	3.976554e-06	0	1	16256	6.151575e-05	0	0	34590	0	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	0	113752	0	0	0	30614	0	0	1	16256	6.151575e-05	0	1	109408	9.140099e-06	0	1	7164	1.395868e-04	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	1	7164	1.395868e-04	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	139534	Pathogenic/Likely_pathogenic	Neu-Laxova_syndrome_1|not_provided	no_assertion_criteria_provided	NC_000001.11:g.119727010G>A	OMIM_Allelic_Variant:606879.0007|UniProtKB_(protein):O43175#VAR_071819	C4551478|CN517202	256520	.	D-isomer specific 2-hydroxyacid dehydrogenase, catalytic domain|D-isomer specific 2-hydroxyacid dehydrogenase, NAD-binding domain	.	. 	.
1	119727010	G	A	G	R	rs587777770	1	120269633	1	120071156	140	PHGDH	ENSG00000092621	ENST00000641074	ENSP00000493446	A0A286YFL2_HUMAN	.	.	.	.	c.418G>A	p.Gly140Arg	.	Y	.	.	+	GGA	1	0	G	G/G	G/G	G/G	NULL	0.91255	.	NULL	0.92824	.	NULL	0.90584	.	NULL	0.97372	.	0.000000	0.84330	D	0.048251	1;1	0.81001	D;D	simple_aae;simple_aae	G140R;G106R	NULL	0.83555	.	NULL	0.81987	.	NULL	0.96368	.	NULL	0.94904	0.6611	0.92684	D	0.7557	0.91675	D	10	0.464384	0.94570	D	0.975	0.99765	0.849	0.95142	O43175	G140R	Loss of sheet (P = 0.007); Gain of MoRF binding (P = 0.0148); Gain of loop (P = 0.0435); Gain of methylation at G140 (P = 0.0524); Gain of disorder (P = 0.1923)	NULL	0.97344	NULL	0.73431	0.747325539589	0.74052	T	NULL	0.98525	.	0.449794	0.92474	D	0.408322	0.92381	D	0.998413443565369	0.94084	D	0.984901	0.97582	D	.	.	.	.	.	.	4.102972	0.82187	27.8	4.331031	0.90425	31	0.99934140671338501	0.99535	0.95568	0.65241	D	AEFDBCI	0.954402	0.97148	D	0.972684274158569	0.94842	13.08549	0.925335415902816	0.96585	14.87952	1.0	0.98316	0.722319	0.85440	0	0.724815	0.89359	0	0.702456	0.68683	0	0.735409	0.98432	0	NULL	NULL	5.68	5.68	0.88021	8.017000	0.88732	1.172000	0.72986	0.672000	0.70159	1.000000	0.71638	0.996000	0.59523	0.995000	0.73285	0.0:0.0:1.0:0.0	18.3597	0.90314	753	0.51500	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251474	3.976554e-06	0	1	16256	6.151575e-05	0	0	34590	0	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	0	113752	0	0	0	30614	0	0	1	16256	6.151575e-05	0	1	109408	9.140099e-06	0	1	7164	1.395868e-04	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	1	7164	1.395868e-04	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	139534	Pathogenic/Likely_pathogenic	Neu-Laxova_syndrome_1|not_provided	no_assertion_criteria_provided	NC_000001.11:g.119727010G>A	OMIM_Allelic_Variant:606879.0007|UniProtKB_(protein):O43175#VAR_071819	C4551478|CN517202	256520	.	D-isomer specific 2-hydroxyacid dehydrogenase, catalytic domain|D-isomer specific 2-hydroxyacid dehydrogenase, NAD-binding domain	.	. 	.
1	119727010	G	A	G	R	rs587777770	1	120269633	1	120071156	140	PHGDH	ENSG00000092621	ENST00000641115	ENSP00000493264	A0A286YFA2_HUMAN	.	.	.	.	c.418G>A	p.Gly140Arg	.	Y	.	.	+	GGA	1	0	G	G/G	G/G	G/G	NULL	0.91255	.	NULL	0.92824	.	NULL	0.90584	.	NULL	0.97372	.	0.000000	0.84330	D	0.048251	1;1	0.81001	D;D	simple_aae;simple_aae	G140R;G106R	NULL	0.83555	.	NULL	0.81987	.	NULL	0.96368	.	NULL	0.94904	0.6611	0.92684	D	0.7557	0.91675	D	10	0.464384	0.94570	D	0.975	0.99765	0.849	0.95142	O43175	G140R	Loss of sheet (P = 0.007); Gain of MoRF binding (P = 0.0148); Gain of loop (P = 0.0435); Gain of methylation at G140 (P = 0.0524); Gain of disorder (P = 0.1923)	NULL	0.97344	NULL	0.73431	0.747325539589	0.74052	T	NULL	0.98525	.	0.449794	0.92474	D	0.408322	0.92381	D	0.998413443565369	0.94084	D	0.992526	0.97582	D	.	.	.	.	.	.	4.102972	0.82187	27.8	4.331031	0.90425	31	0.99934140671338501	0.99535	0.95568	0.65241	D	AEFDBCI	0.954402	0.97148	D	0.972684274158569	0.94842	13.08549	0.925335415902816	0.96585	14.87952	1.0	0.98316	0.722319	0.85440	0	0.724815	0.89359	0	0.702456	0.68683	0	0.735409	0.98432	0	NULL	NULL	5.68	5.68	0.88021	8.017000	0.88732	1.172000	0.72986	0.672000	0.70159	1.000000	0.71638	0.996000	0.59523	0.995000	0.73285	0.0:0.0:1.0:0.0	18.3597	0.90314	753	0.51500	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251474	3.976554e-06	0	1	16256	6.151575e-05	0	0	34590	0	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	0	113752	0	0	0	30614	0	0	1	16256	6.151575e-05	0	1	109408	9.140099e-06	0	1	7164	1.395868e-04	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	1	7164	1.395868e-04	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	139534	Pathogenic/Likely_pathogenic	Neu-Laxova_syndrome_1|not_provided	no_assertion_criteria_provided	NC_000001.11:g.119727010G>A	OMIM_Allelic_Variant:606879.0007|UniProtKB_(protein):O43175#VAR_071819	C4551478|CN517202	256520	.	D-isomer specific 2-hydroxyacid dehydrogenase, catalytic domain|D-isomer specific 2-hydroxyacid dehydrogenase, NAD-binding domain	.	. 	.
1	119727010	G	A	G	R	rs587777770	1	120269633	1	120071156	140	PHGDH	ENSG00000092621	ENST00000641597	ENSP00000493382	SERA_HUMAN	.	.	.	.	c.418G>A	p.Gly140Arg	principal1	Y	.	YES	+	GGA	1	0	G	G/G	G/G	G/G	NULL	0.91255	.	NULL	0.92824	.	1.0	0.90584	D	1.0	0.97372	D	0.000000	0.84330	D	0.048251	1;1	0.81001	D;D	simple_aae;simple_aae	G140R;G106R	2.885	0.83555	M	NULL	0.81987	.	NULL	0.96368	.	NULL	0.94904	0.6611	0.92684	D	0.7557	0.91675	D	10	0.464384	0.94570	D	0.975	0.99765	0.849	0.95142	O43175	G140R	Loss of sheet (P = 0.007); Gain of MoRF binding (P = 0.0148); Gain of loop (P = 0.0435); Gain of methylation at G140 (P = 0.0524); Gain of disorder (P = 0.1923)	NULL	0.97344	NULL	0.73431	0.747325539589	0.74052	T	0.918608	0.98525	D	0.449794	0.92474	D	0.408322	0.92381	D	0.998413443565369	0.94084	D	NULL	0.97582	.	.	.	.	.	.	.	4.102972	0.82187	27.8	4.331031	0.90425	31	0.99934140671338501	0.99535	0.95568	0.65241	D	AEFDBCI	0.954402	0.97148	D	0.972684274158569	0.94842	13.08549	0.925335415902816	0.96585	14.87952	1.0	0.98316	0.722319	0.85440	0	0.724815	0.89359	0	0.702456	0.68683	0	0.735409	0.98432	0	NULL	NULL	5.68	5.68	0.88021	8.017000	0.88732	1.172000	0.72986	0.672000	0.70159	1.000000	0.71638	0.996000	0.59523	0.995000	0.73285	0.0:0.0:1.0:0.0	18.3597	0.90314	753	0.51500	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251474	3.976554e-06	0	1	16256	6.151575e-05	0	0	34590	0	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	0	113752	0	0	0	30614	0	0	1	16256	6.151575e-05	0	1	109408	9.140099e-06	0	1	7164	1.395868e-04	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	1	7164	1.395868e-04	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	139534	Pathogenic/Likely_pathogenic	Neu-Laxova_syndrome_1|not_provided	no_assertion_criteria_provided	NC_000001.11:g.119727010G>A	OMIM_Allelic_Variant:606879.0007|UniProtKB_(protein):O43175#VAR_071819	C4551478|CN517202	256520	.	D-isomer specific 2-hydroxyacid dehydrogenase, catalytic domain|D-isomer specific 2-hydroxyacid dehydrogenase, NAD-binding domain	.	. 	.
1	119727010	G	A	G	R	rs587777770	1	120269633	1	120071156	140	PHGDH	ENSG00000092621	ENST00000641947	ENSP00000492994	A0A286YF22_HUMAN	.	.	.	.	c.418G>A	p.Gly140Arg	.	.	.	.	+	GGA	1	0	G	G/G	G/G	G/G	NULL	0.91255	.	NULL	0.92824	.	NULL	0.90584	.	NULL	0.97372	.	0.000000	0.84330	D	0.048251	1;1	0.81001	D;D	simple_aae;simple_aae	G140R;G106R	NULL	0.83555	.	NULL	0.81987	.	NULL	0.96368	.	NULL	0.94904	0.6611	0.92684	D	0.7557	0.91675	D	10	0.464384	0.94570	D	0.975	0.99765	0.849	0.95142	O43175	G140R	Loss of sheet (P = 0.007); Gain of MoRF binding (P = 0.0148); Gain of loop (P = 0.0435); Gain of methylation at G140 (P = 0.0524); Gain of disorder (P = 0.1923)	NULL	0.97344	NULL	0.73431	0.747325539589	0.74052	T	NULL	0.98525	.	0.449794	0.92474	D	0.408322	0.92381	D	0.998413443565369	0.94084	D	0.965203	0.97582	D	.	.	.	.	.	.	4.102972	0.82187	27.8	4.331031	0.90425	31	0.99934140671338501	0.99535	0.95568	0.65241	D	AEFDBCI	0.954402	0.97148	D	0.972684274158569	0.94842	13.08549	0.925335415902816	0.96585	14.87952	1.0	0.98316	0.722319	0.85440	0	0.724815	0.89359	0	0.702456	0.68683	0	0.735409	0.98432	0	NULL	NULL	5.68	5.68	0.88021	8.017000	0.88732	1.172000	0.72986	0.672000	0.70159	1.000000	0.71638	0.996000	0.59523	0.995000	0.73285	0.0:0.0:1.0:0.0	18.3597	0.90314	753	0.51500	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251474	3.976554e-06	0	1	16256	6.151575e-05	0	0	34590	0	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	0	113752	0	0	0	30614	0	0	1	16256	6.151575e-05	0	1	109408	9.140099e-06	0	1	7164	1.395868e-04	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	1	7164	1.395868e-04	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	139534	Pathogenic/Likely_pathogenic	Neu-Laxova_syndrome_1|not_provided	no_assertion_criteria_provided	NC_000001.11:g.119727010G>A	OMIM_Allelic_Variant:606879.0007|UniProtKB_(protein):O43175#VAR_071819	C4551478|CN517202	256520	.	D-isomer specific 2-hydroxyacid dehydrogenase, catalytic domain|D-isomer specific 2-hydroxyacid dehydrogenase, NAD-binding domain	.	. 	.
1	119727010	G	A	G	R	rs587777770	1	120269633	1	120071156	45	PHGDH	ENSG00000092621	ENST00000493622	ENSP00000493433	A0A286YFE1_HUMAN	.	.	n.607G>A	.	c.133G>A	p.Gly45Arg	.	.	5	.	+	GGA	1	0	G	G/G	G/G	G/G	NULL	0.91255	.	NULL	0.92824	.	NULL	0.90584	.	NULL	0.97372	.	0.000000	0.84330	D	0.048251	1;1	0.81001	D;D	simple_aae;simple_aae	G140R;G106R	NULL	0.83555	.	NULL	0.81987	.	NULL	0.96368	.	NULL	0.94904	0.6611	0.92684	D	0.7557	0.91675	D	10	0.464384	0.94570	D	0.975	0.99765	0.849	0.95142	O43175	G140R	Loss of sheet (P = 0.007); Gain of MoRF binding (P = 0.0148); Gain of loop (P = 0.0435); Gain of methylation at G140 (P = 0.0524); Gain of disorder (P = 0.1923)	NULL	0.97344	NULL	0.73431	0.747325539589	0.74052	T	NULL	0.98525	.	0.449794	0.92474	D	0.408322	0.92381	D	0.998413443565369	0.94084	D	0.990301	0.97582	D	.	.	.	.	.	.	4.102972	0.82187	27.8	4.331031	0.90425	31	0.99934140671338501	0.99535	0.95568	0.65241	D	AEFDBCI	0.954402	0.97148	D	0.972684274158569	0.94842	13.08549	0.925335415902816	0.96585	14.87952	1.0	0.98316	0.722319	0.85440	0	0.724815	0.89359	0	0.702456	0.68683	0	0.735409	0.98432	0	NULL	NULL	5.68	5.68	0.88021	8.017000	0.88732	1.172000	0.72986	0.672000	0.70159	1.000000	0.71638	0.996000	0.59523	0.995000	0.73285	0.0:0.0:1.0:0.0	18.3597	0.90314	753	0.51500	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	.	1	251474	3.976554e-06	0	1	16256	6.151575e-05	0	0	34590	0	0	0	10080	0	0	0	18394	0	0	0	21648	0	0	0	113752	0	0	0	30614	0	0	1	16256	6.151575e-05	0	1	109408	9.140099e-06	0	1	7164	1.395868e-04	0	0	17112	0	0	0	2320	0	0	0	9046	0	0	0	13394	0	0	0	42768	0	0	0	15690	0	0	1	7164	1.395868e-04	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	139534	Pathogenic/Likely_pathogenic	Neu-Laxova_syndrome_1|not_provided	no_assertion_criteria_provided	NC_000001.11:g.119727010G>A	OMIM_Allelic_Variant:606879.0007|UniProtKB_(protein):O43175#VAR_071819	C4551478|CN517202	256520	.	D-isomer specific 2-hydroxyacid dehydrogenase, NAD-binding domain	.	. 	.
1	119764385	G	A	R	C	rs200607527	1	120307008	1	120108531	116	HMGCS2	ENSG00000134240	ENST00000369406	ENSP00000358414	HMCS2_HUMAN	c.346C>T	p.R116C	c.346C>T	p.Arg116Cys	c.346C>T	p.Arg116Cys	principal1	Y	1	YES	-	CGC	1	0	G	G/G	G/G	G/G	0.0	0.91255	D	0.035	0.52389	D	0.853	0.47048	P	0.605	0.50945	P	0.000005	0.62929	D	0.000000	0.999999;0.999998	0.58761	D;D	simple_aae;simple_aae	R116C;R116C	2.955	0.85029	M	-2.62	0.90017	D	-6.17	0.91058	D	0.618	0.63374	0.7350	0.93609	D	0.7716	0.92234	D	10	0.079706	0.73296	D	0.734	0.90842	.	NULL	.	.	.	0.939834670051	0.93920	0.578555744131	0.53760	0.446998775005	0.31534	T	0.93209	0.98860	D	0.132345	0.67590	D	0.132624	0.79062	D	0.979732036590576	0.72985	D	0.940673	0.77758	D	.	.	.	.	.	.	3.927688	0.76186	26.5	3.868091	0.77717	26.7	0.99937519817599851	0.99661	0.89432	0.49893	D	AEFBI	0.879819	0.80602	D	0.627212703098696	0.74901	6.212264	0.601150495750961	0.75025	6.237836	0.997852265020126	0.36112	0.446893	0.09132	0	0.563428	0.19063	0	0.563428	0.18855	0	0.530356	0.10902	0	NULL	NULL	5.13	5.13	0.69729	3.191000	0.50682	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.910000	0.38299	0.846000	0.39970	0.0:0.0:0.8342:0.1658	12.6191	0.55952	804	0.43891	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	2	5.393743257820927E-4	0	0.0	2	2.644802962179318E-4	NULL	NULL	NULL	NULL	3	2.471e-05	3	2.471e-05	0	0	0	0	0	0	0	0	3	4.496e-05	0	0	3	2.825e-05	3	2.825e-05	0	0	0	0	0	0	0	0	3	5.521e-05	0	0	3	3.306e-05	3	3.306e-05	0	0	0	0	0	0	0	0	3	7.120e-05	0	0	.	9	251248	3.582118e-05	0	0	16254	0	0	0	34590	0	0	0	10072	0	0	1	18392	5.437147e-05	0	1	21642	4.620645e-05	0	7	113558	6.164251e-05	0	0	30614	0	0	7	113558	6.164251e-05	0	3	109402	2.742180e-05	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9044	0	0	1	13394	7.466030e-05	0	2	42766	4.676612e-05	0	0	15688	0	0	2	42766	4.676612e-05	0	.	3	143302	2.093481e-05	0	2	42046	4.756695e-05	0	0	13660	0	0	0	3322	0	0	0	3132	0	0	0	10468	0	0	1	64576	1.548563e-05	0	1	64576	1.548563e-05	0	203779	Conflicting_interpretations_of_pathogenicity	mitochondrial_3-hydroxy-3-methylglutaryl-CoA_synthase_deficiency|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.119764385G>A	.	C2751532|CN517202	605911	ORPHA35701	Hydroxymethylglutaryl-coenzyme A synthase, N-terminal	.	. 	.
1	119764385	G	A	R	C	rs200607527	1	120307008	1	120108531	116	HMGCS2	ENSG00000134240	ENST00000544913	ENSP00000439495	HMCS2_HUMAN	c.346C>T	p.R116C	c.346C>T	p.Arg116Cys	c.346C>T	p.Arg116Cys	.	Y	2	.	-	CGC	1	0	G	G/G	G/G	G/G	0.0	0.91255	D	0.049	0.52389	D	NULL	0.47048	.	NULL	0.50945	.	0.000005	0.62929	D	0.000000	0.999999;0.999998	0.58761	D;D	simple_aae;simple_aae	R116C;R116C	2.955	0.85029	M	-2.55	0.90017	D	-6.37	0.91058	D	0.566	0.63374	0.7350	0.93609	D	0.7716	0.92234	D	10	0.079706	0.73296	D	0.734	0.90842	.	NULL	.	.	.	0.939834670051	0.93920	NULL	0.53760	0.446998775005	0.31534	T	NULL	0.98860	.	0.132345	0.67590	D	0.132624	0.79062	D	0.979732036590576	0.72985	D	0.938306	0.77758	D	.	.	.	.	.	.	3.927688	0.76186	26.5	3.868091	0.77717	26.7	0.99937519817599851	0.99661	0.89432	0.49893	D	AEFBI	0.879819	0.80602	D	0.627212703098696	0.74901	6.212264	0.601150495750961	0.75025	6.237836	0.997852265020126	0.36112	0.446893	0.09132	0	0.563428	0.19063	0	0.563428	0.18855	0	0.530356	0.10902	0	NULL	NULL	5.13	5.13	0.69729	3.191000	0.50682	1.176000	0.78918	0.676000	0.76740	1.000000	0.71638	0.910000	0.38299	0.846000	0.39970	0.0:0.0:0.8342:0.1658	12.6191	0.55952	804	0.43891	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	2	5.393743257820927E-4	0	0.0	2	2.644802962179318E-4	NULL	NULL	NULL	NULL	3	2.471e-05	3	2.471e-05	0	0	0	0	0	0	0	0	3	4.496e-05	0	0	3	2.825e-05	3	2.825e-05	0	0	0	0	0	0	0	0	3	5.521e-05	0	0	3	3.306e-05	3	3.306e-05	0	0	0	0	0	0	0	0	3	7.120e-05	0	0	.	9	251248	3.582118e-05	0	0	16254	0	0	0	34590	0	0	0	10072	0	0	1	18392	5.437147e-05	0	1	21642	4.620645e-05	0	7	113558	6.164251e-05	0	0	30614	0	0	7	113558	6.164251e-05	0	3	109402	2.742180e-05	0	0	7164	0	0	0	17112	0	0	0	2320	0	0	0	9044	0	0	1	13394	7.466030e-05	0	2	42766	4.676612e-05	0	0	15688	0	0	2	42766	4.676612e-05	0	.	3	143302	2.093481e-05	0	2	42046	4.756695e-05	0	0	13660	0	0	0	3322	0	0	0	3132	0	0	0	10468	0	0	1	64576	1.548563e-05	0	1	64576	1.548563e-05	0	203779	Conflicting_interpretations_of_pathogenicity	mitochondrial_3-hydroxy-3-methylglutaryl-CoA_synthase_deficiency|not_provided	criteria_provided,_conflicting_interpretations	NC_000001.11:g.119764385G>A	.	C2751532|CN517202	605911	ORPHA35701	.	.	. 	.
1	119768772	G	C	P	A	rs144744634	1	120311395	1	120112918	25	HMGCS2	ENSG00000134240	ENST00000369406	ENSP00000358414	HMCS2_HUMAN	c.73C>G	p.P25A	c.73C>G	p.Pro25Ala	c.73C>G	p.Pro25Ala	principal1	Y	1	YES	-	CCT	1	0	G	G/G	G/G	G/G	0.107	0.29554	T	0.917	0.06109	T	0.003	0.11197	B	0.002	0.06944	B	0.055346	0.22649	N	0.372750	1;1	0.08975	N;N	simple_aae;simple_aae	P25A;P25A	0	0.06538	N	-2.54	0.89496	D	-0.37	0.18459	N	0.224	0.25130	-0.7800	0.56303	T	0.2571	0.62766	T	10	0.009804	0.25563	T	0.127	0.35351	.	NULL	.	.	.	0.890725564957	0.88964	0.0980019385645	0.11061	0.383361041546	0.22732	T	0.187638	0.54130	T	-0.261827	0.12686	T	-0.283871	0.46406	T	0.0233582570659356	0.01067	T	0.574243	0.20591	T	.	.	.	.	.	.	1.560870	0.22818	16.12	0.548487	0.11354	9.848	0.8272219858770874	0.14341	0.30448	0.24085	N	AEFDGBCI	0.213619	0.33918	N	-0.673833080035392	0.16769	0.8573139	-0.634012265142385	0.18622	0.9955855	0.999695475560729	0.41870	0.446893	0.09132	0	0.563428	0.19063	0	0.48864	0.07692	0	0.530356	0.10902	0	NULL	NULL	4.32	2.34	0.28071	2.756000	0.47228	1.176000	0.78918	0.618000	0.50648	0.601000	0.27755	0.016000	0.13351	0.684000	0.33659	0.1076:0.1867:0.7057:0.0	6.3669	0.20664	754	0.51307	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	1	1.1627906976744187E-4	45	3.706e-04	45	3.717e-04	0	0	1	8.664e-05	0	0	5	7.657e-04	39	5.856e-04	0	0	43	4.049e-04	43	4.059e-04	0	0	1	8.943e-05	0	0	5	7.657e-04	37	6.820e-04	0	0	9	9.917e-05	9	9.948e-05	0	0	1	8.673e-05	0	0	2	5.311e-04	6	1.428e-04	0	0	.	84	251122	3.344988e-04	0	0	16252	0	0	6	34582	1.735007e-04	0	1	10068	9.932459e-05	0	0	18394	0	0	25	21640	1.155268e-03	0	51	113446	4.495531e-04	0	0	30616	0	0	51	113446	4.495531e-04	0	32	109402	2.924992e-04	0	0	7164	0	0	4	17110	2.337814e-04	0	1	2320	4.310345e-04	0	0	9046	0	0	7	13394	5.226221e-04	0	20	42764	4.676831e-04	0	0	15690	0	0	20	42764	4.676831e-04	0	.	22	143278	1.535476e-04	0	0	42028	0	0	3	13654	2.197158e-04	0	0	3324	0	0	0	3132	0	0	5	10474	4.773725e-04	0	14	64570	2.168190e-04	0	14	64570	2.168190e-04	0	203778	Conflicting_interpretations_of_pathogenicity	mitochondrial_3-hydroxy-3-methylglutaryl-CoA_synthase_deficiency|not_specified	criteria_provided,_conflicting_interpretations	NC_000001.11:g.119768772G>C	.	C2751532|CN169374	605911	ORPHA35701	.	.	. 	.
1	119768772	G	C	P	A	rs144744634	1	120311395	1	120112918	25	HMGCS2	ENSG00000134240	ENST00000544913	ENSP00000439495	HMCS2_HUMAN	c.73C>G	p.P25A	c.73C>G	p.Pro25Ala	c.73C>G	p.Pro25Ala	.	Y	2	.	-	CCT	1	0	G	G/G	G/G	G/G	0.107	0.29554	T	0.68	0.06109	T	NULL	0.11197	.	NULL	0.06944	.	0.055346	0.22649	N	0.372750	1;1	0.08975	N;N	simple_aae;simple_aae	P25A;P25A	0	0.06538	N	-2.31	0.89496	D	-0.63	0.18459	N	0.223	0.25130	-0.7800	0.56303	T	0.2571	0.62766	T	10	0.009804	0.25563	T	0.127	0.35351	.	NULL	.	.	.	0.890725564957	0.88964	NULL	0.11061	0.383361041546	0.22732	T	NULL	0.54130	.	-0.261827	0.12686	T	-0.283871	0.46406	T	0.0233582570659356	0.01067	T	0.574243	0.20591	T	.	.	.	.	.	.	1.560870	0.22818	16.12	0.548487	0.11354	9.848	0.8272219858770874	0.14341	0.30448	0.24085	N	AEFDGBCI	0.213619	0.33918	N	-0.673833080035392	0.16769	0.8573139	-0.634012265142385	0.18622	0.9955855	0.999695475560729	0.41870	0.446893	0.09132	0	0.563428	0.19063	0	0.48864	0.07692	0	0.530356	0.10902	0	NULL	NULL	4.32	2.34	0.28071	2.756000	0.47228	1.176000	0.78918	0.618000	0.50648	0.601000	0.27755	0.016000	0.13351	0.684000	0.33659	0.1076:0.1867:0.7057:0.0	6.3669	0.20664	754	0.51307	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	0.0	1	1.1627906976744187E-4	45	3.706e-04	45	3.717e-04	0	0	1	8.664e-05	0	0	5	7.657e-04	39	5.856e-04	0	0	43	4.049e-04	43	4.059e-04	0	0	1	8.943e-05	0	0	5	7.657e-04	37	6.820e-04	0	0	9	9.917e-05	9	9.948e-05	0	0	1	8.673e-05	0	0	2	5.311e-04	6	1.428e-04	0	0	.	84	251122	3.344988e-04	0	0	16252	0	0	6	34582	1.735007e-04	0	1	10068	9.932459e-05	0	0	18394	0	0	25	21640	1.155268e-03	0	51	113446	4.495531e-04	0	0	30616	0	0	51	113446	4.495531e-04	0	32	109402	2.924992e-04	0	0	7164	0	0	4	17110	2.337814e-04	0	1	2320	4.310345e-04	0	0	9046	0	0	7	13394	5.226221e-04	0	20	42764	4.676831e-04	0	0	15690	0	0	20	42764	4.676831e-04	0	.	22	143278	1.535476e-04	0	0	42028	0	0	3	13654	2.197158e-04	0	0	3324	0	0	0	3132	0	0	5	10474	4.773725e-04	0	14	64570	2.168190e-04	0	14	64570	2.168190e-04	0	203778	Conflicting_interpretations_of_pathogenicity	mitochondrial_3-hydroxy-3-methylglutaryl-CoA_synthase_deficiency|not_specified	criteria_provided,_conflicting_interpretations	NC_000001.11:g.119768772G>C	.	C2751532|CN169374	605911	ORPHA35701	.	.	. 	.
1	119915499	A	T	L	H	rs35586704	1	120458122	1	120259645	2408	NOTCH2	ENSG00000134250	ENST00000256646	ENSP00000256646	NOTC2_HUMAN	c.7223T>A	p.L2408H	c.7223T>A	p.Leu2408His	c.7223T>A	p.Leu2408His	principal1	Y	1	YES	-	CTC	2	0	A	A/A	A/A	A/A	0.013	0.53900	D	0.054	0.47097	T	0.999	0.77913	D	0.969	0.72001	D	0.005675	0.32605	U	0.000000	0.739179	0.33803	D	simple_aae	L2408H	1.12	0.28775	L	-1.1	0.77336	T	-2.05	0.47008	N	0.554	0.57946	0.0130	0.82518	D	0.4435	0.78068	T	10	0.125954	0.80754	D	0.392	0.71073	.	NULL	.	.	.	0.951370333075	0.95085	0.703745904295	0.61285	0.684659719467	0.64938	T	0.197127	0.55371	T	-0.0435621	0.45419	T	0.16286	0.80982	D	0.0155213662999304	0.00352	T	0.815218	0.46991	T	.	.	.	.	.	.	3.864767	0.74161	26.2	3.730234	0.73322	25.9	0.97995617953956726	0.37438	0.85344	0.44468	D	AEFDGBCI	0.323475	0.42566	N	0.511961180077932	0.67796	5.129705	0.508288666840806	0.68548	5.235119	0.961560136412047	0.28563	0.706548	0.73137	0	0.659912	0.62753	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.35	5.35	0.76297	3.071000	0.49740	1.312000	0.94714	0.691000	0.84096	0.985000	0.35982	1.000000	0.86279	0.994000	0.71098	1.0:0.0:0.0:0.0	14.5066	0.67342	838	0.37812	4	7.987220447284345E-4	0	0.0	4	0.003976143141153081	0	0.0	0	0.0	0	0.0	11	0.0029665587918015104	13	0.0033731188375713543	24	0.003173763554615181	5	0.0011348161597821154	22	0.0025581395348837207	217	1.787e-03	217	1.788e-03	9	8.649e-04	24	2.073e-03	0	0	4	6.048e-04	172	2.579e-03	4	2.424e-04	175	1.648e-03	175	1.648e-03	7	7.721e-04	23	2.051e-03	0	0	4	6.048e-04	133	2.449e-03	4	2.439e-04	172	1.895e-03	172	1.896e-03	9	8.664e-04	24	2.075e-03	0	0	1	2.630e-04	133	3.159e-03	4	2.425e-04	.	509	251304	2.025435e-03	0	14	16256	8.612205e-04	0	81	34586	2.341988e-03	0	0	10056	0	0	0	18392	0	0	26	21556	1.206161e-03	0	365	113712	3.209864e-03	0	4	30614	1.306592e-04	0	365	113712	3.209864e-03	0	201	109314	1.838740e-03	0	5	7164	6.979341e-04	0	39	17110	2.279369e-03	0	0	2314	0	0	0	9044	0	0	14	13316	1.051367e-03	0	135	42764	3.156861e-03	0	3	15688	1.912290e-04	0	135	42764	3.156861e-03	0	.	321	143258	2.240713e-03	0	41	42040	9.752617e-04	0	41	13648	3.004103e-03	0	0	3322	0	0	0	3130	0	0	9	10472	8.594347e-04	0	219	64558	3.392298e-03	0	1	3034	3.295979e-04	0	134987	Likely_benign	Hirschsprung_disease_1|Hajdu-Cheney_syndrome|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.119915499A>T	.	C3888239|C0917715|CN169374	142623|102500	ORPHA955	Domain of unknown function DUF3454, notch|Domain of unknown function DUF3454, notch	.	. 	.
1	119915647	G	C	P	A	rs75831573	1	120458270	1	120259793	2359	NOTCH2	ENSG00000134250	ENST00000256646	ENSP00000256646	NOTC2_HUMAN	c.7075C>G	p.P2359A	c.7075C>G	p.Pro2359Ala	c.7075C>G	p.Pro2359Ala	principal1	Y	1	YES	-	CCC	1	0	G	G/G	G/G	G/G	0.149	0.24758	T	0.24	0.24406	T	0.002	0.09854	B	0.002	0.06944	B	0.039894	0.24120	U	0.205068	0.929629	0.36932	D	simple_aae	P2359A	0.695	0.17993	N	-1.55	0.81727	D	-1.65	0.39503	N	0.103	0.08646	-0.9774	0.35593	T	0.1115	0.40006	T	10	0.030089	0.52471	D	0.154	0.40799	.	NULL	.	.	.	0.628321581913	0.62528	0.140317624047	0.15819	0.469031244516	0.34547	T	0.306187	0.67841	T	-0.352699	0.04560	T	-0.273855	0.47429	T	0.00315059417761962	0.00033	T	0.836416	0.50788	T	.	.	.	.	.	.	1.335678	0.19490	14.64	1.704100	0.27295	17.51	0.59439205950197516	0.06224	0.92634	0.56174	D	AEFBCI	0.312542	0.41795	N	-0.598052377463111	0.19003	0.9912082	-0.372983675731974	0.25806	1.421419	0.636741057247728	0.22016	0.706548	0.73137	0	0.659912	0.62753	0	0.724815	0.87919	0	0.714379	0.83352	0	NULL	NULL	5.4	3.52	0.39415	1.344000	0.33547	0.189000	0.21855	0.676000	0.76740	1.000000	0.71638	0.998000	0.65909	0.995000	0.73285	0.0742:0.1368:0.7891:0.0	10.2015	0.42263	838	0.37812	7	0.0013977635782747603	0	0.0	5	0.004970178926441352	2	0.002881844380403458	0	0.0	0	0.0	28	0.007551240560949299	21	0.005448884276076803	49	0.006479767257339328	5	0.0011348161597821154	30	0.0034883720930232558	548	4.514e-03	548	4.530e-03	15	1.446e-03	32	2.764e-03	0	0	44	6.653e-03	436	6.552e-03	16	9.816e-04	472	4.444e-03	472	4.461e-03	14	1.549e-03	29	2.586e-03	0	0	44	6.653e-03	365	6.736e-03	16	9.879e-04	328	3.614e-03	328	3.632e-03	15	1.449e-03	32	2.767e-03	0	0	22	5.786e-03	239	5.697e-03	16	9.822e-04	.	1148	251234	4.569445e-03	3	19	16254	1.168943e-03	0	135	34580	3.903991e-03	0	5	10056	4.972156e-04	0	0	18394	0	0	176	21508	8.183002e-03	0	751	113708	6.604636e-03	3	28	30602	9.149729e-04	0	751	113708	6.604636e-03	3	543	109250	4.970252e-03	1	10	7162	1.396258e-03	0	63	17104	3.683349e-03	0	0	2318	0	0	0	9046	0	0	127	13264	9.574789e-03	0	316	42760	7.390084e-03	1	14	15682	8.927433e-04	0	316	42760	7.390084e-03	1	.	695	143330	4.848950e-03	2	69	42046	1.641060e-03	0	84	13662	6.148441e-03	0	0	3320	0	0	0	3132	0	0	81	10486	7.724585e-03	0	442	64580	6.844224e-03	2	3	3050	9.836066e-04	0	134983	Benign	Hajdu-Cheney_syndrome|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.119915647G>C	.	C0917715|CN169374	102500	ORPHA955	.	.	. 	.
1	119925578	A	T	L	H	rs41313282	1	120468201	1	120269724	1413	NOTCH2	ENSG00000134250	ENST00000256646	ENSP00000256646	NOTC2_HUMAN	c.4238T>A	p.L1413H	c.4238T>A	p.Leu1413His	c.4238T>A	p.Leu1413His	principal1	Y	1	YES	-	CTC	2	0	A	A/A	A/A	A/A	0.04	0.42199	D	0.165	0.30926	T	0.0	0.02946	B	0.0	0.01387	B	0.483790	0.04996	N	1.436370	1	0.08975	N	simple_aae	L1413H	0.58	0.15352	N	0.87	0.46412	T	-2.6	0.55983	D	0.21	0.23380	-1.0070	0.27850	T	0.0382	0.16462	T	10	0.0066	0.17415	T	0.059	0.17357	.	NULL	.	.	.	0.288221626996	0.28429	0.726126811447	0.62499	0.460606455803	0.33394	T	0.62162	0.88148	D	-0.518974	0.00446	T	-0.514242	0.20880	T	0.00708417585469381	0.00081	T	0.149285	0.01243	T	.	.	.	.	.	.	1.729351	0.25580	17.23	1.353180	0.21680	15.47	0.96695499896027159	0.30755	0.11955	0.16968	N	AEFDBI	0.066263	0.12968	N	-0.645987093578423	0.17577	0.9056599	-0.598119779245758	0.19542	1.048946	0.999570307443399	0.40495	0.732398	0.92422	0	0.588015	0.36545	0	0.743671	0.96076	0	0.714379	0.83352	0	NULL	NULL	5.72	3.29	0.36801	1.395000	0.34129	1.295000	0.87208	0.756000	0.94297	0.003000	0.16062	0.920000	0.39012	0.937000	0.47636	0.7145:0.1459:0.0:0.1396	7.5914	0.27190	825	0.40060	11	0.002196485623003195	0	0.0	5	0.004970178926441352	6	0.008645533141210375	0	0.0	0	0.0	21	0.0056634304207119745	26	0.006746237675142709	47	0.006215286961121396	5	0.0011353315168029065	39	0.0045359385903698535	358	2.949e-03	357	2.968e-03	11	1.087e-03	26	2.247e-03	0	0	0	0	310	4.702e-03	4	2.423e-04	293	2.759e-03	292	2.770e-03	9	1.022e-03	26	2.318e-03	0	0	0	0	247	4.590e-03	4	2.438e-04	308	3.394e-03	307	3.426e-03	11	1.089e-03	26	2.250e-03	0	0	0	0	263	6.363e-03	4	2.424e-04	.	829	250810	3.305291e-03	1	16	16086	9.946537e-04	0	118	34584	3.411982e-03	0	76	10058	7.556174e-03	0	0	18384	0	0	3	21644	1.386065e-04	0	583	113308	5.145268e-03	1	9	30616	2.939639e-04	0	583	113308	5.145268e-03	1	313	109408	2.860851e-03	0	7	7164	9.771078e-04	0	58	17112	3.389434e-03	0	17	2320	7.327586e-03	0	0	9046	0	0	2	13394	1.493206e-04	0	215	42768	5.027123e-03	0	4	15690	2.549395e-04	0	215	42768	5.027123e-03	0	.	526	143180	3.673697e-03	1	47	42000	1.119048e-03	0	85	13646	6.228932e-03	0	32	3322	9.632751e-03	0	0	3124	0	0	1	10452	9.567547e-05	0	351	64542	5.438319e-03	1	1	3042	3.287311e-04	0	134975	Benign/Likely_benign	Hajdu-Cheney_syndrome|not_specified|not_provided	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.119925578A>T	.	C0917715|CN169374|CN517202	102500	ORPHA955	.	.	. 	.
1	119926524	T	C	D	G	rs61752484	1	120469147	1	120270670	1327	NOTCH2	ENSG00000134250	ENST00000256646	ENSP00000256646	NOTC2_HUMAN	c.3980A>G	p.D1327G	c.3980A>G	p.Asp1327Gly	c.3980A>G	p.Asp1327Gly	principal1	Y	1	YES	-	GAT	2	0	T	T/T	T/T	T/T	0.411	0.10115	T	0.407	0.14679	T	0.101	0.25775	B	0.061	0.26820	B	0.028087	0.25656	U	0.187689	0.63999	0.32867	D	simple_aae	D1327G	0.36	0.11994	N	-2.83	0.91249	D	-0.83	0.22727	N	0.233	0.26233	-0.7823	0.56172	T	0.2588	0.62955	T	10	NULL	NULL	.	0.401	0.71783	.	NULL	.	.	.	NULL	NULL	0.902817761121	0.70701	0.378910720348	0.22102	T	0.340968	0.70992	T	-0.255136	0.13476	T	-0.102017	0.63241	T	0.0107099988816602	0.00151	T	0.783822	0.42110	T	.	.	.	.	.	.	2.586117	0.43132	22.6	2.508460	0.43917	22.6	0.96812852524452542	0.31195	0.90332	0.51424	D	AEFBI	0.296564	0.40637	N	-0.406180722580298	0.25253	1.369426	-0.157145179363137	0.33134	1.892235	0.999933978369673	0.46732	0.732398	0.92422	0	0.588015	0.36545	0	0.743671	0.96076	0	0.714379	0.83352	0	NULL	NULL	5.64	5.64	0.86480	2.183000	0.42195	1.138000	0.64695	0.665000	0.62972	0.647000	0.28146	0.999000	0.70432	0.976000	0.56436	0.0:0.0:0.0:1.0	15.3286	0.73896	825	0.40060	55	0.010982428115015975	0	0.0	8	0.007952286282306162	2	0.002881844380403458	0	0.0	45	0.046012269938650305	26	0.007011866235167206	33	0.008562532433834976	59	0.007802168738428987	5	0.0011348161597821154	60	0.0069767441860465115	1417	1.168e-02	1304	1.688e-02	11	1.538e-03	43	5.642e-03	3	4.431e-04	12	3.899e-03	435	1.093e-02	787	6.419e-02	1308	1.233e-02	1197	1.836e-02	9	1.492e-03	42	5.711e-03	0	0	12	3.899e-03	340	1.133e-02	784	6.443e-02	1303	1.438e-02	1205	1.932e-02	11	1.538e-03	43	5.645e-03	3	6.155e-04	5	2.593e-03	344	1.225e-02	787	6.421e-02	.	2633	238222	1.105272e-02	60	21	14762	1.422571e-03	0	140	33666	4.158498e-03	0	49	9550	5.130890e-03	0	3	18210	1.647446e-04	0	49	20908	2.343601e-03	1	813	106542	7.630793e-03	8	1482	28686	5.166283e-02	51	1482	28686	5.166283e-02	51	1172	102556	1.142790e-02	36	8	6034	1.325820e-03	0	71	16612	4.274019e-03	0	9	1954	4.605937e-03	0	0	8940	0	0	29	13206	2.195972e-03	1	268	39288	6.821421e-03	4	760	14714	5.165149e-02	31	760	14714	5.165149e-02	31	.	802	143202	5.600480e-03	6	70	42012	1.666191e-03	0	55	13642	4.031667e-03	0	26	3320	7.831325e-03	0	0	3132	0	0	27	10450	2.583732e-03	0	472	64554	7.311708e-03	4	134	3042	4.404997e-02	2	134972	Benign	Hajdu-Cheney_syndrome|not_specified	criteria_provided,_multiple_submitters,_no_conflicts	NC_000001.11:g.119926524T>C	.	C0917715|CN169374	102500	ORPHA955	EGF-like domain|EGF-like domain|EGF-like calcium-binding domain|EGF-like domain	.	. 	.
1	120069400	C	A	A	S	rs782113557	1	120612014	1	120413537	3	NOTCH2	ENSG00000134250	ENST00000256646	ENSP00000256646	NOTC2_HUMAN	c.7G>T	p.A3S	c.7G>T	p.Ala3Ser	c.7G>T	p.Ala3Ser	principal1	Y	1	YES	-	GCC	1	0	C	./.	./.	./.	0.265	0.16305	T	0.75	0.04807	T	0.981	0.59675	D	0.84	0.60170	P	NULL	NULL	.	NULL	0.997738	0.22531	N	simple_aae	A3S	0.345	0.11182	N	-1.54	0.81640	D	-0.26	0.11185	N	0.052	0.02366	-1.0409	0.17041	T	0.0296	0.12717	T	9	NULL	NULL	.	0.306	0.63094	.	NULL	.	.	.	NULL	NULL	0.513290397049	0.49328	0.821645736694	0.85280	D	0.166785	0.51315	T	0.0310119	0.55858	T	-0.19323	0.55288	T	0.0718511210845599	0.08909	T	0.450755	0.12737	T	.	.	.	.	.	.	2.498785	0.41216	22.4	2.411071	0.41756	22.4	0.98999212721349328	0.50106	0.19780	0.20793	N	ALL	0.073903	0.14797	N	-0.173269002843172	0.34250	1.952703	-0.143752865797118	0.33648	1.927067	0.999999580834266	0.74766	0.242642	0.04205	2	0.298843	0.05288	2	0.391439	0.06340	0	0.581474	0.35302	0	NULL	NULL	2.9	2.9	0.32809	1.236000	0.32286	0.065000	0.15159	0.222000	0.18087	1.000000	0.71638	0.996000	0.59523	0.794000	0.37478	0.0:1.0:0.0:0.0	9.4399	0.37825	889	0.27310	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1483	1.279e-02	1347	1.511e-02	75	1.455e-02	58	6.064e-03	37	5.191e-03	100	2.252e-02	640	1.327e-02	425	3.043e-02	1337	1.297e-02	1216	1.508e-02	58	1.325e-02	56	5.980e-03	32	4.779e-03	100	2.252e-02	536	1.297e-02	425	3.056e-02	1126	1.319e-02	1033	1.625e-02	75	1.459e-02	57	5.965e-03	29	6.633e-03	51	2.237e-02	387	1.393e-02	425	3.045e-02	segdup	428	196556	2.177496e-03	0	36	10224	3.521127e-03	0	30	31084	9.651268e-04	0	11	8578	1.282350e-03	0	14	16018	8.740167e-04	0	49	8814	5.559337e-03	0	213	90442	2.355101e-03	0	65	26362	2.465670e-03	0	36	10224	3.521127e-03	0	165	82136	2.008863e-03	0	16	4600	3.478261e-03	0	12	15292	7.847240e-04	0	3	1924	1.559252e-03	0	6	7664	7.828810e-04	0	18	2466	7.299270e-03	0	71	35236	2.014985e-03	0	35	13374	2.617018e-03	0	16	4600	3.478261e-03	0	.	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	218796	Benign	not_specified	criteria_provided,_single_submitter	NC_000001.11:g.120069400C>A	.	CN169374	.	.	.	.	. 	.